UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark one)
|
|
|
þ |
|
ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the fiscal year ended December 31, 2009
|
|
|
o |
|
TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to .
Commission file number 000-51348
ev3 Inc.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
32-0138874
(I.R.S. Employer Identification No.) |
|
|
|
3033 Campus Drive
Plymouth, Minnesota
(Address of principal executive offices)
|
|
55441
(Zip Code) |
(763) 398-7000
(Registrants telephone number, including area code)
Securities registered pursuant to section 12(b) of the Act:
|
|
|
Title of each class: |
|
Name of each exchange on which registered: |
Common Stock, par value $0.01 per share
|
|
The NASDAQ Stock Market |
Securities registered pursuant to section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of
the Securities Act. YES þ NO o
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or
Section 15(d) of the Act. YES o NO þ
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for
such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. YES þ NO o
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period
that the registrant was required to submit and post such files). YES o NO o
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K
(§229.405 of this chapter) is not contained herein, and will not be contained, to the best of
registrants knowledge, in definitive proxy or information statements incorporated by reference in
Part III of this Form 10-K or any amendment to this Form 10-K. þ
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See definitions of large accelerated
filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.
(Check one):
Large accelerated filer þ |
Accelerated filer o |
Non-accelerated filer o (Do not check if a smaller reporting company) | Smaller reporting company o |
Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the
Act). YES o NO þ
The aggregate market value of the registrants common stock, excluding outstanding shares
beneficially owned by affiliates, computed by reference to the closing sale price at which the
common stock was last sold as of July 3, 2009 (the last business day of the registrants second
fiscal quarter) as reported by the NASDAQ Global Select Market, was approximately $772.1 million.
As of February 18, 2010, 112,618,003 shares of common stock of the registrant were outstanding.
DOCUMENTS INCORPORATED BY REFERENCE
Part III of this annual report on Form 10-K incorporates by reference information (to the extent
specific sections are referred to in this annual report) from the registrants proxy statement for
its 2010 annual meeting of stockholders.
TABLE OF CONTENTS
This annual report on Form 10-K contains and incorporates by reference not only historical
information, but also forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the safe harbor created by those sections. We refer you to the
information under the heading Part I. Item 1. BusinessForward-Looking Statements.
As used in this report, references to ev3, the company, we, our or us, unless the context
otherwise requires, refer to ev3 Inc. and its subsidiaries.
We own or have rights to various trademarks, trade names or service marks, including the following:
ev3®, PROTEGE®, EVERFLEX, PARAMOUNT MINI, PRIMUS, SPIDERFX, THE CLOT BUSTER®, GOOSE NECK®,
VISI-PRO, NITREX®, NEXUS, PIPELINE EMBOLIZATION DEVICE, ONYX®, MORPHEUS, NXT, ECHELON,
ULTRAFLOW, MARATHON, HYPERFORM, REBAR
HYPERGLIDE, MIRAGE, AXIUM, APOLLO, SOLITAIRE, SILVERSPEED®,
X-PEDION, X-CELERATOR, FOXHOLLOW®, SILVERHAWK®, MEC TECHNOLOGY, RINSPIRATOR®, ROCKHAWK,
TURBOHAWK, EVERCROSS, NANOCROSS, POWERCROSS,
TRAILBLAZER and BEVEL 360 . The trademarks PLETAL®, PLAVIX® and ACCULINK®
referred to in this annual report on Form 10-K are the registered trademarks of others.
i
PART I
ITEM 1. BUSINESS
Company Overview
ev3 Inc. is a leading global endovascular company focused on identifying and treating peripheral
vascular disease, including, in particular, lower extremity arterial disease and neurovascular
disease. Since our founding in 2000, we have been dedicated to developing innovative, breakthrough
and clinically proven technologies and solutions for the treatment of peripheral vascular and
neurovascular diseases, a strategy that we believe is uncommon in the medical device industry. We
believe our unique approach of focusing on emerging and under-innovated opportunities which treat
peripheral vascular and neurovascular disease allows us to compete with smaller companies that have
narrow product lines and lack an international sales force and infrastructure, yet also compete
with larger companies that do not have our focus and agility.
The competitive strengths that have been responsible for our past success and the strategies that
we believe will drive our future growth include:
|
|
|
targeting under-innovated and emerging markets; |
|
|
|
|
leveraging our products across major endovascular sub-markets; |
|
|
|
|
investing in clinical research to demonstrate the benefits of our products; |
|
|
|
|
expanding our business through product innovation and strategic acquisitions; |
|
|
|
|
driving our global organization and presence; and |
|
|
|
|
leading our business by an experienced management team. |
Our product portfolio includes a broad spectrum
of over 100 products consisting of over 1,500 stock
keeping units (SKUs), including plaque excision, stents, embolic protection and
thrombectomy devices, carotid stenting solutions, percutaneous transluminal angioplasty (PTA) balloons and
other procedural
support products for the peripheral vascular market and embolic coils, flow
diversion and flow restoration devices, liquid embolics, flow directed and other micro catheters, occlusion balloon
systems, guidewires, neuro stents and retrieval devices, for the neurovascular market.
Our customers include a broad cross-section of physicians, including interventional radiologists,
neuroradiologists, vascular surgeons, neuro surgeons, other endovascular specialists and
interventional cardiologists. We sell our products in more than 65 countries through a direct sales
force in the United States, Canada, Europe, Australia and other countries and distributors in
selected other international markets. As of December 31, 2009, our U.S. sales organization
consisted of 114 sales representatives selling our peripheral vascular products and 25 sales
representatives selling our neurovascular products and our international sales organization
consisted of 43 sales representatives selling our peripheral vascular products, 31 sales
representatives selling our neurovascular products and seven sales representatives selling both.
We have organized our company into two business segments: peripheral vascular and neurovascular. We
manage our business and report our operations internally and externally on this basis. Our
peripheral vascular segment includes products that are used primarily in peripheral vascular
procedures by interventional radiologists, vascular surgeons and interventional cardiologists and
in targeted cardiovascular procedures. Our neurovascular segment includes products that are used
primarily by neuroradiologists, interventional neurologists and neurosurgeons. During 2009 and
2008, these combined segments generated net sales of $449.1 million and $422.1 million,
respectively.
In June of 2009, we acquired Chestnut Medical Technologies, Inc. (Chestnut), a privately-held
California-based company focused on developing minimally invasive therapies for interventional
neuroradiology. We acquired 100
1
percent of the equity interests of Chestnut for total consideration valued at $116.7 million,
consisting of upfront consideration of common stock and cash valued at $79.4 million, as well as an
additional milestone-based contingent payment of up to $75.0 million, payable in a combination of
common stock and equity, upon FDA pre-market approval of the Pipeline Embolization Device. The
transaction broadens our neurovascular product portfolio by adding the Pipeline Embolization Device
for the treatment of cerebral aneurysms and the Alligator Retrieval Device for foreign body
retrieval to our existing neurovascular embolic products and neuro access technologies.
The following represents net sales (in thousands) by our two business segments and revenues from
our former research collaboration with Merck & Co., Inc. as well as by geography during the periods
indicated:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended |
|
|
|
|
|
|
For the Year Ended |
|
|
|
|
|
|
December 31, |
|
|
Percent |
|
|
December 31, |
|
|
Percent |
|
Net Sales by Segment |
|
2009 |
|
|
2008 |
|
|
Change |
|
|
2008 |
|
|
2007 |
|
|
Change |
|
Net product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peripheral vascular (1) |
|
$ |
279,531 |
|
|
$ |
269,929 |
|
|
|
3.6 |
% |
|
$ |
269,929 |
|
|
$ |
173,775 |
|
|
|
55.3 |
% |
Neurovascular |
|
|
169,541 |
|
|
|
132,304 |
|
|
|
28.1 |
% |
|
|
132,304 |
|
|
|
104,451 |
|
|
|
26.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net product sales |
|
|
449,072 |
|
|
|
402,233 |
|
|
|
11.6 |
% |
|
|
402,233 |
|
|
|
278,226 |
|
|
|
44.6 |
% |
Research collaboration (2) |
|
|
|
|
|
|
19,895 |
|
|
|
-100.0 |
% |
|
|
19,895 |
|
|
|
5,957 |
|
|
|
234.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
449,072 |
|
|
$ |
422,128 |
|
|
|
6.4 |
% |
|
$ |
422,128 |
|
|
$ |
284,183 |
|
|
|
48.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended |
|
|
|
|
|
|
For the Year Ended |
|
|
|
|
|
|
December 31, |
|
|
Percent |
|
|
December 31, |
|
|
Percent |
|
Net Sales by Geography |
|
2009 |
|
|
2008 |
|
|
Change |
|
|
2008 |
|
|
2007 |
|
|
Change |
|
United States |
|
$ |
270,961 |
|
|
$ |
275,433 |
|
|
|
-1.6 |
% |
|
$ |
275,433 |
|
|
$ |
177,198 |
|
|
|
55.4 |
% |
International |
|
|
178,111 |
|
|
|
146,695 |
|
|
|
21.4 |
% |
|
|
146,695 |
|
|
|
106,985 |
|
|
|
37.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
449,072 |
|
|
$ |
422,128 |
|
|
|
6.4 |
% |
|
$ |
422,128 |
|
|
$ |
284,183 |
|
|
|
48.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Peripheral vascular net product sales in 2007 include plaque excision (formerly referred to
as atherectomy) net product sales from October 4, 2007, the date of our FoxHollow
Technologies, Inc. acquisition, through December 31, 2007. |
|
(2) |
|
Research collaboration revenue was derived from our former collaboration and license
agreement with Merck & Co., Inc., which we assumed as a result of our acquisition of FoxHollow
Technologies, Inc. on October 4, 2007. Our collaboration and license agreement with Merck was
terminated by Merck effective July 22, 2008. We subsequently reached an arrangement with
Merck to accomplish an orderly wind-down of our research collaboration activities during the
remainder of 2008. Research collaboration for the year ended December 31, 2007 includes
revenue earned from October 4, 2007 through December 31, 2007. For further information see
Note 2 to our consolidated financial statements. |
For additional financial information regarding each of our segments and our foreign
operations, see Note 19 to our consolidated financial statements.
The Endovascular Market
Vascular disease can involve either an artery or a vein, and is generally manifested as an
occlusion (closure) or rupture of a blood vessel. It may occur in any part of the body, and is a
progressive, pathological condition that leads most often to blood vessel narrowing and
obstruction, but can also lead to blood vessel wall weakening and rupture. Vascular disease can
occur in the blood vessels of every organ and anatomic area of the body, and can cause a range of
conditions including pain, functional impairment, amputation and death.
When the treatment for vascular disease is performed from within a vessel, it is referred to as an
endovascular procedure. Endovascular procedures are minimally invasive means of treating the two
major problems that can develop within blood vessels: an occlusion, or stenosis, where the vessel
is blocked or narrowed, and an aneurysm, or focal expansion of the vessel wall. Endovascular
procedures are performed by utilizing an easily accessible artery to reach an occlusion or aneurysm
and may or may not require general anesthesia. During most endovascular procedures, a catheter
is placed into the femoral artery in the groin. X-ray imaging or fluoroscopy is used to help the
physician advance the catheter to the area to be treated. Endovascular procedures are less invasive
and require a smaller incision than conventional, open surgery and we believe have a number of
distinct benefits over surgery, including:
2
|
|
|
the use of local or regional anesthesia frequently instead of general anesthesia; |
|
|
|
|
reduced patient discomfort and shorter recovery times; |
|
|
|
|
the reduced need for blood products and transfusions; |
|
|
|
|
shorter hospital stays for recovery; |
|
|
|
|
lower risks of patient complications related to procedures; and |
|
|
|
|
potentially lower costs. |
The endovascular device markets which we serve are conventionally divided into three specialties
based on anatomic location. We principally focus and serve the peripheral vascular and
neurovascular markets.
|
|
|
The peripheral vascular market includes products used to treat arterial and venous
disease in the legs, pelvis, neck, kidney and any other vascular anatomy other than that
in the brain or the heart. |
|
|
|
|
The neurovascular market includes products used to treat vascular disease and disorders
in the brain, including arterio-venous malformations, or AVMs, and strokes caused by
either vascular occlusion (ischemic) or rupture (hemorrhagic). |
|
|
|
|
The cardiovascular market includes products used to treat coronary artery disease,
atrial fibrillation and other disorders in the heart and adjacent vessels. |
Our Peripheral Vascular Markets
Peripheral Vascular Disease
Peripheral vascular disease is characterized by the narrowing or total occlusion of blood vessels
outside of the heart or brain and can cause conditions including pain, loss of function, amputation
and death. Mortality from peripheral vascular disease can occur as a result of stroke, kidney
failure or diabetes related vascular complications. The most common type of peripheral vascular
disease is peripheral artery disease, which is often used interchangeably with the term peripheral
vascular disease, although technically a subset of peripheral vascular disease.
A common cause of peripheral artery disease is atherosclerosis, or hardening of the arteries.
Atherosclerosis is a complex, progressive and degenerative condition resulting from the build-up of
cholesterol and other obstructive materials, known as plaque, on the walls of the arteries. The
accumulation of plaque narrows the interior or lumen of arteries, thereby reducing blood flow. In
addition, plaque may rupture and trigger the release of a blood clot that can further narrow or
block an artery.
Plaque occurs in the arteries in several different forms and may be located in many different
anatomies throughout the arterial system. Plaque varies in composition, with portions that are hard
and brittle, referred to as calcified plaque, and other portions that are fatty or fibrous. Plaque
lesions can be long or short, focused or diffuse and can be present in all types of arteries,
including straight or curved arteries of varying diameters. Atherosclerosis in arteries outside of
the heart and brain causes peripheral artery disease.
Peripheral artery disease is most common in the arteries of the pelvis and legs. Occlusive disease
of the iliac arteries, the main vessels descending through the pelvis, is a peripheral artery
disease that affects the flow of blood to the legs. Patients with this condition often experience
leg pain and numbness or tingling. Restoring the flow of blood in these occluded vessels is
essential to maintaining leg function and avoiding complications such as significantly reduced
mobility and/or gangrene, which in severe cases can lead to amputation.
Other types of peripheral artery disease involve arteries in the legs, including the superficial
femoral artery, or SFA. The legs receive their supply of blood through the femoral arteries, which
originate at the groin. The SFA extends
3
from the iliac arteries in the upper thigh down the leg to the knee. At the knee, the SFA becomes
the popliteal artery, which branches into arteries that supply blood to the lower leg and foot.
Arteries above the knee are generally long, straight and relatively wide although subjected to
extreme torsion and compression, while arteries below the knee are shorter and branch into arteries
that are progressively smaller in diameter, although still subject to compression.
Plaque build-up in the pelvic and leg arteries reduces blood flow to the surrounding tissue,
causing claudication, the most common early symptom of peripheral artery disease. Claudication
refers to pain, cramping or tiredness in the leg or hip muscles while walking. Symptoms may
progress to include numbness, tingling or weakness in the leg and, in severe cases, burning or
aching pain in the foot or toes while resting. Restoring the flow of blood in these occluded
arteries and vessels is essential to maintaining leg function or quality of life and avoiding
complications such as gangrene, which in severe cases can lead to amputation.
As peripheral artery disease progresses, additional signs and symptoms occur, including loss of
hair on the legs, cooling or color changes in the skin of the legs or feet, and sores on the legs
and feet that do not heal. If untreated, peripheral artery disease may lead to critical limb
ischemia, or CLI, a condition in which the limb does not receive enough oxygenated blood being
delivered to the limb to keep the tissue alive.
The carotid arteries are another common site of peripheral artery disease. Carotid arteries are
located on each side of the neck and provide the primary blood supply to the brain. In carotid
artery disease, plaque accumulates in the artery walls, narrowing the artery and disrupting the
blood supply. This disruption in blood supply, together with plaque debris breaking off the artery
walls and traveling to the brain, are the primary causes of stroke.
While peripheral vascular disease is most common in the arterial side where arteries carry
oxygenated blood to various organs, it can also occur on the venous side where veins carry blood
back to the heart and lungs. Peripheral venous disease is a general term for damage, defects or
blockages in the peripheral veins. Like peripheral artery disease, it can occur almost anywhere in
the body but is most often found in the arms and legs. The most common form of peripheral venous
disease is the formation of blood clots that block the flow of blood in the vessel. Clots that
occur in veins close to the surface of the skin are referred to as superficial venous
thrombophlebitis, while clotting of veins deep within the body are called deep vein thrombosis.
Treatment options for blood clots in the veins are similar to those used to treat clots in
arteries.
Peripheral Vascular Market
According to the American Heart Association, or AHA, peripheral vascular disease, including
peripheral artery disease, affects approximately eight million people in the United States. Primary
risk factors associated with peripheral vascular disease are diabetes and smoking. Other
significant risk factors include advanced age, high cholesterol, high blood pressure, obesity and
physical inactivity. A family history of cardiovascular disease may also put individuals at higher
risk for peripheral vascular disease.
Approximately 20% to 30% of patients with peripheral arterial disease in the U.S. today are
undergoing treatment for the disease, according to the AHA. Underdiagnosis is due in large part to
the fact that over one-half of the peripheral vascular disease population does not display classic
symptoms of the disease. In addition, others dismiss their symptoms as part of the normal aging
process or attribute them to another cause.
Over the next several years, we expect to see continued growth in the peripheral vascular disease
patient population, driven by three specific trends: growing prevalence of the disease, increased
diagnosis rate and approximately 6% to 8% growth in the use of endovascular treatments for
infrainguinal peripheral artery disease. While today only approximately 25% of patients with
peripheral vascular disease are diagnosed, we believe that the following factors are contributing
to a growing diagnosed peripheral vascular disease patient population:
|
|
|
Increased Awareness. Recent emphasis on peripheral vascular disease education from
medical associations, insurance companies and online medical communities, as well as
publication in medical journals, is increasing public and physician awareness of
peripheral vascular disease risk factors, symptoms and treatment options. The Legs for
Life®, P.A.D. Peripheral Arterial Disease Coalition, and Save a Leg Save a Life
FoundationTM are examples of organizations working to increase the awareness
and screening |
4
|
|
|
for peripheral arterial disease. The American Diabetes Association, or ADA, recommends that
all diabetics over the age of 50 be screened for peripheral vascular disease. |
|
|
|
|
Evolving Physician Practice Patterns. Given that many patients with coronary artery
disease also have peripheral vascular disease, we believe that interventional
cardiologists and vascular surgeons are increasingly screening patients for both diseases.
As a consequence, we believe that physicians are diagnosing more cases of peripheral
vascular disease. In addition, heightened awareness of peripheral vascular disease, its
symptoms and treatment options is leading to increased referrals from general
practitioners, podiatrists who treat patients with pain and lesions in the feet that may
be caused by peripheral vascular disease, and nephrologists, diabetologists and
endocrinologists, who treat diabetics often experiencing complications resulting from
peripheral vascular disease. |
|
|
|
|
Increased Peripheral Vascular Disease Screening. Studies and medical articles have
advocated increased peripheral vascular disease screening by primary care physicians using
an ankle-brachial index, or ABI, a simple technique that compares blood pressure in a
patients foot to blood pressure in the patients arm to determine how well blood is
flowing to the foot. In addition to the ABI, physicians are increasingly using established
techniques, such as angiography and ultrasound, to either diagnose or confirm diagnosis of
peripheral vascular disease. |
Peripheral Vascular Disease Treatment Options
Peripheral vascular disease is treated depending upon the severity of the disease with either
non-invasive management, including lifestyle changes and/or drug treatment, for mild to moderate
peripheral vascular disease, or minimally invasive endovascular procedures or surgery for more
severe peripheral vascular disease.
Non-Invasive Management. For some patients, lifestyle changes and/or drug treatment may slow or
reverse the progression of peripheral vascular disease. Lifestyle changes include improving diet,
exercising regularly and quitting smoking. Although these adjustments can be effective, many people
are unable to maintain this new lifestyle. In addition to lifestyle changes, physicians often
prescribe medications that increase blood flow but do not treat the underlying obstruction. Pletal,
a commonly prescribed medication for claudication, should not be taken if the patient also has
heart disease, which often exists in peripheral vascular disease patients. In addition, physicians
often prescribe cholesterol-lowering drugs and drugs for high blood pressure. Patients generally
need to take the prescribed drugs for the rest of their lives.
Minimally Invasive Endovascular Procedures. Minimally invasive endovascular procedures for the
treatment of peripheral vascular disease consist primarily of angioplasty, stenting and
atherectomy, and to a lesser extent, other procedures, such as stents, angioplasty and atherectomy
combined with embolic protection devices, laser therapy, drug-eluting stents and vascular
cryotherapy. In angioplasty, a catheter with a balloon tip is inserted into the blocked or
narrowed part of the artery over a previously positioned guidewire that directs the catheter to the
affected area. The balloon is then inflated to compress the plaque and to stretch the artery wall,
thereby enlarging, or dilating, the opening of the vessel and restoring blood flow. Stenting is
often performed in tandem with angioplasty. Stents are tubular mesh devices typically consisting of
interconnected metal struts, which are inserted inside the artery to act as scaffolding in order to
hold the vessel open. Atherectomy is a procedure for opening up an artery by removing the plaque
that can block arteries throughout the body. It can be performed by various methods of inserting a
catheter into the artery. Plaque excision, a form of atherectomy, uses a tiny rotating blade to
shave away plaque from inside the artery. The plaque is collected in a reservoir nosecone located
at the tip of the device and is subsequently removed from the patient. Laser atherectomy uses a
laser beam to reduce the plaque to relatively small particles which are released in the
bloodstream. Rotational atherectomy uses a rotating shaver to sand the plaque to relatively small
particles which depending on the device are released into the bloodstream or aspirated back into
the device.
Other interventional treatments for peripheral vascular disease include:
|
|
|
stents, angioplasty and atherectomy combined with embolic protection systems, which
protect against plaque and debris from traveling downstream, blocking off the vessel and
disrupting blood flow; |
5
|
|
|
drug-eluting stents, where a stent is coated with a slow-to-moderate release drug
formulation intended to reduce restenosis, which occurs when the treated vessel becomes
blocked again; |
|
|
|
|
drug-coated balloons, where an angioplasty balloon is coated with a drug formulation
intended to reduce restenosis; and |
|
|
|
|
vascular cryotherapy, where an angioplasty balloon is inflated with nitrous oxide in an
attempt to reduce inflammation caused by treatment of the lesion. |
We estimate that in 2009 over 900,000 endovascular procedures to treat peripheral vascular disease
were performed in the United States.
Surgical Procedures. Surgery is used when non-invasive management or minimally invasive
endovascular procedures have failed or if the patient is diagnosed when the peripheral vascular
disease has progressed to an advanced state. The three main types of surgical procedures include
bypass surgery, endarterectomy and amputation.
In bypass surgery, the surgeon reroutes blood around a lesion using a vessel from another part of
the body or a tube made of synthetic fabric. Bypass surgery is not advisable for some patients
because of the inherent risks of surgery, the symptoms are not deemed to be critical enough to
warrant such an intervention, or the existence of other diseases. Bypass surgery has a high risk of
procedure-related complications from blood loss, post-procedural infection or reaction to general
anesthesia and may require patients to remain hospitalized for several days.
Endarterectomy involves the surgical removal of plaque. While endarterectomy is sometimes used, the
procedure is highly invasive and subjects the patient to the same procedural risks and
complications as bypass surgery. Endarterectomy is rarely used below the knee because the arteries
below the knee are generally too small to accommodate the procedure.
If CLI progresses to an advanced state, bypass surgery or endarterectomy may not be used. In this
case, physicians may amputate all or a portion of the limb.
Our Peripheral Vascular Product Portfolio
Our peripheral vascular product portfolio includes products for peripheral vascular procedures
which, in some instances, may also be used for selected cardiovascular procedures. Our strategy is
to provide a broad portfolio of products for the peripheral vascular market that includes devices
used in frequently performed procedures and also innovative devices for use in emerging therapies.
We opportunistically pursue selected cardiovascular markets where some of these products can be
used by our cardiologist customers. We do not compete in cardiovascular markets in which several
large companies are firmly entrenched, such as coronary stents. The increase in the breadth of our
portfolio of peripheral vascular devices has significantly expanded our participation in the
peripheral markets over the last few years. Our peripheral vascular product portfolio includes
atherectomy plaque excision products, stents, embolic protection and thrombectomy products, carotid
stenting solutions, PTA balloons and other procedural support products.
Atherectomy Plaque Excision Products
We offer atherectomy plaque excision products, which are designed to remove plaque from artery
walls in order to re-establish blood flow. Unlike most treatments for peripheral artery disease
that leave the plaque in the artery, atherectomy plaque excision products are designed to remove
the plaque, instead of compressing it against the vessel walls.
SilverHawk Plaque Excision System. The SilverHawk Plaque Excision System is a minimally invasive,
catheter system that treats peripheral artery disease by removing plaque in order to reopen
narrowed or blocked arteries. The SilverHawk uses a tiny rotating blade to shave away plaque from
inside the artery. It is the only currently available device that both allows the operator to
remove the disease and is directional during treatment. SilverHawk also
6
creates the largest vessel opening for blood flow of the currently available atherectomy devices.
The plaque is collected in a reservoir nosecone located at the tip of the device and is
subsequently removed from the patient. The SilverHawk is capable of removing significant amounts
of plaque without overstretching the artery, which could lead to dissection or perforation. Plaque
excision has helped alleviate severe leg pain for thousands of patients and in many cases has
successfully saved the legs of patients who were scheduled for limb amputation after other
peripheral interventions had failed.
The SilverHawk provides a treatment approach for peripheral artery disease that we believe offers
significant benefits, including:
|
|
|
Safety. The SilverHawk is designed not to stretch or damage the artery walls, which
can lead to dissection or perforation of the artery. The SilverHawk procedure is
minimally-invasive and typically performed under local anesthesia. Therefore, it does not
have many of the risks associated with more invasive surgeries and general anesthesia. To
date, we have not conducted studies designed to directly compare the safety of the
SilverHawk against alternative procedures, such as angioplasty, stenting or bypass
grafting. |
|
|
|
|
Efficacy. Unlike most treatments for peripheral artery disease that leave plaque
behind in the artery, the SilverHawk removes plaque. The SilverHawk has removed over 700
milligrams of plaque in a single procedure, with an average of approximately 100
milligrams of plaque per procedure. We believe that excising plaque without causing
stretch injury to the artery wall may minimize restenosis and the need for reintervention.
We also believe that the efficacy of the SilverHawk, measured by low 12-month
reintervention rates is supported by the results of five single site studies as well as
our TALON registry. In order to further evaluate the long term efficacy data of the
SilverHawk during endovascular treatment of peripheral arterial disease, we are conducting
the DEFINITIVE LE (Lower Extremity) Study, a prospective, multi-center, non-randomized,
single-arm study to evaluate the intermediate and long-term effectiveness of stand-alone
SilverHawk Plaque Excision for endovascular treatment of peripheral arterial disease in
femoropopliteal or tibial-peroneal arteries. The primary effectiveness endpoint for
patients with claudication is expected to be primary patency at one year as defined by
duplex ultrasound peak velocity ratio. The primary effectiveness endpoint for patients
with critical limb ischemia is amputation-free survival at 12 months. We commenced
enrollment for the DEFINITIVE LE Study during the second quarter of 2009. |
|
|
|
|
Ability to Treat Difficult to Treat Lesions. The SilverHawk enables physicians to
remove plaque from long, bifurcated and difficult to treat lesions in a wide variety of
locations, including arteries behind and below the knee and in the foot. Approximately
one-third of SilverHawk procedures to date have been performed below the knee, an area
where lesions have traditionally gone untreated until they require bypass surgery or
amputation. Certain treatment locations, such as arteries below the knee or in the foot,
are not suited for physicians with limited experience using the device. |
|
|
|
|
Utilizes Familiar Techniques. The SilverHawk procedure employs techniques similar to
those used in angioplasty, which are familiar to approximately 12,000 interventional
cardiologists, vascular surgeons and interventional radiologists in the United States who
are generally trained in endovascular techniques. This significantly increases the number
of physicians who are able to perform the procedure compared to surgical alternatives that
must be performed by highly-trained vascular surgeons. In addition, the SilverHawk was
designed to be easy to use. The SilverHawk operates with one switch that controls all
device functionality, and has a unique torque shaft designed for a one-to-one correlation
between the handle and the tip, providing physicians with precise control of the position
of the cutting blade. We continue to focus on providing further enhancements to the
SilverHawk as part of our research and development efforts. |
|
|
|
|
Cost and Time Efficient. A single SilverHawk device can be used to treat multiple and
long lesions where more than one stent might otherwise be required. Compared to surgical
alternatives, the SilverHawk procedure reduces cost by allowing physicians to treat
patients in a catheterization lab instead of an operating room, decreasing the length of
hospitalization and reducing complications. |
7
|
|
|
Allows for Follow-Up Treatment Options. Physicians can, and sometimes do, use
adjunctive angioplasty and occasionally stenting during a SilverHawk procedure. When the
SilverHawk procedure is performed without stenting, which we estimate is greater than 90%
of the time, increased future treatment options remain available in the event that
restenosis does occur and reintervention is required as there is no metal left behind post
procedure, as is the case with stenting. |
|
|
|
|
Captures and Removes Plaque. The patient and the physician get immediate feedback by
seeing the volume of plaque removed, visibly reinforcing the benefits of the procedure. |
In the United States, the SilverHawk is approved for use in the peripheral vasculature. This means
that our product may not be marketed in the United States for use in the heart, brain or in
specific peripheral anatomy without additional clearances from the FDA. In the United States, the
SilverHawk is contraindicated, and should therefore not be used, for in-stent restenosis, which is
restenosis after the use of stents, or for use in the carotid, iliac and renal arteries.
The SilverHawk family of products includes MEC (Micro Efficient Compression) Technology, a novel
advancement which features precision laser-drilled vent holes in the tip of the catheter. These
micro vent holes release fluid pressure, providing more space for the collection of tissue in the
tip of the device. This technology has the potential to reduce overall procedure time by enabling
physicians to increase tissue collection during plaque removal procedures in large vessels above
the knee.
The SilverHawk family of products also includes several different catheters, which enable the
treatment of both calcified and non-calcified lesions of any length, pending the specific device
indication. The catheters vary in diameter to treat a wide range of peripheral vessel sizes. The
devices also vary in tip length to accommodate lesions with heavier or lighter plaque burden.
TurboHawk Plaque Excision System. During third quarter of 2009, we announced the U.S. launch of
the TurboHawk Plaque Excision System for surgical use. The TurboHawk features four angled, Super
Cutter blades that are designed to increase the efficiency of directional plaque excision for above
the knee interventions, including severely calcified lesions in varying vessel diameters for which
very limited options are available to date. In November of 2009, the TurboHawk Plaque Excision
System was cleared for endovascular use in mild to moderate calcium. We also received FDA approval
to include the TurboHawk in our DEFINITIVE Ca++ IDE study. We have expanded availability for
the TurboHawk Plaque Excision System to international markets and plan to launch the TurboHawk
Plaque Excision System for below the knee use in the second half of 2010.
Stents
Although our stents, like most of our competitors stents, have been approved by the FDA for the
palliative treatment of malignant neoplasms in the biliary tree, even though not promoted or
marketed for such use, they are used by physicians not only in the biliary duct, which transports
bile from the liver and gall bladder to the small intestines, but also off label in various other
locations in the body, including renal arteries, which transport blood from the aorta to the
kidneys; iliac, femoral and popliteal arteries, which are major arteries in the legs and subclavian
arteries, which are major vessels of the upper body, originating at the aortic arch. We believe
that our portfolio of self-expanding stents is differentiated from our competitors offerings due
to their fracture resistance, flexibility and lengths, and that both our self-expanding and balloon
expandable stent platforms provide advanced radiopacity (visibility under fluoroscopy), placement
accuracy, deliverability and strong clinical performance.
Protégé EverFlex, Protégé GPS and Protégé GPS BIGGS. Our self-expanding stent portfolio includes
our Protégé EverFlex Self-Expanding Stent and our Protégé GPS Family of Self-Expanding Stents, all
of which are shape memory nitinol stents that expand to a predetermined diameter upon deployment.
Nitinol is a highly flexible metal with shape retention and fatigue resistance properties. We offer
a number of sizes of the EverFlex, Protégé GPS and Protégé GPS BIGGS stents. The EverFlex stent has
enhanced flexibility and resistance to fractures, which we believe provides superior performance in
vessels that are subjected to repeated flexing and bending. The EverFlex stent encompasses a
unique spiral cell geometry, which is constructed to withstand extreme movement.
8
We believe the design of our EverFlex stents is unique in that it features:
|
|
|
Spiral cell interconnections that greatly enhance flexibility; |
|
|
|
|
New wave peak structure that more efficiently distributes stress and resists
compression; and |
|
|
|
|
Longer lengths (up to 200 mm and all 6 French compatible), which minimize the need for
overlapping stents when treating long lesions. |
In October 2008, 12-month follow-up results were reported for our European DURABILITY I clinical
study, the worlds first prospective study to specifically test the efficacy and integrity of a
long stent in challenging femoral lesions. It is also the first study to specifically evaluate the
use of a single stent up to 15 centimeters long per patient. A total of 151 patents were treated
in 13 European centers. At 12 months follow-up, primary patency was 72%, which compares quite
favorably to other studies and was notable considering the average lesion length was almost 10
centimeters and 40% of the vessel were occluded. We are currently conducting our DURABILITY II
study in the U.S. with the objective of expanding our Protégé EverFlex Self-Expanding Stents
indication for use to include treatment of peripheral artery disease in the superficial femoral and
proximal popliteal arteries of the leg. Additionally, we have received conditional approval for
our PROVE-IT study in the U.S., which will study the use of both the Protégé EverFlex
Self-Expanding Stent and the Visi-Pro Balloon Expandable Stent in iliac arteries.
PRIMUS and Visi-Pro Balloon Expandable Stents. Our balloon expandable stent portfolio includes
stents that incorporate embedded tantalum markers to provide superior visualization under
fluoroscopy, allowing the physician to quickly confirm the correct placement. The inclusion of
markers is a unique feature in the balloon expandable stent market. We plan to evaluate in our
PROVE-IT study the use of both the Protégé EverFlex Self-Expanding Stent and the Visi-Pro Balloon
Expandable Stent in iliac arteries. To our knowledge, this will be the first study of its kind,
which evaluates the use of two different stent platforms in one study.
Embolic Protection and Thrombectomy Products
During peripheral vascular and cardiovascular procedures, plaque and debris may dislodge or
embolize, potentially blocking blood flow and damaging distal tissue. Embolic protection devices
are intended to trap plaque and debris from traveling downstream, blocking off the vessel and
disrupting blood flow. Similarly, thrombectomy devices are designed to remove blood clots, or
thrombus, in order to re-establish blood flow or to prevent a clot from breaking up and blocking
smaller downstream vessels. We offer thrombectomy tools for peripheral vascular and cardiovascular
procedures that meet a broad spectrum of physician needs, including the mechanical removal of
thrombus and the delivery of peripheral blood clot therapies designed to help dissolve the clot.
SpiderFX Embolic Protection Devices. The SpiderFX family of embolic protection devices are
low-profile devices featuring a unique braided nitinol embolic filter compatible with most
guidewires on the market. Filter-based embolic protection devices allow blood to continue flowing
in the artery while the filter traps the debris, minimizing downstream tissue damage and improving
clinical outcomes. We believe that the SpiderFX family has a significant competitive advantage
because it permits physicians to use their guidewire of choice, allowing improved durability and a
more efficient procedure. We believe the SpiderFX also exhibits superior trackability, enhanced
visibility and excellent stability.
The SpiderFX is indicated for use as a guidewire and embolic protection system to contain and
remove embolic material, such as thrombus or debris, while performing angioplasty and stenting
procedures in carotid arteries, as well as indicated for use as protection, while performing
percutaneous transluminal coronary angioplasty or stenting procedures in coronary saphenous vein
bypass grafts. We are currently conducting the DEFINITIVE Ca++ clinical study to evaluate the
safety and effectiveness of the SilverHawk with Calcium Tip (i.e. RockHawk and TurboHawk) Plaque
Excision System when used in conjunction with the SpiderFX Embolic Protection Device for capture,
containment and removal of excised plaque and embolic debris during endovascular treatment of
moderate to severely calcified peripheral arterial disease in the superficial femoral and/or
popliteal arteries. This study, if successful, should support approval for a combined RockHawk
and SpiderFX system, thereby expanding the
9
indication of the SpiderFX into the periphery. The SpiderFX is currently indicated for general
vascular use outside the United States.
Blood Clot Therapy Products or Infusion Catheters. Our blood clot therapy products include
flexible catheters with small holes that can allow for the delivery of drugs to help dissolve or
break up a clot. Referred to as infusion catheters, this form of treatment relies on various
pharmacologic agents to restore blood flow rather than physically removing or compressing the clot.
Carotid Stenting Solutions
Carotid artery stenting represents an emerging minimally invasive treatment option for carotid
artery disease. We believe it has the opportunity to become a significant alternative to carotid
endarterectomy, where a surgeon accesses the blocked carotid artery though an incision in the neck,
and then surgically removes the plaque. Endovascular techniques using stents and embolic protection
systems, which protect against plaque and debris from traveling downstream, blocking off the vessel
and disrupting blood flow, have been developed and are in an early stage of adoption. The use of a
stent with an embolic protection system avoids open surgery and we believe will increase the number
of patients being treated. In 2005, the Centers for Medicare & Medicaid Services, or CMS, expanded
reimbursement of percutaneous transluminal angioplasty of the carotid artery concurrent with stent
placement outside of trial settings for patients who are at high risk for carotid endarterectomy in
certain circumstances. Coverage is limited to procedures at CMS-approved facilities performed using
FDA-approved carotid artery stenting, or CAS, systems and embolic protection devices, which has
limited the CAS near-term market potential.
Our carotid stenting product offering (Protégé RX straight and tapered stents used together with
our SpiderFX embolic protection devices) are available in the United States, Europe and certain
other countries. In support of our FDA pre-market approval submission, we conducted the CREATE
Pivotal clinical trial, which was designed to evaluate the use of our carotid stenting technology
in patients who are high-risk candidates for carotid endarterectomy. We also have received FDA
510(k) clearance of our SpiderFX embolic protection device for use in carotid artery stenting in
conjunction with the Guidant RX ACCULINK stent. We are currently conducting the CREATE Post
Approval Study with the objective of further studying the Protégé GPS and Protégé RX Carotid Stent
Systems and SpiderFX in the treatment of carotid artery disease in subjects at high risk for
complications during surgical treatment of carotid artery disease.
PTA Balloons and Other Procedural Support Products
As part of our peripheral vascular marketing strategy, we market and sell a number of products to
be used in conjunction with our other peripheral vascular portfolio products, including balloon
angioplasty catheters, snares, microsnares, guidewires and other accessories.
Balloon Angioplasty Catheters. Balloon angioplasty catheters are designed to open up the vessel via
balloon dilation. In angioplasty, a catheter with a balloon tip is inserted into the blocked or
narrowed part of the artery over a previously positioned guidewire that directs the catheter to the
affected area. The balloon is then inflated to compress the plaque and to stretch the artery wall,
thereby enlarging, or dilating, the opening of the vessel and restoring blood flow.
In January of 2009, we globally launched our EverCross and NanoCross percutaneous transluminal
angioplasty (PTA) balloons. In the United Sates and internationally, these balloon catheters are
cleared for non-coronary dilatation of the vascular anatomy excluding the carotid arteries.
The EverCross is a PTA catheter system with 0.035 guidewire compatibility. We believe the design
of our EverCross PTA balloon is unique in that it features:
|
|
|
unmatched longer lengths (up to 200 cm) which allows a physician to use a single balloon
once (vs. a shorter length balloon multiple times); |
10
|
|
|
low tip entry and crossing profile optimizing the ability to cross tight lesions; and |
|
|
|
|
robust catheter shaft and flexible balloon design enhancing the ability to reach the
desired treatment area. |
The NanoCross is a PTA catheter system with 0.014 guidewire compatibility. We believe the design
of our EverCross PTA balloon is unique in that it features:
|
|
|
Bevel 360 technology optimizing the ability to cross tight lesions; |
|
|
|
|
catheter design providing optimal pushability and trackability to reach the target
vessel area of the diseased vessel; and |
|
|
|
|
increased inner diameter catheter lumen allowing for dramatically reduced deflation
times. |
In the first quarter of 2010, we launched our PowerCross PTA catheter system with 0.018 guidewire
compatibility.
Prior to January of 2009, we offered in the United States a portfolio of peripheral vascular
balloon angioplasty catheters, which we purchased from Invatec pursuant to a distribution
agreement, which expired on December 31, 2008. Our distribution agreement with Invatec allowed us
to continue distribution of our remaining inventory of these products through June 30, 2009.
Goose Neck Snares and Microsnares. Foreign objects can be retrieved from the vascular system by
using snares and other devices. Examples of foreign objects that require retrieval include broken
catheter or guidewire tips, as well as stents that are dislodged from their delivery system and
carried downstream. Our Goose Neck snares and microsnares incorporate a single, radiopaque (visible
under fluoroscopy) loop mounted at the tip of a guidewire. The loop is deployed and retrieved
through a catheter. We believe that our snares are unique because the loop remains positioned at a
90 degree angle relative to the wire. This increases the ability of the loop to encircle the
foreign object, thereby improving the rate of success of retrieval. Nitinol shaft technology used
in the wire provides kink resistance and durability. Our Goose Neck snares and microsnares are
available in a wide variety of sizes for optimal fit within the vessel. Our Goose Neck snares are
approved for use in the cardiovascular system or hollow viscus to retrieve and manipulate foreign
objects. Our Goose Neck microsnares are also approved for use in the retrieval and manipulation of
atraumatic foreign bodies located in the coronary and peripheral cardiovascular system and the
extra-cranial neurovascular anatomy.
Nitrex Guidewires. Guidewires are threaded through vessels as a first step in most endovascular
procedures. Balloon and stent catheters are advanced over guidewires to the target treatment area.
For this reason, they are an indispensable component in the catheterization laboratory. Our Nitrex
guidewires are characterized by both flexibility and kink resistance which are particularly useful
when negotiating tortuous vascular anatomy. Some interventional procedures demand a wire with
maximum lubricity, while others require enhanced purchase or ability to maintain placement in a
vessel. Our Nitrex guidewires offer the ability to maintain placement in the vessel and maximum
control through the procedure. Our proprietary manufacturing processes create a wire with a gently
tapered, continuous solid nitinol core that extends from the proximal end through the distal tip.
Gold tungsten coils provide excellent radiopacity for enhanced visualization and to ensure precise
navigation through the vasculature. Our Nitrex guidewires are versatile since they are available
in a variety of tip lengths and angles for broad applications and are used in a wide range of
endovascular procedures.
11
Our Neurovascular Markets
Neurovascular Disease and Strokes
The most devastating complication of neurovascular disease is stroke. A stroke usually occurs when
the flow of oxygen rich blood to the brain is suddenly interrupted. There are two types of stroke:
|
|
|
Ischemic stroke, which is caused by the blockage of an artery to the brain; or |
|
|
|
|
Hemorrhagic stroke, which is caused by a sudden rupture of a brain artery, leading to
bleeding into or around the brain. |
If either stroke is left untreated for more than a few minutes, brain cells may die due to the lack
of blood flow. Both forms of stroke may result in permanent brain damage or even death. Patients
who survive a stroke are often left with disabilities, including paralysis, coma, impaired
cognition, decreased coordination, loss of visual acuity, loss of speech, loss of sensation or some
combination of these conditions. A significant need for effective prevention and treatment of
stroke exists because of the severity of the disorder, its prevalence in society, the shortcomings
of current therapies and the high cost of treatment and care.
Ischemic strokes can be caused by several different kinds of disease, with the most common being a
narrowing of the arteries caused by atherosclerosis or gradual cholesterol deposits. If arteries
become too narrow, clots may form. There are two different types of ischemic stroke: thrombotic
(cerebral thrombosis) and embolic (cerebral embolism). A thrombotic stroke is the most common and
occurs when arteries in the brain become blocked by the formation of a clot within the brain. An
embolic stroke occurs when a clot or small piece of plaque formed in one of the arteries leading to
the brain, such as the heart or carotid artery, travels through the bloodstream to the brain where
it lodges in narrower brain arteries and blocks blood flow.
Transient ischemic attack, commonly referred to as a TIA, is a warning sign of the potential for a
future stroke. By definition, the symptoms of a TIA may last up to 24 hours, but they often last
only a few minutes. TIA occurs when the blood supply to part of the brain is briefly interrupted.
TIA symptoms are similar to those of stroke but do not last as long. Most symptoms of a TIA
disappear within an hour. About one-third of strokes are preceded by one or more TIAs that can
occur days, weeks or even months before a stroke.
Two common causes of hemorrhagic stroke are ruptures of cerebral aneurysms and arterio-venous
malformations, or AVMs. An aneurysm is a weakening of the vessel wall that forms a balloon-shaped
pouch, which fills with blood. Aneurysms typically grow over time and, due to pressure placed on
the wall of the aneurysm, are prone to rupture. Ruptured aneurysms can easily result in death as a
result of massive intracranial bleeding and loss of perfusion to the brain in the area affected by
the aneurysm rupture. Brain aneurysms are all different. They vary in size, shape and location.
Small aneurysms are less than 5 mm (1/4 inch) but can grow as large as 25 mm (11/4 inches) or more.
Aneurysms can be saccular (sac-like), with a well-defined neck, or saccular with a wide neck or
fusiform (spindle shaped) without a distinct neck. An aneurysm is usually located along the major
arteries deep within brain structures. Aneurysms can occur in the front part of the brain
(anterior circulation) or the back part of the brain (posterior circulation). If an aneurysm
ruptures, it leaks blood into the space around the brain. This is called a subarachnoid
hemorrhage. If the hemorrhage bleeds into the brain itself causing damage to the brain directly,
this results in a hemorrhagic stroke. Once an aneurysm bleeds, there is a 30% to 40% chance of
death, and a 20% to 35% chance of moderate to severe brain damage, even if the aneurysm is treated.
If the aneurysm is not treated quickly enough, another bleed may occur from the already ruptured
aneurysm.
In an AVM, the flow of blood between arteries and veins, which normally occurs through very small
capillary vessels, is short circuited by the development of a network of larger vessels directly
connecting the arteries and veins. The higher blood pressure flowing directly to the veins makes
these vessels highly prone to rupture. Although all blood vessel malformations involving the brain
and its surrounding structures are commonly referred to as AVMs, they are actually several types,
including: (1) a true arteriovenous malformation, which is the most common brain vascular
malformation and consists of a tangle of abnormal vessels connecting arteries and veins with no
normal intervening brain tissue; (2) an occult or cryptic AVM or cavernous malformation, which is a
vascular
12
malformation in the brain that does not divert large amounts of blood, but may bleed and often
produce seizures; (3) venous malformation, which is an abnormality only of the veins, which are
either enlarged or appear in abnormal locations within the brain; (4) hemangioma, which are
abnormal blood vessel structures usually found at the surface of the brain and on the skin or
facial structures and represent large and abnormal pockets of blood within normal tissue planes of
the body; and (5) dural fistula, which is an abnormal connection between blood vessels that involve
the covering of the brain called dura matter.
Neurovascular Market
According to the American Heart Association, there are approximately 795,000 strokes annually in
the United States, making stroke the third leading cause of death and a leading cause of long-term
disability. Acute ischemic stroke affects approximately 690,000 patients annually while hemorrhagic
stroke is a less common disorder, affecting approximately 105,000 patients per year in the United
States.
While an estimated 25,000 hemorrhagic stroke deaths in the United States in 2009 were caused by
ruptured cerebral aneurysms, autopsy studies suggest that unruptured aneurysms may exist in
approximately 1.5% to 6% of the general population in the United States. Annually, between 0.5% to
3% of people with a brain aneurysm may suffer from bleeding. If you have one aneurysm, there is a
15-20% chance that you have at least one or more additional aneurysms. It is unknown whether the
presence of multiple aneurysms affects their rupture rates. We believe that with the development of
new diagnostic and interventional technologies, the pool of patients that may benefit from
intervention will continue to expand to include increasing numbers of those with unruptured
aneurysms discovered in conjunction with other examinations.
It is estimated that in the United States, one in 200-500 individuals have an AVM in the brain.
About 5-10% of AVMs are discovered by accident while the individual is being tested for other
unrelated medical problems. Patients with AVMs may have additional vascular anomalies that
increase the complexity of treatment.
Treatment Options
Current interventional therapies serve primarily the hemorrhagic stroke market while some of the
recent developments are focused on the larger and
underserved ischemic stroke market.
Ischemic Strokes. Ischemic strokes are treated with either non-invasive management, including
lifestyle changes and/or drug treatment, surgery or minimally invasive endovascular procedures.
For some patients, lifestyle changes and/or drug treatment may slow or reverse the progression of
neurovascular disease. Lifestyle changes include improving diet, exercising regularly and quitting
smoking. Although these adjustments can be effective, many people are unable to maintain this new
lifestyle. In addition to lifestyle changes, physicians often prescribe medications, such as
clot-dissolving medications, anticoagulants or antiplatelet drugs. If used intravenously, therapy
with clot-busting drugs for the treatment of an ischemic stroke must be started within three hours
of the onset of ischemia. After that, the risks of bleeding or other complications from this type
of therapy begin to outweigh potential benefits. After three hours, these medications may
sometimes be given directly into the site of the clot (intra-arterial therapy). Anticoagulants,
often called blood thinners, such as warfarin, may be prescribed by physicians following a stroke.
By reducing the ability of the blood to clot, they may help to keep blood vessels open and
delivering oxygen and nutrients to brain cells. Antiplatelet drugs, such as aspirin, may be
administered during or immediately after a stroke to help prevent clot formation. While they work
differently from anticoagulants, the result is similar. They help to keep blood vessels open and
delivering oxygen and nutrients to brain cells.
The two main types of surgical procedures include bypass surgery or revascularization and
endarterectomy. In bypass surgery or revascularization, the surgeon reroutes blood around a lesion
using a vessel from another part of the body or a tube made of synthetic fabric. Bypass surgery is
not advisable for some patients because of the inherent risks of surgery, the symptoms are not
deemed to be critical enough to warrant such an intervention, or the existence of other diseases.
Bypass surgery has a high risk of procedure-related complications from blood loss, post-
13
procedural infection or reaction to general anesthesia and may require patients to remain
hospitalized for several days. Endarterectomy involves the surgical removal of plaque. While
endarterectomy in an internal carotid artery is sometimes used, the procedure is highly invasive
and subjects the patient to the same procedural risks and complications as bypass surgery. Carotid
endarterectomy could even trigger a stroke because the operation may dislodge clots or other
material that can then travel through the bloodstream and block an artery.
Minimally invasive endovascular procedures for the treatment of ischemic strokes currently utilize
several different medical device options. In such procedures, often a stent with an umbrella filter
is placed in the carotid artery. The stent helps keep the artery open and the filter catches blood
clots and prevents them from reaching the brain and causing a stroke. Sometimes snare-like devices
are used to access and remove blood clots. Another treatment option is a tiny corkscrew-shaped
device that is attached to a catheter, threaded to the clot, and used to snag the clot. The clot
is then drawn out through the catheter. In addition, the removal of blood clots from the cerebral
vasculature often utilizes aspiration catheters that promote recanalization.
Hemorrhagic Strokes. Hemorrhagic strokes are treated based upon the cause of the stroke.
The best treatment for an aneurysm depends upon many things, including whether the aneurysm has
ruptured or not. If an aneurysm has not ruptured, the treatment decision depends upon its size,
location and shape, and the patients symptoms. Small, unruptured aneurysms that are not creating
any symptoms may not need treatment unless they grow, trigger symptoms or rupture. A ruptured
aneurysm usually requires treatment right away, because the re-bleeding rate remains quite high.
However, the treatment time and options for treatment depend upon the size, location and shape of
the aneurysm, as well as the patients overall medical condition.
Depending on an individuals risk factors, surgical clipping, a microsurgery, of an aneurysm may be
recommended. In this procedure, patients are placed under general anesthesia, an opening is made
in the skull, the brain tissue is spread apart, and the aneurysm is surgically exposed. The
neurosurgeon then places a surgical clip around the aneurysms base. The clip seals off the
aneurysm so blood cannot enter. Possible complications from surgical clipping include infection at
the incision site, rupturing the aneurysm during surgery and damage to the artery and bleeding into
the brain which could result in brain damage. As with other surgical procedures, the anesthesia
used during the procedure also has risks.
Driven by rapid advances in device technology and results from the International Subarachnoid
Aneurysm Trial, or ISAT, the results of which were published in The Lancet in October of 2002, the
treatment of aneurysms, as well as AVMs, has been shifting from open surgical techniques, such as
surgical clipping, to minimally invasive, endovascular techniques, such as embolic coiling. The
ISAT was an independent, randomized clinical trial involving 2,143 patients in Europe, North
America and Australia that compared aneurysm clipping with embolic coiling as a method of treating
cerebral aneurysms. The trial concluded, based on a survey of patients participating in the trial,
endovascular intervention with detachable platinum coils resulted in a 23% relative and 7% absolute
reduction in the risk of major brain injury or death compared with neurosurgical clipping of the
aneurysm at one-year follow up. The seven-year follow up data published in The Lancet in September
2005 indicated a continued clinical advantage for patients who underwent coiling versus clipping
procedures. The market transition to endovascular techniques, such as embolic coiling, has been
more rapid in geographies outside of the United States. The primary endovascular procedure for
treating both aneurysms and AVMs uses a repair technique called embolization, the objective of
which is to induce a blood clot, or thrombus, in the diseased vasculature. The purpose of the
thrombus is to limit blood flow through the diseased vascular anatomy, thereby reducing blood
pressure and flow to a ruptured area or the likelihood of rupture in an unruptured area.
The endovascular embolization of cerebral aneurysms usually involves the deployment of small coils
composed of metal or a combination of metal and polymer. We believe that embolic coils represent
one of the largest categories of products in the neurovascular device market and were used in over
70,000 procedures worldwide in 2009. Embolic coils are used in virtually all endovascular
treatments of aneurysms and in some AVMs. During a coiling procedure, the physician accesses the
femoral artery through a tiny incision in the groin or inner thigh where a tiny hollow tube or
sheath is inserted into the artery wall to allow the introduction of a catheter which is inserted
and guided by a guidewire and with the use of computer-aided X-ray scanners through the artery and
up towards the brain. Once the catheter is in place, the guidewire is removed, leaving the
catheter in place. A contrast dye is introduced via the catheter into the bloodstream in order to
make the artery and the aneurysm clearly visible and to
14
aid in obtaining clear radiographic images. A microcatheter is then introduced through the larger
catheter and used to deliver coils through the neck and into the sac of the aneurysm. The coils
are approximately twice the thickness of a human hair and there are several types of coils which
vary in shape, pliability and levels of softness. They are attached to the end of the
microcatheter. The coils placed are generally of progressively smaller sizes. They are
individually placed and often detached from the microcatheter by a small electric current or a
mechanical detachment mechanism. Within the microcatheter the coils are straight but, after
placement in the aneurysm, they bend in a helix shape and conform to the shape of the aneurysm
walls. This process is repeated until approximately 35% to 45% of the volume of the aneurysm is
filled with coils. The coils then form a mesh similar to steel wool. Eventually, blood cells are
caught and clot on the mesh in a process called thrombosis, effectively filling and sealing off
the aneurysm from the artery circulation. The procedure requires a high level of precision and
skill to avoid either under or over-filling the aneurysm, since over-filling may cause rupture or
painful pressure on adjacent tissue and under-filling may permit the aneurysm to reform or grow.
Balloon-assisted coiling involves a tiny balloon catheter which covers the neck or entrance to the
aneurysm, holding the coils in place. Stent-assisted coiling involves a small cylindrical mesh
tube which acts as scaffolding along the neck of the aneurysm to hold the mass of coils in place.
The development of supple, more flexible stents and balloons has allowed stent-assisted and
balloon-assisted coiling of irregular fusiform and wide-necked aneurysms in some cases. Coiling
does not involve surgically opening the head and may be done under local or general anesthesia.
Possible complications include rupture of the aneurysm during treatment and damage to the artery
and bleeding into the brain which could result in brain damage, as well as risks from the
anesthesia. However, because coiling is a less invasive procedure than surgical clipping and
results in lower treatment costs, shorter recovery times and less trauma to the patient, it has
become a widely accepted treatment for aneurysms.
Embolic coiling, however, is not as effective in treating large and giant, wide-neck or
non-saccular aneurysms. In addition, incomplete aneurysm occlusion and recurrence are major
shortcomings of embolic coiling, as well as other current therapy options. An alternative
treatment to coiling or one that could be used in conjunction with coiling is flow diversion. Flow
diversion represents a new class of cerebral embolization device that is designed to divert blood
flow away from an aneurysm in order to provide a complete and durable aneurysm embolization while
maintaining patency of the parent vessel. Although flow diversion devices are used in certain
European countries to treat aneurysms, they have not yet gained regulatory approval in the United
States.
The best treatment for an AVM depends upon what type it is, the symptoms it may be causing, its
location and size and whether the AVM has bled before. If there are no symptoms or almost none, or
if an AVM is in an area of the brain that cannot be easily treated, no medical intervention may be
recommended. Instead, the person is often advised to simply avoid any activities that may
excessively elevate blood pressure, such as heavy lifting or straining, and avoid blood thinners,
like warfarin. If an AVM has bled, there is an increased risk that it will bleed again thus
prompting a more aggressive approach to treatment. If the AVM is located in an area that can be
easily operated upon, then surgical resection, or removal, may be recommended. An AVM that is not
too large, but is in an area that is difficult to reach by regular surgery, may be treated by
performing stereotactic radiosurgery. In this procedure, a cerebral angiogram is done to localize
the AVM and focused-beam high energy sources are then concentrated on the brain AVM to produce
direct damage to the vessels that will cause a scar and allow the AVM to clot off. Finally, as
with aneurysms, minimally invasive, endovascular techniques are increasingly being used to treat
AVMs and may be used in conjunction with surgical resection or radiosurgery. In such procedures, a
catheter is placed inside the blood vessels that supply the AVM, and the abnormal blood vessels are
intentionally blocked to stop blood flowing to the AVM with a variety of different materials, such
as liquid glues, liquid polymers or other very small polymer particles, microcoils and other
materials.
Our Neurovascular Product Portfolio
Our neurovascular product portfolio includes embolic coils, flow diversion and restoration devices,
liquid embolics, flow directed and other micro catheters, occlusion balloon systems, guidewires,
neuro stents and retrieval devices.
Embolic Coils
Our embolic coil products are delivered using a combination of our minimally invasive guidewires,
microcatheters, stents and balloons. During an aneurysm procedure, the embolization coils are
attached to a hypotube and are passed
15
through a delivery catheter into the aneurysm space. The coil is then detached from the hypotube,
the hypotube is removed and the next coil is advanced through the catheter.
Axium Detachable Coil System. We launched our Axium Detachable Coil System on a worldwide basis in
the fourth quarter of 2007. During the fourth quarter of 2009, we concluded our physician
preference testing for two new versions of the Axium coil, the Axium PGLA and Axium Nylon
microfilament coils, in the U.S. and Europe and are in the process of launching these products for
broad commercial availability. Our Axium coils are intended for the endovascular embolization of
intracranial aneurysms and the embolization of other neurovascular abnormalities, such as AVMs and
arteriovenous fistulae. They are also indicated for use in the European Union for the treatment of
peripheral vascular abnormalities. We designed our Axium coils in an effort to meet the
performance criteria of a diverse group of leading neurosurgeons and interventional
neuroradiologists. Unique features and benefits of our Axium coils include:
|
|
|
a high degree of coil conformability, which facilitates the physicians goal of more
easily and completely filling and packing the aneurysm, regardless of its shape and size; |
|
|
|
|
coil softness combined with stretch resistance, which allows the coil to be positioned
or re-positioned within the aneurysm without adding to the risk of bleeding or hemorrhagic
stroke; |
|
|
|
|
ease of coil placement though the microcatheter, providing the physician with enhanced
control and deliverability; and |
|
|
|
|
rapid, safe and simple detachment of the coil through a proprietary, micro-machined
mechanical detachment system that offers instantaneous coil detachment without the use of
wires or syringes. This facilitates precise and rapid coil deployment thereby minimizing
procedure time, which may be especially important in a ruptured aneurysm or when blood
flow to the brain has been restricted. |
Nexus Embolic Coils. We also offer our Nexus line of coils in the United States and international
markets, including our latest addition to the Nexus family, the Nexus Morpheus. Our Nexus coils
are intended for the endovascular embolization of intracranial aneurysms that because of their
morphology, their location or the patients general medical condition are considered by the
treating neurosurgical team to be very high risk for management by traditional operative techniques
or inoperable. Our Nexus coils are also intended for the embolization of other neurovascular
abnormalities, such as AVMs and arteriovenous fistulae. Our Nexus line of coils consists of
framing, filling and finishing coil offerings, allowing physicians to treat a wide range of
aneurysm shapes and sizes. All Nexus coils incorporate a nitinol filament, which offers improved
shape retention and increased resistance to coil compaction. Nexus also incorporates a bioactive
microfilament technology to enhance aneurysm healing. The Morpheus is a three-dimensional soft and
conformable coil that does not sacrifice the compaction resistance
inherent with the nitinol core.
NXT. We also offer our older generation NXT line of detachable coils in the United States and
international markets. The NXT family includes framing, filling and finishing coils and are sold in
a wide range of shapes and configurations. Many of the NXT products incorporate the use of nitinol
technology, resulting in less stretching for more confident positioning and better resistance to
compaction, while its enhanced shape memory provides a more supportive basket and optimal bridging
of the neck of the aneurysm, compared to coils without nitinol.
Flow Diversion Devices
Pipeline Embolization Device. As a result of our acquisition of Chestnut Medical Technologies,
Inc. in June of 2009, we market and sell the Pipeline Embolization Device in Europe and on a
limited basis in other international markets such as Canada,
Australia and the Middle East and are in the process of
conducting two clinical studies under U.S. FDA investigational device exemptions (IDE) to gain
approval for the Pipeline Embolization Device in the United States. Our Pipeline Embolization
Device is a new class of cerebral embolization device that is designed to divert blood flow away
from an aneurysm in order to provide a complete and durable aneurysm embolization while maintaining
patency of the parent vessel. The Pipeline Embolization Device is a self-expanding,
microcatheter-delivered, cylindrical mesh device composed of individual braided cobalt chromium and
platinum strands. Multiple devices
16
can be deployed within each other (telescoped) to create a composite endovascular construct. The
degree of metal surface area coverage can be manipulated by varying the technique of device
deployment, as well as by choosing the number of overlapping devices placed in a particular
vascular segment. Because the Pipeline Embolization Device reconstructs the entire length of the
treated parent vessel, it has proven effective despite the neck width of the aneurysm, large or
giant size, or the presence of intra-aneurysmal thrombus. The flexibility of the Pipeline
Embolization Device allows it to be delivered and used in tortuous anatomy and because it is an
intravascular as opposed to intrasaccular therapy, the device can be used to treat even thin
walled aneurysms.
In a trial known as the PITA trial, 31 patients at four study sites received the Pipeline
Embolization Device for the treatment of difficult-to-treat intracranial aneurysms. All patients
had either wide-necked saccular aneurysms or aneurysms that had failed to respond to previous
endovascular coiling. The average aneurysm size was 11.5 mm, with an average neck width of 5.8 mm;
thus, the study was predominantly one of large, wide-necked aneurysms. Overall, the device was
delivered successfully in 100% of the cases, with a 6% rate of periprocedural complications (two
strokes, no deaths). At 6-month follow-up, 28 of 30 lesions (93%) available for evaluation
demonstrated complete angiographic occlusion.
PUFS and COCOA are two clinical studies we are currently conducting under IDEs from the FDA. These
studies are investigating the use of the Pipeline Embolization Device in the treatment of
uncoilable aneurysm and coilable aneurysm, respectively. We expect to submit the results of the
PUFS study to the FDA in first quarter of 2010. Outside of these clinical studies, there
is commercial use of the Pipeline Embolization Device in our international markets as well as
compassionate use cases within the United States.
Liquid Embolics
We estimate that liquid embolics were used in approximately 15,000 worldwide neurovascular
procedures in 2009, including the majority of AVM and some aneurysm procedures. One embolization
technique for AVMs involves the injection of acrylic-based glue. We believe, however, that glues
have multiple drawbacks including the lack of controlled delivery and extreme adhesion to all
surfaces, including that of the delivery catheter. Glue solidifies upon contact with blood which
reduces physician control during filling and necessitates very rapid withdrawal of the delivery
catheter in order to avoid it being permanently glued in place. We believe our Onyx Liquid Embolic
System is a superior solution to glue.
Onyx Liquid Embolic System. Onyx is our proprietary biocompatible copolymer which is delivered, in
liquid form, through proprietary microcatheters to blood vessels in the brain, where it fills a
vascular defect and transforms into a solid polymer cast. Onyx offers a unique form, fill and seal
approach to the interventional treatment of aneurysms and AVMs associated with hemorrhagic stroke.
Because Onyx is non-adhesive, and solidifies over a few minutes time, the injection and filling of
the vascular defect can take place in a very controlled manner. When the vascular defect is
completely filled with the Onyx polymer cast, the delivery catheter is removed. We believe our
randomized clinical trial revealed that Onyx was at least as effective as acrylic-based glue in
filling aneurysms, had a better percentage reduction in AVMs and resulted in the use of fewer
coils. In addition to providing a controlled and measured delivery, other benefits of Onyx include
the soft malleable cast for ease of surgical resection and enhanced radiopacity for bright
visualization of material.
In April of 2007, we received Humanitarian Device Exemption, or HDE, approval from the FDA for our
Onyx HD 500 Liquid Embolic System for the treatment of intracranial aneurysms. This approval
allows us to commercialize our Onyx Liquid Embolic System to a population of patients with
wide-necked cerebral aneurysms. The approval is limited to saccular, sidewall aneurysms with a
dome to neck ratio less than 2 millimeters that are not amenable to treatment with surgical
clipping.
17
Flow Directed and Other Micro Catheters
We market several micro catheters that are intended to allow access to, and treatment in,
difficult-to-reach anatomical locations such as the remote vessels in the brain or other
challenging vascular structures. In addition to their use with our embolic coils and liquid
embolics, these products are compatible with, and are often used with, our competitors products.
UltraFlow and Marathon Flow Directed Micro Catheters. The UltraFlow Flow Directed Micro Catheter
and Marathon Flow Directed Micro Catheter are intended to access the peripheral and neuro
vasculature for the controlled selective infusion of physician-specified therapeutic agents, such
as embolization materials and of diagnostic materials, such as contrast media. The UltraFlow micro
catheter is specifically designed to enable access to distal locations and to allow super-selective
vessel positioning. The Marathon is an improved flow directed micro catheter that contains both a
nitinol braid and a stainless steel helical wire, which improves navigability while retaining
pushability and tip softness. We believe that both the UltraFlow and Marathon micro catheters
provide excellent trackability over a wire.
Echelon and Pre-shaped Echelon Micro Catheters. Using a unique blend of materials and construction,
our Echelon family of over-the-wire micro catheters provide what we believe to be one of the
largest inner channels in its class while still enabling the physician to access difficult anatomy
and deliver a wide range of coils. The pre-shaped Echelon catheter represents a key line extension
for our Echelon family of products, and offers improved navigation, deliverability and stability.
Other Micro Catheters. We also market several other micro catheters, including the Rebar
Reinforced Micro Catheter which is designed to deliver a wide variety of pharmacologic, diagnostic
and therapeutic agents, including detachable coils and the Onyx Liquid Embolic System, and the
Nautica Micro Catheter, which is an over-the-wire micro catheter designed to deliver detachable
coils. In addition, we have recently developed the Apollo microcatheter. This unique
microcatheter is specially designed with a detachable tip for the delivery of the Onyx Liquid
Embolic System.
Occlusion Balloon Systems
HyperForm and HyperGlide Occlusion Balloon Systems. Our HyperForm and HyperGlide Occlusion Balloon
families are highly flexible balloons designed for use in blood vessels where temporary occlusion
is desired. They are useful in selectively stopping or controlling blood flow, and are capable of
accessing small diameter and tortuous vessels. Accordingly, they may be used to control blood flow
to remote sites to allow for embolization treatment of vascular abnormalities such as aneurysms.
Guidewires
Hydrophilic Guidewires. Our portfolio of neurovascular guidewires includes the Mirage Hydrophilic
Guidewire. This guidewire is designed for precise torque control and is compatible with several
sizes of flow-directed and over-the-wire micro catheters. It assists the physician in micro
catheter navigation and remote vessel access while providing a flexible and shapeable tip. Its
durable coating allows it to glide through tortuous vasculature. Other hydrophilic guidewires
include the SilverSpeed, Meridian, X-Pedion and the X-Celerator.
Neuro Stents
Solitaire AB Neck Bridging Device. Stenting is of increasing importance in the aneurysm and
ischemic stroke markets. The Solitaire is a self-expanding nitinol stent, for use in bridging the
neck of aneurysms to facilitate more secure coil placement. The
Solitaire AB device is fully retrievable before detachment, allowing
for more precise placement and if required, replacement of the stent
is possible. Solitaire AB is available in
our international markets.
Solitaire FR Revascularization Device. In July of 2009, we received a CE mark for the
neurovascular use of the Solitaire FR Revascularization Device. We have initiated commercialization
of the Solitaire platform outside the United States. Solitaire FR is used to immediately restore
blood flow and assist in the removal of clot burden and
18
with intracranial stenotic disease where vessels within the brain become narrowed. Solitaire FR
products are fully retrievable, allowing for more precise placement and if required, replacement of
the stent is possible.
Retrieval Devices
Endovascular retrieval devices are used in intravascular foreign body retrieval procedures.
Examples of foreign objects that require retrieval include misplaced coils, broken catheter or
guidewire tips, as well as stents that are dislodged from their delivery system and carried
downstream.
Alligator Retrieval Device. Our Alligator Retrieval Device is a dedicated microforceps which allows
intravascular access and retrieval of foreign objects. The Alligator Retrieval Device consists of
four small microprecision grasping arms mounted on a flexible microguidewire and is used with a
standard 0.21 mm microcatheter. Once the system is advanced adjacent to the foreign body, the
microguidewire is held in place and its atraumatic gripping arms are deployed by withdrawing the
microcatheter. The Alligator Retrieval Device has been specifically designed and indicated for use
in the peripheral and neurovasculature for foreign body retrieval.
Sales, Marketing and Distribution
Structure and Strategy
We have dedicated substantial resources to establish a direct sales capability in the United
States, Canada, Europe, Australia and other countries as well as establishing distribution networks
in selected international markets. We believe our global presence enables us to embrace and
capitalize on the growing market for endovascular devices that exists outside of the United States.
In addition, our global strategy allows us to commercialize technologies internationally while
pursuing regulatory approval in the United States, increasing near-term sales and helping us refine
our commercialization strategies in anticipation of product launches in the United States.
Individuals in our sales organization generally have substantial medical device experience and are
responsible for marketing our products directly to a variety of specialists engaged in endovascular
therapies. Our direct sales representatives provided 84% and 86% of our net sales in 2009 and 2008,
respectively, with the balance generated by independent distributors who represent us in certain
international markets.
As of December 31, 2009, our global endovascular marketing team was comprised of approximately 54
individuals covering product management, corporate communications and education and training. We
devote significant resources to training and educating physicians in the use and benefits of our
products. In the United States, we instruct our employees, including our sales professionals, not
to discuss the use of our products outside of the FDA-approved indication. If unsolicited questions
are posed by physicians, we inform them of the approved use of our products. Although we do not
promote or market our products for off-label uses, physicians may choose to use our products as
they see fit, including outside of the FDA-approved applications. For example, although our stent
products are approved in the United States for use in the biliary duct, as are most competing
peripheral stent systems in the United States, some physicians choose to use the stents in
peripheral vessels. If the FDA concludes, however, that we promote our device for such off-label
uses or that our promotional activities otherwise fail to comply with the FDAs regulations or
guidelines, we may be subject to warning letters from, or other enforcement action by, the FDA or
the U.S. Department of Justice.
United States
As of December 31, 2009, we had 114 direct sales representatives selling our peripheral vascular
products and 25 direct sales representatives selling our neurovascular products in the United
States. Our U.S. sales force is organized by geographic sales territories, and each territory is
managed by a district sales manager, or direct sales representative, who acts as the primary
customer contact. Our regional sales managers supervise the district sales managers and also focus
on maintaining key customer relationships.
During 2009, we replaced several U.S. peripheral vascular territory and referral manager positions
with several newly created SilverHawk specialist positions. As of December 31, 2009, we had 36 of
the Hawk Specialists.
19
These Hawk Specialists partner with each of our regions to drive focused selling and clinical
case support for our plaque excision business.
In August of 2007, we were awarded three, three-year contracts by Novation, the health care
contracting and services company of VHA Inc. and the University HealthSystem Consortium covering
our peripheral interventional, thrombus management and neuro interventional products. In March of
2007, we were awarded a single-source, new technology agreement by Novation for our Onyx Liquid
Embolic System. In January of 2009, we were awarded a one-year contract by Premier, a healthcare
purchasing network, covering our self-expanding and balloon-expandable stent line. All of these
group purchasing organization contracts are up for renewal during 2010.
Europe, Canada and Australia
Our direct selling organization in Europe has a presence in Austria, Belgium, Denmark, Finland,
France, Germany, Italy, Luxembourg, the Netherlands, Norway, Poland, Spain, Sweden, Switzerland and
the United Kingdom. As of December 31, 2009, our European sales team had 67 direct sales
representatives, including 38 selling our peripheral vascular products, 24 selling our
neurovascular products and five selling both.
We also sell our products in Canada and Australia through a four and one person direct sales force,
respectively, as of December 31, 2009.
Other International
In the major markets of Asia Pacific, Latin America, Eastern Europe and the Middle East, we sell
our products through distributors. In addition to sales, these distributors are involved in product
launch planning, education and training, physician support and clinical trial management. Through
dedicated distributors and several sales managers and support professionals, we have a sales
presence in all major other international markets, including Brazil, Argentina, Singapore, Japan
and China.
Manufacturing
We currently have a manufacturing facility located in Plymouth, Minnesota, at which we manufacture
most of our peripheral vascular products, and a manufacturing facility located in Irvine,
California, at which we manufacture most of our neurovascular products and a few of our peripheral
vascular products. As a result of our acquisition of Chestnut, we also have a manufacturing
facility in Menlo Park, California, where we manufacture our flow diversion and foreign retrieval
neurovascular devices. In order to streamline our operations and improve efficiencies, we
relocated the sales, manufacturing and research and development activities performed in our former
Redwood City, California facility to our existing facilities located in Plymouth and Irvine. We
manufacture our products at facilities in a controlled environment and have implemented quality
control systems as part of our manufacturing processes. We believe we are in material compliance
with FDA Quality System Regulations for medical devices, with ISO 9001 quality standards and
applicable medical device directives promulgated by the European Union and Canada and ISO/EN 13485,
which facilitates entry of our products into the European Union and Canada. The FDA and European
Union competent authorities have recently inspected our manufacturing facilities and found no
significant issues. We rely on independent manufacturers for certain product components and
processes. On an ongoing basis, to improve yields and cycle times, we are investing in developing
internal capabilities and applying lean manufacturing concepts at all of our manufacturing
facilities.
Research and Development
Our research efforts are directed toward the development of new endovascular products that expand
the therapeutic alternatives available to physicians, and improvements to and extensions of our
existing product offerings. Our product development process incorporates teams organized around
each of our core technologies, with each team having representatives from research and development,
marketing, regulatory, quality, clinical affairs and manufacturing. Consultants are used when
additional specialized expertise is required.
20
Our research and development team has a demonstrated record of new product initiatives and
significant product improvements. Specific product improvement initiatives have included:
|
|
|
broadening acquired technologies in order to address a larger share of the target
markets; |
|
|
|
|
incorporating important features which we believe appeal to the physicians who use our
products; and |
|
|
|
|
leveraging core technologies to develop new product platforms and enter new markets. |
Our research and development expenditures were $49.1 million in 2009, compared with $48.8 million
and $48.4 million in 2008 and 2007, respectively. Our research and development costs include
traditional research and development expenses as well as the cost of our clinical studies.
Clinical Studies
We support many of our new product initiatives with clinical studies in order to obtain regulatory
approval and new indications and provide demonstrated medical evidence and best practices on our
technologies. The goal of a clinical trial is to meet the primary endpoints, which measures the
clinical effectiveness and safety of a device and is the basis for FDA or other regulatory
approvals. Primary endpoints for clinical trials are selected based on the intended benefit of the
medical device. Although clinical trial endpoints are measurements at an individual patient level,
the results are extrapolated to an entire population of patients based on clinical similarities to
patients in the clinical trials.
We continually evaluate the potential financial benefits and costs of our clinical trials and the
products being evaluated in them. If we determine that the costs associated with attaining
regulatory approval of a product or new indication exceed the potential financial benefits of that
product or new indication, or if the projected development timeline is inconsistent with our
investment horizon, we may choose to stop a clinical trial and/or the development of a product.
The following tables summarize our key current and planned clinical trials.
Peripheral Stent Clinical Trials:
|
|
|
|
|
|
|
Trial |
|
Product |
|
Study Design |
|
Status |
PROVE-IT (Global)
|
|
EverFlex stent,
Protégé GPS stent
and Visi-Pro stent
|
|
Prospective,
multi-center,
global study to
evaluate the safety
and effectiveness
of primary stenting
for the treatment
of iliac lesions
|
|
Enrollment
anticipated to
begin in the second
half of 2010 |
|
|
|
|
|
|
|
|
|
|
|
Protocol currently
under development |
|
|
|
|
|
|
|
|
|
DURABILITY II (Global)
|
|
EverFlex Stent
|
|
Prospective,
multi-center,
non-randomized
study to evaluate
the safety and
effectiveness of
the primary
stenting compared
to PTA performance
goals for the
treatment of SFA
lesions
|
|
Enrollment and
follow-up
continuing |
|
|
|
|
|
|
|
|
|
|
|
Primary safety
endpoint of 30-day
major adverse event |
|
|
|
|
|
|
|
|
|
|
|
|
|
Primary
effectiveness
endpoint of
12-month patency by
duplex |
|
|
21
Plaque Excision Clinical Trials:
|
|
|
|
|
|
|
Trial |
|
Product |
|
Study Design |
|
Status |
DEFINITIVE Ca++ (U.S.)
|
|
RockHawk and TurboHawk
Peripheral Calcium Tip
Plaque Excision System
with SpiderFX Embolic
Protection Device
|
|
U.S. IDE, prospective,
multi-center,
non-randomized,
single-arm study to
evaluate the safety
and effectiveness
of the SilverHawk
with Calcium Tip
(i.e.
RockHawk/TurboHawk)
Plaque Excision
System when used in
conjunction with
the SpiderFX
Embolic Protection
Device in the
treatment of
moderate to heavily
calcified lesions
in the
femoropopliteal
arteries
|
|
Enrollment and
follow-up
continuing |
|
|
|
|
|
|
|
DEFINITIVE LE (Global)
|
|
SilverHawk and TurboHawk
|
|
Prospective,
multi-center,
non-randomized,
single-arm study to
evaluate the
intermediate and
long-term
effectiveness of
stand-alone
SilverHawk/TurboHawk
Plaque Excision
Catheter for
endovascular
treatment of
peripheral arterial
disease in
femoropopliteal or
tibial-peroneal
arteries.
|
|
Enrollment and
follow up
continuing |
|
|
|
|
|
|
|
DEFINITIVE AR (Europe)
|
|
SilverHawk, TurboHawk
and drug coated balloon
|
|
Treatment of
femoropopliteal
arteries
Protocol currently
under development
|
|
Enrollment
anticipated to
begin in the second
half of 2010 |
Carotid Clinical Trials:
|
|
|
|
|
|
|
Trial |
|
Product |
|
Study Design |
|
Status |
CREATE PAS (U.S)
|
|
Protégé GPS Stent
with an ev3 Embolic
Protection Device
|
|
Prospective,
multi-center
single-arm
confirmatory
post-approval study
|
|
Enrollment and
follow-up
continuing |
|
|
|
|
|
|
|
|
|
|
|
Primary endpoint of
major adverse
cardiovascular and
cerebral event rate
in broad use at
investigative
centers |
|
|
Neuro Clinical Trials:
|
|
|
|
|
|
|
Trial |
|
Product |
|
Study Design |
|
Status |
SWIFT
Solitaire With the Intention For Thrombectomy
Trial (U.S./Europe)
|
|
Solitaire FR Stent
|
|
U.S. IDE,
prospective,
randomized, 2-arm,
multi-center study
|
|
Enrollment
anticipated to
begin first quarter
2010 |
|
|
|
|
|
|
|
|
|
|
|
Goal: FDA approval |
|
|
22
|
|
|
|
|
|
|
Trial |
|
Product |
|
Study Design |
|
Status |
RACER Axium Post
Market and Expanded
Approvals Trial(U.S.)
|
|
Axium Coil
|
|
Prospective,
single-arm,
multi-center study
Goal: Scientific
clinical data for
publications and
possible outside
the United States
regulatory
submissions
|
|
Enrollment
completed and
follow-up
continuing |
|
|
|
|
|
|
|
PUFS Pipeline
for Uncoilable or
Failed Aneurysms (U.S.)
|
|
Pipeline
Embolization Device
|
|
U.S. IDE,
non-randomized,
single-arm study
using historical
control
|
|
Enrollment
completed and
follow-up
continuing |
|
|
|
|
|
|
|
|
|
|
|
6-mo safety (death
and ipsilateral
stroke) and
effectiveness
(complete occlusion
no recurrence)
endpoints |
|
|
|
|
|
|
|
|
|
|
|
|
|
Goal: Pre-market
approval for large
aneurysms |
|
|
|
|
|
|
|
|
|
COCOA Complete
Occlusion of
Coilable Aneurysms (U.S.)
|
|
Pipeline
Embolization Device
|
|
U.S. IDE,
prospective,
randomized 2-arm
study (Pipeline
Embolization Device
vs coils)
|
|
Enrollment and
follow-up
continuing |
|
|
|
|
|
|
|
|
|
|
|
6-mo safety (death
and ipsilateral
stroke) and
effectiveness
(complete occlusion
no recurrence)
endpoints |
|
|
|
|
|
|
|
|
|
|
|
|
|
Goal: Pre-market
approval for
smaller aneurysms
(<10 mm) |
|
|
Government Regulation
United States
Our products are regulated in the United States as medical devices by the FDA and other regulatory
bodies. FDA regulations govern, among other things, the following activities that we perform:
|
|
|
product design, development and manufacture; |
|
|
|
|
conduct of clinical trials; |
|
|
|
|
product safety, testing, labeling and storage; |
|
|
|
|
submission to FDA for pre-marketing clearance or approval; |
|
|
|
|
record keeping procedures; |
|
|
|
|
product marketing, sales and distribution; and |
|
|
|
|
post-marketing surveillance, reporting of deaths or serious injuries and medical device
reporting. |
23
Unless an exemption applies, each medical device we wish to commercially distribute in the United
States will require either prior 510(k) clearance or prior pre-market approval from the FDA. The
FDA classifies medical devices into one of three classes, depending on the degree of risk
associated with each medical device and the extent of controls that are needed to ensure safety and
effectiveness. Devices deemed to pose the least risk are placed in Class I. Intermediate risk
devices are placed in class II, which, in most instances, requires the manufacturer to submit to
the FDA a pre-market notification requesting authorization for commercial distribution, known as
510(k) clearance. A 510(k) clearance is provided when the device is deemed substantially
equivalent to a predicate device, i.e. one that was previously cleared by the FDA. Class II 510(k)
devices may be subjected to special controls such as performance standards, guidance documents
specific to the device or post-market surveillance. Most Class I and some low-risk Class II devices
are exempted from this 510(k) requirement. Class III devices are deemed by the FDA to pose the
greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed
to be not substantially equivalent to previously cleared 510(k) devices. In general, a Class III
device cannot be marketed in the United States unless the FDA approves the device after submission
of a pre-market approval application.
510(k) Clearance Pathway. When we are required to obtain 510(k) clearance for devices that we wish
to market, we must submit a pre-market notification to the FDA demonstrating that the device is
substantially equivalent to a previously cleared 510(k) device or a device that was in commercial
distribution before May 28, 1976 (or to a pre-1976 class III device for which the FDA has not yet
called for the submission of pre-market approval applications). In essence, the basic safety and
effectiveness of the predicate device supports clearance of the new product. The 510(k) applicant
is typically only required to demonstrate substantial equivalence to the predicate device. The FDA
attempts to respond to a 510(k) pre-market notification within 90 days of submission of the
notification, but the response may be a request for additional information or data, sometimes
including clinical data. As a practical matter, pre-market clearance can take significantly longer
than 90 days, including up to one year or more.
After a device receives 510(k) clearance for a specific intended use, any modification that could
significantly affect its safety or effectiveness, or that would constitute a major change in its
intended use, design or manufacture, will require a Special 510(k) clearance, a new 510(k)
clearance, or could require pre-market approval. In addition, new claims not found in the cleared
labeling for the device can be deemed a new intended use and can trigger the requirement for a new
510(k). The FDA requires each manufacturer to make its own determination whether a change requires
a new submission, but the FDA can review and can disagree with a manufacturers determination. If
the FDA disagrees with a manufacturers determination that a new clearance or approval is not
required for a particular modification, the FDA can require the manufacturer to cease marketing
and/or recall the modified device until 510(k) clearance or pre-market approval is obtained. Also,
in these circumstances, the manufacturer may be subject to significant regulatory fines or
penalties.
The FDA recently has requested that the Institute of Medicine perform a study on whether
legislative, regulatory or administrative changes are needed to the FDAs 510(k) process. The
Institute of Medicine report is due in 2011. The FDA also announced an internal working group to
evaluate and improve the consistency of FDA decision making in the clearance process, and recently
released an internal report in which FDA officials questioned the 510(k) process in general.
Various committees of the U.S. Congress also have indicated that they may consider investigating
the FDAs 510(k) process.
Pre-Market Approval Pathway. A pre-market approval, or PMA, application must be submitted if the
device cannot be cleared through the 510(k) process. The PMA process is much more demanding than
the 510(k) pre-market notification process. A PMA application must be supported by extensive data
and information including, but not limited to, technical, pre-clinical, clinical, manufacturing and
labeling, to establish to the FDAs satisfaction the safety and effectiveness of the device.
If the FDA determines that a PMA application is complete, the FDA can accept the application and
begin an in-depth review of the submitted information. The FDA, by statute and regulation, has 180
days to review an accepted PMA application, although the review generally occurs over a
significantly longer period of time, and can take up to several years. During this review period,
the FDA may request additional information or clarification of information already provided. Also
during the review period, an advisory panel of experts from outside the FDA may be convened to
review and evaluate the application and provide recommendations to the FDA as to the approvability
of
24
the device. In addition, the FDA will typically conduct a pre-approval inspection of the
manufacturing facility to ensure compliance with the Quality System Regulations. New PMA
applications or Supplemental PMA applications are required for significant modifications to the
manufacturing process, labeling, use and design of a device that is approved through the PMA
process. PMA Supplements often require submission of the same type of information as a pre-market
approval, except that the supplement is limited to information needed to support any changes from
the device covered by the original PMA application, and may not require as extensive clinical data
or the convening of an advisory panel.
Clinical Trials. A clinical trial is almost always required to support an original PMA application.
Historically, clinical trials were infrequently required for a 510(k) clearance. Today, information
from clinical trials is increasingly required to support 510(k) clearance. Clinical trials for a
significant risk device require submission of an application for an investigational device
exemption, or IDE, to the FDA. The IDE application must be supported by appropriate data, such as
animal and laboratory testing results, showing that it is safe to test the device in humans and
that the testing protocol is scientifically sound. Clinical trials for a significant risk device
may begin once the application is approved by the FDA. In addition, the Institutional Review
Board, or IRB, overseeing the clinical trial at each clinical site must approve the clinical study
and an executed Investigator Agreement must be in place prior to patient enrollment at the site. If
the product is deemed a non-significant risk device under FDA regulations, only the abbreviated
IDE requirements apply. Clinical trials must be monitored by the study sponsor and are subject to
extensive record keeping and reporting requirements. Clinical trials must be conducted in
accordance with applicable regulations and policies including, but not limited to, the FDAs good
clinical practice, or GCP, requirements.
For the protection of human subjects in a clinical trial, the FDA and IRB require patients to be
informed of both the benefits and risks of the investigational device and the treatment and/or
procedure. This is called informed consent and the subject must sign a written document stating
that he or she understands the risks and consent to be involved in the trial. In addition, study
subjects are protected by the Health Insurance Portability and Accountability Act of 1996, or
HIPAA. The study subject is asked to provide authorization to the clinical trial site and
manufacturer so they can collect and use certain personally identifiable health information about
the patient from the clinical trial for use in seeking FDA approval and any other specified uses
outlined in the HIPAA authorization.
The study sponsor, the FDA or the IRB at each site at which a clinical trial is being performed may
suspend a clinical trial at any time for various reasons, including a belief that the risks to
study subjects outweigh the anticipated benefits. The FDA may inspect a clinical investigation and,
if it determines that the study sponsor failed to comply with the FDA regulations governing
clinical investigations, it may issue a warning letter to or take other enforcement action against
the study sponsor, the clinical investigation site or the principal investigator. There is always a
risk that the results of clinical testing may not be sufficient to obtain approval of the product.
De Novo Pathway. There is another pathway that may be used to market a medical device. This is
called the de novo clearance which was established by the Food and Drug Administration Act of
1997, known as FDAMA. The de novo pathway is for products that do not qualify for 510(k)
clearance because there is no predicate upon which to claim substantial equivalence. If the FDA,
after reviewing a 510(k) application, sends a not substantially equivalent or NSE letter to a
manufacturer, that manufacturer can request a de novo clearance. This is done by making the request
in writing within 30 days of receipt of the NSE letter. The FDA then has 60 days to review the
510(k) application de novo and decide whether to clear the product. If the product is cleared via
this pathway, the FDA publishes the clearance in the Federal Register and the cleared product
receives a 510(k) and becomes a predicate for future products. If the product fails to be cleared
by this pathway, it can only be approved via the PMA pathway.
Humanitarian Device Exemptions. A Humanitarian Device Exemption, or HDE, authorizes the marketing
of a humanitarian use device for a limited patient population. An HDE designation is based on the
FDAs determination that a device is intended for the treatment and diagnosis of a disease or
condition that affects fewer than 4,000 individuals in the United States per year. Once an HDE
designation has been obtained, an applicant may seek marketing approval under an HDE. While the HDE
application is similar to a pre-market approval application and requires a demonstration of safety,
unlike a pre-market approval application, an HDE does not require a demonstration of effectiveness.
Certain limitations apply to the sale and use of devices under an HDE.
25
Post-Marketing Requirements. After a device is approved for marketing, numerous regulatory
requirements apply, including:
|
|
|
Quality System Regulations, which require manufacturers to follow design, testing,
control, documentation and other quality assurance procedures during the manufacturing
process; |
|
|
|
|
labeling, advertising and promotion regulations, which govern product labels and
labeling, prohibit the promotion of products for unapproved or off-label uses and impose
other restrictions on labeling and promotional activities; |
|
|
|
|
medical device reporting regulations, which require that manufacturers report to the
FDA if their device may have caused or contributed to a death or serious injury or
malfunctioned in a way that would likely cause or contribute to a death or serious injury
if it were to recur; and |
|
|
|
|
notices of correction or removal, and recall regulations. |
The advertising and promotion of restricted devices, i.e. those requiring a prescription, are
regulated by the FDA. The advertising and promotion of all other devices are regulated by the
Federal Trade Commission, or FTC, and by state regulatory and enforcement authorities. But the FDA
often asserts itself in those situations as well because it has continuing authority over the
labeling of a product that can be affected by the way it is advertised. Recently, some promotional
activities for FDA-regulated products have been the subject of enforcement actions brought under
health care reimbursement laws and consumer protection statutes. In addition, under the federal
Lanham Act, competitors and others can initiate litigation relating to advertising claims.
We have registered with the FDA as a medical device manufacturer. Compliance with regulatory
requirements is tested through periodic, pre-scheduled or unannounced for cause facility
inspections by the FDA and these inspections may include the manufacturing facilities of our
subcontractors. For cause inspections are generally conducted when FDA suspects the manufacturer
is in serious violations of current Good Manufacturing Practice regulations that have not been
remedied. Failure to comply with applicable regulatory requirements can result in enforcement
action by the FDA, which may include any of the following sanctions:
|
|
|
warning letters, fines, injunctions, and civil penalties; |
|
|
|
|
repair, replacement, refund, recall or seizure of our products; |
|
|
|
|
operating restrictions, partial suspension or total shutdown of production; |
|
|
|
|
refusing a request for 510(k) clearance or pre-market approval of new products; |
|
|
|
|
withdrawing 510(k) clearance or pre-market approvals that are already granted; and |
|
|
|
|
criminal prosecution. |
International
We conduct sales and marketing activities in various foreign countries. Most major markets have
different levels of regulatory requirements for medical devices. Modifications to the approved
products often require a new regulatory submission in major markets. The regulatory requirements,
and the review times, vary significantly from country to country. Our products also can be marketed
in several other countries that have minimal requirements for medical devices. Frequently, we
obtain regulatory approval for medical devices in foreign countries first because their regulatory
approval is faster and simpler than the FDA. However, as a general matter, foreign regulatory
requirements are becoming increasingly stringent.
In the European Union, a single harmonized regulatory approval process has been created according
to the New Approach regulations. Devices granted market access can be recognized by the European
Conformance (CE) Mark,
26
under the European Medical Devices Directive, 93/42/EEC as amended 2007/47/EC. Medical devices for
human use that receive CE designation in one Member State can be sold in all EU Member States. In
the European Union, the European Community uses third parties called notified bodies, to review
products for approval. They are private, independent third parties certified by the competent
authorities (or Member State representative) to review and approve medical device applications and
grant products labeled with the CE Mark to be sold in the European Union. The competent authorities
designate and accredit and otherwise oversee the notified bodies they accredit. To obtain a CE Mark
in the European Union, defined products must meet minimum standards of safety and quality and then
comply with one or more of a selection of conformity routes. The European Community has regulations
similar to that of the FDA for pre-market review and approval of medical devices, clinical
investigations, and adverse events. Certification of our quality system for product distribution in
the European Union is performed by Société Générale de Surveillance (SGS), located in the United
Kingdom.
In China, medical devices must be approved by the China State Food and Drug Administration (SFDA)
prior to importation and commercial sale. In addition, medical devices must be approved in the
country of origin before the registration process can begin in China and as such we must first
obtain FDA approval before applying for market approval in China. China requires sample product
testing at SFDA Accredited Laboratories for most products. Fees and testing requirements depend on
the risk category of the device being registered. Initial registration of medical devices takes
approximately 18 to 24 months to obtain marketing approval. Licenses are issued in the name of the
device manufacturer for a period of four years. A local after-sale service provider must be
located in China and is designated in the registration process. After the device is registered
with the health authorities, manufacturers can sell product through multiple distributors. Medical
devices imported into China must be labeled in Chinese and include the registration number, product
features and the scope of usage for the product. New regulations went into effect on December 30,
2008 which require medical device manufacturers and distributors to include the device shelf life
duration on the product labeling as well as adverse event reporting to Chinese authorities. The
new regulation has tight reporting deadlines and does not follow the Global Harmonization Task
Force recommendations for reporting adverse events. In addition, the Chinese Government has
recently suggested that they will require clinical data collected from clinical sites within China
prior to approval of new medical devices. If these requirements go into effect, the approval cycle
for the market release of new medical devices in China will be significantly increased.
In Japan, medical devices must be approved prior to importation and commercial sale by the Ministry
of Health, Labor and Welfare, or MHLW. Manufacturers of medical devices outside of Japan that do
not operate through a Japanese entity are required to use a contractually bound in-country
caretaker to submit an application for device approval to the MHLW. The MHLW evaluates each device
for safety and efficacy. As part of the approval process, the MHLW may require that the product be
tested in Japanese laboratories. The approval process ranges in length and certain medical devices
may require a longer review period for approval. Once approved, the manufacturer may import the
device into Japan for sale by the manufacturers contractually bound office, importer or
distributor. After a device is approved for importation and commercial sale in Japan, the MHLW
continues to monitor sales of approved products for compliance with labeling regulations, which
prohibit promotion of devices for unapproved uses, and reporting regulations, which require
reporting of product malfunctions, including serious injury or death caused by any approved device.
In addition to MHLW oversight, the regulation of medical devices in Japan is also governed by the
Japanese Pharmaceutical Affairs Law, or PAL. PAL was substantially revised in July of 2002, and the
new provisions were implemented in stages through April of 2005. The revised law changes class
categorizations of medical devices in relation to risk, introduces a third-party certification
system, strengthens safety countermeasures for biologically derived products and reinforces safety
countermeasures at the time of resale or rental.
You should read the information set forth under Item 1A. Risk FactorsOur products and our
product development and marketing activities are subject to extensive regulation as a result of
which we may not be able to obtain required regulatory approvals for our products in a
cost-effective manner or at all, which could adversely affect our business and operating results.
27
Fraud and Abuse Laws
A variety of U.S. federal and state laws apply to the sale, marketing and promotion of medical
devices that are paid for, directly or indirectly, by federal or state health care programs, such
as Medicare, Medicaid and TRICARE. The restrictions imposed by these laws are in addition to those
imposed by the FDA, FTC and corresponding state agencies. Some of these laws significantly restrict
or prohibit certain types of sales, marketing and promotional activities by medical device
manufacturers. Violation of these laws can result in significant criminal, civil and administrative
penalties, including imprisonment of individuals, fines and penalties and exclusion or debarment
from federal and state health care and other programs.
The principal federal laws include: (1) the Anti-Kickback Statute, which prohibits offers to pay or
receive remuneration of any kind for the purpose of inducing or rewarding referrals of items of
services reimbursable by a federal healthcare program; (2) the False Claims Act, which prohibits
the submission of false or otherwise improper claims for payment to a federally-funded health care
program; (3) the Stark law, which prohibits physicians from referring Medicare or Medicaid patients
to an entity for the provision of certain designated health services if the physician (or a member
of the physicians immediate family) has a financial relationship with that entity, and (4) HIPAA,
which prohibits knowingly and willfully executing a scheme to defraud any health care benefit
program, including private payors, and falsifying, concealing or covering up a material fact or
making any materially false, fictitious or fraudulent statement in connection with the delivery of
or payment for health care benefits, items or services.
Privacy and Security
HIPAA requires certain covered entities to comply with established standards regarding the
privacy and security of protected health information, or PHI, and to use standardized code sets
when conducting certain electronic transactions. HIPAA further requires that covered entities enter
into agreements meeting certain regulatory requirements with their business associates, which
effectively obligate the business associates to safeguard the covered entitys protected health
information against improper use and disclosure. While not directly regulated by HIPAA, a business
associate may face significant contractual liability pursuant to such an agreement if the business
associate breaches the agreement or causes the covered entity to fail to comply with HIPAA. The
company often has possession of PHI in situations such as where clinical studies are conducted or
sales representatives are asked by a surgeon to be in a surgical suite to provide technical advice
on a device during surgery. HIPAA does not require a business associate agreement to be signed in
these circumstances. In the course of our business operations, we may become the business associate
of one or more covered entities. Accordingly, we may incur compliance related costs in meeting
HIPAA-related obligations under business associates agreements to which we become a party.
The European Union has its own privacy standards to which we are subject. Recognizing that our
business continues to expand internationally, we intend to review our compliance with these
standards and update or enhance our procedures and practices.
Third Party Reimbursement
In the United States, as well as in foreign countries, government-funded or private insurance
programs, commonly known as third-party payors, pay the cost of a significant portion of a
patients medical expenses. A uniform policy of reimbursement does not exist among all these
payors. Therefore, reimbursement can be quite different from payor to payor. We believe that
reimbursement is an important factor in the success of any medical device. Consequently, we seek to
obtain reimbursement for all of our products.
Reimbursement in the United States depends on our ability to obtain FDA clearances and approvals to
market these products. Reimbursement also depends on our ability to demonstrate the short-term and
long-term clinical and cost-effectiveness of our products from the results we obtain from clinical
experience and formal clinical trials. We present these results at major scientific and medical
meetings and publish them in respected, peer-reviewed medical journals.
28
The United States Center for Medicare and Medicaid Services, or CMS, sets reimbursement policy for
the Medicare program in the United States. CMS policies may alter coverage and payment for vascular
device technologies in the future. These changes may occur as the result of National Coverage
Decisions issued by CMS headquarters or as the result of local or regional coverage decisions by
contractors under contract with CMS to review and make coverage and payment decisions. This
administration has a national coverage policy, which provides for the diagnosis and treatment of
vascular disease in Medicare beneficiaries.
All third-party reimbursement programs, whether government funded or insured commercially, whether
inside the United States or outside, are developing increasingly sophisticated methods of
controlling health care costs through prospective reimbursement and capitation programs, group
purchasing, redesign of benefits, second opinions required prior to major surgery, careful review
of bills and exploration of more cost-effective methods of delivering health care. These types of
programs and legislative changes to reimbursement policies could potentially limit the amount which
health care providers may be willing to pay for medical devices.
International Trade
The sale and shipment of our products and services across international borders, as well as the
purchase of components and products from international sources, subject us to extensive
governmental trade regulations. A variety of laws and regulations, both in the United States and in
the countries in which we transact business, apply to the sale, shipment and provision of goods,
services and technology across international borders, which include import and export laws and
regulations, anti-boycott laws and anti-bribery laws. Because we are subject to extensive
regulations in the countries in which we operate, we are subject to the risk that laws and
regulations could change in a way that would expose us to additional costs, penalties or
liabilities.
Environmental
We are subject to various environmental health and safety laws, directives and regulations both in
the U.S. and abroad. Our operations, like those of other medical device companies, involve the use
of substances regulated under environmental laws, primarily in manufacturing and sterilization
processes. We do not expect that compliance with environmental protection laws will have a material
impact on our capital expenditures, earnings or competitive position. Given the scope and nature of
these laws, however, there can be no assurance that environmental laws will not have a material
impact on our results of operations. Our leased Redwood City facility sits on property formerly
occupied by Rohm & Haas and Occidental Chemical Company and contains residual contamination in soil
and groundwater from these past industrial operations. Rohm & Haas and Occidental Chemical Company
previously performed soil remediation on the property under the supervision of the California
Regional Water Quality Control Board. Rohm & Haas has indemnified the owner of the facility and its
tenants against costs associated with the residual contamination.
Competition
The markets in which we compete are highly competitive, subject to change and impacted by new
product introductions and other activities of industry participants. We compete primarily on the
basis of our ability to treat vascular diseases and disorders safely and effectively. Our success
can be impacted by the ease and predictability of product use, adequate third-party reimbursement,
brand name recognition and cost. We believe we compete favorably with respect to these factors,
although there can be no assurance that we will be able to continue to do so in the future or that
new products that perform better than those we offer will not be introduced. Because of the size of
the peripheral vascular and neurovascular markets, competitors and potential competitors have
historically dedicated and will continue to dedicate significant resources to aggressively promote
their products and develop new and improved products.
Our competitors range from small start-up companies to much larger companies. The larger companies
with which we compete include Abbott Laboratories, Boston Scientific Corporation, Cook
Incorporated, Cordis Corporation (a Johnson & Johnson company), Covidien Public Limited Company,
C.R Bard Inc., Medtronic, Inc., Terumo/MicroVention, Inc. and W.L. Gore & Associates, Inc. All of
these larger companies have substantially greater capital resources, larger customer bases, broader
product lines, larger sales forces, greater marketing and management resources, larger research and
development staffs and larger facilities than ours and have established
29
reputations and relationships with our target customers, as well as worldwide distribution channels
that are more effective than ours. We also compete, however, and in some cases even more
intensely, with smaller manufacturers. In the peripheral vascular market, we compete against, among
others: MEDRAD, Inc., Cardiovascular Systems, Inc., Pathway Medical Technologies, Inc., Idev
Technologies, Inc., Invatec s.r.l. (which recently agreed to be acquired by Medtronic) and
Spectranetics Corporation. In the neurovascular market, we compete against, among others: Balt
Extrusion, Inc. and Micrus Corporation. In addition, we compete with a number of drug therapy
treatments manufactured by major pharmaceutical companies, including Otsuka Pharmaceutical, the
manufacturer of Pletal, and Sanofi Aventis, the manufacturer of Plavix.
Many of our physician customers like to experiment with new technologies. Within the plaque
excision market, although we believe our SilverHawk plaque excision products compete favorably
against other competing technologies, surgical procedures and pharmaceutical products, recently
introduced atherectomy products have adversely affected and may continue to adversely affect future
sales of our plaque excision products, at least in the short term while physician customers
experiment with such new products. Within the peripheral vascular stent market, we may experience
increased competition from C. R. Bard Inc. which announced in 2009 that the FDA approved certain of
its stents for use in the superficial femoral arteries and proximal popliteal arteries, if
physicians decide to use C. R. Bard Inc.s FDA cleared stents rather than our stents off-label.
We believe our continued success depends on our ability to:
|
|
|
continue to innovate and maintain scientifically advanced technology, being responsive
to the changing needs of our diverse customer base; |
|
|
|
|
apply our technology across disease states, product lines and markets; |
|
|
|
|
attract and retain skilled personnel; |
|
|
|
|
obtain and maintain regulatory approvals; and |
|
|
|
|
cost-effectively manufacture and successfully market our products. |
Employees
As of December 31, 2009, we had approximately 1,350 employees worldwide. From time to time, we also
employ independent contractors to support our operations.
Intellectual Property Rights
We believe that in order to maintain a competitive advantage in the marketplace, we must develop
and maintain protection of the proprietary aspects of our technology. We rely on a combination of
patent, trademark, trade secret, copyright and other intellectual property rights and measures to
aggressively protect our intellectual property that we consider important to our business.
We have developed a patent portfolio internally, as well as through acquisitions, that cover many
aspects of our product offerings. As of December 31, 2009, we had 498 issued patents and over 475
pending patent applications in the United States, Europe, Japan, Australia, Canada and other
countries throughout the world. The expiration dates of our material patents range from 2010 to
2026. Additionally, we own or have rights to material trademarks or trade names that we use in
conjunction with the sale of our products.
We continue to invest in internal research and development of concepts and product ideas for the
peripheral vascular and neurovascular markets. This, combined with our patent program, has
increased the number of patentable concepts we generate. We also continually evaluate the
potential financial benefits and costs of the development of our products and maintenance of our
intellectual property rights. If we determine that the costs associated with developing our
products and/or maintaining our intellectual property rights exceed the potential financial
benefits of
30
that product or right, or if the projected development timeline is inconsistent with our investment
horizon, we may choose to stop development of a product and sell the underlying intellectual
property rights.
We manufacture and market our products both under our own patents and under license agreements.
While we believe that our patents are valuable, our knowledge and experience, our creative product
development teams and marketing staff, and our confidential information regarding manufacturing
processes, materials and product design have been equally important in maintaining our proprietary
product offering. To protect that value, we have instituted policies and procedures, as well as a
requirement that, as a condition of employment, all employees execute a confidentiality agreement
relating to proprietary information and the assignment of intellectual property rights to us.
We also rely on unpatented proprietary technology. We seek to protect our trade secrets and
proprietary know-how, in part, with confidentiality agreements with consultants, vendors and
employees.
Despite measures we have taken to protect our intellectual property, we cannot be certain that such
measures will be successful or that unauthorized parties will not copy aspects of our products or
obtain and use information that we regard as proprietary. In such instances, we may not have
adequate remedies for any such breach. These and other risks related to our intellectual property
rights are described in more detail under Item 1A. Risk Factors. We may be subject to intellectual
property litigation and infringement claims, which could cause us to incur liabilities and costs,
prevent us from selling our products, cause us to redesign our products, require us to enter into
costly license agreements and result in other adverse consequences and Item 1A. Risk FactorsIf
our patents and other intellectual property rights do not adequately protect our products, we may
lose market share to our competitors, which would harm our business.
Forward-Looking Statements
This annual report on Form 10-K contains and incorporates by reference not only historical
information, but also forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the safe harbor created by those sections. In addition, we or others
on our behalf may make forward-looking statements from time to time in oral presentations,
including telephone conferences and/or web casts open to the public, in press releases or reports,
on our Internet web site or otherwise. All statements other than statements of historical facts
included in this report that address activities, events or developments that we expect, believe or
anticipate will or may occur in the future are forward-looking statements including, in particular,
the statements about our plans, objectives, strategies and prospects regarding, among other things,
our financial condition, results of operations and business. We have identified some of these
forward-looking statements with words like believe, may, could, would, might, forecast,
possible, potential, project, will, should, expect, intend, plan, predict,
anticipate, estimate, approximate outlook or continue or the negative of these words or
other words and terms of similar meaning or the use of future dates. These forward-looking
statements may be contained in the notes to our consolidated financial statements and elsewhere in
this report, including under the heading Part II. Item 7. Managements Discussion and Analysis of
Financial Condition and Results of Operations.
Forward-looking statements involve risks and uncertainties. These uncertainties include factors
that affect all businesses as well as matters specific to us. Some of the factors known to us that
could cause our actual results to differ materially from what we have anticipated in our
forward-looking statements are described under the heading Item 1A. Risk Factors below.
We wish to caution readers not to place undue reliance on any forward-looking statement that speaks
only as of the date made and to recognize that forward-looking statements are predictions of future
results, which may not occur as anticipated. Actual results could differ materially from those
anticipated in the forward-looking statements and from historical results, due to the risks and
uncertainties described under the heading Item 1A. Risk Factors below, as well as others that we
may consider immaterial or do not anticipate at this time. Although we believe that the
expectations reflected in our forward-looking statements are reasonable, we do not know whether our
expectations will prove correct. Our expectations reflected in our forward-looking statements can
be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties,
including those described below under the heading Item 1A. Risk Factors. The risks and
uncertainties described under the heading Item 1A. Risk
31
Factors below are not exclusive and further information concerning us and our business, including
factors that potentially could materially affect our financial results or condition, may emerge
from time to time. We assume no obligation to update forward-looking statements to reflect actual
results or changes in factors or assumptions affecting such forward-looking statements. We advise
you, however, to consult any further disclosures we make on related subjects in our quarterly
reports on Form 10-Q and current reports on Form 8-K that we file with or furnish to the Securities
and Exchange Commission.
Available Information
ev3 LLC, our predecessor company prior to our initial public offering in June 2005, was formed in
September 2003. Immediately prior to the consummation of our initial public offering in June 2005,
ev3 LLC merged with and into ev3 Inc., at which time ev3 Inc. became the holding company for all of
ev3 LLCs subsidiaries. Our principal executive offices are located at 3033 Campus Drive, Plymouth,
Minnesota 55441. Our telephone number is (763) 398-7000, and our Internet web site address is
www.ev3.net. We are a Delaware corporation. The information contained on our web site or connected
to our website is not incorporated by reference into and should not be considered part of this
report.
We make available, free of charge and through our Internet web site, our annual reports on Form
10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and any amendments to any such
reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of
1934, as amended, as soon as reasonably practicable after we electronically file such material
with, or furnish it to, the Securities and Exchange Commission. We also make available, free of
charge and through our Internet web site under the InvestorsCorporate Governance section, to any
stockholder who requests, the charters of our board committees and our Code of Business Conduct.
Requests for copies can be directed to Investor Relations at (949) 680-1375.
ITEM 1A. RISK FACTORS
The following are significant factors known to us that could materially adversely affect our
business, financial condition or operating results.
Risks Related to Our Business and Industry
Despite our recent profitability, we have a history of net losses and no assurance can be provided
that we will continue to remain profitable.
We had net income of $41.9 million for the year ended December 31, 2009. We recognized net income
in each of our last three quarters of 2009. Although we expect to be profitable for the year
ending December 31, 2010, our quarterly results are subject to substantial fluctuations and no
assurance can be provided that we will be profitable for each quarter of 2010 or achieve our goal
of sustained profitability. Especially in light of the current economic conditions, it is
difficult to predict our future financial performance and our failure to accurately predict future
financial performance may lead to volatility in the price of our common stock. Our ability to
achieve our goal of sustained profitable operations will be influenced by many factors, including
the level and timing of future sales and expenditures, our ability to increase net sales and
decrease costs, market acceptance of our products, the results and scope of ongoing research and
development projects, the volatility of changes in contingent consideration, the effect of
competing technologies, market and regulatory developments and the other risks described in this
section. If we do not achieve sustained profitability within expected time frames, our business
and stock price will be negatively impacted.
Adverse worldwide economic conditions may continue to result in reduced procedures using our
products, which would adversely affect our net sales.
We believe the adverse worldwide economic conditions during the past 18 months or so have resulted
and may continue to result in reduced procedures using our products. Many of the procedures that
use our products are, to some extent, elective and therefore can be deferred by patients. In the
face of adverse economic conditions, patients may not be as willing to take time off from work or
spend their money on deductibles and co-payments often
32
required in connection with the procedures that use our products. In particular, patients that have
high-deductible health plans and health savings accounts and thus require the patients to incur
significant out-of-pocket costs are especially more apt to defer procedures at times when cash is
tight. Although the specific impact of worldwide economic conditions is difficult to measure and
although we believe such conditions did not have a material adverse effect on our net sales for
2009, we are unable to predict whether continuing adverse economic conditions will impact our sales
in 2010 or beyond.
Adverse worldwide economic conditions may have other adverse implications on our business,
operating results and financial condition.
Beyond patient demand, adverse worldwide economic conditions, including in particular continuing
tight credit and capital markets, may have other adverse implications on our business. For
example, our customers and distributors ability to borrow money from their existing lenders or to
obtain credit from other sources to purchase our products may be impaired resulting in a decrease
in sales. Although we review our customers financial condition and ability to pay on an ongoing
basis and we maintain allowances for doubtful accounts for estimated losses resulting from the
inability of our customers to make required payments and such losses have historically been within
our expectations and the provisions established, we cannot guarantee that we will continue to
experience the same loss rates that we have in the past. A significant change in the liquidity or
financial condition of our customers or distributors could cause unfavorable trends in our
receivable collections and additional allowances may be required, which could adversely affect our
operating results. In addition, adverse worldwide economic conditions may adversely impact our
suppliers ability to provide us with materials and components, which could adversely affect our
business and operating results.
Finally, we believe adverse worldwide economic conditions have caused many of our hospital
customers to demand purchasing our products on a consignment basis and thus purchase our products
as they use them as opposed to purchasing large stocking orders from time to time. Selling
products on consignment involves other risks. For example, in these consignment locations, we do
not have physical possession of our products. We therefore must rely on information from our
customers as well as periodic inspections by our sales personnel to determine when our products
have been used. Our efforts to strengthen our monitoring and management of consigned inventory may
not be adequate to meaningfully reduce the risk of inventory loss. If we are not able to
effectively manage appropriate consigned inventory levels, we may suffer inventory losses which
will reduce our operating results.
Disruptions in the global financial markets could impact the ability of our counterparties and
others to perform their obligations to us and our ability to obtain any additional future financing
if needed or desired.
Disruptions in the global financial markets, including the bankruptcy, failure, collapse or sale of
various financial institutions and an unprecedented level of intervention from the United States
and other governments and the related liquidity crisis, considerably disrupted the credit and
capital markets at the end of 2008 and have not fully recovered since then. Our credit risk
consists of cash and cash equivalents, trade receivables, lending commitments and insurance
relationships in the ordinary course of business. We place cash and cash equivalents with high
quality financial institutions, which we monitor regularly and take action where possible to
mitigate risk. We do not hold investments in auction rate securities, mortgage backed securities,
collateralized debt obligations, individual corporate bonds, special investment vehicles or any
other investments which were directly impacted by the worldwide financial crisis. Our insurance
programs are with carriers that remain highly rated and we have no significant pending claims.
However, future disruptions in the credit and capital markets could cause our counterparties and
others to breach their obligations or commitments to us under our contracts with them. To date,
our credit arrangement with Silicon Valley Bank remains available to us. Although we do not
anticipate requiring any additional financing in the near future, in the event we needed or desired
such additional financing, we may be unable to obtain it by borrowing money in the credit markets
and/or raising money in the capital markets.
Our business, financial condition, results of operations and cash flows could be significantly and
adversely affected if certain types of healthcare reform programs are adopted in our key markets
and other administration and legislative proposals are enacted into law.
Recently, President Obama and members of Congress have proposed significant reforms to the U.S.
healthcare system. Both the U.S. Senate and House of Representatives have conducted hearings about
healthcare reform. The
33
Obama administrations fiscal year 2010 budget included proposals to limit Medicare payments,
reduce drug spending and increase taxes. In addition, members of Congress have proposed a
single-payer healthcare system, a government health insurance option to compete with private plans
and other expanded public healthcare measures, including an excise tax on all medical devices that
could require the medical device industry to contribute over $2 billion to healthcare reform each
year. Various healthcare reform proposals also have emerged at the state level. We cannot predict
what healthcare initiatives, if any, will be implemented at the federal or state level, or the
effect any future legislation or regulation will have on us. However, an expansion in governments
role in the U.S. healthcare industry may lower reimbursements for our products, reduce medical
procedure volumes and adversely affect our business and results of operations, possibly materially.
In addition, if an excise tax on medical devices is enacted into law, our operating results could
be materially and adversely affected.
Our marketing activities are subject to regulation regarding the promotion of off-label uses,
which restrict our ability to market our products. If we are found to have improperly promoted
off-label use of our products, we may become subject to enforcement action by the FDA or the U.S.
Department of Justice and/or incur significant liabilities. Any off-label use of our products also
may result in injuries that could lead to product liability claims against us.
We sell a number of our products to physicians who may elect to use the products in ways that are
not within the scope of the approval or clearance given by the FDA or for other than FDA-approved
indications, often referred to as off-label use. For example, although our SilverHawk Plaque
Excision System received FDA clearance for the treatment of atherosclerosis in the peripheral
vasculature, off-label use of our SilverHawk outside the peripheral vasculature, in coronary and
carotid arteries, has occurred, as well as off-label use of the SilverHawk for treatment of
in-stent restenosis. In addition, although most of our stents received FDA clearance for the
palliative treatment of malignant neoplasms in the biliary tree, off-label use of our stents occurs
regularly in the peripheral arteries for the treatment of peripheral artery disease. In fact, most
of our U.S. stent sales are attributable to off-label use. While off-label uses of medical devices
are common and the FDA does not regulate physicians choice of treatments, the FDA does restrict a
manufacturers communications regarding such off-label use. Such laws and regulations prohibiting
the promotion of products for off-label use restrict our ability to market our products. Although
we have strict policies against the unlawful promotion of products for off-label use and we train
our employees on these policies, it is possible that one or more of our employees will not follow
the policies, or that regulations would change in a way that may hinder our ability to sell such
products or make it more costly to do so, which could expose us to enforcement action by the FDA
and the potential loss of approval to market and sell the affected products and/or significant
financial and other penalties and liabilities.
The FDA and other regulatory agencies actively enforce regulations prohibiting promotion of
off-label uses and the promotion of products for which marketing clearance has not been obtained.
During a March of 2007 meeting, the FDA warned device makers, including us, about promoting biliary
stents for off-label uses. It is our understanding that certain biliary stent manufacturers,
including some at the March 2007 FDA meeting, have since become involved in civil investigations by
the U.S. Department of Justice alleging that they have improperly promoted their biliary stents for
off-label uses. Although we have received no notice of any such investigation involving the sales
practices of our biliary stents, no assurance can be provided that we will not become the subject
of such an investigation, which could adversely affect our business, operating results and stock
price. It is also possible that our company or board of directors could become subject to civil
litigation or breach of fiduciary duty claims alleging that we improperly promoted off-label use of
our products, which in turn improperly inflated our historical net sales.
Off-label use of our products may not be safe or effective and may result in unfavorable outcomes
to patients, resulting in potential liability to us. For example, the use or misuse of the
SilverHawk in the peripheral and coronary arteries has resulted in complications, including damage
to the treated artery, internal bleeding, limb loss and death, potentially leading to a product
liability claim. In addition, the use or misuse of our biliary stents in the peripheral arteries
to treat peripheral artery disease has resulted in complications, potentially leading to a product
liability claim. A third-party study published in 2008 found that off-label use of biliary stents
was increasing and that the majority of adverse events and device malfunctions associated with the
use of such stents occurs during off-label usage.
34
If we want to market any of our products in the U.S. for uses in ways for which they are not
currently approved or cleared, we will need to obtain approval or clearance from the FDA and in
most cases conduct additional clinical trials to support such approvals and clearances. Such
trials are often time-consuming and costly. Although we continue to enroll patients for our
DEFINITIVE Ca++ trial to support an FDA application to use our RockHawk/TurboHawk and SpiderFX in
the treatment of lower extremity (SFA/Popliteal) calcified lesions and intend to conduct other
clinical trials to expand the indication of use of our RockHawk/TurboHawk, no assurance can be
provided that the results of these trials will adequately demonstrate the safety and efficacy of
the SilverHawk for use in those expanded indications. In addition, although we continue to enroll
patients for our DURABILITY II IDE trial to support an FDA application to use our EverFlex stent in
long lesions in the superficial femoral artery, no assurance can be provided that the results of
this trial will adequately demonstrate the safety and efficacy of our EverFlex stent for use in the
peripheral arteries. In 2009, C. R. Bard Inc. announced that the FDA cleared certain of its stents
for use in the superficial femoral arteries and proximal popliteal arteries. It is possible that
physicians have decided to use and may continue to decide to use C. R. Bard Inc.s FDA cleared
stents rather than our stents off-label, which would harm sales of our stents. It is also possible
that governmental or private health care payors could limit reimbursement for products used
off-label, in which case, sales of our products and our business would be materially adversely
affected.
Since a significant portion of our sales are derived from products that physicians in the past have
elected to use and may continue to elect to use off-label, ultimately, if physicians cease or
lessen their use of our products for other than FDA-approved indications, sales of our products
likely would decline, which could materially adversely affect our net sales and operating results.
In addition, if we are perceived not to be in compliance with all of the restrictions limiting the
promotion of our products for off-label use, we could be subject to various enforcement measures,
including investigations, administrative proceedings and federal and state court litigation, which
likely would be costly to defend and harmful to our business. If the FDA or another governmental
authority ultimately concludes we are not in compliance with such restrictions, we could be subject
to significant liability, including civil and administrative remedies, injunctions against sales
for off-label uses, significant monetary and punitive penalties and criminal sanctions, any or all
of which would be harmful to our business.
Our business strategy relies on assumptions about the market for our products, which, if incorrect,
would adversely affect our business and operating results.
We are focused on the market for endovascular devices used to treat vascular diseases and
disorders. We believe that the aging of the general population and inactive lifestyles will
continue and that these trends will increase the need for our products. However, the projected
demand for our products could materially differ from actual demand if our assumptions regarding
these trends and acceptance of our products by the medical community prove to be incorrect or do
not materialize or if drug therapies gain more widespread acceptance as a viable alternative
treatment, which in each case, would adversely affect our business and operating results.
If we fail to comply with laws prohibiting kickbacks and false or fraudulent claims and other
similar laws, we could be subject to criminal and civil penalties and exclusion from governmental
health care programs, which could have a material adverse effect on our business and operating
results.
We are subject to various federal, state and foreign laws concerning health care fraud and abuse,
including false claims laws, anti-kickback laws, physician self-referral laws and other similar
laws. Many of these laws constrain the sales, marketing and other promotional activities of
manufacturers of medical devices by limiting the kinds of financial arrangements, including sales
programs, with physicians, hospitals, laboratories and other potential purchasers of medical
devices. The scope of these laws and related regulations are very broad and many of their
provisions have not been uniformly or definitively interpreted by existing case law or regulations,
and thus are subject to evolving interpretations. There is very little precedent related to these
laws and regulations. All of our financial relationships with health care providers and others who
provide products or services to federal health care program beneficiaries are potentially governed
by these laws. While we have established policies and procedures based on the AdvaMed Code of
Ethics on Interactions with Health Care Professionals and implemented a broad-based corporate
compliance program in order to inform our employees regarding these laws and maintain compliance
with them, no assurance can be given that we will not be subject to investigations or litigation
alleging violations of these laws. Increased funding for enforcement of these laws and regulations
has resulted in greater scrutiny of financial relationships with physicians and marketing practices
and resulted in several governmental
35
investigations by various governmental authorities, including investigations of the sales practices
of several of our competitors. Any investigation or litigation against us, even if we were to
successfully defend against it, would likely be time-consuming and costly for us to defend. It
also would likely divert the attention of our management from the operation of our business, cause
adverse publicity and damage our reputation. If our arrangements were found to have violated any
of these laws, we and our officers and employees could be subject to severe criminal and/or civil
penalties, including fines, imprisonment and exclusion from participation in government health care
programs, which could have a material adverse effect on our reputation, business and operating
results. Similarly, if the physicians or other providers or entities with which we do business are
found to be non-compliant with such laws, they may be subject to sanctions, which also could have a
negative impact on us.
Some of our products are emerging technologies or have only recently been introduced into the
market. If physicians do not recommend and endorse them or if our working relationships with
physicians deteriorate, our products may not be accepted in the marketplace, which would adversely
affect our business and operating results.
In order for us to sell our products, physicians must recommend and endorse them. We may not
obtain the necessary recommendations or endorsements from physicians. Acceptance of our products
depends on educating the medical community as to the distinctive characteristics, perceived
benefits, safety, clinical efficacy and cost-effectiveness of our products compared to products of
our competitors, and on training physicians in the proper application of our products. We often
need to invest in significant training and education of our sales representatives or our physician
customers to achieve market acceptance of our products with no assurance of success. For example,
the future success of our plaque excision products are dependent in part upon us educating first
our sales representatives and second, physicians, and in particular interventional cardiologists,
vascular surgeons, as well as general practitioners and other physicians, about screening for
peripheral artery disease, or PAD, referral opportunities and the benefits of our plaque excision
products in relating to competitive products and other treatment options. As another example, the
future success of our Pipeline Embolization Device is also dependent in part upon us educating our
sales organization and physician customers regarding the advantages of flow diversion and our
Pipeline product in particular in treating wide-necked aneurysms. If we are not successful in
obtaining the recommendations or endorsements of physicians for our products, if customers prefer
our competitors products or if our products otherwise do not gain market acceptance, our business
could be adversely affected.
In addition, if we fail to maintain our working relationships with physicians, many of our products
may not be developed and marketed consistent with the needs and expectations of professionals who
use and support our products. We rely on these professionals to provide us with considerable
knowledge and experience regarding our products and the marketing of our products. If we are
unable to maintain these strong relationships with these professionals and continue to receive
their advice and input, the development and marketing of our products could suffer, which could
adversely affect the acceptance of our products in the marketplace and our operating results. At
the same time, we recognize and are careful to ensure that our relationships with physicians comply
with applicable fraud and abuse and other laws and regulations and our Code of Ethics on
Interactions with Health Care Professionals, which is based on the AdvaMed Code of Ethics on
Interactions with Health Care Professionals.
We acquired Chestnut Medical Technologies, Inc. primarily for its Pipeline Embolization Device. If
the Pipeline Embolization Device cannot be shown to be safe and effective in clinical trials, is
not approvable or not commercially successful, or if we do not receive the pre-market approval
letter from the FDA for any reason, then the benefits of our acquisition of Chestnut may never be
fully realized.
In June of 2009, we acquired Chestnut primarily for its Pipeline Embolization Device, which is a
new class of embolization device that is designed to divert blood flow away from an aneurysm in
order to provide a complete and durable aneurysm embolization while maintaining patency of the
parent vessel. The Pipeline Embolization Device has received CE Mark approval in Europe and we are
currently conducting two clinical studies under FDA investigational device exemptions to gain
approval for the Pipeline device in the United States. Under the terms of our agreement and plan of
merger with Chestnut, we made an initial closing payment in the amount of approximately $75.0
million, approximately $26 million of which was paid in cash with the remaining approximately $49
million paid in shares of our common stock. In addition to the initial closing payment, we may be
obligated to make an additional milestone payment of up to $75 million if the FDA issues a letter
granting pre-market approval for the commercialization of the Pipeline Embolization Device in the
United States pursuant to an
36
indication to treat intracranial aneurysms on or before December 31, 2012. If the Pipeline
Embolization Device cannot be shown to be safe and effective in clinical trials, is not approvable
or not commercially successful, or if we do not receive the pre-market approval letter from the FDA
for any reason, then the benefits of our acquisition of Chestnut may never be fully realized.
Demand for our plaque excision products in the United States has suffered due in part, we believe,
to the lack of long-term clinical data regarding their safety and efficacy. Future long-term data
regarding the safety and efficacy of our plaque excision products may not be positive or consistent
with data currently available, which would adversely affect their market acceptance and our
operating results.
One of the primary reasons we completed our acquisition of FoxHollow Technologies, Inc. in October
of 2007 was to add FoxHollows SilverHawk and other products to our broad spectrum of
technologically advanced products to treat vascular disease in the peripheral market to allow us to
offer a more comprehensive and better integrated set of endovascular products to our customers. At
the time of the acquisition, we expected SilverHawk sales to represent a significant portion of our
future net sales. However, we experienced decreased demand and sales of the SilverHawk compared to
levels experienced by FoxHollow prior to our acquisition due in part to sales force integration
challenges, elevated inventory levels of the product at some of our customers and increased
competition. We also believe the decreased demand and sales was due in part to a lack of
definitive long-term clinical data regarding the safety and efficacy of the SilverHawk.
In 2008, we retained a third party research firm to help us examine our U.S. plaque excision
business. The research firm conducted interviews with a significant number of physicians and sales
force representatives and analyzed secondary data to understand factors driving the change in
SilverHawk usage and plaque excision procedures. The results of this research confirmed our
previously stated belief in the importance of investing in the necessary clinical trials to build
the clinical foundation for the SilverHawk and capitalizing on our next generation technologies to
expand clinical usage, particularly in treating calcified lesions, total occlusions and longer
lesions.
Based on this third party research and our own due diligence, we believe that future demand for our
plaque excision products will not increase if physicians are not presented with compelling data
from long-term studies of the safety and efficacy of our products compared against alternative
procedures, such as angioplasty, stenting or bypass grafting and alternative technologies. As a
result, we have commenced our DEFINITIVE trial series, which we expect to consist of three trials
using our plaque excision products. We are currently enrolling patients into our DEFINITIVE Ca++
trial to evaluate RockHawk/TurboHawk and SpiderFX in the treatment of lower extremity
(SFA/Popliteal) calcified lesions and our DEFINITIVE LE trial, which is a post-market
non-randomized study of SilverHawk/TurboHawk in the treatment of femoropopliteal and tibial
arteries. We anticipate commencing enrollment in our DEFINITIVE AR trial in the second half of
2010 to evaluate SilverHawk/TurboHawk in the treatment of femoropopliteal arteries. These studies
will be expensive and time consuming and there are no assurances that the results will prove
favorable for our plaque excision products. If the results do not meet physicians expectations,
our plaque excision products may not become widely adopted and physicians may recommend alternative
treatments for their patients.
Other significant factors that physicians will consider include acute safety data on complications
that occur during the SilverHawk procedure. If the results obtained from any future clinical
studies or clinical or commercial experience indicate that the SilverHawk is not as safe or
effective as other treatment options or as prior short-term or long-term data would suggest, market
acceptance of the product may suffer and the number of SilverHawk procedures may decrease, which
would harm our business. Even if the data collected from clinical studies or clinical experience
indicate positive results, each physicians actual experience with the SilverHawk may vary and may
not be as favorable, which would also adversely affect the demand for our SilverHawk product.
Other factors that may adversely affect the market acceptance of the SilverHawk include the time
required to perform the procedure and the lack of on-board visualization capability. If we do not
incorporate certain design improvements to the SilverHawk to respond to these and other physician
preferences, we may be unable to generate new customers or retain our existing customers. However,
we have limited funds dedicated to research and development; and therefore, we will not be able to
pursue all of these suggested design changes. A decrease in SilverHawk procedures and any failure
by us to generate additional demand for the SilverHawk will likely adversely affect our future net
sales as well as our other operating results.
37
The demand for our products, the prices which customers and patients are willing to pay for our
products and the number of procedures performed using our products depend upon the ability of our
customers and patients to obtain sufficient third party reimbursement for their purchases of our
products.
Sales of our products depend in part on sufficient reimbursement by governmental and private health
care payors to our physician customers or their patients for the purchase and use of our products.
In the United States, health care providers that purchase our products generally rely on
third-party payors, principally federal Medicare, state Medicaid and private health insurance
plans, to pay for all or a portion of the cost of endovascular procedures. Reimbursement systems
in international markets vary significantly by country, and by region within some countries, and
reimbursement approvals must be obtained on a country-by-country basis and can take up to 18 months
or longer. Many international markets have government-managed health care systems that govern
reimbursement for new devices and procedures. In most markets, there are private insurance systems
as well as government-managed systems. Additionally, some foreign reimbursement systems provide
for limited payments in a given period and therefore result in extended payment periods. Any
delays in obtaining, or an inability to obtain, reimbursement approvals or sufficient reimbursement
for our products could significantly affect the acceptance of our products and have a material
adverse effect on our business. For example, international sales of our plaque excision products
and Pipeline Embolization Device may be hampered by delay in obtaining reimbursement. In addition,
if the reimbursement policies of domestic or foreign governmental or private health care payors
were to change, our customers likely would change their purchasing patterns and/or the frequency of
their purchases of the affected products. Additionally, payors continue to review their coverage
policies carefully for existing and new therapies and can, without notice, deny coverage for
treatments that include the use of our products. Our business would be negatively impacted to the
extent any such changes reduce reimbursement for our products.
Healthcare costs have risen significantly over the past decade. There have been and may continue
to be proposals by legislators, regulators and third-party payors to keep these costs down. The
continuing efforts of governments, insurance companies and other payors of healthcare costs to
contain or reduce these costs, combined with closer scrutiny of such costs, could lead to patients
being unable to obtain approval for payment from these third-party payors. The cost containment
measures that healthcare providers are instituting both in the United States and internationally
could harm our business. Some health care providers in the United States have adopted or are
considering a managed care system in which the providers contract to provide comprehensive health
care for a fixed cost per person. Health care providers may attempt to control costs by
authorizing fewer elective surgical procedures or by requiring the use of the least expensive
devices possible, which could adversely affect the demand for our products or the price at which we
can sell our products.
We also sell a number of our products to physician customers who may elect to use these products in
ways that are not within the scope of the approval or clearance given by the FDA, often referred to
as off-label use. In the event that governmental or private health care payors limit
reimbursement for products used off-label, sales of our products and our business would be
materially adversely affected.
Our stents and plaque excision products generate a significant portion of our product sales.
Accordingly, if sales of these products were to decline, our operating results would be adversely
affected.
Our stents and plaque excision products generate a significant portion of our net sales. During
2009, our stents and plaque excision products generated approximately 26% and 19% of our product
sales, respectively. A decline in sales from these products as a result of increased competition,
regulatory matters, intellectual property matters or any other reason would negatively impact our
operating results.
Our products face the risk of technological obsolescence, which, if realized, could have a material
adverse effect on our business and operating results.
The medical device industry is characterized by extensive research and development and rapid and
significant technological change. The peripheral vascular and neurovascular markets in which we
compete are in particular highly competitive and new technologies and products are often
introduced. Therefore, product life cycles are relatively short. Developments by us and other
companies of new or improved products, processes or technologies may make our products or proposed
products obsolete or less competitive and may negatively impact our net sales or cause us to incur
significant charges or write-offs. For example, new procedures and medications that are more
38
effective or less invasive or expensive could be developed that replace or reduce the importance of
current procedures that use our products or our future products or may cause our customers to
cease, delay or defer purchasing our products, which would adversely affect our business and
operating results. As another example, it is possible that our recently acquired Pipeline
Embolization Device could, over time, have an adverse effect on sales of our neurovascular coils.
Our future success depends in part on the introduction of new products. Failure to introduce and
market new products in a timely fashion that are accepted by the marketplace could adversely affect
our business and operating results.
Our success depends in part upon our ability to respond quickly to medical and technological
changes through the development or acquisition and introduction of new products. If we do not
introduce new products and technologies, or if our new products and technologies are not accepted
by the physicians who use them or the payors who reimburse the costs of the procedures performed
with them, or if there are any delays in our introduction of new products, we may not be successful
and our business and operating results would suffer. Accordingly, we must devote substantial
efforts and financial resources to develop or acquire scientifically advanced technologies and
products, obtain patent and other protection for our technologies and products, obtain required
regulatory and reimbursement approvals and successfully manufacture and market our products. For
example, in June of 2009, we acquired Chestnut and paid $75.0 million up front and agreed to pay an
additional $75.0 million milestone payment if the FDA issues a letter granting pre-market approval
for the commercialization of the Pipeline Embolization Device in the United States pursuant to an
indication to treat intracranial aneurysms on or before December 31, 2012. We cannot assure you
that the Pipeline Embolization Device will obtain regulatory approval or will be accepted by the
marketplace, which if not would adversely affect our business and operating results.
We plan to introduce additional products during 2010 which we expect to result in additional net
sales. We may experience delays in any phase of a product launch, including during research and
development, clinical trials, regulatory approvals, manufacturing, marketing and the education
process. The relative speed with which we can develop or acquire products, complete clinical
testing and regulatory clearance or approval processes, train physicians in the use of our
products, gain reimbursement acceptance and supply commercial quantities of the products to the
market are important competitive factors. Any delays could result in a loss of market acceptance
and market share.
Product development involves a high degree of risk, and we cannot provide assurance that our
product development efforts will result in any commercially successful products. Many of our
clinical trials have durations of several years and it is possible that such trials may not be
successful or that competing therapies, such as drug therapies, may be introduced while our
products are still undergoing clinical trials. New products and technologies introduced by
competitors may reach the market earlier, may be more effective or less invasive or expensive than
our products or render our products obsolete, all of which would harm our business and operating
results.
A number of our proposed products are in the early stages of development and some are in clinical
trials. If the development of these products is not successfully completed or if these trials are
unsuccessful, or if the FDA or other regulatory agencies require additional trials to be conducted,
these products may not be commercialized and our business prospects may suffer.
Several of our products are in the early stages of development. Some only recently emerged from
clinical trials and others have not yet reached the clinical trial stage. Our ability to market
our products in the United States and abroad depends upon our ability to demonstrate the safety,
and in the case of the United States, efficacy, of our products with clinical data to support our
requests for regulatory approval. Our products may not be found to be safe and, where required,
effective in clinical trials and may not ultimately be approved for marketing by U.S. or foreign
regulatory authorities. Our failure to develop safe and effective products that are approved for
sale on a timely basis would have a negative impact on our net sales.
Our current and anticipated trials for 2010 include the PROVE-IT (U.S.), CREATE Post Approval Study
(U.S.), DURABILITY II Trial (U.S.), the DEFINITIVE Ca++ Trial (U.S.), the DEFINITIVE LE Trial
(U.S), the DEFINITIVE AR Trial (Europe), the SWIFT Trial (U.S.) and the RACER Trial (U.S.). In
addition, as a result of our acquisition of Chestnut, we are currently conducting two clinical
studies in the U.S., PUFS and COCOA, under
39
Investigational Device Exemptions from the FDA investigating the use of Chestnuts Pipeline
Embolization Device in the treatment of uncoilable aneurysms and coilable aneurysms, respectively.
There is no assurance that we will be successful in achieving the endpoints in these trials or, if
we do, that the FDA or other regulatory agencies will approve the devices for sale without the need
for additional clinical trial data to demonstrate safety and efficacy. Some of the products for
which we are currently conducting trials are already approved for sale outside of the United
States. As a result, while our trials are ongoing, unfavorable data may arise in connection with
usage of our products outside the United States which could adversely impact the approval of such
products in the United States. Conversely, unfavorable data from clinical trials in the United
States may adversely impact sales of our products outside of the United States.
We continually evaluate the potential financial benefits and costs of clinical trials and the
products being evaluated in them. If we determine that the costs associated with obtaining
regulatory approval of a product exceed the potential financial benefits of that product or if the
projected development timeline is inconsistent with our investment horizon, we may choose to stop a
clinical trial and/or the development of a product, which could result in a decrease in our stock
price if investors are disappointed in our decision.
Our future success depends in part on our ability to sell our products internationally. There are
risks inherent in operating internationally and selling and shipping our products and purchasing
our components internationally, which may adversely impact our business, operating results and
financial condition.
One of our strategic objectives is to leverage our strong international presence to increase sales
of our products, including in particular the Pipeline Embolization Device that we recently acquired
from Chestnut and our plaque excision products that we acquired from FoxHollow. For the year ended
December 31, 2009 and 2008, 40% and 35%, respectively, of our net sales were derived from our
international operations. We expect to continue to derive a significant portion of our net sales
from operations in international markets. Our international distribution system consisted of 10
direct sales offices and 56 stocking distribution partners as of December 31, 2009. In addition,
we purchase some of our components and products from international suppliers.
The sale and shipping of our products and services across international borders, as well as the
purchase of components and products from international sources, subject us to extensive U.S. and
foreign governmental trade regulations. Compliance with such regulations is costly and exposes us
to penalties for non-compliance. Other laws and regulations that can significantly impact us
include various anti-bribery laws, including the U.S. Foreign Corrupt Practices Act, laws
restricting business with suspected terrorists and anti-boycott laws. Any failure to comply with
applicable legal and regulatory obligations could impact us in a variety of ways that include, but
are not limited to, significant criminal, civil and administrative penalties, including
imprisonment of individuals, fines and penalties, denial of export privileges, seizure of
shipments, restrictions on certain business activities, and exclusion or debarment from government
contracting. Also, the failure to comply with applicable legal and regulatory obligations could
result in the disruption of our shipping and sales activities.
In addition, many of the countries in which we sell our products are, to some degree, subject to
political, economic and/or social instability. Our international sales operations expose us and
our representatives, agents and distributors to risks inherent in operating in foreign
jurisdictions. These risks include:
|
|
|
the imposition of additional U.S. and foreign governmental controls or regulations; |
|
|
|
|
the imposition of costly and lengthy new export licensing requirements; |
|
|
|
|
the imposition of U.S. and/or international sanctions against a country, company,
person or entity with whom the company does business that would restrict or prohibit
continued business with the sanctioned country, company, person or entity; |
|
|
|
|
a shortage of high-quality sales people and distributors; |
|
|
|
|
loss of any key personnel that possess proprietary knowledge, or who are otherwise
important to our success in certain international markets;
|
40
|
|
|
the imposition of different reimbursement requirements and changes in reimbursement
policies that may require some of the patients who receive our products to directly
absorb medical costs or that may necessitate the reduction of the selling prices of our
products; |
|
|
|
|
changes in duties and tariffs, license obligations and other non-tariff barriers to
trade; |
|
|
|
|
the imposition of new trade restrictions; |
|
|
|
|
the imposition of restrictions on the activities of foreign agents, representatives
and distributors; |
|
|
|
|
scrutiny of foreign tax authorities which could result in significant fines,
penalties and additional taxes being imposed on us; |
|
|
|
|
pricing pressure that we may experience internationally; |
|
|
|
|
laws and business practices favoring local companies; |
|
|
|
|
significantly longer payment cycles; |
|
|
|
|
difficulties in maintaining consistency with our internal guidelines; |
|
|
|
|
difficulties in enforcing agreements and collecting receivables through certain
foreign legal systems; |
|
|
|
|
difficulties in enforcing or defending intellectual property rights; |
|
|
|
|
exposure to different legal and political standards due to our conducting business
in over 65 countries; and |
|
|
|
|
fluctuation in the rate of exchange between the U.S. dollar and foreign currencies
which may make the effective price of our products more expensive to our distributors
in foreign markets. |
No assurance can be given that one or more of the factors will not harm our business. Any material
decrease in our international sales would adversely impact our operating results and financial
condition. Our international sales are predominately in Europe. In Europe, health care regulation
and reimbursement for medical devices vary significantly from country to country. This changing
environment could adversely affect our ability to sell our products in some European countries.
Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies in which we
transact business could adversely affect our financial results or cause our results to fluctuate.
We sell our products to customers in the United States, Europe and elsewhere throughout the world.
Although most of our sales are made in U.S. dollars, a significant portion of our sales are
denominated in foreign currencies, especially the Euro. Approximately 27% and 24% of our net sales
were denominated in foreign currencies in 2009 and 2008, respectively. Our principal exposure to
movements in foreign currency exchange rates relate to non-U.S. dollar denominated sales in Europe
and throughout the world, as well as non-U.S. dollar denominated operating expenses incurred in
Europe and throughout the world. Our reported net earnings may be significantly affected by
fluctuations in currency exchange rates, with earnings generally decreasing with a strengthening
U.S. dollar and increasing with a weaker U.S. dollar. For sales not denominated in U.S. dollars,
if there is an increase in the rate at which a foreign currency is exchanged for U.S. dollars, it
will require more of the foreign currency to equal a specified amount of U.S. dollars than before
the rate increase. In such cases, we will receive less in U.S. dollars than we did before the
exchange rate increase went into effect. Thus, a strengthening U.S. dollar relative to the foreign
currencies in which we transact business will adversely affect the U.S. dollar value of our foreign
currency-denominated sales and earnings. Although we may raise international pricing in such
circumstances, such price increases may potentially reduce demand for our products, and thus in
most circumstances, due to competition or
41
other reasons, we may decide not to raise local prices to the full extent of the U.S. dollars
strengthening or at all. A weakening of the U.S dollar relative to the foreign currencies in which
we transact business is generally beneficial to our foreign currency-denominated sales and
earnings. However, it may cause us to reduce our international pricing, thereby limiting the
benefit. Additionally, strengthening of foreign currencies also may increase our operating costs
or costs of product components denominated in those currencies, thus adversely affecting our gross
margins. If we price our products in U.S. dollars and competitors price their products in local
currency, an increase in the relative strength of the U.S. dollar could result in our price not
being competitive in a market where business is transacted in the local currency.
We have hedged and may continue to hedge exposure to foreign currency exchange rates in the future.
If we engage in hedging activities, such activities involve risk and may not limit our underlying
exposure from currency fluctuations or minimize our net sales and earnings volatility associated
with foreign currency exchange rate changes.
A substantial portion of our assets consist of goodwill and intangible assets and any impairment in
the value of our goodwill and intangible assets would have the effect of decreasing our earnings or
increasing our losses.
As of December 31, 2009, goodwill and intangible assets represented $621.8 million, or
approximately 69%, of our total assets. During 2008, we recorded $288.8 million in goodwill and
intangible asset impairment charges. The accounting standards require goodwill to be reviewed at
least annually for impairment, and do not permit amortization. In the event that impairment is
identified, a charge to earnings will be recorded and our stock price may decline as a result. We
review our intangible assets for impairment when events or changes in circumstances indicate that
the carrying amount of the assets may not be recoverable. An impairment loss on intangible assets
is recognized when future undiscounted cash flows expected to result from the use of the asset and
its eventual disposition are less than the carrying amount. If we experience additional
substantial declines in our market capitalization or if we experience other events or changes in
circumstances that may indicate that the carrying amount of our goodwill and/or other intangible
assets may not be recoverable, we may incur additional non-cash impairment charges to both our
goodwill and intangible assets in future periods. For example, such other events or changes in
circumstances may include a significant adverse change in the extent or manner in which an asset is
being used or in the business climate that could affect the value of the asset, or significant
reductions in operating cash flows, or a projection or forecast that demonstrates continuing losses
associated with the use of the asset and a current expectation that, more likely than not, an asset
will be sold or otherwise disposed of significantly before the end of its previously estimated
useful life. If we are required to record an impairment charge to earnings relating to goodwill or
intangible assets, it will have the effect of decreasing our earnings or increasing our losses.
Consolidation in the healthcare industry could lead to demands for price concessions or to the
exclusion of some suppliers from certain of our markets, which could have an adverse effect on our
business, financial condition or operating results.
Because healthcare costs have risen significantly over the past decade, numerous initiatives and
reforms initiated by legislators, regulators and third-party payors to curb these costs have
resulted in a consolidation trend in the healthcare industry to create new companies with greater
market power, including hospitals. As the healthcare industry consolidates, competition to provide
products and services to industry participants has become and will continue to become more intense.
This in turn has resulted and will likely continue to result in greater pricing pressures and the
exclusion of certain suppliers from important market segments as group purchasing organizations,
independent delivery networks and large single accounts continue to use their market power to
consolidate purchasing decisions for some of our hospital customers. We expect that market demand,
government regulation, third-party reimbursement policies and societal pressures will continue to
change the worldwide healthcare industry, resulting in further business consolidations and
alliances, which may increase competition, exert further downward pressure on the prices of their
products and may adversely impact our business, financial condition or operating results.
42
Our group purchasing organization contracts are up for renewal during 2010 and if such contracts
are not renewed, our net sales could suffer.
Our ability to sell our products to hospitals in the United States depends in part on our
relationships with group purchasing organizations, or GPOs. Many existing and potential customers
for our products are or become members of GPOs. GPOs negotiate pricing arrangements and contracts,
sometimes on an exclusive basis, with medical supply manufacturers and distributors, and these
negotiated prices are made available to a GPOs affiliated hospitals and other members. If we are
not one of the providers selected by a GPO, affiliated hospitals and other members may be less
likely to purchase our products, and if the GPO has negotiated a strict sole source, market share
compliance or bundling contract for another manufacturers products, we may be precluded from
making sales to members of the GPO for the duration of the contractual arrangement.
We currently have contracts with multiple GPOs, several of which are subject to renewal during
2010. More than 50% of our total U.S. net sales in 2009 was derived from the GPO relationships that
are subject to renewal this year. Our failure to renew one or more of these GPO contracts may cause
us to lose market share and could have a material adverse effect on our net sales and operating
results. We cannot assure you that we will be able to renew, renegotiate or replace these
contracts at the current or substantially similar terms. If we are unable to maintain our current
GPO relationships and/or develop new GPO relationships, our net sales and competitive position
likely would suffer.
We may be subject to intellectual property litigation and infringement claims, which could cause us
to incur liabilities and costs, prevent us from selling our products, cause us to redesign our
products, require us to enter into costly license agreements and result in other adverse
consequences.
The medical device industry is litigious with respect to patents and other intellectual property
rights. Companies operating in our industry routinely seek patent protection for their product
designs, and many of our principal competitors have large patent portfolios. Companies in the
medical device industry have used intellectual property litigation to gain a competitive advantage,
including aggressively challenging the patent rights of other companies in order to prevent the
marketing of new products. The fact that we have patents issued to us for our products does not
mean that we will always be able to successfully defend our patents and proprietary rights against
challenges or claims of infringement by our competitors. Whether a product infringes a patent
involves complex legal and factual issues, the determination of which is often uncertain. We have
incurred in the past significant costs in connection with patent litigation, including in
connection with our previous litigation with the Regents of the University of California and Boston
Scientific Corporation. We continue to face the risk of claims that we have infringed on third
parties intellectual property rights.
From time to time, in the ordinary course of business, we receive notices from third parties
alleging infringement or misappropriation of the patent, trademark or other intellectual property
rights of third parties by us or our customers in connection with the use of our products or we
otherwise may become aware of possible infringement claims against us. We routinely analyze such
claims and determine how best to respond in light of the circumstances existing at the time,
including the importance of the intellectual property right to us and the third party, the relative
strength of our position of non-infringement or non-misappropriation and the product or products
incorporating the intellectual property right at issue.
We also may be unaware of intellectual property rights of others that may cover some of our
technology. Prior to launching major new products in our key markets, we normally evaluate
existing intellectual property rights. However, our competitors may have filed for patent
protection which is not as yet a matter of public knowledge or claim trademark rights that have not
been revealed through our availability searches. Our efforts to identify and avoid infringing on
third parties intellectual property rights may not always be successful.
Any claims of patent or other intellectual property infringement, even those without merit, could:
|
|
|
be expensive and time consuming to defend; |
|
|
|
|
result in us being required to pay significant damages to third parties; |
43
|
|
|
cause us to cease making or selling products that incorporate the challenged
intellectual property; |
|
|
|
|
require us to redesign, reengineer or rebrand our products, if feasible; |
|
|
|
|
require us to enter into license agreements in order to obtain the right to use a
third partys intellectual property, which agreements may require us to pay significant
license fees, including royalties, or may not be available on terms acceptable to us or
at all and which licenses may be non-exclusive, which could provide our competitors
access to the same technologies; |
|
|
|
|
divert the attention of our management and other personnel from other business
issues; or |
|
|
|
|
result in our customers or potential customers deferring or limiting their purchase
or use of the affected products until resolution of the litigation. |
In addition, new patents obtained by our competitors could threaten a products continued life in
the market even after it has already been introduced. Any of these adverse consequences could have
a material adverse effect on our business, operating results and financial condition.
If our patents and other intellectual property rights do not adequately protect our products, we
may lose market share to our competitors, which would harm our business.
Our future success depends significantly on our ability to protect our proprietary rights to the
technologies used in our products. We rely on patent protection, as well as a combination of
copyright and trademark laws and nondisclosure, confidentiality and other contractual arrangements
to protect our proprietary technology. However, these legal means afford only limited protection
and may not adequately protect our rights or permit us to gain or keep any competitive advantage.
In addition, we cannot be assured that any of our pending patent applications will result in the
issuance of a patent to us. The United States Patent and Trademark Office, or PTO, may deny or
require significant narrowing of claims in our pending patent applications, and patents issued as a
result of the pending patent applications, if any, may not provide us with significant commercial
protection or be issued in a form that is advantageous to us. We also could incur substantial
costs in proceedings before the PTO. These proceedings could result in adverse decisions as to the
priority of our inventions and the narrowing or invalidation of claims in issued patents. Our
issued patents and those that may be issued in the future may be challenged, invalidated or
circumvented, which could limit our ability to stop competitors from marketing related products.
Litigation also may be necessary to enforce patent rights we hold or to protect trade secrets or
techniques we own. Intellectual property litigation is costly and may adversely affect our
operating results. Although we have taken steps to protect our intellectual property and
proprietary technology, there is no assurance that third parties will not be able to design around
our patents. We also rely on unpatented proprietary technology. In addition, we rely on the use
of registered trademarks with respect to the brand names of some of our products. We also rely on
common law trademark protection for some brand names, which are not protected to the same extent as
our rights in the use of our registered trademarks. We cannot assure you that we will be able to
meaningfully protect all of our rights in our unpatented proprietary technology or that others will
not independently develop substantially equivalent proprietary products or processes or otherwise
gain access to our unpatented proprietary technology. We seek to protect our know-how and other
unpatented proprietary technology, in part with confidentiality agreements and intellectual
property assignment agreements with our employees, independent distributors and consultants.
However, such agreements may not be enforceable or may not provide meaningful protection for our
proprietary information in the event of unauthorized use or disclosure or other breaches of the
agreements or in the event that our competitors discover or independently develop similar or
identical designs or other proprietary information. For example, we are currently involved in
litigation with Cardiovascular Systems, Inc. in which we allege misappropriation and use of our
confidential information by CSI and certain of CSIs employees who were formerly employees of our
subsidiary, FoxHollow. The complaint also alleges that certain of CSIs employees violated their
employment agreements with FoxHollow requiring them to refrain from soliciting FoxHollow employees.
Furthermore, the laws of foreign countries may not protect our intellectual property rights to the
same extent as the laws of the United States. For example, foreign countries generally do not
allow patents to cover methods for performing surgical procedures. If we cannot adequately protect
our intellectual property rights in these foreign
44
countries, our competitors may be able to compete more directly with us, which could adversely
affect our competitive position and business.
We also hold licenses from third parties that are necessary to use certain technologies used in the
design and manufacturing of some of our products. The loss of such licenses would prevent us from
manufacturing, marketing and selling these products, which could harm our business and operating
results.
We manufacture our products at single locations. Any disruption in these manufacturing facilities,
any patent infringement claims with respect to our manufacturing process or otherwise any inability
to manufacture a sufficient number of our products to meet demand could adversely affect our
business and operating results.
We rely on our manufacturing facilities in Plymouth, Minnesota, Irvine, California and Menlo Park,
California. Any damage or destruction to our facilities and the manufacturing equipment we use to
produce our products would be difficult to replace and could require substantial lead-time to
repair or replace. The lease for our Plymouth manufacturing facility expires in 2010. If we are
unable to renew this lease or find an alternative location on a timely basis, our manufacturing
capabilities could be disrupted. Our facilities may be affected by natural or man-made disasters.
In the event we are unable to renew our Plymouth manufacturing facility lease or if one of our
facilities was affected by a disaster, we would be forced to rely on third-party manufacturers if
we could not shift production to one of our other manufacturing facilities. In the case of a
device with a premarket approval application, we might in such event be required to obtain prior
FDA or notified body approval of an alternate manufacturing facility, which could delay or prevent
our marketing of the affected product until such approval is obtained. Although we believe that we
possess adequate insurance for damage to our property and the disruption of our business from
casualties, such insurance may not be sufficient to cover all of our potential losses and may not
continue to be available to us on acceptable terms, or at all. It is also possible that one of our
competitors could claim that our manufacturing process violates an existing patent. If we were
unsuccessful in defending such a claim, we might be forced to stop production at one of our
manufacturing facilities in the United States and to seek alternative facilities. Even if we were
able to identify such alternative facilities, we might incur additional costs and experience a
disruption in the supply of our products until those facilities are available. Any disruption in
our manufacturing capacity could have an adverse impact on our ability to produce sufficient
inventory of our products or may require us to incur additional expenses in order to produce
sufficient inventory, and therefore would adversely affect our net sales and operating results.
We have limited experience in manufacturing our products in commercial quantities and therefore may
encounter unforeseen situations that could result in delays or shortfalls. Manufacturers often
experience difficulties in increasing production, including problems with production yields and
quality control and assurance. Any disruption or delay at our manufacturing facilities, any
inability to accurately predict the number of products to manufacture or to expand our
manufacturing capabilities if necessary could impair our ability to meet the demand of our
customers and these customers may cancel orders or purchase products from our competitors, which
could adversely affect our business and operating results.
Our dependence on key suppliers puts us at risk of interruptions in the availability of our
products, which could reduce our net sales and adversely affect our operating results. In
addition, increases in prices for raw materials and components used in our products could adversely
affect our operating results.
We rely on a limited number of suppliers for certain raw materials and components used in our
products. For reasons of quality assurance, cost effectiveness or availability, we procure certain
raw materials and components from sole and limited source suppliers. We generally acquire such raw
materials and components through purchase orders placed in the ordinary course of business, and as
a result we do not have a significant inventory of these materials and components and do not have
any guaranteed or contractual supply arrangements with many of these suppliers. In addition, we
also rely on independent contract manufacturers for some of our products. Independent
manufacturers have possession of, and in some cases hold title to, molds for certain manufactured
components of our products. Our dependence on third-party suppliers involves several risks,
including limited control over pricing, availability, quality and delivery schedules, as well as
manufacturing yields and costs. Suppliers of raw materials and components may decide, or be
required, for reasons beyond our control to cease supplying raw materials and components to us or
to raise their prices.
45
Shortages of raw materials, quality control problems, production capacity constraints or delays by
our contract manufacturers could negatively affect our ability to meet our production obligations
and result in increased prices for affected parts. Any such shortage, constraint or delay may
result in delays in shipments of our products or components, which could adversely affect our net
sales and operating results. Increases in prices for raw materials and components used in our
products could also adversely affect our operating results.
In addition, the FDA and foreign regulators may require additional testing of any raw materials or
components from new suppliers prior to our use of these materials or components. In the case of a
device with a premarket approval application, we may be required to obtain prior FDA approval of a
new supplier, which could delay or prevent our access or use of such raw materials or components or
our marketing of affected products until such approval is granted. In the case of a device with
clearance under section 510(k) of the Federal Food, Drug and Cosmetic Act, referred to as a 510(k),
we may be required to submit a new 510(k) if a change in a raw material or component supplier
results in a change in a material or component supplied that is not within the 510(k) cleared
device specifications. If we need to establish additional or replacement suppliers for some of
these components, our access to the components might be delayed while we qualify such suppliers and
obtain any necessary FDA approvals. Our suppliers of finished goods also are subject to regulatory
inspection and scrutiny. Any adverse regulatory finding or action against those suppliers could
impact their ability to supply us raw materials and components for our products.
Our inability to successfully grow through future acquisitions, our failure to integrate any
acquired businesses successfully into our existing operations or our discovery of previously
undisclosed liabilities could negatively affect our business and operating results.
In order to build our core technology platforms, we have acquired several businesses since our
inception. For example, most recently, in June of 2009, we completed our acquisition of Chestnut.
In October of 2007, we completed our acquisition of FoxHollow. In September of 2006, FoxHollow
acquired Kerberos Proximal Solutions, Inc. In January of 2006, we acquired the outstanding shares
of Micro Therapeutics, Inc. that we did not already own. We expect to continue to actively pursue
additional targeted acquisitions of, investments in or alliances with, other companies and
businesses in the future as a component of our business strategy. Our ability to grow through
future acquisitions, investments and alliances will depend upon our ability to identify, negotiate,
complete and integrate attractive candidates on favorable terms and to obtain any necessary
financing. Our inability to complete one or more acquisitions, investments or alliances could
impair our ability to develop our product lines and to compete against many industry participants,
many of whom have product lines broader than ours. Acquisitions, investments and alliances involve
risks, including:
|
|
|
difficulties in integrating any acquired companies, personnel and products into our
existing business; |
|
|
|
|
delays in realizing projected efficiencies, cost savings, revenue synergies and
other benefits of the acquired company or products; |
|
|
|
|
inaccurate assessment of the future market size or market acceptance of any acquired
products or technologies or the hurdles in obtaining regulatory approvals of such
products; |
|
|
|
|
inaccurate assessment of undisclosed, contingent or other liabilities or problems; |
|
|
|
|
diversion of our managements time and attention from other business concerns; |
|
|
|
|
limited or no direct prior experience in new markets or countries we may enter; |
|
|
|
|
higher costs of integration than we anticipated; |
|
|
|
|
adverse accounting consequences; or |
|
|
|
|
difficulties in retaining key employees of the acquired business who are necessary
to manage the acquired business. |
46
In addition, an anticipated or completed acquisition, investment or alliance could materially
impair our operating results and liquidity by causing us to use our cash resources to pay the
purchase price, incur debt or reallocate amounts of capital from other operating initiatives or
requiring us to expense incurred transaction and restructuring costs and amortize acquired assets,
incur non-recurring charges as a result of incorrect estimates made in the accounting for such
transactions or record asset impairment charges. For example, we incurred impairment charges to our
goodwill and other intangible assets totaling $288.8 million in our fourth quarter of 2008 which
charges related primarily to assets derived from previous acquisitions. We also may discover
deficiencies in internal controls, data adequacy and integrity, product quality, regulatory
compliance and product liabilities which we did not uncover prior to our acquisition of such
businesses, which could result in us becoming subject to penalties or other liabilities. Any
difficulties in the integration of acquired businesses or unexpected penalties or liabilities in
connection with such businesses could have a material adverse effect on our operating results and
financial condition. These risks could be heightened if we complete several acquisitions within a
relatively short period of time. Finally, any acquisitions that involve the issuance of our common
stock could be dilutive to our stockholders.
Our products and our product development and marketing activities are subject to extensive
regulation as a result of which we may not be able to obtain required regulatory approvals for our
products in a cost-effective manner or at all, which could adversely affect our business and
operating results.
The production and marketing of our products and our ongoing research and development, preclinical
testing and clinical trial activities are subject to extensive regulation and review by numerous
governmental authorities both in the United States and abroad. U.S. and foreign regulations
applicable to medical devices are wide-ranging and govern, among other things, the development,
testing, marketing and premarket review of new medical devices, in addition to regulating
manufacturing practices, reporting, advertising, exporting, labeling and record keeping procedures.
We are required to obtain FDA approval or clearance before we can market our products in the
United States and certain foreign countries. The regulatory process requires significant time,
effort and expenditures to bring products to market, and it is possible that our products will not
be approved for sale.
The FDA recently has requested that the Institute of Medicine perform a study on whether
legislative, regulatory or administrative changes are needed to the FDAs 510(k) clearance process.
The Institute of Medicine report is due in 2011. The FDA also announced an internal working group
to evaluate and improve the consistency of FDA decision making in the clearance process, and
recently released an internal report in which FDA officials questioned the 510(k) process in
general. Various committees of the U.S. Congress also have indicated that they may consider
investigating the FDAs 510(k) process. Under the current 510(k) rules, certain types of medical
device can obtain FDA approval without lengthy and expensive clinical trials. Among our product
offerings, those products that require FDA approval have received such approval under the 510(k)
rules. Most of our research and development programs and new product programs contemplate
obtaining any required FDA approvals under the current 510(k) rules. Any changes to the current
510(k) or related FDA rules that make such rules more stringent or require more clinical data,
could significantly increase the time and costs associated with bringing new products to market.
This likely would have a material adverse effect on our business, financial condition and operating
results.
Even if regulatory approval or clearance of a product is granted, it may not be granted within the
timeframe that we expect, which could have an adverse effect on our operating results and financial
condition. In addition, even if regulatory approval or clearance of a product is granted, the
approval or clearance could limit the uses for which the product may be labeled and promoted, which
may limit the market for our products. Even after a product is approved or cleared by the FDA, we
may have ongoing responsibilities under FDA regulations, non-compliance of which could result in
the subsequent withdrawal of such approvals or clearances, or such approvals or clearances could be
withdrawn due to the occurrence of unforeseen problems following initial approval. We also are
subject to medical device reporting regulations that require us to report to the FDA if any of our
products causes or contributes to a death or serious injury or if a malfunction were it to occur
might cause or contribute to a death or serious injury. Any failure to obtain regulatory approvals
or clearances on a timely basis or the subsequent withdrawal of such approvals or clearances could
prevent us from successfully marketing our products, which could adversely affect our business and
operating results.
47
Our failure to comply with applicable regulatory requirements could result in governmental
agencies:
|
|
|
imposing fines and penalties on us; |
|
|
|
|
preventing us from manufacturing or selling our products; |
|
|
|
|
bringing civil or criminal charges against us; |
|
|
|
|
delaying the introduction of our new products into the market; |
|
|
|
|
suspending any ongoing clinical trials; |
|
|
|
|
issuing an injunction preventing us from manufacturing or selling our products or
imposing restrictions; |
|
|
|
|
recalling or seizing our products; or |
|
|
|
|
withdrawing or denying approvals or clearances for our products. |
Our failure to comply with applicable regulatory requirements also may result in us not being able
to meet the demands of our customers and our customers canceling orders or purchasing products from
our competitors, which could adversely affect our business and operating results.
When required, with respect to the products we market in the United States, we have obtained
premarket notification clearance under section 510(k), but do not believe certain modifications we
have made to our products require us to submit new 510(k) notifications. However, if the FDA
disagrees with us and requires us to submit a new 510(k) notification for modifications to our
existing products, we may be subject to enforcement actions by the FDA and be required to stop
marketing the products while the FDA reviews the 510(k) notification. If the FDA requires us to go
through a lengthier, more rigorous examination than we had expected, our product introductions or
modifications could be delayed or canceled, which could cause our sales to decline. In addition,
the FDA may determine that future products will require the more costly, lengthy and uncertain
premarket approval application process. Products that are approved through a premarket approval
application generally need FDA approval before they can be modified. If we fail to submit changes
to products developed under IDEs or premarket approval applications in a timely or adequate manner,
we may become subject to regulatory actions.
In addition, we market our products in certain countries outside of the United States. In order to
market our products abroad, we are required to obtain separate regulatory approvals and comply with
numerous requirements. If additional regulatory requirements are implemented in the foreign
countries in which we sell our products, the cost of developing or selling our products may
increase. We depend on our distributors outside the United States in seeking regulatory approval
to market our devices in certain other countries and we therefore are dependent on persons outside
of our direct control to secure such approvals. For example, we are highly dependent on
distributors in emerging markets such as China and Brazil for regulatory submissions and approvals
and do not have direct access to health care agencies in those markets to ensure timely regulatory
approvals or prompt resolution of regulatory or compliance matters. If our distributors fail to
obtain the required approvals or do not do so in a timely manner, our sales from our international
operations and our operating results may be adversely affected.
48
If we or others identify side effects after any of our products are on the market, we may be
required to withdraw our products from the market, which would hinder or preclude our ability to
generate sales.
As part of our post-market regulatory responsibilities for our products classified as medical
devices, we are required to report all serious injuries or deaths involving our products, and any
malfunctions where a serious injury or death would be likely if the malfunction were to recur. If
we or others identify side effects after any of our products are on the market:
|
|
|
regulatory authorities may withdraw their approvals; |
|
|
|
|
we may be required to redesign or reformulate our products; |
|
|
|
|
we may have to recall the affected products from the market and may not be able to
reintroduce them onto the market; |
|
|
|
|
our reputation in the marketplace may suffer; and |
|
|
|
|
we may become the target of lawsuits, including class action suits. |
Any of these events, some of which have happened to us in the recent past, could harm or prevent
sales of the affected products or could substantially increase the costs and expenses of
commercializing or marketing these products.
Our manufacturing facilities are subject to extensive governmental regulation with which compliance
is costly and which expose us to penalties for non-compliance.
We and our third party manufacturers are required to register with the FDA as device manufacturers
and as a result, we and our third party manufacturers are subject to periodic inspections by the
FDA for compliance with the FDAs Quality System Regulation, or QSR, requirements, which require
manufacturers of medical devices to adhere to certain regulations, including testing, quality
control and documentation procedures. In addition, the federal Medical Device Reporting
regulations require us and our third party manufacturers to provide information to the FDA whenever
there is evidence that reasonably suggests that a device may have caused or contributed to a death
or serious injury or, if a malfunction were to occur, could cause or contribute to a death or
serious injury. Compliance with applicable regulatory requirements is subject to continual review
and is rigorously monitored through periodic inspections by the FDA. We also are subject to
similar state requirements and licenses. In the European Community, we are required to maintain
certain International Organization for Standardization, or ISO, certifications in order to sell
products and we are required to undergo periodic inspections by notified bodies to obtain and
maintain these certifications. If we or our manufacturers fail to adhere to QSR or ISO
requirements, this could delay production of our products and lead to fines, difficulties and
delays in obtaining regulatory approvals and clearances, the withdrawal of regulatory approvals and
clearances, recalls or other consequences, which could in turn have a material adverse effect on
our financial condition and operating results. In addition, regulatory agencies may not agree with
the extent or speed of corrective actions relating to product or manufacturing problems.
Our operations are subject to environmental, health and safety, and other laws and regulations,
with which compliance is costly and which expose us to penalties for non-compliance.
Our business, properties and products are subject to foreign, federal, state and local laws and
regulations relating to the protection of the environment, natural resources and worker health and
safety and the use, management, storage, and disposal of hazardous substances, wastes, and other
regulated materials. Because we operate real property, various environmental laws also may impose
liability on us for the costs of cleaning up and responding to hazardous substances that may have
been released on our property, including releases unknown to us. These environmental laws and
regulations also could require us to pay for environmental remediation and response costs at
third-party locations where we disposed of or recycled hazardous substances. The costs of
complying with these various environmental requirements, as they now exist or may be altered in the future, could adversely
affect our financial condition and operating results.
49
We may require additional capital in the future, which may not be available or may be available
only on unfavorable terms. In addition, any equity financings may be dilutive to our stockholders.
As of December 31, 2009, we had $98.1 million in cash and cash equivalents. We believe that our
proposed operating plan can be accomplished without additional financing based on our cash and cash
equivalent balance, current and projected net sales and expenses, working capital and current and
anticipated financing arrangements. However, there can be no assurance that our anticipated net
sales or expense projections will be realized. Furthermore, there may be delays in obtaining
necessary governmental approvals of our products or introducing our products to market or other
events that may cause our actual cash requirements to exceed those for which we have budgeted. Our
capital requirements will depend on many factors, including our ability to sustain profitability,
the amount and timing of any losses, our cash flows from operations, expenditures on intellectual
property and technologies, the number of clinical trials which we will conduct, new product
development and acquisitions. To the extent that our then existing capital, including amounts
available under our current and anticipated financing arrangements, is insufficient to cover any
losses and meet these requirements, we will need to raise additional funds through financings or
borrowings or curtail our growth and reduce our assets. Any equity or debt financing, if available
at all, may be on terms that are not favorable to us, especially in light of the difficult market
conditions for raising additional financing. Equity or debt financing arrangements could result in
dilution to our stockholders, and the securities issued in future financings as well as in any
future acquisitions may have rights, preferences and privileges that are senior to those of our
common stock. If we obtain debt financing, a portion of our operating cash flow would be dedicated
to the payment of principal and interest on such indebtedness, thus limiting funds available for
our business activities, and we could be subject to covenants that restrict our ability to operate
our business and make distributions to our stockholders. If our need for capital arises because of
continued losses, the occurrence of these losses may make it more difficult for us to raise the
necessary capital.
Our quarterly operating results are subject to substantial fluctuations and you should not rely on
them as an indication of our future results.
Our quarterly operating and financial results may fluctuate from period to period due to a
combination of factors, many of which are beyond our control. These include:
|
|
|
the seasonality of our product sales, which typically results in higher demand in
our fourth quarter and lower sales volumes in our third quarter; |
|
|
|
|
the mix of our products sold; |
|
|
|
|
demand for, and pricing of, our products and the products of our competitors; |
|
|
|
|
timing of or failure to obtain regulatory approvals for products; |
|
|
|
|
costs, benefits and timing of new product introductions by us and our competitors; |
|
|
|
|
increased competition; |
|
|
|
|
the timing and extent of promotional pricing or volume discounts; |
|
|
|
|
the timing of larger orders by customers and the timing of shipment of such orders; |
|
|
|
|
field inventory levels; |
|
|
|
|
changes in average selling prices; |
|
|
|
|
the availability and cost of components and materials; |
|
|
|
|
the number of selling days; |
50
|
|
|
fluctuations in foreign currency exchange rates; |
|
|
|
|
the possible deferral of revenue under our revenue recognition policies; |
|
|
|
|
the timing of operating expenses in anticipation of sales; |
|
|
|
|
the timing of operating expenses for clinical and other product development
activities; |
|
|
|
|
unanticipated expenses; |
|
|
|
|
the accounting treatment of the contingent consideration we agreed to pay in
connection with our acquisition of Chestnut; |
|
|
|
|
the accounting treatment for income taxes, including the
potential future reversal of our valuation allowance and the
resulting impact on our future recorded effective tax rate; |
|
|
|
|
other costs related to acquisitions of technologies or businesses; |
|
|
|
|
restructuring, impairment and other special charges; and |
|
|
|
|
fluctuations in investment returns on invested cash balances. |
Because of these and other factors, our quarterly sales and other operating results may vary
significantly in the future and thus period to period comparisons may not be meaningful and should
not be relied upon as indications of our future performance. Any shortfalls in sales or earnings
from levels expected by securities analysts or investors could cause our stock price to decline
significantly.
We may become obligated to make large milestone payments that are not reflected in our consolidated
financial statements in certain circumstances, which would negatively impact our cash flows. In
addition, due to changes in applicable generally accepted accounting principles, the milestone
payment for our recent acquisition of Chestnut likely could negatively impact our future operating
results.
Pursuant to the acquisition agreements relating to our purchases of Chestnut, MitraLife and Appriva
and FoxHollows purchase of Kerberos Proximal Solutions, Inc., we and/or our subsidiaries agreed to
make additional payments to the sellers of these businesses in the event that we achieve
contractually defined milestones. Generally, in each case, these milestone payments become due
upon the completion of specific regulatory steps in the product commercialization process.
Under the terms of our acquisition agreement with Chestnut, we may be obligated to make an
additional milestone payment of up to $75 million if the FDA issues a letter granting pre-market
approval for the commercialization of the Pipeline Embolization Device in the United States
pursuant to an indication to treat intracranial aneurysms on or before December 31, 2012. The
milestone payment is to be made in cash and shares of our common stock and is subject to certain
rights of set-off for permitted indemnification claims by us against Chestnut. If we are required
to make an additional milestone payment of cash and common stock to the former Chestnut
shareholders and if we do not have a sufficient amount of cash and cash equivalents to make this
milestone payment, we will be required to raise additional financing, which may be difficult or
impossible, depending upon our business and operating results and the market for such financings at
that time.
With respect to the MitraLife acquisition, the maximum potential milestone payments totaled $25
million, and with respect to the Appriva acquisition, the maximum potential milestone payments
totaled $175 million. Although we do not believe that it is likely that the milestone payment
obligations to MitraLife or Appriva became due, the former stockholders of Appriva disagree with
our position and have brought litigation against us making a claim for such payments and it is
possible that the former stockholders of MitraLife also could disagree with our position and
make a claim for such payments. Pursuant to the acquisition agreement relating to FoxHollows
purchase of Kerberos Proximal Solutions, Inc., FoxHollow agreed to pay certain earn-out payments
which are capped at $117 million upon the achievement of contractually defined net sales
milestones. We have received correspondence from counsel for the shareholder representatives of
Kerberos alleging that FoxHollow has not used commercially reasonable efforts to market, promote,
sell and distribute Kerbeross Rinspirator products, as required under the
51
agreement and plan of
merger. There can be no assurance that the stockholder representatives of Kerberos will not
commence litigation on the alleged claims. The defense of the outstanding litigation related to
our Appriva acquisition and the outstanding claims related to FoxHollows Kerberos acquisition is,
and any such additional dispute with MitraLife would likely be, costly and time-consuming and
divert our managements time and attention away from our business. In the event any such milestone
payments become due and/or any other damages become payable, our costs would increase
correspondingly which would negatively impact our cash flow from operations.
We have accounted for our acquisition of Chestnut using the acquisition method. The fair value of
the potential $75 million milestone payment in connection with our acquisition of Chestnut has been
included as a component of consideration transferred at the acquisition date fair value and is
classified as a liability on our consolidated balance sheet and is remeasured at fair value at each
reporting date with changes in fair value recognized as income or expense. Therefore, any change in
the fair value will impact our earnings in such reporting period thereby resulting in potential
variability in our earnings until the contingent consideration is resolved. Assuming that we
continue to expect to achieve the regulatory milestone, the accounting impact of the future
milestone payment likely will negatively impact our future operating results.
We rely on independent sales distributors and sales associates to market and sell our products
outside of the United States, Canada, Australia and Europe.
Our future success outside of the United States, Canada, Australia and Europe depends largely upon
marketing arrangements with independent sales distributors and sales associates, in particular
their sales and service expertise and relationships with the customers in the marketplace.
Independent distributors and sales associates may terminate their relationship with us, or devote
insufficient sales efforts to our products. We are not able to control our independent
distributors, including their sales activities. Accordingly, although we require all of our
independent sales distributors and sales associates to comply with all applicable laws and
regulations, we cannot assure that they will do so. In addition, because we have no control over
their sales activities, we cannot assure that they will be successful in implementing our marketing
plans. Many of our independent distributors outside of the United States, Canada, Australia and
Europe initially obtain and maintain foreign regulatory approval for sale of our products in their
respective countries. Our failure to maintain our relationships with our independent distributors
and sales associates outside of the United States, Canada, Australia and Europe, or our failure to
recruit and retain additional skilled independent sales distributors and sales associates in these
locations, could have an adverse effect on our operations. We have experienced turnover with some
of our independent distributors in the past that has adversely affected our short-term financial
results while we transitioned to new independent distributors. Similar occurrences could happen to
us in the future. Fluctuations in foreign currency exchange rates, including in particular any
strengthening of the U.S. dollar may cause our independent sales distributors to seek longer
payment terms to offset the higher prices they are paying in local currency for our products. In
addition, in light of adverse worldwide economic conditions, the ability of our distributors to
borrow money from their existing lenders or to obtain credit from other sources to purchase our
products may be impaired or our distributors could experience a significant change in their
liquidity or financial condition, all of which could impair their ability to distribute our
products and eventually lead to distributor turnover.
We are exposed to product liability claims that could have an adverse effect on our business and
operating results.
The design, manufacture and sale of medical devices expose us to significant risk of product
liability claims, some of which may have a negative impact on our business. Most of our products
were developed relatively recently and defects or risks that we have not yet identified may give
rise to product liability claims. Our product liability insurance coverage may be inadequate to
protect us from any liabilities we may incur or we may not be able to maintain adequate product
liability insurance at acceptable rates. If a product liability claim or series of claims is
brought against us for uninsured liabilities or in excess of our insurance coverage and it is
ultimately determined that we are liable, our business could suffer. Additionally, we could
experience a material design defect or
manufacturing failure in our products, a quality system failure, other safety issues or heightened
regulatory scrutiny that would warrant a recall of some of our products. A recall of our products
also could result in increased product liability claims. Further, while we train our physician
customers on the proper usage of our products, there can be no assurance that they will implement
our instructions accurately. If our products are used incorrectly by our customers, injury may
result and this could give rise to product liability claims against us. Even a meritless or
52
unsuccessful product liability claim could harm our reputation in the industry, lead to significant
legal fees and could result in the diversion of managements attention from managing our business
and may have a negative impact on our business and our operating results. In addition, successful
product liability claims against one of our competitors could cause claims to be made against us.
We face competition from other companies, which could adversely impact our business and operating
results.
The markets in which we compete are highly competitive, subject to change and significantly
affected by new product introductions and other activities of industry participants. Because of
the size of the peripheral vascular and neurovascular markets, competitors and potential
competitors have historically dedicated and will continue to dedicate significant resources to
aggressively promote their products, develop new and improved products and/or acquire smaller
companies with established and/or promising product lines. Our competitors and potential
competitors may develop or acquire technologies and products that are safer, more effective, easier
to use, less expensive or more readily accepted than ours. Their products could make our
technology and products obsolete or noncompetitive. None of our customers have long-term purchase
agreements with us and at any time may switch to the use of our competitors products. Many of our
physician customers like to experiment with new technologies. Within the plaque excision market,
although we believe our plaque excision products compete favorably against other competing
technologies, surgical procedures and pharmaceutical products, recently introduced plaque excision
products by our competitors have adversely affected and may continue to adversely affect future
sales of our plaque excision products, at least in the short term while physician customers
experiment with such new products. Within the peripheral vascular stent market, we have
experienced and may continue to experience increased competition from C. R. Bard Inc. which
announced in 2009 that the FDA cleared certain of its stents for use in the superficial femoral
arteries and proximal popliteal arteries, if physicians decide to use C. R. Bard Inc.s FDA cleared
stents rather than our stents off-label.
Our competitors range from small start-up companies to much larger companies. The larger companies
with which we compete include Abbott Laboratories, Boston Scientific Corporation, Cook
Incorporated, Cordis Corporation (a Johnson & Johnson company), Covidien Public Limited Company,
C.R. Bard Inc., Medtronic, Inc., Terumo/MicroVention, Inc. and W.L. Gore & Associates, Inc. All of
these larger companies have substantially greater capital resources, larger customer bases, broader
product lines, larger sales forces, greater marketing and management resources, larger research and
development staffs and larger facilities than ours and have established reputations and
relationships with our target customers, as well as worldwide distribution channels that are more
effective than ours. We also compete, however, and in some cases even more intensely, with smaller
manufacturers. In the peripheral vascular market, we compete against, among others: MEDRAD, Inc.,
Cardiovascular Systems, Inc., Pathway Medical Technologies, Inc., Idev Technologies, Inc., Invatec
s.r.l. (which recently agreed to be acquired by Medtronic) and Spectranetics Corporation. In the
neurovascular market, we compete against, among others: Balt Extrusion, Inc. and Micrus
Corporation. In addition, we compete with a number of drug therapy treatments manufactured by
major pharmaceutical companies, including Otsuka Pharmaceutical, the manufacturer of Pletal, and
Sanofi Aventis, the manufacturer of Plavix.
We also compete with other manufacturers of medical devices for clinical sites to conduct human
trials. If we are not able to locate clinical sites on a timely or cost-effective basis, this
could impede our ability to conduct trials of our products and, therefore, our ability to obtain
required regulatory clearance or approval.
53
We rely on our management information systems for accounting and finance, inventory management,
distribution and other functions and to maintain our research and development and clinical data.
If our information systems fail to adequately perform these functions or if we experience an
interruption in their operation, our business and operating results could be adversely affected.
The efficient operation of our business is dependent on our management information systems, on
which we rely to effectively manage accounting and financial functions; manage order entry, order
fulfillment and inventory replenishment processes; and to maintain research and development and
clinical data. The failure of our management information systems to perform as we anticipate could
disrupt our business and product development and could result in decreased sales, increased
overhead costs, excess inventory and product shortages, causing our business and operating results
to suffer. In addition, our management information systems are vulnerable to damage or
interruption from:
|
|
|
earthquake, fire, flood and other natural disasters; |
|
|
|
|
terrorist attacks and attacks by computer viruses or hackers; and |
|
|
|
|
power loss or computer systems, Internet, telecommunications or data network
failure. |
Any such interruption could adversely affect our business and operating results.
We face a risk of non-compliance with certain financial covenants in our loan agreement with
Silicon Valley Bank. If we are unable to meet the financial or other covenants under the agreement
or negotiate future waivers or amendments of the covenants, we could be in default under the
agreement, which would give Silicon Valley Bank a range of remedies, including declaring all
outstanding debt to be due and payable, foreclosing on the assets securing the loan agreement
and/or ceasing to provide additional revolving loans or letters of credit, which could have a
material adverse effect on us.
Our operating subsidiaries, ev3 Endovascular, Inc., ev3 International, Inc., Micro Therapeutics,
Inc. and FoxHollow Technologies, Inc., are parties to a loan and security agreement with Silicon
Valley Bank. The facility consists of a $50.0 million revolving line of credit and a $10.0 million
term loan. As of December 31, 2009, we had approximately $6.5 million in outstanding borrowings
under the term loan and no outstanding borrowings under the revolving line of credit; however, we
had approximately $934,000 of outstanding letters of credit issued by Silicon Valley Bank. The
loan agreement requires us to maintain a monthly specified liquidity ratio and a quarterly adjusted
earnings before interest, taxes, depreciation and amortization, or EBITDA, level. The loan
agreement contains customary events of default, including, among others, the failure to comply with
certain covenants or other agreements. Upon the occurrence and during the continuation of an event
of default, amounts due under the loan agreement may be accelerated by Silicon Valley Bank. If we
are unable to meet the financial or other covenants under the loan agreement or negotiate future
waivers or amendments of such covenants, an event of default could occur under the loan agreement.
Upon the occurrence and during the continuance of an event of default under the loan agreement,
Silicon Valley Bank has available a range of remedies customary in these circumstances, including
declaring all outstanding debt, together with accrued and unpaid interest thereon, to be due and
payable, foreclosing on the assets securing the loan agreement and/or ceasing to provide additional
revolving loans or letters of credit, which could have a material adverse effect on us.
54
The restrictive covenants in our loan agreement could limit our ability to conduct our business and
respond to changing economic and business conditions and may place us at a competitive disadvantage
relative to other companies that are subject to fewer restrictions.
Our loan and security agreement with Silicon Valley Bank requires us to maintain a specified
liquidity ratio and an adjusted EBITDA level. Our failure to comply with these financial covenants
could adversely affect our financial condition. The loan agreement limits our ability and the
ability of certain of our subsidiaries to, among other things:
|
|
|
transfer all or any part of our business or properties; |
|
|
|
|
permit or suffer a change in control; |
|
|
|
|
merge or consolidate, or acquire any entity; |
|
|
|
|
engage in any material new line of business; |
|
|
|
|
incur additional indebtedness or liens with respect to any of their properties; |
|
|
|
|
pay dividends or make any other distribution on or purchase of, any of their capital
stock; |
|
|
|
|
make investments in other companies; or |
|
|
|
|
engage in related party transactions, |
subject in each case to certain exceptions and limitations. As of December 31, 2009, our cash and
cash equivalents were $98.1 million. In light of the amount of our cash and cash equivalents and
the amounts outstanding under the loan agreement, it is possible that if we needed to we could pay
off the outstanding amounts under the loan agreement at this time. However, it is also possible
that if we do not generate cash from operations as we anticipate or if we incur significant
unanticipated costs that we may need the flexibility provided under our Silicon Valley Bank loan
agreement. The restrictive covenants under the loan agreement could limit our ability, and that of
certain of our subsidiaries, to obtain future financing, withstand a future downturn in our
business or the economy in general or otherwise conduct necessary corporate activities. The
financial and restrictive covenants contained in the loan agreement also could adversely affect our
ability to respond to changing economic and business conditions and place us at a competitive
disadvantage relative to other companies that may be subject to fewer restrictions. Transactions
that we may view as important opportunities, such as acquisitions, may be subject to the consent of
Silicon Valley Bank, which consent may be withheld or granted subject to conditions specified at
the time that may affect the attractiveness or viability of the transaction.
If we remain profitable, we cannot assure you that our net operating losses will be available to
reduce our tax liability.
Our ability to use, or the amount of, our net operating losses may be limited or reduced. Generally
under section 382 of the Internal Revenue Code of 1986, in the event of an ownership change of a
company, the company is only allowed to use a limited amount of its net operating losses arising
prior to the ownership change for each taxable year thereafter. As a result of prior acquisitions,
including Chestnut and FoxHollow, and potential future acquisitions, our ability to use existing
net operating losses to offset U.S. federal taxable income, if we continue to generate taxable
income, may be subject to substantial limitations. These limitations could potentially result in
increased future tax liability for us.
55
Risks Related to our Common Stock
One of our principal stockholders and its affiliates are able to influence matters requiring
stockholder approval and could discourage the purchase of our outstanding shares at a premium.
As of December 31, 2009, Warburg Pincus beneficially owned approximately 24.2% of our outstanding
common stock. In addition, under a holders agreement, we are required to nominate and use our best
efforts to have elected to our board of directors two persons designated by Warburg Pincus and
certain of its affiliates, which we refer to collectively as the Warburg Pincus Entities, and
Vertical Fund I, L.P. and Vertical Fund II, L.P., which we refer to together as the Vertical
Funds, if the Warburg Pincus Entities, the Vertical Funds and their affiliates collectively
beneficially own 20% or more of our common stock. As a result of Warburg Pincuss share ownership
and representation on our board of directors, Warburg Pincus is able to influence our affairs and
actions, including matters requiring stockholder approval, such as the election of directors and
approval of significant corporate transactions. The interests of Warburg Pincus may differ from
the interests of our other stockholders. For example, Warburg Pincus could oppose a third party
offer to acquire us that the other stockholders might consider attractive, and the third party may
not be able or willing to proceed unless Warburg Pincus, as one of our significant stockholders,
supports the offer. Warburg Pincuss concentration of ownership may have the effect of delaying,
preventing or deterring a change in control of our company, could deprive our stockholders of an
opportunity to receive a premium for their common stock as part of a sale or merger of our company
and may negatively affect the market price of our common stock. Transactions that could be
affected by this concentration of ownership include proxy contests, tender offers, mergers or other
purchases of common stock that could give our stockholders the opportunity to realize a premium
over the then-prevailing market price for shares of our common stock. In such case and in similar
situations, our other stockholders may disagree with Warburg Pincus as to whether the action
opposed or supported by Warburg Pincus is in the best interest of our stockholders.
Certain of our principal stockholders may have conflicts of interests with our other stockholders
or our company in the future.
Certain of our principal stockholders, including Warburg Pincus, may make investments in companies
and from time to time acquire and hold interests in businesses that compete directly or indirectly
with us. These other investments may:
|
|
|
create competing financial demands on our principal stockholders; |
|
|
|
|
create potential conflicts of interest; and |
|
|
|
|
require efforts consistent with applicable law to keep the other businesses separate
from our operations. |
These principal stockholders also may pursue acquisition opportunities that may be complementary to
our business and, as a result, those acquisition opportunities may not be available to us.
Furthermore, these principal stockholders may have an interest in us pursuing acquisitions,
divestitures, financings or other transactions that, in their judgment, could enhance their equity
investment, even though such transactions might involve risks to our stockholders. In addition,
these principal stockholders rights to vote or dispose of equity interests in us are not subject
to restrictions in favor of us other than as may be required by applicable law.
Our corporate documents and Delaware law contain provisions that could discourage, delay or prevent
a change in control of our company.
Provisions in our certificate of incorporation and bylaws may discourage, delay or prevent a merger
or acquisition involving our company that our stockholders may consider favorable. For example,
our certificate of incorporation authorizes our board of directors to issue up to 100 million
shares of blank check preferred stock. Without stockholder approval, the board of directors has
the authority to attach special rights, including voting and dividend rights, to this preferred
stock. With these rights, preferred stockholders could make it more difficult for a third party to
acquire our company. In addition, our certificate of incorporation provides for a staggered board
of directors,
56
whereby directors serve for three-year terms, with approximately one-third of the directors coming
up for reelection each year. Having a staggered board makes it more difficult for a third party to
obtain control of our board of directors through a proxy contest, which may be a necessary step in
an acquisition of our company that is not favored by our board of directors.
We also are subject to the anti-takeover provisions of Section 203 of the Delaware General
Corporation Law. Under these provisions, if anyone becomes an interested stockholder, we may not
enter into a business combination with that person for three years without special approval,
which could discourage a third party from making a takeover offer and could delay or prevent a
change of control. For purposes of Section 203, interested stockholder means, generally, someone
owning 15% or more of our outstanding voting stock or an affiliate of our company that owned 15% or
more of our outstanding voting stock during the past three years, subject to certain exceptions as
described in Section 203. Under one such exception, Warburg Pincus does not constitute an
interested stockholder.
A large percentage of our outstanding common stock is held by insiders, and, as a result, the
trading market for our common stock may not be as liquid as the stock of other public companies,
and our common stock price could be volatile.
As of December 31, 2009, we had 112.3 million shares of common stock outstanding and 27.1% of the
shares were beneficially owned by directors, executive officers and their respective affiliates.
Companies with a substantial amount of stock held by insiders can be subject to a more volatile
stock price. Fluctuations in the price of our common stock could be significant and likely will be
impacted by a number of factors, such as:
|
|
|
the introduction of new products or product enhancements by us or our competitors; |
|
|
|
|
changes in our growth rate or our competitors growth rates; |
|
|
|
|
strategic actions by us or our competitors, such as acquisitions or restructurings; |
|
|
|
|
our ability to develop, obtain regulatory clearance or approval for, and market new
and enhanced products on a timely basis; |
|
|
|
|
loss of any of key management personnel; |
|
|
|
|
disputes or other developments with respect to intellectual property rights; |
|
|
|
|
product liability claims or other litigation; |
|
|
|
|
public concern as to the safety or efficacy of our products; |
|
|
|
|
the publics reaction to our press releases and other public announcements and our
filings with the SEC; |
|
|
|
|
sales of common stock by us, our significant stockholders, executive officers or
directors; |
|
|
|
|
changes in stock market analyst recommendations or earnings estimates regarding our
common stock, other comparable companies or our industry generally; |
|
|
|
|
changes in expectations or future performance;
|
57
|
|
|
new laws or regulations or new interpretations of existing laws or regulations
applicable to our business; and |
|
|
|
|
changes in health care policy in the United States and internationally, including
changes in the availability of third-party reimbursement. |
A significant decline in the price of our common stock could result in substantial losses for
individual stockholders and could lead to costly and disruptive securities litigation. Securities
class action litigation is sometimes brought against a company following periods of volatility in
the market price of its securities or for other reasons. We may become the target of similar
litigation. Securities litigation, whether with or without merit, could result in substantial costs
and divert managements attention and resources, which could harm our business and financial
condition, as well as the market price of our common stock.
We do not intend to pay cash dividends for the foreseeable future.
We have never declared or paid any cash dividends on our common stock and we currently intend to
retain all of our earnings for the foreseeable future to finance the operation and expansion of our
business, and do not anticipate paying any cash dividends in the future. As a result, our
stockholders will only receive a return on their investment in our common stock if the market price
of our common stock increases.
|
|
|
ITEM 1B. |
|
UNRESOLVED STAFF COMMENTS |
None.
Our worldwide corporate headquarters is located in Plymouth, Minnesota. The sales, manufacturing
and research and development activities of our peripheral vascular business are primarily located
in Plymouth, and to a lesser extent, in Irvine, California. The sales, manufacturing and research
and development activities of our neurovascular business are primarily located in Irvine and Menlo
Park, California. Our U.S. distribution center is located in Plymouth. Outside the United States,
our European headquarters is in Paris, France, and includes our sales and marketing, and
administrative activities. Our European warehouse facilities are located in Maastricht,
Netherlands. In addition to our sales office in Paris, we have European sales and marketing offices
in Bonn, London, Madrid, Maastricht, Milan and Stockholm. Our total manufacturing space is
approximately 160,000 square feet and our total warehouse space is approximately 39,000 square
feet. All of our real properties are leased with terms ending at various times from 2010 to 2017.
We believe that our premises are adequate for our needs for the foreseeable future.
We are subject to three leases associated with our former FoxHollow operations in Redwood City,
California, which operations we relocated to our Irvine and Plymouth facilities in 2008. We have
entered into an agreement to sublease one of the Redwood City leases until January 15, 2012.
Although we plan to sublease the other two facilities, we have not yet entered into definitive
agreements to do so.
|
|
|
ITEM 3. |
|
LEGAL PROCEEDINGS |
We are from time to time subject to, and are presently involved in, various pending or threatened
legal actions and proceedings, including those that arise in the ordinary course of our business.
Our significant legal proceedings are discussed in Note 18 to our consolidated financial statements
and incorporated herein by reference. While it is not possible to predict the outcome for most of
the legal proceedings discussed in Note 18, the costs associated with such proceedings could have a
material adverse effect on our consolidated results of operations, financial position or cash flows
of a future period.
58
|
|
|
ITEM 4. |
|
SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS |
No matter was submitted to a vote of our security holders during the fourth quarter ended December
31, 2009.
|
|
|
ITEM 4A. |
|
EXECUTIVE OFFICERS OF THE REGISTRANT |
Our executive officers, their ages and positions held, as of February 19, 2010, are as follows:
|
|
|
|
|
|
|
Name |
|
Age |
|
Position |
Robert J. Palmisano
|
|
|
65 |
|
|
President and Chief Executive Officer |
Pascal E.R. Girin
|
|
|
50 |
|
|
Executive Vice President and Chief Operating Officer |
Stacy Enxing Seng
|
|
|
45 |
|
|
Executive Vice President and President, Worldwide
Peripheral Vascular |
Kevin M. Klemz
|
|
|
48 |
|
|
Senior Vice President, Secretary and Chief Legal Officer |
Shawn McCormick
|
|
|
45 |
|
|
Senior Vice President and Chief Financial Officer |
Gregory Morrison
|
|
|
46 |
|
|
Senior Vice President, Human Resources |
David H. Mowry
|
|
|
47 |
|
|
Senior Vice President and President, Worldwide Neurovascular |
Julie D. Tracy
|
|
|
48 |
|
|
Senior Vice President, Chief Communications Officer |
Brett A. Wall
|
|
|
44 |
|
|
Senior Vice President and President, International |
Each of our executive officers serves at the discretion of our board of directors and holds office
until his or her successor is elected and qualified or until his or her earlier resignation or
removal. Information regarding the business experience of our executive officers is set forth
below.
Robert
J. Palmisano has served as
our President and Chief Executive Officer and as one of our directors since April 2008. Mr. Palmisano served
as President and Chief Executive Officer of IntraLase Corp., a company engaged in
the design, development and manufacture of laser products for vision correction, from April 2003 to April 2007,
when IntraLase was acquired by Advanced Medical Optics, Inc. From April 2001 to April 2003,
Mr. Palmisano was the President, Chief Executive Officer and a director of MacroChem Corporation, a development stage pharmaceutical corporation.
From April 1997 to January 2001, Mr. Palmisano served as President and Chief Executive Officer and a director of Summit Autonomous, Inc., a global medical products company that was acquired by Alcon, Inc. in October 2000.
Prior to 1997, Mr. Palmisano held various executive positions with
Bausch & Lomb Incorporated, a global eye care company. Mr. Palmisano earned his B.A.
in Political Science from Providence College. Mr. Palmisano serves on the board of
directors of Osteotech, Inc., a publicly held company, Bausch & Lomb Incorporated and
LenSx Lasers Inc., both privately held companies and is a member of the Board of Trustees
for Providence College in Providence, Rhode Island. During the past five years,
Mr. Palmisano previously served on the board of directors of Abbott Medical Optics Inc.
Pascal E.R. Girin has served as our Executive Vice President and Chief Operating Officer since
January 2010. Mr. Girin served as our Executive Vice President and President, Worldwide
Neurovascular and International from July 2008 to December 2009. Mr. Girin served as our Senior
Vice President from August 2007 to July 2008 and President, International from August 2005 to
October 2009. Mr. Girin previously served as our General Manager, Europe from September 2003 to
July 2005. From September 1998 to August 2003, Mr. Girin served in various capacities at
BioScience Europe Baxter Healthcare Corporation, most recently as Vice President. Mr. Girin
received an Engineering Education at the French Ecole des Mines.
Stacy Enxing Seng has served as our Executive Vice President and President, Worldwide Peripheral
Vascular since January 2010. Prior to January 2010, Ms. Enxing Seng served as Executive Vice
President and President, U.S. Peripheral Vascular since December 2008. Prior to December 2008, Ms.
Enxing Seng served as President, FoxHollow Technologies Division since October 2007, Senior Vice
President since August 2007 and President, Peripheral Vascular Division since March 2005. Ms.
Enxing Seng also previously served as our Vice President, Marketing and New Business Development.
Ms. Enxing Seng has served in various positions at our company since April 2001. Ms. Enxing Seng
has been in the endovascular business since joining Scimed Life Systems, Inc. in 1993, and
immediately prior to joining ev3, she served as Vice President of Global Marketing for the
cardiology division at Boston Scientific/Scimed. Ms. Enxing Seng has a Bachelor of Arts in Public
Policy from Michigan State University and a Master of Business Administration from Harvard
University.
59
Kevin M. Klemz has served as our Senior Vice President since August 2007 and Secretary and Chief
Legal Officer since January 2007. Prior to joining ev3, Mr. Klemz was a partner in the law firm
Oppenheimer Wolff & Donnelly LLP where he was a corporate lawyer for over 20 years. Mr. Klemz has
a Bachelor of Arts in Business Administration from Hamline University and a Juris Doctorate from
William Mitchell College of Law.
Shawn McCormick has served as our Senior Vice President and Chief Financial Officer since January
2009. Prior to joining ev3, Mr. McCormick served as Vice President, Corporate Development at
Medtronic, Inc., a global medical device company, where he was responsible for leading Medtronics
worldwide business development activities and previously had served in key corporate and divisional
financial leadership roles within the Medtronic organization. Mr. McCormick joined Medtronic in
July 1992 and held various finance positions during his tenure. From May 2008, he served as Vice
President, Corporate Technology and New Ventures of Medtronic. From July 2002 to July 2007, he was
Vice President, Finance for Medtronics Spinal, Biologics and Navigation business. Prior to that,
Mr. McCormick held various other positions with Medtronic, including Corporate Development
Director, Principal Corporate Development Associate, Manager, Financial Analysis, Senior Financial
Analyst and Senior Auditor. Prior to joining Medtronic, he spent almost four years with the public
accounting firm KPMG Peat Marwick. Mr. McCormick earned his Master of Business Administration from
the University of Minnesotas Carlson School of Management and his Bachelor of Science in
Accounting from Arizona State University. He is a Certified Public Accountant.
Gregory Morrison has served as our Senior Vice President, Human Resources since August 2007 and
from March 2002 to August 2007 as our Vice President, Human Resources. From March 1999 to February
2002, Mr. Morrison served as Vice President of Organizational Effectiveness for Thomson Legal &
Regulatory, a division of The Thomson Corporation that provides integrated information solutions to
legal, tax, accounting, intellectual property, compliance, business and government professionals.
Mr. Morrison has a Bachelor of Arts in English and Communications from North Adams State College
and a Master of Arts in Corporate Communications from Fairfield University.
David H. Mowry has served as our Senior Vice President and President, Worldwide Neurovascular since
January 2010. From July 2008 to December 2009, Mr. Mowry served as Senior Vice President,
Strategic and Corporate Operations and from October 2007 to July 2008, served as Senior Vice
President, Corporate Manufacturing. Prior to October 2007, Mr. Mowry served as Vice President of
Operations for ev3 Neurovascular since November 2006. From February 2004 to November 2006, Mr.
Mowry served as Vice President of Operations and Logistics at the Zimmer Spine division of Zimmer
Holdings Inc., a reconstructive and spinal implants, trauma and related orthopaedic surgical
products company. Prior to Zimmer, Mr. Mowry was the President and Chief Operating Officer of
HeartStent Corp., a medical device company. Mr. Mowry is a graduate of the United States Military
Academy in West Point, New York with a degree in Engineering and Mathematics.
Julie D. Tracy has served as our Senior Vice President and Chief Communications Officer since
January 2008. From March 2007 to November 2007, Ms. Tracy served as Vice President, Chief
Communications Officer of Kyphon Inc., a medical device company that was purchased by Medtronic,
Inc. in November 2007. From April 2005 to March 2007, Ms. Tracy served as Vice President, Investor
Relations and Corporate Marketing of Kyphon Inc. From January 2003 to April 2005, Ms. Tracy served
as Vice President of Marketing at Kyphon Inc. Prior to joining Kyphon Inc., Ms. Tracy held senior
level positions in marketing, business development and reimbursement at Thoratec Corporation from
January 1998 to January 2003. Ms. Tracy has a Bachelor of Science in Business Administration from
the University of Southern California and a Master of Business Administration from Pepperdine
University.
Brett A. Wall has served as our Senior Vice President and President, International since October
2009. From August 2008 to October 2009, Mr. Wall served as Vice President, Sales and Marketing for
ev3 Neurovascular. Mr. Wall has served in various Vice President positions since April 2001. Mr.
Wall served as Vice President of Marketing for ev3 Peripheral Vascular from January 2008 to August
2008, Vice President of Marketing for ev3 Neurovascular from April 2007 to January 2008, Vice
President of Marketing for ev3 Peripheral Vascular from November 2005 to April 2007 and Vice
President of Marketing for ev3 Neurovascular from April 2001 to November 2005. Mr. Wall was an
early employee of MicroTherapeutics, Inc., serving in a variety of positions. We acquired
MicroTherapeutics in 2006. From September 1995 to September 2000, Mr. Wall served in a variety of
positions for Boston Scientific
60
including Director of Cardiovascular Marketing for the Asia Pacific region. Mr. Wall holds a
Bachelor of Science Degree in Comprehensive Business Administration from the University of Nebraska
at Kearney.
61
PART II
|
|
|
ITEM 5. |
|
MARKET FOR REGISTRANTS COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF
EQUITY SECURITIES |
Market Price
Our common stock is listed for trading on the NASDAQ Global Select Market under the symbol EVVV.
Our common stock has traded on that market, which was formerly known as the NASDAQ National Market
System, since the date of our initial public offering on June 16, 2005.
The following table sets forth the high and low daily sales prices for our common stock, as
reported by the NASDAQ Global Select Market, for each quarter during 2009 and 2008.
|
|
|
|
|
|
|
|
|
|
|
High |
|
Low |
2009 |
|
|
|
|
|
|
|
|
First Quarter |
|
$ |
7.82 |
|
|
$ |
4.40 |
|
Second Quarter |
|
$ |
11.19 |
|
|
$ |
7.05 |
|
Third Quarter |
|
$ |
13.19 |
|
|
$ |
9.60 |
|
Fourth Quarter |
|
$ |
13.93 |
|
|
$ |
11.20 |
|
|
|
|
|
|
|
|
|
|
|
|
High |
|
Low |
2008 |
|
|
|
|
|
|
|
|
First Quarter |
|
$ |
12.72 |
|
|
$ |
7.36 |
|
Second Quarter |
|
$ |
10.69 |
|
|
$ |
7.32 |
|
Third Quarter |
|
$ |
12.58 |
|
|
$ |
8.60 |
|
Fourth Quarter |
|
$ |
9.92 |
|
|
$ |
3.37 |
|
Number of Record Holders; Dividends
As of February 18, 2010, there were 188 record holders of our common stock. To date,
we have not declared or paid any cash dividends on our common stock. The restrictive covenants in
our loan agreement with Silicon Valley Bank limit our ability to pay cash dividends.
Recent Sales of Unregistered Equity Securities
During the fourth quarter ended December 31, 2009, we did not issue or sell any shares of our
common stock or other equity securities of our company without registration under the Securities
Act of 1933, as amended.
62
Issuer Purchases of Equity Securities
The following table sets forth the information with respect to purchases made by or on behalf of us
or any affiliated purchaser (as defined in Rule 10b-18(a)(3) under the Securities Exchange Act of
1934, as amended), of shares of our common stock during each month of our fourth quarter ended
December 31, 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
|
|
|
Total Number of |
|
Maximum Number of |
|
|
Number |
|
|
|
|
|
Shares Purchased as |
|
Shares that May Yet |
|
|
of |
|
Average Price |
|
Part of Publicly |
|
Be Purchased Under |
|
|
Shares |
|
Paid Per |
|
Announced Plans or |
|
the Plans or |
Period |
|
Purchased(1) |
|
Share |
|
Programs(2) |
|
Programs(2) |
Month # 1
(October 5, 2009 November 8, 2009) |
|
|
2,144 |
|
|
$ |
12.18 |
|
|
|
N/A |
|
|
|
N/A |
|
Month # 2
(November 9, 2009 December 6, 2009) |
|
|
34,600 |
|
|
|
12.57 |
|
|
|
N/A |
|
|
|
N/A |
|
Month # 3
(December 7, 2009 December 31, 2009) |
|
|
|
|
|
|
|
|
|
|
N/A |
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total: |
|
|
36,744 |
|
|
$ |
12.55 |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
|
(1) |
|
Consists of shares repurchased from employees in connection with the required payment of
withholding or employment-related tax obligations due in connection with the vesting of
restricted stock awards. |
|
(2) |
|
Our board of directors has not authorized any repurchase plan or program for purchase of
shares of our common stock or other equity securities on the open market or otherwise, other
than an indefinite number of shares in connection with the cashless exercise of outstanding
stock options and the surrender of shares of our common stock upon the issuance or vesting of
stock grants to satisfy any required withholding or employment-related tax obligations. |
Except as set forth in the table above, we did not purchase any shares of our common stock or
other equity securities of our company registered pursuant to Section 12 of the Securities Exchange
Act of 1934, as amended, during the fourth quarter ended December 31, 2009.
63
Stock Performance Graph
The following graph compares the annual cumulative total stockholder return on our common stock
from June 16, 2005, the date of our initial public offering, until December 31, 2009, with the
annual cumulative total return over the same period of The NASDAQ Stock Market (U.S.) Index and The
NASDAQ Medical Equipment Index.
The comparison assumes the investment of $100 in each of our common stock, The NASDAQ Stock Market
(U.S.) Index and The NASDAQ Medical Equipment Index on June 16, 2005, and the reinvestment of all
dividends.
The foregoing Stock Performance Graph shall not be deemed to be filed with the Securities and
Exchange Commission or subject to the liabilities of Section 18 of the Securities Exchange Act of
1934, as amended. Notwithstanding anything to the contrary set forth in any of our previous filings
under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended,
that might incorporate future filings, including this annual report on Form 10-K, in whole or in
part, the foregoing Stock Performance Graph shall not be incorporated by reference into any such
filings.
64
ITEM 6. SELECTED FINANCIAL DATA
The following selected consolidated financial data set forth our results of operations and balance
sheet data for the fiscal years and as of the dates indicated. Certain prior year items have been
reclassified to conform to the current year presentation.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31, |
|
|
|
2009(1) |
|
|
2008 |
|
|
2007(2) |
|
|
2006 |
|
|
2005 |
|
|
|
(dollars in thousands, except per unit and per share amounts) |
|
Results of Operations: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net product sales |
|
$ |
449,072 |
|
|
$ |
402,233 |
|
|
$ |
278,226 |
|
|
$ |
202,438 |
|
|
$ |
133,696 |
|
Research collaboration |
|
|
|
|
|
|
19,895 |
|
|
|
5,957 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
|
449,072 |
|
|
|
422,128 |
|
|
|
284,183 |
|
|
|
202,438 |
|
|
|
133,696 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product cost of goods sold |
|
|
120,613 |
|
|
|
136,847 |
|
|
|
99,879 |
|
|
|
71,321 |
|
|
|
55,094 |
|
Research collaboration |
|
|
|
|
|
|
6,051 |
|
|
|
1,065 |
|
|
|
|
|
|
|
|
|
Sales, general and administrative |
|
|
225,023 |
|
|
|
232,200 |
|
|
|
194,289 |
|
|
|
141,941 |
|
|
|
130,627 |
|
Research and development |
|
|
49,060 |
|
|
|
48,784 |
|
|
|
48,413 |
|
|
|
26,725 |
|
|
|
39,280 |
|
Amortization of intangible assets |
|
|
25,143 |
|
|
|
31,072 |
|
|
|
20,306 |
|
|
|
17,223 |
|
|
|
10,673 |
|
Contingent consideration |
|
|
4,876 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Goodwill and intangible asset
impairment(3) |
|
|
|
|
|
|
299,263 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Acquired in-process research and
development |
|
|
|
|
|
|
|
|
|
|
70,700 |
|
|
|
1,786 |
|
|
|
868 |
|
Special charges (4) |
|
|
|
|
|
|
|
|
|
|
19,054 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
424,715 |
|
|
|
754,217 |
|
|
|
453,706 |
|
|
|
258,996 |
|
|
|
236,542 |
|
Income (loss) from operations |
|
|
24,357 |
|
|
|
(332,089 |
) |
|
|
(169,523 |
) |
|
|
(56,558 |
) |
|
|
(102,846 |
) |
Other (income) expense: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Gain) loss on investments, net |
|
|
(4,113 |
) |
|
|
(487 |
) |
|
|
116 |
|
|
|
(1,063 |
) |
|
|
(4,611 |
) |
Interest expense (income), net |
|
|
788 |
|
|
|
(223 |
) |
|
|
(1,910 |
) |
|
|
(1,695 |
) |
|
|
9,916 |
|
Minority interest in loss of subsidiary |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2,013 |
) |
Other expense (income), net |
|
|
1,588 |
|
|
|
2,427 |
|
|
|
(2,934 |
) |
|
|
(2,117 |
) |
|
|
3,360 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
|
|
26,094 |
|
|
|
(333,806 |
) |
|
|
(164,795 |
) |
|
|
(51,683 |
) |
|
|
(109,498 |
) |
Income tax (benefit) expense |
|
|
(15,823 |
) |
|
|
1,816 |
|
|
|
949 |
|
|
|
688 |
|
|
|
526 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
|
41,917 |
|
|
|
(335,622 |
) |
|
|
(165,744 |
) |
|
|
(52,371 |
) |
|
|
(110,024 |
) |
Accretion of preferred membership units
to redemption value(5) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,061 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) attributable to common
unit/share holders |
|
$ |
41,917 |
|
|
$ |
(335,622 |
) |
|
$ |
(165,744 |
) |
|
$ |
(52,371 |
) |
|
$ |
(122,085 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per common
unit/share(6): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.39 |
|
|
$ |
(3.22 |
) |
|
$ |
(2.37 |
) |
|
$ |
(0.93 |
) |
|
$ |
(4.48 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
$ |
0.38 |
|
|
$ |
(3.22 |
) |
|
$ |
(2.37 |
) |
|
$ |
(0.93 |
) |
|
$ |
(4.48 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average units/shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
107,997,738 |
|
|
|
104,378,828 |
|
|
|
69,909,708 |
|
|
|
56,585,025 |
|
|
|
27,242,712 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
|
108,998,528 |
|
|
|
104,378,828 |
|
|
|
69,909,708 |
|
|
|
56,585,025 |
|
|
|
27,242,712 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
We acquired Chestnut Medical Technologies, Inc. on June 23, 2009. In connection with the
acquisition, we recorded $4.9 million of contingent consideration and recognized a tax benefit
of $19.0 million which resulted from the reversal of existing deferred tax valuation
allowance. For a more complete description of these items and their impact on our consolidated
financial results, see Note 3 to our consolidated financial statements. |
|
(2) |
|
We acquired FoxHollow Technologies, Inc. on October 4, 2007. In connection with the
acquisition, we recorded $14.9 million of integration costs associated with the acquisition
and recognized $70.7 million for in-process research and development charges. For a more
complete description of these items and their impact on our consolidated financial results,
see Note 3 to our consolidated financial statements. |
65
|
|
|
(3) |
|
We recorded $288.8 million in non-cash, asset impairment charges in our peripheral vascular
segment to reduce the carrying values of goodwill and certain other intangible assets to their
estimated fair values in 2008. In 2008, we also recorded an asset impairment charge of $10.5
million, as a result of the termination of our research collaboration with Merck & Co., Inc.,
to write-off the remaining carrying value of the related Merck intangible asset that was
established at the time of our acquisition of FoxHollow. For a more complete description of
these items and their impact on our consolidated financial results, see Note 9 to our
consolidated financial statements. |
|
(4) |
|
We recorded $19.1 million of special charges as a result of the settlement of the global coil
patent litigation with The Regents of the University of California and Boston Scientific
Corporation in 2007. |
|
(5) |
|
The accretion of preferred membership units to redemption value presented above is based on
the rights to which the Class A and Class B preferred membership unit holders of ev3 LLC were
entitled related to a liquidation, dissolution or winding up of ev3 LLC. Notwithstanding this
accretion right, in connection with the merger of ev3 LLC with and into ev3 Inc., each
membership unit representing a preferred equity interest in ev3 LLC was converted into one
share of our common stock and did not receive any additional rights with respect to the
liquidation preference. Accretion was discontinued upon conversion of the preferred units to
common equity at the time of our initial public offering on June 21, 2005. |
|
(6) |
|
Net income (loss) per common unit/share and number of units/shares used in per unit/share
calculations reflect our June 21, 2005 one-for-six reverse stock split for all periods
presented. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, |
|
|
2009 |
|
2008 |
|
2007 |
|
2006 |
|
2005 |
|
|
|
|
|
|
(dollars in thousands) |
|
|
|
|
Balance Sheet Data: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
98,050 |
|
|
$ |
59,652 |
|
|
$ |
81,060 |
|
|
$ |
24,053 |
|
|
$ |
69,592 |
|
Short-term investments |
|
|
|
|
|
|
|
|
|
|
9,744 |
|
|
|
14,700 |
|
|
|
12,000 |
|
Total current assets |
|
|
240,460 |
|
|
|
187,123 |
|
|
|
228,370 |
|
|
|
135,845 |
|
|
|
151,675 |
|
Total assets |
|
|
896,289 |
|
|
|
720,664 |
|
|
|
1,087,106 |
|
|
|
352,826 |
|
|
|
296,828 |
|
Total current liabilities |
|
|
73,929 |
|
|
|
67,448 |
|
|
|
119,159 |
|
|
|
41,767 |
|
|
|
37,671 |
|
Long-term debt |
|
|
3,958 |
|
|
|
6,458 |
|
|
|
6,429 |
|
|
|
5,357 |
|
|
|
|
|
Total liabilities |
|
|
141,795 |
|
|
|
80,123 |
|
|
|
128,625 |
|
|
|
47,592 |
|
|
|
38,523 |
|
Total stockholders equity |
|
|
754,494 |
|
|
|
640,541 |
|
|
|
958,481 |
|
|
|
305,234 |
|
|
|
245,455 |
|
66
ITEM 7. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
This Managements Discussion and Analysis provides material historical and prospective disclosures
intended to enable investors and other users to assess our financial condition and results of
operations. Statements that are not historical are forward-looking and involve risks and
uncertainties discussed under the headings Part I. Item 1. BusinessForward-Looking Statements
and Part I. Item 1A. Risk Factors of this report. The following discussion of our results of
operations and financial condition should be read in conjunction with our consolidated financial
statements and the related notes thereto included elsewhere in this report. This Managements
Discussion and Analysis is organized in the following major sections:
|
|
|
Business Overview. This section provides a brief overview description of our
business, focusing in particular on developments during the most recent year. |
|
|
|
|
Summary of 2009 Results and 2010 Outlook. This section provides a brief summary of
our financial results and financial condition for 2009 and our outlook for 2010. |
|
|
|
|
Items Impacting Comparability. This section provides a brief description of the
significant items impacting comparability for 2009, 2008 and 2007. |
|
|
|
|
Sales and Expense Components. This section provides a brief description of the
significant line items in our consolidated statements of operations. |
|
|
|
|
Results of Operations. This section provides our analysis of the significant line
items in our consolidated statements of operations. |
|
|
|
|
Seasonal and Quarterly Fluctuations. This section describes the effects of seasonal
and quarterly fluctuations in our business. |
|
|
|
|
Liquidity and Capital Resources. This section provides an analysis of our liquidity
and cash flows and a discussion of our outstanding debt and commitments. |
|
|
|
|
Critical Accounting Policies and Estimates. This section discusses the accounting
estimates that are considered important to our financial condition and results of
operations and require us to exercise subjective or complex judgments in their
application. All of our significant accounting policies, including our critical
accounting estimates, are summarized in Note 2 to our consolidated financial
statements. |
|
|
|
|
Recently Issued Accounting Pronouncements. This section discusses recently issued
accounting pronouncements that have had or may affect our results of operations and
financial condition. |
Business Overview
We are a leading global endovascular company focused on identifying and treating peripheral
vascular disease, including, in particular, lower extremity arterial disease, and neurovascular
disease. Since our founding in 2000, we have been dedicated to developing innovative, breakthrough
and clinically proven technologies and solutions for the treatment of peripheral vascular and
neurovascular diseases, a strategy that we believe is uncommon in the medical device industry. We
believe our unique approach of focusing on emerging and under-innovated opportunities, which treat
peripheral vascular and neurovascular disease, allows us to compete with smaller companies that
have narrow product lines and lack an international sales force and infrastructure, yet also
compete with larger companies that do not have our focus and agility.
We believe the overall market for endovascular devices will grow as the demand for minimally
invasive treatment of vascular diseases and disorders continues to increase. We intend to
capitalize on this market opportunity through the continued introduction of new products. We expect
to originate these new products primarily through our internal
67
research and development and clinical efforts, but we may supplement them with targeted
acquisitions or other external collaborations. Most recently, in June 2009, we acquired Chestnut
Medical Technologies, Inc., a then privately held, California-based company focused on developing
minimally invasive therapies for interventional neuroradiology. This transaction broadened our
neurovascular product portfolio by adding the Pipeline Embolization Device for the treatment of
cerebral aneurysms and the Alligator Retrieval Device for foreign body retrieval to our existing
embolic product and neuro access technologies. Additionally, our growth has been, and will
continue to be, impacted by our expansion and penetration into new geographic markets, the
expansion and penetration of our direct sales organization in existing geographic markets, and our
continuing focus to increase the efficiency of our existing direct sales organization.
Our product portfolio includes a broad spectrum of over 100 products consisting of over 1,500 stock
keeping units (SKUs), including plaque excision, stents, embolic protection and
thrombectomy devices, carotid stenting solutions, percutaneous transluminal angioplasty (PTA) balloons, and other procedural
support products for the peripheral vascular market and embolic coils, flow
directed and other micro catheters, liquid embolics, occlusion
balloon systems, guidewires, neuro stents and retrieval devices for the
neurovascular market. Our management, including our chief executive officer who is our chief operating decision maker,
report and manage our operations in two reportable business segments based on similarities in the
products sold, customer base and distribution system. We have corporate infrastructure and direct sales capabilities in the United States, Europe,
Canada, Australia and other countries and have established distribution relationships in selected
international markets. In order to drive sales growth, we have invested heavily throughout our history in not only the
expansion of our global distribution system, but also new product development and clinical trials
to obtain regulatory approvals. A significant portion of our net sales historically has been, and
we expect to continue to be, attributable to new and enhanced products.
During 2009, our neurovascular net sales were benefited by continued market penetration of the
Axium coil, Onyx Liquid Embolic System and the launch of our Pipeline Embolization Device in Europe
and other international markets. Building on the success we have experienced to date with our
Axium coils, we concluded our physician preference testing for two new versions of the Axium coil,
the Axium PGLA and Axium Nylon microfilament coils in the U.S. and Europe during the fourth quarter
of 2009 and are in the process of launching these products for broad commercial availability. We
recently launched our new Marksman delivery catheter and Alligator Retrieval Device in the U.S. and
Europe and introduced access product line extensions, including the HyperGlide 5.0 balloon in the
U.S. and Europe and the HyperGlide 3.0 balloon in the U.S. Since receiving the CE Mark for our
Solitaire FR, or flow restoration, device to treat ischemic stroke in July of 2009, we have completed
our European physician preference testing, and the Solitaire FR device is now fully launched in
Europe. We also expect to launch our new Apollo delivery catheter for our Onyx Liquid Embolic System in
2010.
Our peripheral vascular net sales for 2009 were benefited by increased market
penetration of our
EverFlex family of stents and our new PTA balloons. During fourth quarter of 2009, we launched our
new TurboHawk Plaque Excision System, which we expect to positively affect our plaque excision
sales in 2010, and our redesigned TrailBlazer Support Catheter. At the beginning of 2010, we also
launched our PowerCross 0.018 PTA balloon platform and now have a variety of platform sizes
available worldwide.
We expect to continue to further validate the clinical and competitive benefits of our technology
platforms to drive utilization of our current products and the development of new and enhanced
products. To accomplish this, we have a number of clinical trials underway and others that are
currently in development, including our DURABILITY II trial in the U.S. with the objective of
expanding our EverFlex stents U.S. indication to include treatment of peripheral artery disease
and our DEFINITIVE trial series designed to expand the clinical evidence supporting the value of
our plaque excision systems to drive increased procedure adoption, expand clinical indications and
support the use of atherectomy as a front-line therapy. In our neurovascular business, we
anticipate commencing enrollment during the first quarter of 2010 of our Solitaire with Immediate
Flow Restoration, or SWIFT, study under a U.S. investigational device exemption, or IDE, to obtain
FDA clearance for our Solitaire neuro stent, and will continue with our PUFS and COCOA studies of
our Pipeline Embolization Device.
68
It is our understanding that certain biliary stent manufacturers have received subpoenas from the
U.S. Department of Justice. Based on publicly available information, we believe that these
subpoenas requested information regarding the sales and marketing activities of these
manufacturers biliary stent products and that the Department of Justice is seeking to determine
whether any of these activities violated civil and/or criminal laws, including the Federal False
Claims Act, the Food and Drug Cosmetic Act and the Anti-Kickback Statute in connection with
Medicare and/or Medicaid reimbursement paid to third parties. As of the date of this report, we
have not received a subpoena from the U.S. Department of Justice relating to this investigation. No
assurance can be provided, however, that we will not receive such a subpoena or become the subject
of such an investigation, which could adversely affect our business and stock price.
Summary of 2009 Financial Results and Outlook for 2010
During 2009, we achieved profitability and cash generation. Our operating results reflect sales
growth in both our peripheral vascular and neurovascular segments, continued expansion of our
international business, improvement in our gross margins and continued expense control. During
2010, we will continue to focus on growing our revenue at or above market rates, improving
profitability and generating cash.
Our 2009 results and financial condition included the following items of significance, some of
which we expect also may affect our results and financial condition in 2010:
|
|
|
Net sales of our peripheral vascular products increased 4% to $279.5 million in 2009
compared to 2008 primarily as a result of continued market penetration of our embolic
protection devices and EverFlex family of stents, partially offset by a decline in
sales of our plaque excision products. We expect continued growth of our EverFlex
family of stents during 2010, although we are prohibited from marketing and promoting
these devices in the U.S. outside of their approved indication and, we remain cautious
of the current regulatory environment regarding the off-label utilization of our stents
and the increased competition we may experience. Although our plaque excision sales
decreased in 2009 compared to 2008, we expect the recent launch of our new TurboHawk
Plaque Excision System to have a positive impact on our Plaque Excision sales going
forward. |
|
|
|
|
Net sales of our neurovascular products increased 28% to $169.5 million in 2009
compared to $132.3 million in 2008 primarily as a result of continued market
penetration of our Axium coil and Onyx Liquid Embolic System and the launch of our
Pipeline Embolization Device in Europe and other international markets. We believe our
neurovascular business should benefit from the continued market penetration of the
Axium coil and Onyx Liquid Embolic System in 2010, from new product introductions,
including our Pipeline and Solitaire FR devices, and expanded geographic presence. |
|
|
|
|
On a geographic basis, 60% of our net sales for 2009 were generated in the United
States and 40% were generated outside the United States. Our international net sales
increased 21% to $178.1 million in 2009 compared to 2008 primarily driven by market
penetration of the Axium coil and neuro stent, as well as the launch of our Pipeline
Embolization Device. We expect our international business to continue to benefit from
our ability to sell our EverCross, NanoCross and PowerCross PTA balloon catheters, the
recent launch of our Pipeline Embolization Device in Europe and other international
markets, the launch of our Axium PGLA and Nylon microfilament coils, Marksman delivery
catheter and Alligator Retrieval Device, and expansion of sales of our
plaque excision devices. Changes in foreign currency exchange rates had a negative
impact on our 2009 net sales of $6.7 million compared to 2008, principally resulting
from the relationship of the U.S. dollar as compared to the euro. At current exchange
rates, we expect foreign currency exchange rates to have a negligible impact on our
2010 net sales compared to our 2009 net sales. |
|
|
|
|
Product gross margin increased to 73% in 2009 compared to 66% in 2008 primarily
attributable to manufacturing efficiencies in our peripheral vascular segment,
including synergies related to the consolidation of our FoxHollow manufacturing
operations and manufacturing process improvements associated with our self-expanding
stents. Product gross margin was also positively impacted by selling our own line of
PTA balloons and the mix of neurovascular products sold. We expect to continue to |
69
|
|
|
increase our product gross margins through our focus on manufacturing efficiencies and
opportunities to increase product pricing. Product gross margin for internal measurement
purposes is defined as net product sales less product cost of goods sold, excluding
amortization of intangible assets, divided by net product sales. |
|
|
|
Our sales, general and administrative expenses decreased in absolute dollars in 2009
compared to 2008, and as a percentage of net sales, represented 50% of our net sales in
2009 compared to 55% of our net sales in 2008. We expect our sales, general and
administrative expenses as a percentage of net sales to continue to decrease in 2010
compared to 2009 primarily as a result of our ability to improve our processes and
leverage our infrastructure to grow expenses at a lesser rate than our anticipated
revenue growth. |
|
|
|
|
Our net income for 2009 was $41.9 million, or $0.38 per diluted common share,
compared to a net loss of $335.6 million, or $3.22 per diluted share, in 2008. |
|
|
|
|
We had $98.1 million of cash and cash equivalents at December 31, 2009, an increase
of $38.4 million compared to December 31, 2008. This increase was primarily a result
of cash provided by operating activities, totaling $69.3 million during 2009 driven
primarily by our operating performance, offset by $24.7 million of net cash paid in
conjunction with our acquisition of Chestnut. We plan to continue to focus on
generating positive cash flow from operations during 2010. |
Items Impacting Comparability
The following items impacted the comparability of our financial results for 2009, 2008 and 2007:
2009
|
|
|
Charge of $3.4 million to increase reserves on our vacated FoxHollow lease facilities. |
|
|
|
Gain of $4.1 million attributed to the divestiture of non-strategic investments. |
|
|
|
Tax benefit of $19.0 million triggered by the purchase accounting for our acquisition of Chestnut. |
|
|
|
Charges relating to the estimated change in fair value of the contingent consideration
of $4.9 million associated with the Chestnut acquisition. |
2008
|
|
|
Research collaboration revenue and expense of $19.9 million and $6.1 million, respectively,
from our former collaboration and license agreement with Merck. |
|
|
|
An aggregate of $288.8 million in non-cash, asset impairment charges in our peripheral vascular segment to
reduce the carrying amounts of goodwill and other intangible assets to their estimated fair values, which were driven
primarily by the then substantial disruption in the general credit and equity markets and in particular the decline in
our stock price and market capitalization and certain product discontinuations during our fourth quarter of 2008. |
|
|
|
Non-cash asset impairment charge of $10.5 million to write off the remaining carrying amount of
the Merck intangible asset that was established at the time of our acquisition of FoxHollow.
|
2007
|
|
|
Incremental net sales from FoxHollow products of $20.9 million. |
|
|
|
Research collaboration revenue and expense of $6.0 million and $1.1 million,
respectively, from our former collaboration and license agreement with Merck. |
|
|
|
Charge of $70.7 million for acquired in-process research and development, integration costs of $14.9 million
and a charge of $3.3 million for excess and obsolete inventory associated with our FoxHollow acquisition.
|
|
|
|
Special charges of $19.1 million recorded as a result of entering into agreements in principle to settle certain patent infringement and other
litigation with The Regents of the University of California and Boston Scientific Corporation.
|
70
Sales and Expense Components
The following is a description of the primary components of net sales and expenses:
Net product sales. We derive our net product sales from the sale of endovascular devices in two
primary business segments: peripheral vascular and neurovascular devices. Sales are generated by
our global, direct sales force and are shipped and billed to hospitals or clinics throughout the
world. In countries where we do not have a direct sales force, sales are generated by shipments to
distributors who, in turn, sell to hospitals and clinics. In cases where our products are held in
consignment at a customers location, we generate sales at the time the product is used in a
procedure and we are notified in writing by the hospital that the product was used, rather than at
shipment. We charge our customers for shipping and record shipping income as part of net sales.
Research collaboration (revenue). Research collaboration revenue was derived from our former
collaboration and license agreement with Merck, which we assumed as a result of our acquisition of
FoxHollow. For additional discussion, see Note 2 to our consolidated financial statements included
elsewhere in this report.
Product cost of goods sold. We manufacture a substantial majority of the products that we sell. Our
product cost of goods sold consists primarily of direct labor, allocated manufacturing overhead,
raw materials, components and royalties and excludes amortization of intangible assets, which is
presented as a separate component of operating expenses.
Research collaboration (expense). Research collaboration expense consists primarily of costs
associated with our former collaboration and license agreement with Merck.
Sales, general and administrative. Our selling and marketing expenses consist primarily of sales
commissions and support costs for our global, direct distribution system, marketing costs and
freight expense that we pay to ship products to customers. General and administrative expenses
consist primarily of salaries and benefits, compliance systems, and other costs for our accounting,
finance, legal, information technology and human resources functions.
Research and development. Research and development expense includes costs associated with the
design, development, testing, deployment, enhancement and regulatory approval of our products. It
also includes costs associated with the design and execution of our clinical trials and regulatory
submissions.
Amortization of intangible assets. This caption includes amortization expense for intangible
assets, such as purchased developed technology, distribution channels and intellectual property,
including patents and trademarks.
Contingent consideration. Contingent consideration is recorded at the acquisition-date estimated
fair value of the contingent payment for all acquisitions beginning in 2009. The fair value of the
contingent consideration is remeasured at each reporting date with the change in fair value
included in our consolidated statements of operations. For additional discussion, see Note 4 to
our consolidated financial statements included elsewhere in this report.
Goodwill and other intangible asset impairment. Goodwill and other intangible asset impairment
consists of non-cash charges to reduce the carrying amounts of goodwill and other intangible
assets to their estimated fair values. For additional discussion, see Note 9 to our consolidated
financial statements included elsewhere in this report.
Acquired in-process research and development. Acquired in-process research and development reflects
amounts assigned to those projects acquired in business combinations prior to January 1, 2009 or
the acquisition of assets for which the related products have not received regulatory approval and
have no alternative future use. In-process research and development acquired in business
combinations subsequent to December 31, 2008 have been recorded as indefinite-lived intangible
assets on the consolidated balance sheets.
Special charges. Special charges relate to settlements of certain former patent
infringement and other litigation between us, The Regents of the University of California and
Boston Scientific Corporation. The special charges include amounts paid by us to the parties and
legal fees and expenses associated with the litigation.
71
(Gain) loss on investments, net. (Gain) loss on investments, net includes the difference between
the proceeds received from the sale of an investment and its carrying amount. In addition, this
caption includes losses from other than temporary declines in investments accounted for on a cost
basis.
Interest expense, net. Interest expense, net results primarily from interest associated with loans
from Silicon Valley Bank. Interest income consists of interest earned on investments in
investment-grade, interest-bearing securities and money market accounts.
Other expense (income), net. Other expense (income), net primarily includes foreign currency
exchange gains and losses net of gains and losses incurred on forward exchange contracts intended
to partially offset our exposure to foreign currency exchange rate fluctuations.
Income tax (benefit) expense. Income tax (benefit) expense includes federal income taxes (primarily
alternative minimum tax), income tax in foreign jurisdictions, state income tax and changes to our
deferred tax valuation allowance.
72
Results of Operations
The following table sets forth, for the periods indicated, our results of operations expressed as
dollar amounts (in thousands), and the changes between the specified periods expressed as percent
increases or decreases or NM if such increases or decreases are not material or applicable:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended |
|
|
For the Year Ended |
|
|
|
December 31, |
|
|
December 31, |
|
|
|
|
|
|
|
|
|
|
|
Percent |
|
|
|
|
|
|
|
|
|
|
Percent |
|
Results
of Operations: |
|
2009(1) |
|
|
2008 |
|
|
Change |
|
|
2008 |
|
|
2007(2) |
|
|
Change |
|
Sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net product sales |
|
$ |
449,072 |
|
|
$ |
402,233 |
|
|
|
11.6 |
% |
|
$ |
402,233 |
|
|
$ |
278,226 |
|
|
|
44.6 |
% |
Research collaboration |
|
|
|
|
|
|
19,895 |
|
|
|
-100.0 |
% |
|
|
19,895 |
|
|
|
5,957 |
|
|
234.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
|
449,072 |
|
|
|
422,128 |
|
|
|
6.4 |
% |
|
|
422,128 |
|
|
|
284,183 |
|
|
|
48.5 |
% |
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product cost of goods sold |
|
|
120,613 |
|
|
|
136,847 |
|
|
|
-11.9 |
% |
|
|
136,847 |
|
|
|
99,879 |
|
|
|
37.0 |
% |
Research collaboration |
|
|
|
|
|
|
6,051 |
|
|
|
-100.0 |
% |
|
|
6,051 |
|
|
|
1,065 |
|
|
NM |
|
Sales, general and administrative |
|
|
225,023 |
|
|
|
232,200 |
|
|
|
-3.1 |
% |
|
|
232,200 |
|
|
|
194,289 |
|
|
|
19.5 |
% |
Research and development |
|
|
49,060 |
|
|
|
48,784 |
|
|
|
0.6 |
% |
|
|
48,784 |
|
|
|
48,413 |
|
|
|
0.8 |
% |
Amortization of intangible assets |
|
|
25,143 |
|
|
|
31,072 |
|
|
|
-19.1 |
% |
|
|
31,072 |
|
|
|
20,306 |
|
|
|
53.0 |
% |
Contingent consideration |
|
|
4,876 |
|
|
|
|
|
|
NM |
|
|
|
|
|
|
|
|
|
|
NM |
|
Goodwill and intangible asset
impairment(3) |
|
|
|
|
|
|
299,263 |
|
|
|
-100.0 |
% |
|
|
299,263 |
|
|
|
|
|
|
NM |
|
Acquired in-process research and
development |
|
|
|
|
|
|
|
|
|
NM |
|
|
|
|
|
|
|
70,700 |
|
|
|
-100.0 |
% |
Special charges(4) |
|
|
|
|
|
|
|
|
|
NM |
|
|
|
|
|
|
|
19,054 |
|
|
|
-100.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
424,715 |
|
|
|
754,217 |
|
|
|
-43.7 |
% |
|
|
754,217 |
|
|
|
453,706 |
|
|
|
66.2 |
% |
Income (loss) from operations |
|
|
24,357 |
|
|
|
(332,089 |
) |
|
NM |
|
|
|
(332,089 |
) |
|
|
(169,523 |
) |
|
-95.9 |
% |
Other (income) expense: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Gain) loss on investments, net |
|
|
(4,113 |
) |
|
|
(487 |
) |
|
NM |
|
|
|
(487 |
) |
|
|
116 |
|
|
NM |
|
Interest expense (income), net |
|
|
788 |
|
|
|
(223 |
) |
|
NM |
|
|
|
(223 |
) |
|
|
(1,910 |
) |
|
88.3 |
% |
Other expense (income), net |
|
|
1,588 |
|
|
|
2,427 |
|
|
-34.6 |
% |
|
|
2,427 |
|
|
|
(2,934 |
) |
|
NM |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
|
|
26,094 |
|
|
|
(333,806 |
) |
|
NM |
|
|
|
(333,806 |
) |
|
|
(164,795 |
) |
|
-102.6 |
% |
Income tax (benefit) expense |
|
|
(15,823 |
) |
|
|
1,816 |
|
|
NM |
|
|
|
1,816 |
|
|
|
949 |
|
|
|
91.4 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
41,917 |
|
|
$ |
(335,622 |
) |
|
NM |
|
|
$ |
(335,622 |
) |
|
$ |
(165,744 |
) |
|
-102.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
In connection with the acquisition of Chestnut Medical Technologies, Inc. on June 23, 2009,
we recorded $4.9 million of contingent consideration and recognized a tax benefit of $19.0
million which resulted from the reversal of existing deferred tax valuation allowance. For a
more complete description of these items and their impact on our consolidated financial
results, see Note 3 to our consolidated financial statements. |
|
(2) |
|
In connection with the acquisition of FoxHollow Technologies, Inc. on October 4, 2007, we
recorded $14.9 million of integration costs associated with the acquisition and recognized
$70.7 million for in-process research and development charges. For a more complete description
of these items and their impact on our consolidated financial results, see Note 3 to our
consolidated financial statements. |
|
(3) |
|
During 2008, we recorded $288.8 million in non-cash, asset impairment charges in our
peripheral vascular segment to reduce the carrying amounts of goodwill and other intangible
assets to their estimated fair values. Additionally, during 2008, as a result of the
termination of our research collaboration with Merck, we recorded a non-cash asset impairment
charge of $10.5 million to write off the remaining carrying amount of the related Merck
intangible asset that was established at the time of our acquisition of FoxHollow. For a more
complete description of these items and their impact on our consolidated financial results,
see Note 9 to our consolidated financial statements. |
|
(4) |
|
We recorded $19.1 million of special charges as a result of the settlement of the former
litigation with The Regents of the University of California and Boston Scientific Corporation
in 2007. |
73
The following tables set forth, for the periods indicated, our net sales by segment and
geography expressed as dollar amounts (in thousands) and the changes in net sales between the
specified periods expressed as percentages:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended |
|
|
|
|
|
|
For the Year Ended |
|
|
|
|
|
|
December 31, |
|
|
Percent |
|
|
December 31, |
|
|
Percent |
|
NET
SALES BY SEGMENT |
|
2009 |
|
|
2008 |
|
|
Change |
|
|
2008 |
|
|
2007 |
|
|
Change |
|
Net sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peripheral vascular: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Plaque excision(1) |
|
$ |
84,072 |
|
|
$ |
88,800 |
|
|
|
-5.3 |
% |
|
$ |
88,800 |
|
|
$ |
20,884 |
|
|
|
325.2 |
% |
Stents |
|
|
114,900 |
|
|
|
107,146 |
|
|
|
7.2 |
% |
|
|
107,146 |
|
|
|
86,035 |
|
|
|
24.5 |
% |
Thrombectomy and embolic protection |
|
|
31,513 |
|
|
|
27,779 |
|
|
|
13.4 |
% |
|
|
27,779 |
|
|
|
25,998 |
|
|
|
6.9 |
% |
Procedural support and other |
|
|
49,046 |
|
|
|
46,204 |
|
|
|
6.2 |
% |
|
|
46,204 |
|
|
|
40,858 |
|
|
|
13.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total peripheral vascular |
|
$ |
279,531 |
|
|
$ |
269,929 |
|
|
|
3.6 |
% |
|
$ |
269,929 |
|
|
$ |
173,775 |
|
|
|
55.3 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Neurovascular: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Embolic products |
|
$ |
103,081 |
|
|
$ |
74,642 |
|
|
|
38.1 |
% |
|
$ |
74,642 |
|
|
$ |
56,003 |
|
|
|
33.3 |
% |
Neuro access and delivery products |
|
|
66,460 |
|
|
|
57,662 |
|
|
|
15.3 |
% |
|
|
57,662 |
|
|
|
48,448 |
|
|
|
19.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total neurovascular |
|
$ |
169,541 |
|
|
$ |
132,304 |
|
|
|
28.1 |
% |
|
$ |
132,304 |
|
|
$ |
104,451 |
|
|
|
26.7 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net product sales |
|
|
449,072 |
|
|
|
402,233 |
|
|
|
11.6 |
% |
|
|
402,233 |
|
|
|
278,226 |
|
|
|
44.6 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research collaboration: |
|
$ |
|
|
|
$ |
19,895 |
|
|
|
-100.0 |
% |
|
$ |
19,895 |
|
|
$ |
5,957 |
|
|
|
234.0 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total net sales |
|
$ |
449,072 |
|
|
$ |
422,128 |
|
|
|
6.4 |
% |
|
$ |
422,128 |
|
|
$ |
284,183 |
|
|
|
48.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended |
|
|
|
|
|
|
For the Year Ended |
|
|
|
|
|
|
December 31, |
|
|
Percent |
|
|
December 31, |
|
|
Percent |
|
NET
SALES BY GEOGRAPHY |
|
2009 |
|
|
2008 |
|
|
Change |
|
|
2008 |
|
|
2007 |
|
|
Change |
|
United States |
|
$ |
270,961 |
|
|
$ |
275,433 |
|
|
|
-1.6 |
% |
|
$ |
275,433 |
|
|
$ |
177,198 |
|
|
|
55.4 |
% |
International |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Before foreign exchange impact |
|
|
184,803 |
|
|
|
146,695 |
|
|
|
26.0 |
% |
|
|
141,704 |
|
|
|
106,985 |
|
|
|
32.5 |
% |
Foreign exchange impact |
|
|
(6,692 |
) |
|
|
|
|
|
NM |
|
|
|
4,991 |
|
|
|
|
|
|
NM |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
178,111 |
|
|
|
146,695 |
|
|
|
21.4 |
% |
|
|
146,695 |
|
|
|
106,985 |
|
|
|
37.1 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
449,072 |
|
|
$ |
422,128 |
|
|
|
6.4 |
% |
|
$ |
422,128 |
|
|
$ |
284,183 |
|
|
|
48.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Formerly referred to as atherectomy |
Comparison of the Year Ended December 31, 2009 to the Year Ended December 31, 2008
Net sales. Net sales increased 6% to $449.1 million in 2009 compared to $422.1 million in 2008.
Our net sales in 2009 did not include any research collaboration revenue compared with $19.9
million of research collaboration revenue in 2008. Net product sales increased 12% to $449.1
million for 2009 compared to $402.2 million for 2008 driven by increased sales in all product
categories, with the exception of our plaque excision (formerly referred to as atherectomy)
products, which declined primarily as a result of increased competition.
Net sales of peripheral vascular products. Net sales of our peripheral vascular products increased
4% to $279.5 million in 2009 compared to $269.9 million in 2008. Net sales in our stent product
line increased 7% to $114.9 million in 2009 compared to $107.1 million in 2008. This increase was
attributable to increased market penetration of both our EverFlex family of stents and our balloon
expandable stents. Net sales of our thrombectomy and embolic protection devices increased 13% to
$31.5 million in 2009 compared to $27.8 million in 2008 largely due to increases in sales of our
embolic protection devices. Net sales of our procedural support and other products, which include
our PTA balloon devices, increased 6% to $49.0 million in 2009 compared to $46.2 million in 2008.
Net
74
sales in our plaque excision product line decreased to $84.1 million in 2009 compared to $88.8
million in 2008 as a result of increased competition.
Net sales of neurovascular products. Net sales of our neurovascular products increased 28% to
$169.5 million in 2009 compared to $132.3 million in 2008, driven by increases in all product
categories. Net sales of our embolic products increased 38% to $103.1 million in 2009 compared to
$74.6 million in 2008 primarily due to the continued market penetration of the Axium coil, Onyx
Liquid Embolic System, neuro stents and launch of our Pipeline Embolization Device in Europe and
other international markets. Net sales of our neuro access and delivery products increased 15% to
$66.5 million in 2009 compared to $57.7 million in 2008 largely as a result of volume growth across
multiple product lines including our catheters, neuro balloons and guidewires.
Net sales by geography. Net sales in the United States declined 2% to $271.0 million in 2009
compared to $275.4 million in 2008. Net sales in the U.S. in 2008 included $19.9 million of
research collaboration revenue from Merck. Net product sales in the U.S. increased compared to 2008
primarily as a result of increased market penetration of our Onyx Liquid Embolic System, embolic
protection devices and EverFlex family of stents.
International net sales increased 21% to $178.1 million in 2009 compared to $146.7 million in 2008
and represented 40% and 35% of our total net sales during 2009 and 2008, respectively.
International growth was driven by an increase across all product categories including market
penetration of the Axium coil and neuro stents and launch of our Pipeline Embolization Device and
PTA balloons. Our international net sales in 2009 included the unfavorable impact of foreign
currency of $6.7 million compared to a favorable impact of $5.0 million in 2008.
Research collaboration (revenue). Research collaboration revenue associated with our former
collaboration agreement with Merck was $19.9 million in 2008. We did not recognize research
collaboration revenue in 2009.
Product cost of goods sold. As a percentage of net product sales, product cost of goods sold
declined to 27% of net product sales in 2009 compared to 34% in 2008. The improvement in our
product costs of goods sold was mainly driven by cost improvements in our peripheral vascular
division, as described in more detail below, and the mix of neurovascular products sold, which
generally have lower product cost of goods sold.
In our peripheral vascular segment, product cost of goods sold as a percentage of product sales
decreased to 29% in 2009 compared to 38% in 2008 as a result of improved manufacturing efficiencies
including synergies related to the consolidation of our FoxHollow manufacturing operations,
manufacturing process improvements associated with our self-expanding stents and selling our own
line of PTA balloons, and volume growth. During 2008, we also incurred costs related to the
consolidation of our FoxHollow manufacturing operations that did not recur in 2009.
In our neurovascular segment, product cost of goods sold as a percentage of product sales was 23%
in 2009 compared to 26% in 2008 as a result of leverage due to volume growth and sales mix. Our
product costs of goods sold in 2009 includes a $1.0 million impairment of an intellectual property
asset.
Research collaboration (expense). Research collaboration expense incurred as a result of our
former collaboration with Merck was $6.1 million in 2008. We did not incur research collaboration
expense in 2009.
Sales, general and administrative. Sales, general and administrative expenses decreased 3% to
$225.0 million in 2009 compared to $232.2 million in 2008 primarily as a result of synergies
related to the consolidation of our FoxHollow facilities and cost management efforts. Sales,
general and administrative expense as a percentage of net product sales declined to 50% of net
product sales in 2009 compared to 58% of net product sales in 2008 primarily as a result of higher
net product sales, improved sales productivity and continued expense leverage. During 2009
personnel and marketing costs decreased by $5.3 million compared to the prior year, slightly offset
by $3.4 million of expense recorded in 2009 to increase accrued liabilities on our vacated
FoxHollow leased facilities. In 2008, in connection with the resignation of our former chairman,
president and chief executive officer, we recorded $2.8 million which consisted of a lump sum cash
payment of $1.3 million and $1.5 million of non-cash stock-based compensation expense.
75
Research and development. Research and development expense increased slightly to $49.1 million in
2009 compared to $48.8 million in 2008. As a percentage of net sales, research and development
expense decreased to 11% of net sales in 2009 compared to 12% of net sales in 2008.
Amortization of intangible assets. Amortization of intangible assets decreased 19% to $25.1
million in 2009 compared to $31.1 million in 2008 primarily as a result of lower gross intangible
balances related to assets we impaired in 2008 and the full amortization of certain intangible
assets, partially offset by the amortization of intangible assets purchased in connection with our
acquisition of Chestnut. See Note 8 to our consolidated financial statements contained elsewhere
in this report.
Contingent consideration. The change in the fair value of contingent consideration associated with
our acquisition of Chestnut was $4.9 million in 2009. For additional discussion, see Note 3 and
Note 4 of our consolidated financial statements.
Goodwill and intangible asset impairment. We did not incur goodwill and intangible asset
impairment in 2009 compared to $299.3 million in 2008. We recorded $288.8 million in non-cash,
impairment charges in our peripheral vascular segment to reduce the carrying amounts of goodwill
and intangible assets to their estimated fair values. The impairment charges were driven primarily
by the then substantial disruption in the general credit and equity markets and in particular the
decline in our stock price and market capitalization and certain product discontinuations during
our fourth quarter of 2008. As a result of the termination of our research collaboration with
Merck in 2008, we also recorded a non-cash asset impairment charge of $10.5 million to write-off
the remaining carrying amount of the Merck intangible asset that was established at the time of our
acquisition of FoxHollow. See Note 9 to our consolidated financial statements contained elsewhere
in this report.
(Gain) loss on investments, net. Gain on investments, net of $4.1 million in 2009 was for the
realized gain on the sale of non-strategic investment assets. Gain on investments, net of $487,000
in 2008 was attributed to realized gains for various investments partly offset by other than
temporary impairments.
Interest expense (income), net. Interest expense, net was $788,000 in 2009 compared to interest
income, net of $223,000 in 2008. Interest expense for 2009 was $1.1 million and interest income
was $278,000. Interest income for 2008 was $1.4 million and interest expense was $1.1 million.
The change in interest income was due primarily to lower interest rates on invested cash balances
in 2009 compared to 2008.
Other expense, net. Other expense, net was $1.6 million in 2009 compared to $2.4 million in 2008,
and relates to net foreign currency exchange rate transaction gains and losses offset by gains and
losses on forward foreign exchange contracts.
Income tax (benefit) expense. We recorded an income tax benefit of $15.8 million in 2009 and an
expense of $1.8 million in 2008. In connection with our acquisition of Chestnut, we established net
deferred tax liabilities which resulted in the reversal of $19.0 million of existing deferred tax
valuation allowance. The reversal of our deferred tax valuation allowance is recorded as Income
tax (benefit) expense on our consolidated statements of operations. This tax benefit amount is
offset by $3.3 million of tax expense related primarily to estimated federal alternative minimum
tax, income tax in foreign jurisdictions, and state income tax due in several states. The 2008
income tax expense related to certain foreign and U.S. state jurisdictions.
Comparison of the Year Ended December 31, 2008 to the Year Ended December 31, 2007
Net sales. Net sales increased 49% to $422.1 million in 2008 compared to $284.2 million in 2007,
reflecting sales growth in each of our reportable business segments and geographic markets. In
particular, our sales growth was positively affected by our FoxHollow acquisition, the launch of
our Axium coil during the fourth quarter of 2007 and continued market penetration of the EverFlex
family of stents and the Onyx Liquid Embolic System. Our net sales in 2008 included $88.8 million
of net sales from our plaque excision products and $19.9 million of research collaboration revenue
from our former collaboration arrangement with Merck.
76
Net sales of peripheral vascular products. Net sales of our peripheral vascular products increased
55% to $269.9 million in 2008 compared to $173.8 million in 2007. This sales growth was primarily
the result of our FoxHollow acquisition and increased market penetration of our EverFlex family of
stents.
Net sales in our plaque excision product line increased to $88.8 million in 2008 compared to $20.9
million in 2007 as a result of a full year of plaque excision sales in 2008. Net sales in our
stent product line increased 25% to $107.1 million in 2008 compared to $86.0 million in 2007. This
increase was attributable to increased market penetration of our EverFlex family of stents. Net
sales of our thrombectomy and embolic protection devices increased 7% to $27.8 million in 2008
compared to $26.0 million in 2007. Net sales of our procedural support and other products
increased 13% to $46.2 million in 2008 compared to $40.9 million in 2007 largely due to increased
market penetration of Invatecs PTA balloon catheters in the United States.
Net sales of neurovascular products. Net sales of our neurovascular products increased 27% to
$132.3 million in 2008 compared to $104.4 million in 2007 as a result of increased penetration of
new and existing products and sales growth in virtually all of our neurovascular access and
delivery products. Net sales of our embolic products increased 33% to $74.7 million in 2008
compared to $56.0 million in 2007 primarily due to the launch of the Axium coil and increased
market penetration of the Onyx Liquid Embolic System, partially offset by sales declines in older
generation products. Net sales of our neuro access and delivery products increased 19% to $57.6
million in 2008 compared to $48.4 million in 2007 largely as a result of volume increases across
virtually all neuro access and delivery product lines.
Research collaboration (revenue). Research collaboration revenue was $19.9 million in 2008 compared
to $6.0 million in 2007.
Net sales by geography. Net sales in the United States increased 55% to $275.4 million in 2008
compared to $177.2 million in 2007 and was driven mainly by the acquisition of FoxHollow, increased
market penetration of our EverFlex family of stents, and the launch of the Axium coil.
International net sales increased 37% to $146.7 million in 2008 compared to $107.0 million in 2007
and represented 35% and 38% of our total net sales during 2008 and 2007, respectively.
International growth was primarily due to the launch of the Axium coil, further market penetration
of the EverFlex family of stents and the Onyx Liquid Embolic System, and the continued penetration
of our plaque excision products into international markets. Our international net sales in 2008
included a favorable foreign currency exchange rate impact of approximately $5.0 million compared
to a favorable impact of $6.0 million in 2007, principally resulting from the relationship of the
U.S. dollar to the euro.
Product cost of goods sold. As a percentage of product sales, product cost of goods sold was 34%
in 2008 compared to 36% in 2007. In our peripheral vascular segment, product cost of goods sold as
a percentage of net product sales decreased to 38% in 2008 compared to 42% in 2007 primarily
attributable to manufacturing efficiencies and increased sales volumes, partially offset by costs
associated with the consolidation of our Redwood City manufacturing operations into our Irvine and
Plymouth facilities. In our neurovascular segment, product cost of goods sold as a percentage of
net product sales was 26% in 2008 and 2007 and was attributable to manufacturing efficiencies and
increased sales volumes, partially offset by additional excess and obsolete inventory reserves
related to our planned product transitions to next generation devices.
Research collaboration (expense). Research collaboration expense incurred as a result of our
former collaboration with Merck was $6.1 million in 2008 compared to $1.1 million incurred in 2007.
Sales, general and administrative. Sales, general and administrative expenses increased 20% to
$232.2 million in 2008 compared to $194.3 million in 2007 primarily as a result of the acquisition
of FoxHollow. Included in the increase were higher personnel costs of $30.8 million due to
increases in overall staffing levels including the consolidated sales force as a result of our
acquisition of FoxHollow, an increase of $7.1 million of additional marketing and selling costs,
and a $3.6 million increase in non-cash stock-based compensation costs, offset by a decrease of
$5.8 million in legal and litigation fees due to settlement of The Regents of the University of
California and Boston Scientific Corporation litigation in 2007. Although sales, general and
administrative expenses increased in absolute dollars, as a percentage of net sales, sales, general
and administrative expenses decreased to 55% of net sales in 2008 compared to 68% of net sales in
2007 as a result of cost synergies implemented in the fourth quarter of 2007 and throughout 2008
and increased net sales.
77
Research and development. Research and development expense increased to $48.8 million in 2008
compared to $48.4 million in 2007. As a percentage of net sales, research and development expense
decreased to 12% of net sales in 2008 compared to 17% of net sales in 2007 primarily as a result of increased net sales and
cost saving efforts.
Amortization of intangible assets. Amortization of intangible assets increased 53% to $31.1
million in 2008 compared to $20.3 million in 2007 primarily as a result of the amortization of
intangible assets purchased in connection with our acquisition of FoxHollow. See Note 8 to our
consolidated financial statements contained elsewhere in this report.
Goodwill and other intangible asset impairment. Goodwill and other intangible asset impairment was
$299.3 million in 2008. We recorded $288.8 million in non-cash, asset impairment charges in our
peripheral vascular segment to reduce the carrying values of goodwill and other intangible assets
to their estimated fair values. The impairment charges were driven primarily by the substantial
disruption in the general credit and equity markets and in particular the decline in our stock
price and market capitalization and certain product discontinuations during our fourth quarter of
2008. As a result of the termination of our research collaboration with Merck in 2008, we also
recorded a non-cash asset impairment charge of $10.5 million to write-off the remaining carrying
value of the related Merck intangible asset that was established at the time of our acquisition of
FoxHollow. We did not incur goodwill and intangible asset impairment in 2007. See Note 9 to our
consolidated financial statements contained elsewhere in this report.
Acquired in-process research and development. In 2007, we recorded $70.7 million in acquired
in-process research and development projects that had not yet reached technological feasibility and
had no future alternative use in connection with the FoxHollow acquisition. For further
discussion, see Note 3 to our consolidated financial statements included elsewhere in this report.
Special charges. We recorded special charges of $19.1 million in 2007 as a result of us entering
into agreements in principle to settle certain patent infringement and other litigation with The
Regents of the University of California and Boston Scientific Corporation. The special charges
consisted of amounts paid by us to the parties and our legal fees and expenses associated with the
litigation.
(Gain) loss on investments, net. During 2008, we recorded a net realized gain of $487,000 related
to various investments net of other than temporary impairments. During 2007, we recorded a loss of
$116,000 realized on the sale of investments.
Interest expense (income), net. Interest income, net was $223,000 in 2008 compared to $1.9 million
in 2007. Interest income for 2008 was $1.4 million and interest expense was $1.1 million.
Interest income for 2007 was $3.3 million and interest expense was $1.4 million. The decrease in
interest income was primarily due to lower average cash balances and decreased interest rates in
2008 compared to 2007.
Other expense (income), net. Other expense, net was an expense of $2.4 million in 2008 compared to
other income, net of $2.9 million in 2007. The other expense (income), net in 2008 and 2007 was
primarily due to foreign currency exchange rate transaction gains and losses. The stronger U.S.
dollar compared to the euro negatively impacted our euro-designated accounts receivable in 2008.
Income tax expense. We incurred modest levels of income tax expense in 2008 related to certain
foreign and U.S. state jurisdictions. In 2007, we incurred modest levels of income tax expense
related to certain foreign jurisdictions. We did not record a provision for U.S. income taxes in
2007 due to our history of operating losses.
78
Seasonality and Quarterly Fluctuations
Our business is seasonal in nature. Historically, demand for our products has been the highest in
our fourth quarter. We traditionally experience lower sales volumes in our third quarter than
throughout the rest of the year as a result of the European holiday schedule during the summer
months.
We have experienced and expect to continue to experience meaningful variability in our net sales
and gross profit among quarters, as well as within each quarter, as a result of a number of
factors, including, among other things, the number and mix of products sold in the quarter; the
demand for, and pricing of, our products and the products of our competitors; the timing of or
failure to obtain regulatory approvals for products; costs, benefits and timing of new product
introductions; increased competition; the timing and extent of promotional pricing or volume
discounts; the timing of larger orders by customers and the timing of shipment of such orders;
changes in average selling prices; the availability and cost of components and materials; number of
selling days; fluctuations in foreign currency exchange rates; and restructuring, impairment and
other special charges. In addition, as a result of our recent acquisition of Chestnut, the
potential $75 million milestone payment in connection with this acquisition is classified as a
liability on our consolidated balance sheet, and remeasured at fair value at each reporting date,
with changes in fair value recognized as income or expense. Therefore, any change in fair value
impacts our earnings until the contingent consideration is resolved. Assuming that we continue to
expect to achieve the regulatory milestone, the accounting impact of the future milestone payment
will negatively impact our future quarterly operating results.
Liquidity and Capital Resources
The following table highlights several items from our consolidated balance sheet:
|
|
|
|
|
|
|
|
|
|
|
As of December 31, |
Balance Sheet Data |
|
2009 |
|
2008 |
|
|
(dollars in thousands) |
Cash and cash equivalents |
|
$ |
98,050 |
|
|
$ |
59,652 |
|
Total current assets |
|
|
240,460 |
|
|
|
187,123 |
|
Total assets |
|
|
896,289 |
|
|
|
720,664 |
|
Total current liabilities |
|
|
73,929 |
|
|
|
67,448 |
|
Total liabilities |
|
|
141,795 |
|
|
|
80,123 |
|
Total stockholders equity |
|
|
754,494 |
|
|
|
640,541 |
|
Working Capital
Cash and cash equivalents. Our cash and cash equivalents available to fund our current operations
were $98.1 million and $59.7 million at December 31, 2009 and 2008, respectively. We expect to
generate cash from operations in 2010, although no assurance can be provided that we will do so,
especially if we incur significant unanticipated costs or do not achieve our anticipated net sales
during 2010. We believe our cash and cash equivalents, anticipated cash from operations and
current and anticipated financing arrangements will be sufficient to meet our liquidity
requirements through at least the next 12 months.
Letters of credit and restricted cash. As of December 31, 2009, we had outstanding commitments of
$4.2 million which are supported by irrevocable standby letters of credit and restricted cash. The
letters of credit and restricted cash support various obligations, such as operating leases, tender
arrangements with customers and automobile leases.
Financing history. Although we recognized net income during 2009, prior to such time, we generated
significant operating losses including cumulative non-cash charges of $199.4 million for acquired
in-process research and development and $299.3 million of non-cash asset impairment charges of
goodwill and intangible assets that resulted in an accumulated deficit of $1.1 billion as of
December 31, 2009.
Historically, our liquidity needs have been met primarily through equity issuances, our bank
financing with Silicon Valley Bank and more recently cash generated from operations. In April of
2007, we completed a secondary public offering of our common stock in which we sold 2,500,000
shares of our common stock at $19.00 per share, resulting
79
in net proceeds to us of approximately
$44.5 million. In October of 2007, we completed our acquisition of FoxHollow, which at the time
had $166.9 million in cash, cash equivalents and short-term investments. We used $99.3 million to
pay FoxHollow stockholders the cash portion of the merger consideration. In June of 2009, we
completed our acquisition of Chestnut, and made a $26.2 million payment to the Chestnut
stockholders for the cash portion of the acquisition consideration. For additional discussion, see
Note 3 to our consolidated financial statements included elsewhere in this report.
Credit facility. Our operating subsidiaries, ev3 Endovascular, Inc., ev3 International, Inc., Micro
Therapeutics, Inc. and FoxHollow Technologies, Inc., which we collectively refer to as the
borrowers, are parties to a loan and security agreement, with Silicon Valley Bank, which was
amended most recently in December of 2008. The amended facility consists of a $50.0 million revolving
line of credit and a $10.0 million term loan. The revolving line of credit expires on June 25,
2010 and the term loan matures on June 23, 2012. Pursuant to the terms of the loan agreement and
subject to specified reserves, we may borrow under the revolving line of credit up to $12.0 million
without any borrowing base limitations. Aggregate borrowings under the revolving line of credit
that exceed $12.0 million will subject the revolving line to borrowing base limitations. These
limitations allow us to borrow, subject to specified reserves, up to 80% of eligible domestic and
foreign accounts receivables plus up to 30% of eligible inventory. Additionally, borrowings against
the eligible inventory may not exceed the lesser of 33% of the amount advanced against eligible
accounts receivable or $10.0 million. As of December 31, 2009, we had $6.5 million outstanding
under the term loan and no outstanding borrowings under the revolving line of credit; however, we
had approximately $934,000 of outstanding letters of credit issued by Silicon Valley Bank, which
reduced the maximum amount available under our revolving line of credit to approximately $49.1
million.
Borrowings under the revolving line of credit bear interest at a variable annual rate equal to
Silicon Valley Banks prime rate plus 0.5%. Borrowings under the term loan bear interest at a
variable annual rate equal to Silicon Valley Banks prime rate plus 1.0%. Silicon Valley Banks
prime rate at December 31, 2009 was 4.0%. Accrued interest on any outstanding balance under the
revolving line and the term loan is payable monthly in arrears. Principal amounts outstanding
under the term loan are payable in 48 consecutive equal monthly installments on the last day of
each month.
Both the revolving line of credit and term loan are secured by a first priority security interest
in substantially all of our assets, excluding intellectual property, which is subject to a negative
pledge, and are guaranteed by ev3 Inc. and all of our U.S. direct and indirect subsidiaries which
are not borrowers. We are required to maintain a minimum adjusted quick ratio and a minimum
consolidated earnings level. The loan agreement contains customary events of default, including
the failure to make required payments, the failure to comply with certain covenants or other
agreements, the occurrence of a material adverse change, failure to pay certain other indebtedness
and certain events of bankruptcy or insolvency. Upon the occurrence and during the continuation of
an event of default, amounts due under the loan agreement may be accelerated. We were in
compliance with all of our financial and non-financial covenants at December 31, 2009.
Cash Flows
Operating activities. Net cash provided by operating activities was $69.3 million in 2009 compared
to net cash used in operating activities of $13.9 million in 2008 and $49.2 million in 2007. We
generated cash from operations during 2009 as a result of our improved operating results and
working capital management. In 2009, our net income included a non-cash income tax benefit of $19.0
million recorded in connection with our acquisition of Chestnut (see Note 3 to our consolidated
financial statements). Our net income in 2009 also included $50.9 million of non-cash charges for
depreciation, amortization and stock-based compensation expense compared with $57.8 million during
2008. In 2008, our net loss also included $299.3 million of non-cash asset impairment charges of
goodwill and other intangible assets. In 2007, our net loss included approximately $39.9 million
of non-cash charges for depreciation, amortization and stock-based compensation expense, and $70.7
million of acquired in-process research and development expense.
Investing activities. Net cash used in investing activities was $32.4 million in 2009 compared to
$9.6 million in 2008 and net cash provided by investing activities of $51.9 million in 2007. During
2009, in connection with the acquisition of Chestnut, we paid $24.7 million, net of cash received,
for the cash portion of the acquisition consideration. During 2009, we also increased our
restricted cash by $2.7 million and purchased $6.7 million of
80
property and equipment and $2.1 million of patents and licenses, offset by $4.1 million received in proceeds from the sale of
non-strategic investment assets. Cash used in investing activities during 2008 was primarily due
to purchases of $10.9 million of property and equipment, $7.5 million paid in connection with an
earn-out contingency of a previous acquisition and $2.7 million of payments for patents and
licenses, partially offset by $9.7 million in proceeds from the sale of short-term investments and
$1.2 million in proceeds from the sale of assets. Net cash provided by investing activities in
2007 was primarily attributed to acquiring $166.9 million in cash as a result of our acquisition of
FoxHollow and using $99.3 million of it to pay the cash portion of the merger consideration.
During 2007, we also purchased $13.8 million of property and equipment, $6.5 million of
distribution rights related to our former agreement with Invatec and $3.3 million of patents and
licenses, partially offset by $6.9 million in proceeds from the sale of short-term investments and
$2.0 million from the sale of assets. Historically, our capital expenditures have consisted of
purchases of manufacturing equipment, research and testing equipment, computer systems and office
furniture and equipment. We expect to continue to make investments in property and equipment and to
incur approximately $10 million in capital expenditures during 2010.
Financing activities. Net cash provided by financing activities was $1.6 million in 2009, $1.6
million in 2008 and $54.0 million in 2007. During 2009, cash provided by financing activities was
generated primarily from $2.8 million of proceeds from employee stock purchase plan purchases and
$1.9 million of proceeds from stock option exercises, partially offset by payments on our term loan
with Silicon Valley Bank. During 2008, we received $10.0 million in borrowings under our amended
term loan with Silicon Valley Bank, $1.9 million in proceeds from our employee stock purchase plan
purchases and $1.3 million in proceeds from stock option exercises, partially offset by $11.0
million in payments under our Silicon Valley Bank equipment financing. During 2007, we received
$44.5 million in proceeds from the issuance of our common stock in our secondary public offering,
$6.7 million in proceeds from stock option exercises and $5.0 million in borrowings under our
equipment term loan with Silicon Valley Bank, partially offset by $2.5 million in payments under
our equipment financing line with Silicon Valley Bank.
Contractual Cash Obligations
At December 31, 2009, we had contractual cash obligations and commercial commitments as follows (in
thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period |
|
|
|
|
|
|
|
Less than |
|
|
|
|
|
|
|
|
|
|
More than |
|
|
|
|
|
|
Total |
|
|
1 Year |
|
|
1-3 Years |
|
|
3-5 Years |
|
|
5 Years |
|
|
Other |
|
|
|
|
|
|
|
|
|
|
|
(dollars in thousand) |
|
|
|
|
|
|
|
|
|
Notes payable |
|
$ |
6,458 |
|
|
$ |
2,500 |
|
|
$ |
3,958 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
Interest obligations |
|
|
409 |
|
|
|
258 |
|
|
|
151 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating leases(1) |
|
|
27,238 |
|
|
|
7,316 |
|
|
|
8,548 |
|
|
|
5,904 |
|
|
|
5,470 |
|
|
|
|
|
Uncertain income
tax obligations,
including interest
and penalties(2) |
|
|
1,588 |
|
|
|
216 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,372 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
35,693 |
|
|
$ |
10,290 |
|
|
$ |
12,657 |
|
|
$ |
5,904 |
|
|
$ |
5,470 |
|
|
$ |
1,372 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
The amounts reflected in the table above for operating leases represent future minimum
lease payments under non-cancelable operating leases primarily for certain office space,
warehouse space, computers and vehicles. Portions of these payments are denominated in foreign
currencies and were translated in the tables above based on their respective U.S. dollar
exchange rates at December 31, 2009. These future payments are subject to foreign currency
exchange rate risk. In accordance with U.S. generally accepted accounting principles, our
operating leases are not recognized on our consolidated balance sheet. |
|
(2) |
|
The uncertain income tax obligations of $1.4 million included in the other column in the
table above represent an amount of potential tax liabilities that we are uncertain as to if or
when such amounts may be settled. |
Not included in the table above is a payment for contingent consideration related to our
acquisition of Chestnut. The milestone-based payment of up to $75 million, if due, will be paid in
a combination of cash and shares of our common stock, the amount and form of which will be determined
at the date of payment. This amount was not included in the table above due to our inability to
predict the amount and timing of the cash portion of the payment. See Notes 3 and 4 to our
consolidated financial statements contained elsewhere in this report.
81
Off-Balance Sheet Arrangements
We do not have any off-balance sheet arrangements, as defined by the rules and regulations of the
SEC, that have or are reasonably likely to have a material effect on our financial condition,
changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources. As a result,
we are not materially exposed to any financing, liquidity, market or credit risk that could arise
if we had engaged in these arrangements.
Other Liquidity Information
The acquisition agreement relating to our purchase of Chestnut Medical Technologies, Inc. requires
us to make an additional milestone-based payment of up to $75.0 million to the sellers of the
business upon the FDA pre-market approval of the Pipeline Embolization Device. This milestone-based
contingent payment could range from: (1) $75.0 million upon FDA approval prior to October 1, 2011,
(2) $75.0 million less $3.75 million per month upon FDA approval from October 1, 2011 through
December 31, 2012 and (3) no payment required if FDA approval is not obtained by December 31, 2012.
The milestone-based payment of up to $75.0 million will consist of cash and equity paid in the
form of shares of our common stock ranging from 30% cash and 70% equity to 85% cash and 15% equity.
The acquisition agreement relating to our purchase of Appriva Medical, Inc. requires us to make
additional payments of up to an aggregate of $175.0 million to the sellers of the business if
certain milestones related to regulatory steps in the product commercialization process were
achieved during the period of 2003 to 2009. We believe the first milestone was not achieved by the
January 1, 2005 milestone date and that the first milestone was not payable. In September 2005, we
announced that we had decided to discontinue the development and commercialization of the
technology we acquired in the Appriva transaction. We are currently involved in litigation
regarding this agreement as described in more detail in Note 18 to our consolidated financial
statements included elsewhere in this report.
Pursuant to the acquisition agreement relating to FoxHollows purchase of Kerberos Proximal
Solutions, Inc., FoxHollow agreed to pay certain earn-out payments up to an aggregate of $117.0
million upon the achievement of contractually defined net sales milestones. Counsel for the
shareholder representatives of Kerberos have alleged that FoxHollow has not used commercially
reasonable efforts to market, promote, sell and distribute Kerbeross Rinspirator products, as
required under the agreement. We discontinued the sale of the Rinspirator products in January
2009. Although no formal litigation has been commenced by the stockholder representatives of
Kerberos regarding the alleged claims, there can be no assurance that the ultimate resolution of
this matter will not result in a material adverse effect on our business, financial condition,
results of operations or cash flows of a future period.
Our future liquidity and capital requirements will be influenced by numerous factors, including any
future operating losses, the level and timing of future sales and expenditures, the results and
scope of ongoing research and product development programs, working capital to support our sales
growth, receipt of and time required to obtain regulatory clearances and approvals, sales and
marketing programs, acceptance of our products in the marketplace, competing technologies, market
and regulatory developments, acquisitions and the future course of pending and threatened
litigation. We believe that our cash and cash equivalents, anticipated funds from operations and
current and anticipated financing arrangements will be sufficient to meet our liquidity
requirements through at least the next 12 months. However, there is no assurance that additional
funding will not be needed or sought prior to such time. In the event that we require additional
working capital to fund future operations and any future acquisitions, we may sell shares of our
common stock or other equity securities, sell debt securities, or enter into additional credit and
financing arrangements with one or more independent institutional lenders. There is no assurance
that any financing transaction will be available on terms acceptable to us, or at all, or that any
financing transaction will not be dilutive to our current stockholders. See Note 18 to our
consolidated financial statements included elsewhere in this report.
82
Credit Risk
At December 31, 2009, our accounts receivable balance was $90.7 million, compared to $72.8 million
at December 31, 2008. We monitor the creditworthiness of our customers to which we grant credit
terms in the normal course of business. We believe that concentrations of credit risk with respect
to our accounts receivable are limited due to the large number of customers and their dispersion across many geographic areas. However, a
significant amount of our accounts receivable are with national healthcare systems in many
countries. Although we do not currently foresee a credit risk associated with these receivables,
repayment depends upon the financial stability of the economies of those countries. As of December
31, 2009, no customer represented more than 10% of our outstanding accounts receivable or sales.
From time to time, we offer certain distributors in foreign markets who meet our credit standards
extended payment terms, which may result in a longer collection period and reduce our cash flow
from operations. We have not experienced significant losses with respect to the collection of
accounts receivable from groups of customers or any particular geographic area nor experienced any
material cash flow reductions as a result of offering extended payment terms.
Critical Accounting Policies and Estimates
Our consolidated financial statements and related financial information are based on the
application of generally accepted accounting principles in the United States of America (U.S.
GAAP). Our most significant accounting policies are described in Note 2 to our consolidated
financial statements included elsewhere in this report. The preparation of our consolidated
financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions
that affect the amounts reported in our consolidated financial statements and accompanying notes.
Certain of our more critical accounting policies require the application of significant judgment by
management in selecting the appropriate assumptions for calculating financial estimates. By their
nature, these judgments are subject to an inherent degree of uncertainty. These judgments are based
on our historical experience, terms of existing contracts, our observance of trends in the
industry, information provided by our physician customers and information available from other
outside sources, as appropriate. Changes in accounting estimates are reasonably likely to occur
from period to period. Changes in these estimates and changes in our business could have a material
impact on the presentation of our financial condition, changes in financial condition or results of
operations.
We believe that the following financial estimates are both important to the portrayal of our
financial condition and results of operations and require subjective or complex judgments. Further,
we believe that the items discussed below are properly recognized in our consolidated financial
statements for all periods presented. Management has discussed the development, selection and
disclosure of our critical financial estimates with the audit committee and our board of directors.
The judgments about those financial estimates are based on information available as of the date of
our consolidated financial statements. Our critical financial policies and estimates are described
below:
Revenue Recognition
We recognize revenue in accordance with four basic criteria that must be met before sales can be
recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services
have been rendered; (3) the price is fixed or determinable; and (4) collectibility is reasonably
assured. These criteria are met at the time of shipment when risk of loss and title passes to the
customer or distributor, unless a consignment arrangement exists. Sales from consignment
arrangements are recognized upon written notification that the product has been used by the
customer indicating that a sale is complete. Our normal terms of sale for regular sales are
typically FOB shipping point, net 30 days. Regular sales include orders from customers for
replacement of customer stock, replenishment of consignment product used by customers, orders for a
scheduled case/surgery and stocking orders. We may agree to extended payment terms for certain
international distributors based upon their payment history, financial condition and other general
financial factors.
We allow customers to return defective or damaged products for credit. Our estimate for sales
returns is based upon contractual commitments and historical return experience which we analyze by
geography and is recorded as a reduction of sales for the period in which the related sales
occurred. Historically, our return experience has been low with return rates of less than 4% of our
net sales.
83
Stock-Based Compensation
We currently use the Black-Scholes option pricing model to determine the fair value of stock
options and other equity incentive awards. The determination of the fair value of stock-based
compensation awards on the date of grant using an option-pricing model is affected by our stock
price, as well as assumptions regarding a number of complex and subjective variables which include the expected life of the award, the expected stock
price volatility over the expected life of the awards, expected dividend yield, risk-free interest
rate and the forfeiture rate.
We estimate the expected term of options based upon our historical experience. We estimate expected
volatility and forfeiture rates based on a combination of historical factors related to our common
stock. The risk-free interest rate is determined using U.S. Treasury rates appropriate for the
expected term. Dividend yield is estimated to be zero as we have never paid dividends and have no
plans to do so in the future.
We estimate forfeitures at the time of grant and revise those estimates in subsequent periods as
necessary. We use historical data to estimate forfeitures and record stock-based compensation
expense only for those awards that are expected to vest. Generally, all stock-based compensation is
amortized on a straight-line basis over the respective requisite service periods, which are
generally the vesting periods.
If factors change and we employ different assumptions for estimating stock-based compensation
expense in future periods, the future periods may differ significantly from what we have recorded
in the current period and could materially affect our results of operations. It may also result in
a lack of comparability with other companies that use different models, methods and assumptions.
See Note 2 and Note 15 to our consolidated financial statements for further information regarding
our stock-based compensation disclosures.
Assessment of Goodwill and Intangible Asset Impairment
Goodwill represents the excess of the aggregate purchase price over the fair value of net assets of
acquired businesses. Intangible assets arise from the allocation of the purchase price of
businesses acquired to identifiable assets. Our definite-lived intangible assets consist primarily
of purchased developed technology, patents, customer relationships and trademarks and are amortized
over their estimated useful lives, ranging from 2.5 to 11 years. Our indefinite-lived intangible
assets consist of in-process research and development costs from the acquisition of Chestnut.
We assign goodwill to reporting units based on the allocation of purchase price to the assets
acquired and the liabilities assumed. Goodwill is tested for impairment using a two-step approach
at the reporting unit levelperipheral vascular and neurovascular. In the first step, the fair
value of the reporting unit is compared to its carrying amount, including goodwill. If the
carrying amount of a reporting unit exceeds its fair value, then the amount of the impairment loss
must be measured. The impairment loss, if any, is calculated by comparing the implied fair value
of reporting unit goodwill to its carrying amount.
We evaluate the carrying amount of goodwill and intangible assets during the fourth quarter of each
year and between annual evaluations if events occur that indicate that the carrying amount of
goodwill or intangible assets may be impaired. We use the income and market approaches to
determine the fair value of reporting units in the goodwill valuation. Our valuation is weighted
entirely using the income approach which is supported by a discounted cash flow analysis. We do
not believe that there are any comparable companies to our reporting units, and therefore do not
use the results of the market approach in our valuation.
The impairment evaluation related to goodwill and intangible assets with indefinite lives requires
the use of considerable management judgment to determine discounted future cash flows, including
estimates and assumptions regarding the amount and timing of cash flows, cost of capital and growth
rates. Cash flow assumptions used in the assessment are estimated using assumptions in our annual
operating plan as well as our five-year strategic plan. Our annual operating plan and strategic
plan contain revenue assumptions that are derived from existing technology as well as future
revenues attributed to in-process technologies and the associated launch, growth and decline
84
assumptions normal for the life cycle of those technologies. In addition, management considers
relevant market information, peer company data and five years of historical financial information.
In the goodwill analysis, the estimated fair value of the reporting units used in the impairment
analysis is reconciled to our market capitalization at the measurement date to ensure the estimated
enterprise fair values are consistent with those of a market participant.
For 2009, our goodwill impairment analysis indicated that the fair value of our reporting units
exceeded the carrying amount by over 70%, substantiated by the increase in our stock price and
market capitalization during the year. Had we increased the discount rate assumptions in our
analysis by 500 basis points and decreased our terminal value multiplier by 10%, the fair value of
our reporting units would have still exceeded the carrying amount and no impairment indicator would
have existed. During 2008, we recognized a goodwill impairment charge of $281.9 million related to
our peripheral vascular business. The impairment charge was driven primarily by the substantial
disruption in the general credit and equity markets and, in particular, the decline in our stock
price and market capitalization during our fourth quarter of 2008. The decline in our stock price
and market capitalization were primarily a result of the then general market conditions and the
associated increase in general market risk as well as changes in our future estimated cash flows
which were significantly driven by the changes in the performance of our plaque excision (formerly
atherectomy) business. The amount of goodwill was $367.5 million and $315.7 million at December
31, 2009 and 2008, respectively. See Note 9 to our consolidated financial statements for further
information regarding our goodwill impairment disclosures.
We recorded impairment charges in 2008 of $6.9 million related to certain definite-lived intangible
assets in our peripheral vascular business due to certain product discontinuations, and $10.5
million to write off the remaining carrying amount of the Merck intangible asset that was
established at the time of our FoxHollow acquisition as a result of the termination of the Merck
collaboration and license agreement. Definite-lived intangible assets, net of accumulated
amortization, were $254.3 million and $185.3 million at December 31, 2009 and 2008, respectively.
See Note 9 to our consolidated financial statements for further information regarding our
intangible asset impairment disclosures.
Impairment of our indefinite-lived intangible assets is measured as the amount by which the
carrying amount of the intangible asset exceeds its fair value. The estimated fair value is
generally determined on the basis of discounted future cash flows. Based on our impairment
analysis performed during the year ended December 31, 2009, the estimated fair value of our
intangible assets with indefinite lives exceeded the carrying amount. The amount of
indefinite-lived intangible assets was $27.4 million at December 31, 2009 with no amount recorded
at December 31, 2008.
Contingent Consideration
Contingent consideration is recorded at the acquisition-date estimated fair value of the contingent
milestone payment for all acquisitions beginning in 2009. Our 2009 acquisition of Chestnut
included an agreement to pay a contingent milestone-based payment of cash and equity upon the FDA
pre-market approval of the Pipeline Embolization Device. The acquisition-date fair value was
measured based on the probability-adjusted present value of the amount expected to be paid. The
probability-adjusted contingent consideration amounts were discounted at 26%, the weighted average
cost of capital for the Chestnut transaction. We remeasure the fair value of the contingent
milestone payment at each reporting period using Level 3 inputs. There were no changes in the
assumptions utilized in the fair value of the contingent consideration at December 31, 2009. The
change in fair value was $4.9 million for 2009 and is reflected as Contingent consideration in
our consolidated statements of operations.
Excess and Obsolete Inventory
We calculate an inventory reserve for estimated obsolescence or excess inventory based on
historical turnover and assumptions about future demand for our products and market conditions
which includes estimates of the impact of the introduction of new or enhanced products on existing
inventory. Our industry is characterized by regular new product development, and as such, our
inventory is at risk of obsolescence following the introduction and development of new or enhanced
products. Our estimates and assumptions for excess and obsolete inventory are reviewed and updated
on a quarterly basis. The estimates we use for demand also are used for near-term capacity
85
planning and inventory purchasing and are consistent with our sales forecasts. Future product introductions
and related inventories may require additional reserves based upon changes in market demand or
introduction of competing technologies. Increases in the reserve for excess and obsolete inventory
result in a corresponding expense to cost of goods sold. Our reserve for excess and obsolete
inventory was $11.0 million and $10.3 million at December 31, 2009 and 2008, respectively.
Allowance for Doubtful Accounts
We maintain a large customer base that mitigates the risk of concentration with one customer. We
make judgments as to our ability to collect outstanding receivables and provide allowance for a
portion of receivables when collection becomes doubtful. Provisions are made based upon a specific
review of all significant outstanding account balances and the overall quality and age of those
balances not specifically reviewed. In determining the provision for invoices not specifically
reviewed, we analyze historical collection experience and current economic trends. If the
historical data used to calculate the allowance provided for doubtful accounts does not reflect our
future ability to collect outstanding receivables or if the financial condition of customers were
to deteriorate, resulting in impairment of their ability to make payments, an increase in the
provision for doubtful accounts may be required. We write off accounts receivable when we determine
that the accounts receivable are uncollectible, typically upon customer bankruptcy or the
customers non-response to continuous collection efforts. Approximately 22% of our receivables
outstanding as of December 31, 2009 were from foreign distributors, which carry a potentially
higher degree of collection risk due to potential disruptions in the global financial markets and a
potential inability for our distributors to obtain credit to continue to operate their businesses.
In addition, if the overall condition of the health care industry were to deteriorate as a result
of the recent financial and economic crisis or otherwise, resulting in an impairment of our
customers ability to make payments, significant additional allowances could be required.
Our accounts receivable balance was $90.7 million and $72.8 million, net of accounts receivable
allowances, comprised of both allowances for doubtful accounts and sales returns, of $7.3 million
and $8.1 million at December 31, 2009 and 2008, respectively.
Valuation of Acquired In-Process Research and Development
When we acquire another company, the purchase price is allocated, as applicable, between acquired
in-process research and development, other identifiable intangible assets, tangible net assets and
goodwill as required by U.S. GAAP. In-process research and development is defined as the value
assigned to those projects for which the related products have not received regulatory approval and
have no alternative future use. Determining the portion of the purchase price allocated to
in-process research and development and other intangible assets requires us to make significant
estimates that may change over time. During 2007, we recorded an in-process research and
development charge of $70.7 million related to our October 2007 acquisition of FoxHollow. For
acquisitions subsequent to December 31, 2008, acquired in-process research and development assets
are capitalized as indefinite-lived intangible assets. In connection with the acquisition of
Chestnut we capitalized $27.4 million of acquired in-process research and development. If
development of a marketable product results, the asset will be amortized upon completion of
development. Development costs incurred after the acquisition are charged to expense.
The income approach was used to determine the fair values of the acquired in-process research and
development for both the FoxHollow and Chestnut acquisitions. This approach establishes fair value
by estimating the after-tax cash flows attributable to the in-process project over its useful life
and then discounting these after-tax cash flows back to the present value. Revenue estimates were
based on relative market size, expected market growth rates and market share penetration. Gross
margin estimates were based on the estimated cost of the product at the time of introduction and
historical gross margins for similar products offered by us or by competitors in the marketplace.
The estimated selling, general and administrative expenses were based on historical operating
expenses of the acquired company as well as long-term expense levels based on industry comparables.
The costs to complete each project were based on estimated direct project expenses as well as the
remaining labor hours and related overhead costs. In arriving at the value of acquired in-process
research and development projects, we considered each projects stage of completion, the complexity
of the work to be completed, the costs already incurred, the remaining costs to complete the
project, the contribution of core technologies, the expected introduction date and the estimated
useful life of the technology. The discount rate used to arrive at the present value of acquired
in-process research and development as of the
86
acquisition date was based on the time value of money
and medical technology investment risk factors. We believe that the estimated acquired in-process
research and development amounts determined represent the fair value at the date of acquisition and
do not exceed the amount a third party would pay for the projects.
Accounting for Income Taxes
As part of the process of preparing our consolidated financial statements, we are required to
determine our income taxes in each of the jurisdictions in which we operate. This process involves
estimating our actual current tax expense together with assessing temporary differences resulting
from recognition of items for income tax and accounting purposes. These differences result in
deferred tax assets and liabilities, which are included on our consolidated balance sheets. We must
then assess the likelihood that our deferred tax assets will be recovered from future taxable
income and, to the extent we believe that recovery is not likely, we must establish a valuation
allowance. To the extent we establish a valuation allowance or increase this allowance in a period,
we must reflect this increase as an expense within the tax provision in our consolidated statements
of operations.
Managements judgment is required in determining our provision for income taxes, our deferred tax
assets and liabilities and any valuation allowance recorded against our net deferred tax assets. A
portion of the valuation allowance was reversed in 2009 due to income earned in the current year
and offsetting the deferred tax liability on the Chestnut acquisition. We will continue to monitor
the realizability of our deferred tax assets and adjust the valuation allowance accordingly. For
2009, except for the deferred tax liability relating to an indefinite-lived intangible acquired in
the Chestnut acquisition, we recorded a full valuation allowance on our net deferred tax asset.
Recently Issued Accounting Pronouncements
In the third quarter of 2009, we adopted the Financial Accounting Standards Boards (FASB)
Accounting Standards Codification (ASC) Topic 105 as the single official source of authoritative,
nongovernmental generally accepted accounting principles in the United States. On the effective
date, all then-existing non-SEC accounting literature and reporting standards were superseded and
deemed nonauthoritative. The adoption of this pronouncement did not have a material impact on our
consolidated financial statements; however, the ASC affected the way we reference authoritative
guidance in our consolidated financial statements.
In December 2007, the FASB issued additional guidance on business combinations contained in ASC
Topic 805 and additional guidance on noncontrolling interests in consolidated financial statements
contained in ASC Topic 810, which are effective for fiscal years beginning after December 15, 2008.
These new standards represent the completion of the FASBs first major joint project with the
International Accounting Standards Board and are intended to improve, simplify and converge
internationally the accounting for business combinations and the reporting of noncontrolling
interests (formerly minority interests) in consolidated financial statements.
ASC Topic 805 changes the application of the acquisition method in a number of significant
respects, including the requirement to expense transaction fees and expected restructuring costs as
incurred, rather than including these amounts in the allocated purchase price; the requirement to
recognize the fair value of contingent consideration at the acquisition date, rather than the
amount when the contingency is resolved; the requirement to recognize the fair value of acquired
in-process research and development assets at the acquisition date, rather than immediately
expensing; and the requirement to recognize a gain in relation to a bargain purchase price, rather
than reducing the allocated basis of long-lived assets. We adopted these standards at the beginning
of 2009. See Note 3 for further discussion of the impact the adoption of ASC Topic 805 had on our
results of operations and financial conditions as a result of our Chestnut acquisition in 2009.
In May 2009, the FASB issued additional guidance on managements assessment of subsequent events.
This guidance is contained in ASC Topic 855 and clarifies that management must evaluate, as of each
reporting period, events or transactions that occur for potential recognition or disclosure in the
financial statements and the circumstances under which an entity should recognize events or
transactions occurring after the balance sheet date through the date that the financial statements
are issued or are available to be issued. ASC Topic 855 requires the disclosure of the date
through which an entity has evaluated subsequent events and the basis for that date. This
disclosure alerts all users of financial statements that an entity has not evaluated subsequent
events after that date in
87
the set of financial statements being presented. We adopted ASC Topic
855 in the second quarter of 2009. The implementation of ASC Topic 855 did not have a material
impact on our consolidated financial statements.
In April 2008, the FASB issued guidance on the determination of the useful life of intangible
assets, (ASC Topic 350-30-35-1), which amended the factors considered in developing renewal or
extension assumptions used to determine the useful life of recognized intangible assets. ASC Topic
350-30-35-1 requires a consistent approach between the useful life of a recognized intangible asset
and the period of expected cash flows used to measure the fair value of an asset. The ASC Topic 350-30-35-1 also requires enhanced disclosure when an
intangible assets expected future cash flows are affected by an entitys intent and/or ability to
renew or extend the arrangement. We adopted ASC Topic 350-30-35-1 as of January 1, 2009. The
adoption did not have a significant impact on our consolidated financial statements.
In 2006, the FASB issued an accounting pronouncement to provide enhanced guidance when using fair
value to measure assets and liabilities. The pronouncement defines fair value, establishes a
framework for measuring fair value in GAAP and expands disclosures about fair value measurements.
The pronouncement applies whenever other pronouncements require or permit assets or liabilities to
be measured by fair value. We adopted the pronouncement as of the beginning of 2008 as it relates
to recurring measurements of financial assets and liabilities, and as of the beginning of 2009, as
it relates to nonrecurring fair value measurement requirements for nonfinancial assets and
liabilities. These assets and liabilities include goodwill and intangible assets not subject to
amortization.
88
ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to various market risks, which are potential losses arising from adverse changes in
market rates and prices, such as interest rates and foreign currency exchange rate fluctuations. We
do not enter into derivatives or other financial instruments for trading or speculative purposes.
We believe we are not exposed to a material market risk with respect to our invested cash and cash
equivalents.
Interest Rate Risk
Borrowings under our revolving line of credit with Silicon Valley Bank bear interest at a variable
annual rate equal to Silicon Valley Banks prime rate plus 0.5%. Borrowings under the term loan
bear interest at a variable annual rate equal to Silicon Valley Banks prime rate plus 1.0%. We
currently do not use interest rate swaps to mitigate the impact of fluctuations in interest rates.
As of December 31, 2009, we had no borrowings under our revolving line of credit and had $6.5
million in borrowings under the term loan. Based upon this debt level, a 10% increase in the
interest rate on such borrowings would cause us to incur an increase in interest expense of
approximately $32,000 on an annual basis.
At December 31, 2009, our cash and cash equivalents were $98.1 million. Based on our annualized
average interest rate, a 10% decrease in the interest rate on such balances would result in a
reduction in interest income of approximately $15,000 on an annual basis.
Foreign Currency Exchange Rate Risk
Fluctuations in the rate of exchange between the U.S. dollar and foreign currencies in which we
transact business could adversely affect our financial results. Approximately 27% and 24% of our
net sales were denominated in foreign currencies in 2009 and 2008, respectively. Selling, marketing
and administrative costs related to these sales are largely denominated in the same respective
currency, thereby limiting our transaction risk exposure. If we price our products in U.S. dollars
and competitors price their products in local currency, an increase in the relative strength of the
U.S. dollar could result in our price not being competitive in a market where business is
transacted in the local currency.
Our principal foreign currency exchange rate risks exist between the U.S. dollar and the euro.
Approximately 74% and 76% of our net sales denominated in foreign currencies in 2009 and 2008,
respectively, were derived from European Union countries and were denominated in the euro.
Fluctuations during any given reporting period result in the remeasurement of our foreign
currency-denominated cash, receivables and payables, generating currency transaction gains or
losses and are reported in other expense (income), net in our consolidated financial statements. We
recorded $1.6 million and $2.4 million of foreign currency exchange rate transaction losses in 2009
and 2008, respectively, net of activities from forward exchange contracts, primarily related to the
translation of our foreign currency-denominated net receivables into U.S. dollars. Our 2009 forward
contracts were settled prior to the end of 2009 and there were no outstanding forward exchange
contracts as of December 31, 2009. We will continue to assess the use of forward contracts in the
future and entered into three forward contracts at the beginning of the first quarter 2010 to
economically hedge our risk of the euro, British pound and Canadian dollar. At December 31, 2009,
we had euro-denominated accounts receivable and cash of 22.6 million and 924,000, respectively.
A 10% increase in the foreign currency exchange rate between the U.S. dollar and the euro as a
result of a weakening dollar would have the effect of approximately a $3.4 million foreign currency
transaction gain. A 10% decrease in the foreign currency exchange rate between the U.S. dollar and
the euro as a result of a strengthening dollar would have the effect of approximately a $3.4
million foreign currency transaction loss.
89
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
|
|
|
Description |
|
Page |
|
|
|
|
|
F-1 |
|
|
|
|
|
F-2 F-3 |
|
|
|
|
|
F-4 |
|
|
|
|
|
F-5 |
|
|
|
|
|
F-6 |
|
|
|
|
|
F-7 F-8 |
|
|
|
|
|
F-9 F-37 |
|
|
|
|
|
F-38 |
90
MANAGEMENTS REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING
As management of ev3 Inc., we are responsible for establishing and maintaining an adequate system
of internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the
Securities Exchange Act of 1934, as amended, for ev3 Inc. and its subsidiaries. This system is
designed to provide reasonable assurance regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in accordance with U.S. generally
accepted accounting principles.
ev3s internal control over financial reporting includes those policies and procedures that (1)
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the assets of ev3; (2) provide reasonable assurance that
transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of ev3 are being
made only in accordance with authorizations of management and directors of ev3; and (3) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of ev3s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or
detect misstatements and even when determined to be effective, can only provide reasonable
assurance with respect to financial statement preparation and presentation. Also, projection of any
evaluation of the effectiveness of internal control over financial reporting to future periods is
subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree or compliance with the policies or procedures may deteriorate.
With our participation, management evaluated the effectiveness of ev3s internal control over
financial reporting as of December 31, 2009. In making this evaluation, management used the
criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO)
in Internal ControlIntegrated Framework. Based on this assessment, management concluded that
ev3s internal control over financial reporting was effective as of December 31, 2009.
Ernst & Young LLP, ev3s independent registered public accounting firm, audited the effectiveness
of ev3s internal control over financial reporting as of December 31, 2009 and, based on that
audit, issued the report which is included elsewhere in this report.
|
|
|
|
|
/s/ Robert J. Palmisano
|
|
/s/ Shawn McCormick
|
|
|
|
|
|
|
|
Robert J. Palmisano
|
|
Shawn McCormick |
|
|
President and Chief Executive Officer
|
|
Senior Vice President and Chief Financial Officer |
|
|
February 25, 2010
Further discussion of our internal controls and procedures is included under the heading Part II.
Item 9A. Controls and Procedures of this report.
F-1
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders
ev3 Inc.
We have audited ev3 Inc.s internal control over financial reporting as of December 31, 2009 based
on criteria established in Internal ControlIntegrated Framework issued by the Committee of
Sponsoring Organizations of the Treadway Commission (the COSO criteria). ev3 Inc.s management is
responsible for maintaining effective internal control over financial reporting, and for its
assessment of the effectiveness of internal control over financial reporting included in the
accompanying Managements Report on Internal Control over Financial Reporting. Our responsibility
is to express an opinion on ev3 Inc.s internal control over financial reporting based on our
audit.
We conducted our audit in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control over financial reporting was
maintained in all material respects. Our audit included obtaining an understanding of internal
control over financial reporting, assessing the risk that a material weakness exists, testing and
evaluating the design and operating effectiveness of internal control based on the assessed risk,
and performing such other procedures as we considered necessary in the circumstances. We believe
that our audit provides a reasonable basis for our opinion.
A companys internal control over financial reporting is a process designed to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles. A
companys internal control over financial reporting includes those policies and procedures that (1)
pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the assets of the company; (2) provide reasonable assurance that
transactions are recorded as necessary to permit preparation of financial statements in accordance
with generally accepted accounting principles, and that receipts and expenditures of the company
are being made only in accordance with authorizations of management and directors of the company;
and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized
acquisition, use, or disposition of the companys assets that could have a material effect on the
financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or
detect misstatements. Also, projections of any evaluation of effectiveness to future periods are
subject to the risk that controls may become inadequate because of changes in conditions, or that
the degree of compliance with the policies or procedures may deteriorate.
In our opinion, ev3 Inc. maintained, in all material respects, effective internal control over
financial reporting as of December 31, 2009, based on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight
Board (United States), the consolidated balance sheets of ev3 Inc. as of December 31, 2009 and
2008, and the related consolidated statements of operations, stockholders equity, and cash flows
for each of the three years in the period ended December 31, 2009 and our report dated February 25,
2010 expressed an unqualified opinion thereon.
/s/ Ernst & Young LLP
Minneapolis, Minnesota
February 25, 2010
F-2
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The Board of Directors and Stockholders
ev3 Inc.
We have audited the accompanying consolidated balance sheets of ev3 Inc. as of December 31, 2009
and 2008, and the related consolidated statements of operations, stockholders equity, and cash
flows for each of the three years in the period ended December 31, 2009. Our audits also included
the financial statement schedule listed in the Index at Item 15. These financial statements and
schedule are the responsibility of the Companys management. Our responsibility is to express an
opinion on these financial statements and schedule based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement. An
audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the
financial statements. An audit also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating the overall financial statement
presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material
respects, the consolidated financial position of ev3 Inc. at December 31, 2009 and 2008, and the
consolidated results of its operations and its cash flows for each of the three years in the period
ended December 31, 2009, in conformity with U.S. generally accepted accounting principles. Also,
in our opinion, the related financial statement schedule, when considered in relation to the basic
financial statements taken as a whole, presents fairly, in all material respects, the information
set forth herein.
As discussed in Note 2, Summary of Significant Accounting Policies, to the consolidated financial
statements, effective January 1, 2009 the Company adopted the provisions of the Financial
Accounting Standards Boards Accounting Standards Codification Topic 805 and changed its method of
accounting for business combinations.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight
Board (United States), ev3 Inc.s internal control over financial reporting as of December 31,
2009, based on criteria established in Internal Control-Integrated Framework issued by the
Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 25,
2010 expressed an unqualified opinion thereon.
/s/ Ernst & Young LLP
Minneapolis, Minnesota
February 25, 2010
F-3
ev3 Inc.
CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2009 |
|
|
2008 |
|
Assets |
|
|
|
|
|
|
|
|
Current assets |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
98,050 |
|
|
$ |
59,652 |
|
Accounts receivable, less allowances of
$7,260 and $8,098 respectively |
|
|
90,711 |
|
|
|
72,814 |
|
Inventories, net |
|
|
45,054 |
|
|
|
47,687 |
|
Prepaid expenses and other current assets |
|
|
6,645 |
|
|
|
6,970 |
|
|
|
|
|
|
|
|
Total current assets |
|
|
240,460 |
|
|
|
187,123 |
|
Restricted cash |
|
|
4,346 |
|
|
|
1,531 |
|
Property and equipment, net |
|
|
29,159 |
|
|
|
30,681 |
|
Goodwill |
|
|
367,486 |
|
|
|
315,654 |
|
Intangible assets, net |
|
|
254,288 |
|
|
|
185,292 |
|
Other assets |
|
|
550 |
|
|
|
383 |
|
|
|
|
|
|
|
|
Total assets |
|
$ |
896,289 |
|
|
$ |
720,664 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and stockholders equity |
|
|
|
|
|
|
|
|
Current liabilities |
|
|
|
|
|
|
|
|
Current portion of long-term debt |
|
$ |
2,500 |
|
|
$ |
2,500 |
|
Accounts payable |
|
|
16,737 |
|
|
|
15,657 |
|
Accrued compensation and benefits |
|
|
32,239 |
|
|
|
29,547 |
|
Accrued liabilities |
|
|
22,453 |
|
|
|
19,744 |
|
|
|
|
|
|
|
|
Total current liabilities |
|
|
73,929 |
|
|
|
67,448 |
|
Long-term debt |
|
|
3,958 |
|
|
|
6,458 |
|
Other long-term liabilities |
|
|
63,908 |
|
|
|
6,217 |
|
|
|
|
|
|
|
|
Total liabilities |
|
|
141,795 |
|
|
|
80,123 |
|
Stockholders equity |
|
|
|
|
|
|
|
|
Preferred stock, $0.01 par value, 100,000,000
shares authorized, none issued and
outstanding as of December 31, 2009 and 2008 |
|
|
|
|
|
|
|
|
Common stock, $0.01 par value, 300,000,000
shares authorized, 112,345,500 and
105,822,444 shares issued and outstanding as
of December 31, 2009 and 2008, respectively |
|
|
1,123 |
|
|
|
1,058 |
|
Additional paid-in capital |
|
|
1,828,655 |
|
|
|
1,756,832 |
|
Accumulated deficit |
|
|
(1,074,744 |
) |
|
|
(1,116,661 |
) |
Accumulated other comprehensive loss |
|
|
(540 |
) |
|
|
(688 |
) |
|
|
|
|
|
|
|
Total stockholders equity |
|
|
754,494 |
|
|
|
640,541 |
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity |
|
$ |
896,289 |
|
|
$ |
720,664 |
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
F-4
ev3 Inc.
CONSOLIDATED STATEMENTS OF OPERATIONS
(Dollars in thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the years ended December 31, |
|
|
|
2009 |
|
|
2008 |
|
|
2007 |
|
Sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Net product sales |
|
$ |
449,072 |
|
|
$ |
402,233 |
|
|
$ |
278,226 |
|
Research collaboration |
|
|
|
|
|
|
19,895 |
|
|
|
5,957 |
|
|
|
|
|
|
|
|
|
|
|
Net sales |
|
|
449,072 |
|
|
|
422,128 |
|
|
|
284,183 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Product cost of goods sold |
|
|
120,613 |
|
|
|
136,847 |
|
|
|
99,879 |
|
Research collaboration |
|
|
|
|
|
|
6,051 |
|
|
|
1,065 |
|
Sales, general and administrative |
|
|
225,023 |
|
|
|
232,200 |
|
|
|
194,289 |
|
Research and development |
|
|
49,060 |
|
|
|
48,784 |
|
|
|
48,413 |
|
Amortization of intangible assets |
|
|
25,143 |
|
|
|
31,072 |
|
|
|
20,306 |
|
Contingent consideration |
|
|
4,876 |
|
|
|
|
|
|
|
|
|
Goodwill and intangible asset impairment |
|
|
|
|
|
|
299,263 |
|
|
|
|
|
Acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
70,700 |
|
Special charges |
|
|
|
|
|
|
|
|
|
|
19,054 |
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
424,715 |
|
|
|
754,217 |
|
|
|
453,706 |
|
Income (loss) from operations |
|
|
24,357 |
|
|
|
(332,089 |
) |
|
|
(169,523 |
) |
Other (income) expense: |
|
|
|
|
|
|
|
|
|
|
|
|
(Gain) loss on investments, net |
|
|
(4,113 |
) |
|
|
(487 |
) |
|
|
116 |
|
Interest expense (income), net |
|
|
788 |
|
|
|
(223 |
) |
|
|
(1,910 |
) |
Other expense (income), net |
|
|
1,588 |
|
|
|
2,427 |
|
|
|
(2,934 |
) |
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
|
|
26,094 |
|
|
|
(333,806 |
) |
|
|
(164,795 |
) |
Income tax (benefit) expense |
|
|
(15,823 |
) |
|
|
1,816 |
|
|
|
949 |
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
41,917 |
|
|
$ |
(335,622 |
) |
|
$ |
(165,744 |
) |
|
|
|
|
|
|
|
|
|
|
Earnings per share: |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per common share |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
$ |
0.39 |
|
|
$ |
(3.22 |
) |
|
$ |
(2.37 |
) |
|
|
|
|
|
|
|
|
|
|
Diluted |
|
$ |
0.38 |
|
|
$ |
(3.22 |
) |
|
$ |
(2.37 |
) |
|
|
|
|
|
|
|
|
|
|
Weighted average shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
107,997,738 |
|
|
|
104,378,828 |
|
|
|
69,909,708 |
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
|
108,998,528 |
|
|
|
104,378,828 |
|
|
|
69,909,708 |
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
F-5
ev3 Inc.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY
(Dollars in thousands, except per share amounts)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other |
|
|
Total |
|
|
|
Common Stock |
|
|
|
|
|
|
Accumulated |
|
|
Comprehensive |
|
|
Stockholders |
|
|
|
Shares |
|
|
Amount |
|
|
APIC |
|
|
Deficit |
|
|
Income (Loss) |
|
|
Equity |
|
Balance December 31, 2006 |
|
|
57,594,742 |
|
|
$ |
576 |
|
|
$ |
919,221 |
|
|
$ |
(614,578 |
) |
|
$ |
15 |
|
|
$ |
305,234 |
|
Comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(165,744 |
) |
|
|
|
|
|
|
(165,744 |
) |
Unrealized losses on investments, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(174 |
) |
|
|
(174 |
) |
Foreign currency translation
adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(436 |
) |
|
|
(436 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(166,354 |
) |
Cumulative effect of adoption of
ASC 740 (FASB Interpretation No. 48) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(717 |
) |
|
|
|
|
|
|
(717 |
) |
Common stock issued in secondary
offering |
|
|
2,500,000 |
|
|
|
25 |
|
|
|
44,517 |
|
|
|
|
|
|
|
|
|
|
|
44,542 |
|
Compensation expense on equity awards
and stock purchase plan |
|
|
|
|
|
|
|
|
|
|
11,127 |
|
|
|
|
|
|
|
|
|
|
|
11,127 |
|
Equity based compensation plans |
|
|
1,867,775 |
|
|
|
19 |
|
|
|
7,068 |
|
|
|
|
|
|
|
|
|
|
|
7,087 |
|
Common stock issued in acquisition of
FoxHollow |
|
|
43,118,667 |
|
|
|
431 |
|
|
|
757,131 |
|
|
|
|
|
|
|
|
|
|
|
757,562 |
|
FoxHollow stock transactions, other |
|
|
(2,415 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance December 31, 2007 |
|
|
105,078,769 |
|
|
$ |
1,051 |
|
|
$ |
1,739,064 |
|
|
$ |
(781,039 |
) |
|
$ |
(595 |
) |
|
$ |
958,481 |
|
Comprehensive loss: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(335,622 |
) |
|
|
|
|
|
|
(335,622 |
) |
Unrealized gains on investments, net |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
45 |
|
|
|
45 |
|
Foreign currency translation
adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(138 |
) |
|
|
(138 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(335,715 |
) |
Compensation expense on equity awards
and stock purchase plan |
|
|
|
|
|
|
|
|
|
|
15,159 |
|
|
|
|
|
|
|
|
|
|
|
15,159 |
|
Equity based compensation plans |
|
|
743,675 |
|
|
|
7 |
|
|
|
2,609 |
|
|
|
|
|
|
|
|
|
|
|
2,616 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance December 31, 2008 |
|
|
105,822,444 |
|
|
$ |
1,058 |
|
|
$ |
1,756,832 |
|
|
$ |
(1,116,661 |
) |
|
$ |
(688 |
) |
|
$ |
640,541 |
|
Comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
41,917 |
|
|
|
|
|
|
|
41,917 |
|
Foreign currency translation
adjustment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
148 |
|
|
|
148 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
42,065 |
|
Compensation expense on equity awards
and stock purchase plan |
|
|
|
|
|
|
|
|
|
|
14,556 |
|
|
|
|
|
|
|
|
|
|
|
14,556 |
|
Equity based compensation plans |
|
|
1,462,546 |
|
|
|
14 |
|
|
|
4,189 |
|
|
|
|
|
|
|
|
|
|
|
4,203 |
|
Common stock issued in acquisition of
Chestnut |
|
|
5,060,510 |
|
|
|
51 |
|
|
|
53,078 |
|
|
|
|
|
|
|
|
|
|
|
53,129 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance December 31, 2009 |
|
|
112,345,500 |
|
|
$ |
1,123 |
|
|
$ |
1,828,655 |
|
|
$ |
(1,074,744 |
) |
|
$ |
(540 |
) |
|
$ |
754,494 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
F-6
ev3 Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Dollars in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the years ended December 31, |
|
|
|
2009 |
|
|
2008 |
|
|
2007 |
|
Operating activities |
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
41,917 |
|
|
$ |
(335,622 |
) |
|
$ |
(165,744 |
) |
Adjustments to reconcile net income (loss) to net cash provided by
(used in) operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
36,340 |
|
|
|
42,595 |
|
|
|
28,726 |
|
Contingent consideration |
|
|
4,876 |
|
|
|
|
|
|
|
|
|
Provision for bad debts and sales returns |
|
|
(942 |
) |
|
|
2,538 |
|
|
|
2,024 |
|
Provision for inventory obsolescence |
|
|
10,030 |
|
|
|
8,870 |
|
|
|
8,308 |
|
Acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
70,700 |
|
Gain on sale or disposal of investments and assets, net |
|
|
(4,055 |
) |
|
|
(244 |
) |
|
|
(978 |
) |
Stock-based compensation expense |
|
|
14,556 |
|
|
|
15,159 |
|
|
|
11,127 |
|
Goodwill and intangible asset impairment |
|
|
1,000 |
|
|
|
299,263 |
|
|
|
|
|
Deferred income taxes |
|
|
(19,171 |
) |
|
|
|
|
|
|
|
|
Change in operating assets and liabilities, net of acquired: |
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
(15,998 |
) |
|
|
(8,281 |
) |
|
|
1,340 |
|
Inventories |
|
|
(6,846 |
) |
|
|
6,169 |
|
|
|
(14,524 |
) |
Prepaid expenses and other assets |
|
|
642 |
|
|
|
294 |
|
|
|
2,836 |
|
Accounts payable |
|
|
(683 |
) |
|
|
(6,804 |
) |
|
|
3,060 |
|
Accrued expenses and other liabilities |
|
|
7,683 |
|
|
|
(28,774 |
) |
|
|
(5,408 |
) |
Deferred revenue |
|
|
|
|
|
|
(9,043 |
) |
|
|
9,347 |
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) operating activities |
|
|
69,349 |
|
|
|
(13,880 |
) |
|
|
(49,186 |
) |
Investing activities |
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from sale of investments |
|
|
4,118 |
|
|
|
9,744 |
|
|
|
6,900 |
|
Purchase of investments |
|
|
(300 |
) |
|
|
|
|
|
|
|
|
Purchase of property and equipment |
|
|
(6,695 |
) |
|
|
(10,875 |
) |
|
|
(13,804 |
) |
Purchase of patents and licenses |
|
|
(2,067 |
) |
|
|
(2,728 |
) |
|
|
(3,270 |
) |
Purchase of distribution rights |
|
|
|
|
|
|
|
|
|
|
(6,500 |
) |
Proceeds from sale of assets |
|
|
|
|
|
|
1,244 |
|
|
|
2,035 |
|
Acquisitions, net of cash acquired |
|
|
(24,735 |
) |
|
|
(7,627 |
) |
|
|
65,556 |
|
Change in restricted cash |
|
|
(2,731 |
) |
|
|
646 |
|
|
|
1,007 |
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by investing activities |
|
|
(32,410 |
) |
|
|
(9,596 |
) |
|
|
51,924 |
|
The accompanying notes are an integral part of these consolidated financial statements.
F-7
ev3 Inc.
CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
(Dollars in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the years ended December 31, |
|
|
|
2009 |
|
|
2008 |
|
|
2007 |
|
Financing activities |
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from issuance of common stock, net |
|
$ |
|
|
|
$ |
|
|
|
$ |
44,542 |
|
Proceeds from issuance of debt |
|
|
|
|
|
|
10,000 |
|
|
|
5,000 |
|
Payments on long-term debt and capital lease obligations |
|
|
(2,649 |
) |
|
|
(11,042 |
) |
|
|
(2,499 |
) |
Proceeds from exercise of stock options |
|
|
1,850 |
|
|
|
1,275 |
|
|
|
6,726 |
|
Proceeds from employee stock purchase plan |
|
|
2,823 |
|
|
|
1,903 |
|
|
|
868 |
|
Other |
|
|
(470 |
) |
|
|
(541 |
) |
|
|
(646 |
) |
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities |
|
|
1,554 |
|
|
|
1,595 |
|
|
|
53,991 |
|
Effect of exchange rate changes on cash |
|
|
(95 |
) |
|
|
473 |
|
|
|
278 |
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents |
|
|
38,398 |
|
|
|
(21,408 |
) |
|
|
57,007 |
|
Cash and cash equivalents, beginning of period |
|
|
59,652 |
|
|
|
81,060 |
|
|
|
24,053 |
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents, end of period |
|
$ |
98,050 |
|
|
$ |
59,652 |
|
|
$ |
81,060 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental cash flow information: |
|
|
|
|
|
|
|
|
|
|
|
|
Cash paid for interest |
|
$ |
588 |
|
|
$ |
839 |
|
|
$ |
1,400 |
|
Cash paid for income taxes |
|
$ |
3,303 |
|
|
$ |
943 |
|
|
$ |
610 |
|
|
Supplemental non-cash disclosure: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Non-cash consideration in conjunction with the
acquisition of Chestnut (see Note 3) |
|
$ |
90,461 |
|
|
$ |
|
|
|
$ |
|
|
Net assets acquired in conjunction with the acquisition
of FoxHollow (see Note 3) |
|
$ |
|
|
|
$ |
|
|
|
$ |
757,562 |
|
Leasehold improvement tenant allowance |
|
$ |
2,606 |
|
|
$ |
|
|
|
$ |
|
|
Goodwill and intangible asset impairment (see Note 9) |
|
$ |
|
|
|
$ |
299,263 |
|
|
$ |
|
|
Earn-out payment accrued |
|
$ |
|
|
|
$ |
|
|
|
$ |
7,500 |
|
The accompanying notes are an integral part of these consolidated financial statements.
F-8
ev3 Inc.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Description of Business
ev3 Inc. (we, our or us) is a global endovascular company focused on identifying and treating
peripheral vascular disease, including, in particular, lower extremity arterial disease and
neurovascular disease. We develop, manufacture and market a wide range of products that include
plaque excision products, stents, embolic protection and thrombectomy devices, carotid stenting solutions, percutaneous
transluminal angioplasty (PTA) balloons and other procedural support products for the peripheral
vascular market and embolic coils, flow diversion and flow
restoration devices, liquid embolics, flow directed and other
micro catheters, occlusion balloon systems, guidewires, neuro
stents and retrieval devices for the neurovascular market. We
market our products in the United States, Europe, Canada, Australia and other countries through a
direct sales force and through distributors in certain other international markets.
2. Summary of Significant Accounting Policies
Principles of Consolidation
The consolidated financial statements include our accounts and the accounts of our wholly-owned
subsidiaries. All significant intercompany balances and transactions have been eliminated. On
October 4, 2007, we acquired FoxHollow Technologies, Inc. (FoxHollow) and on June 23, 2009, we
acquired Chestnut Medical Technologies, Inc. (Chestnut). In connection with those acquisitions,
FoxHollow and Chestnut became our wholly-owned subsidiaries (see Note 3).
We have evaluated all subsequent events through February 25, 2010, the date the financial
statements were issued.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted
in the United States of America requires management to make estimates and assumptions that affect
the reported amounts and disclosures in the consolidated financial statements and accompanying
notes. Actual results could differ from those estimates.
Cash Equivalents
We consider highly liquid investments with maturities of three months or less from the date of
purchase to be cash equivalents. These investments are stated at cost, which approximates fair
value.
Accounts Receivable
Trade accounts receivable are recorded at the invoiced amount and do not bear interest. We make
judgments as to our ability to collect outstanding receivables and provide an allowance for credit
losses when collection becomes doubtful. Provisions are made based upon a specific review of all
significant outstanding account balances and the overall quality and age of those balances not
specifically reviewed. Outstanding receivables are considered past due based upon invoice due
dates. In determining the allowance required, we analyze historical collection experience and
current economic trends. If the historical data used to calculate the allowance for doubtful
accounts does not reflect our future ability to collect outstanding receivables or if the financial
condition of customers were to deteriorate, an increase in the provision for doubtful accounts may
be required. We write-off accounts receivable when we determine that the accounts receivable are
uncollectible, typically upon customer bankruptcy or the customers non-response to continuous
collection efforts.
F-9
Inventories
Inventories include material, labor and overhead and are stated at the lower of cost or net
realizable value, determined on a first-in, first-out basis.
We calculate a reserve for estimated obsolete or excess inventory based on historical turnover and
assumptions about future demand for our products and market conditions. This includes estimates of
the impact of the introduction of new or enhanced products on existing inventory. Our industry is
characterized by continuous product development, and as such, our inventory is at risk of
obsolescence following the introduction and development of new or enhanced products. Our estimate
and assumptions for excess and obsolete inventory are reviewed and updated on a quarterly basis.
The estimates we use for demand are also used for near-term capacity planning and inventory
purchasing and are consistent with our sales forecasts. Future product introductions and related
inventories may require additional reserves based upon changes in market demand or introduction of
competing technologies. Adjustments for excess and obsolete inventory are recorded in product cost
of goods sold.
Restricted Cash
Restricted cash consists of various deposits supporting credit arrangements and security deposits
for our building leases.
Property and Equipment
Property and equipment are stated at cost, less accumulated depreciation and amortization.
Additions and improvements that extend the lives of assets are capitalized, while expenditures for
repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line
method over the estimated useful lives of the assets. Amortization of capital leases and leasehold
improvements is provided on a straight-line basis over the estimated lives of the related assets or
the life of the lease, whichever is shorter, and generally ranges from three to seven years.
Machinery and other equipment are depreciated over three to ten years, computer hardware and
software are depreciated over three to five years, furniture and fixtures over seven years.
Property and equipment classified as construction in process are not depreciated until the related
asset is placed in service.
Goodwill and Indefinite-Lived Intangible Assets
Goodwill represents the excess of the aggregate purchase price over the fair value of net assets of
acquired businesses. Intangible assets arise from the allocation of the purchase price of
businesses acquired to identifiable assets. Our indefinite-lived intangible assets consist of
in-process research and development costs.
We assign goodwill to reporting units based on the allocation of purchase price to the assets
acquired and the liabilities assumed. Goodwill is tested for impairment using a two-step approach
at the reporting unit levelperipheral vascular and neurovascular. In the first step, the fair
value of the reporting unit is compared to its carrying amount, including goodwill. If the
carrying amount of a reporting unit exceeds its fair value, then the goodwill of the reporting unit
is potentially impaired and we complete step two. In the second step, the amount of the potential
impairment loss is measured. The impairment loss, if any, is calculated by comparing the implied
fair value of reporting unit goodwill to its carrying amount.
We evaluate the carrying amount of goodwill and indefinite-lived intangible assets as of the first
day of our fourth quarter of each year and between annual evaluations if events occur that indicate
that the carrying amount of goodwill or intangible assets may be impaired. We use the income and
market approaches to determine the fair value of reporting units in the goodwill valuation. We
also use the income method to measure the fair value of indefinite-lived intangible assets.
The impairment evaluation for goodwill and intangible assets with indefinite lives requires the use
of considerable management judgment to determine discounted future cash flows, including estimates
and assumptions regarding
F-10
the amount and timing of cash flows, cost of capital and growth rates. Cash flow assumptions used
in the assessment are estimated using our annual operating plan as well as our five-year strategic
plan. The annual operating plan and strategic plan contain assumptions for revenue derived from
existing technology as well as future revenues attributed to in-process technologies and the
associated launch, growth and decline assumptions normal for the life cycle of those technologies.
In addition, management considers relevant market information, peer company data and five years of
historical financial information. In the goodwill analysis, the estimated fair value of the
reporting units used in the impairment analysis is reconciled to the companys market
capitalization at the measurement date to ensure the estimated enterprise fair values are
consistent with those of a market participant.
Impairment of Long-Lived Assets and Amortizable Intangible Assets
Long-lived assets such as property, equipment, and definite-lived intangible assets are reviewed
for impairment when events or changes in circumstances indicate that the carrying amount of the
assets may not be recoverable. An impairment loss is recognized when estimated future undiscounted
cash flows expected to result from the use of the asset and its eventual disposition are less than
the carrying amount. Where available, quoted market prices are used to determine fair value. When
quoted market prices are not available, various valuation techniques, including the discounted
value of estimated future cash flows, are utilized.
Investments
We have made certain strategic investments in companies of less than 20% of their outstanding
equity interests and in various stages of development. These investments were accounted for under
the cost method of accounting. The valuation of investments accounted for under the cost method is
based on all available financial information related to the investee, including valuations based on
recent third party equity investments in the investee. If an unrealized loss on any investment is
considered to be other-than-temporary, the loss is recognized in the period the determination is
made. All investments are reviewed for changes in circumstances or occurrence of events that
suggest our investment may not be recoverable.
Revenue Recognition
We sell the majority of our products via direct shipment to hospitals or clinics. Sales are made
through our direct sales force, distributors or through consignment arrangements with hospitals and
clinics. We recognize revenue when all of the following criteria are met: persuasive evidence of an
arrangement exists; delivery has occurred; the sales price is fixed or determinable; and
collectibility is reasonably assured. These criteria are met at the time of shipment when the risk
of loss and title passes to the customer or distributor, unless a consignment arrangement exists.
Revenue from consignment arrangements is recognized when we receive written notification from the
hospital or clinic that the product has been used. We record estimated sales returns, discounts and
rebates as a reduction of net sales in the same period revenue is recognized.
Sales to distributors are recognized at the time of shipment, provided that we have received an
order, the price is fixed or determinable, collectibility of the resulting receivable is reasonably
assured and we can reasonably estimate returns.
In conjunction with our acquisition of FoxHollow on October 4, 2007, we assumed all rights and
obligations associated with an Amended and Restated Collaboration and License Agreement
(Collaboration and License Agreement) with Merck & Co., Inc. (Merck), which was terminated by
Merck effective July 22, 2008. Under the former Collaboration and License Agreement, we were
obligated to grant Merck certain exclusive rights and to perform certain research activities under
Mercks direction, including removal of atherosclerotic plaque from patient arteries for analysis,
conduct clinical trials and drug profiling by Merck. The revenue streams for the Collaboration and
License Agreement included a minimum of $60.0 million in aggregate for collaboration for three
years beginning November 2006 and a total of $40.0 million in license/exclusivity payments for four
years beginning on the same date. Both the collaboration and license components were accounted for
as a single unit of accounting. The revenue was being recognized on a straight-line basis over the
four-year term of the license/exclusivity portion of the Collaboration and License Agreement until
the termination at which time the remaining amount of deferred revenue was recognized.
F-11
During 2008, we also recognized revenue related to our arrangement with Merck to accomplish an
orderly wind-down of our research and collaboration activities. We concluded that our arrangement
regarding wind-down activities was separate from our former Collaboration and License Agreement
with Merck as the substance, manner and terms of the arrangement substantially differed from the
original agreement. Pursuant to the arrangement, Merck agreed to reimburse us for costs incurred
subject to a mark-up. Under the new arrangement we recognized revenue using the proportional
performance method and recognized revenue as services were performed. As of December 31, 2008, we
had completed all services under the our former Collaboration and License Agreement and arrangement
regarding wind-down activities with Merck.
Costs related to products delivered are recognized in the period revenue is recognized. Cost of
goods sold consists primarily of direct labor, allocated manufacturing overhead, raw materials and
components and excludes the amortization of intangible assets.
Contingent Consideration
Contingent consideration is recorded at the acquisition-date estimated fair value of the contingent
milestone payment for all acquisitions subsequent to December 31, 2008. The fair value of the
contingent milestone consideration is remeasured at the estimated fair value at each reporting
period with the change in fair value included as Contingent consideration in our consolidated
statements of operations.
Shipping and Handling Costs
All shipping and handling costs are expensed as incurred and recorded as a component of sales,
general and administrative expense in the consolidated statements of operations. Shipping and
handling costs included in sales, general and administrative expenses
were $2.9 million, $3.5
million, and $2.9 million in 2009, 2008 and 2007, respectively. Shipping and handling amounts, if
any, billed to customers are included in net product sales.
Advertising Costs
All advertising costs are expensed as incurred. We market our products primarily through a direct
sales force and advertising expenditures are not material.
Research and Development
Research and development costs are expensed as incurred and include the costs to design, develop,
test, deploy and enhance our products. It also includes costs related to the execution of clinical
trials and costs incurred to obtain regulatory approval for our products.
Acquired In-process Research and Development (IPR&D)
When we acquire another company or group of assets, the purchase price is allocated, as applicable,
between IPR&D, net tangible assets, goodwill and intangible assets. We define IPR&D as the value
assigned to those projects for which the related products have not received regulatory approval and
have no alternative future use. Determining the portion of the purchase price allocated to IPR&D
requires us to make significant estimates. The amount of the purchase price allocated to IPR&D is
determined by discounting estimated future cash flows of each project or technology. The discount
rate used is determined at the time of the acquisition and includes consideration of the assessed
risk of the project not being successfully developed to a stage of commercial feasibility. For
acquisitions prior to January 1, 2009, amounts allocated to IPR&D were expensed at the time of
acquisition. For acquisitions subsequent to December 31, 2008, acquired in-process research and
development assets are capitalized as indefinite-lived intangible assets until the completion of or
abandonment of the associated research and development efforts. During the development period,
these assets are assessed for impairment at least annually. Upon completion of the development
process for the acquired IPR&D, the associated asset is considered definite-lived and amortized
over the estimated useful life of the asset. Development costs incurred after the acquisition date
are charged to research and development.
F-12
Special Charges
During 2007, we recorded a charge of $19.1 million as a result of the settlement of the litigation
with The Regents of the University of California and Boston Scientific Corporation.
Foreign Currency Translation/Forward Foreign Currency Contracts
The local currency is generally designated as the functional currency for our international
operations. Accordingly, assets and liabilities are translated from the local currency into U.S.
dollars at period-end exchange rates and currency translation adjustments resulting from
fluctuations in exchange rates are recorded in Accumulated other comprehensive loss in the
consolidated balance sheets. Revenues and expenses are translated at weighted average exchange
rates for the year. Gains and losses on foreign currency transactions are included in Other
expense (income), net in the consolidated statements of operations. Foreign currency transactions,
net of gains and losses on forward foreign currency contracts, resulted in losses of $1.6 million
and $2.4 million for 2009 and 2008, respectively, and transaction gains of $2.9 million for 2007.
We use forward foreign currency contracts to economically hedge the volatility of foreign currency
rates for foreign cash balances and accounts receivable for which payment is settled in a currency
other than our local operations functional currency. We did not have any forward foreign currency
contracts outstanding at the end of 2009 and 2008. During the years ended December 31, 2009 and
December 31, 2008, we recorded $2.3 million and $941,000 of losses, respectively, as Other expense
(income), net in our consolidated statements of operations associated with the settlement of our
foreign currency contracts.
Income Taxes
Deferred income taxes are recognized for the tax consequences in future years of differences
between the tax basis of assets and liabilities and their financial reporting amounts at each year
end, based on enacted tax laws and statutory tax rates applicable to the periods in which the
differences are expected to affect taxable earnings. Valuation allowances are established when
necessary to reduce deferred tax assets to the amount that is more likely than not to be realized.
The effect of changes in tax rates is recognized in the period in which the rate change occurs.
On January 1, 2007, we adopted the provisions which require certain disclosures of uncertain tax
matters and indicate how any tax reserves should be classified in a balance sheet. As a result, we
recorded a charge of $717,000, which was accounted for as an increase to the January 1, 2007
balance of accumulated deficit.
Net Income (Loss) per Common Share
Basic net earnings (loss) per share is computed based on the weighted average number of common
shares outstanding. Diluted earnings (loss) per share is computed based on the weighted average
number of common shares outstanding adjusted, to the extent dilutive, by the number of additional
shares that would have been outstanding had the potentially dilutive common shares been issued and
reduced by the number of shares we could have repurchased with the proceeds from the potentially
dilutive shares. Potentially dilutive shares include stock options and other share-based awards
granted under share-based compensation plans.
Comprehensive Income (Loss)
Comprehensive income (loss) consists of net income (loss), the effects of foreign currency
translation and unrealized (losses) gains on available-for-sale investments.
Concentrations of Credit Risk
Financial instruments that potentially subject us to credit risk consist principally of cash and
cash equivalents and accounts receivable.
F-13
We maintain cash and cash equivalents with various major financial institutions; however, we are
exposed to credit risk in the event of default by these financial institutions for amounts in
excess of Federal Deposit Insurance Corporation insured limits. We perform periodic evaluations of
the relative credit standings of these financial institutions and attempt to limit the amount of
credit exposure with any one institution by maintaining accounts at multiple institutions.
Management believes that our investments in cash and cash equivalents are financially sound and
have minimal credit risk.
We have a credit policy and perform ongoing credit evaluations of our customers. We do not
generally require collateral or other security and maintain an allowance for potential credit
losses. Management believes this risk is limited due to the large number and diversity of hospitals
and distributors who comprise our customer base.
Accounting for Stock-Based Compensation
We measure and recognize the cost of employee services received in exchange for awards of equity
instruments based on the grant date fair value of those awards. Compensation cost is recognized
ratably using the straight-line attribution method over the expected vesting period, which is
considered to be the requisite service period. In addition, we estimate the amount of expected
forfeitures when calculating the compensation costs.
The fair value of options are estimated at the date of grant using the Black-Scholes option pricing
model. Risk free interest rate is based on U.S. Treasury rates appropriate for the expected term.
Expected volatility and forfeiture rates are based on historical factors related to our common
stock. The assumed dividend yield is zero as we do not expect to declare any dividends in the
foreseeable future. The expected term is based on the weighted average time between grant and
employee exercise. The fair value of stock granted to employees is based upon the closing market
value of our common stock on the date of grant. The key assumptions used in estimating the fair
value of our stock-based compensation awards were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
2009 |
|
2008 |
|
2007 |
Risk free interest rate |
|
|
1.6 |
% |
|
|
2.6 |
% |
|
|
4.4 |
% |
Expected dividend yield |
|
|
0.0 |
% |
|
|
0.0 |
% |
|
|
0.0 |
% |
Expected volatility |
|
|
53.5 |
% |
|
|
44.8 |
% |
|
|
43.6 |
% |
Expected option term |
|
|
3.85 |
years |
|
|
3.85 |
years |
|
|
3.85 |
years |
Non-employee equity-based awards, in which goods or services are the consideration received for the
equity instruments issued, are classified as liability awards and are recorded at fair value.
The following table summarizes the stock-based compensation expense (in thousands) for employees
and non-employees recognized in our consolidated statements of operations for each period:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2009 |
|
|
2008 |
|
|
2007 |
|
Product cost of goods sold |
|
$ |
1,007 |
|
|
$ |
834 |
|
|
$ |
926 |
|
Sales, general and administrative |
|
|
11,985 |
|
|
|
12,438 |
|
|
|
8,832 |
|
Research and development |
|
|
1,564 |
|
|
|
1,887 |
|
|
|
1,369 |
|
|
|
|
|
|
|
|
|
|
|
Total stock-based compensation expense |
|
$ |
14,556 |
|
|
$ |
15,159 |
|
|
$ |
11,127 |
|
|
|
|
|
|
|
|
|
|
|
The resignation of our former chairman, president and chief executive officer on April 6, 2008,
resulted in the recognition of approximately $1.5 million of non-cash stock-based compensation in
Sales, general and administrative expenses which we recorded in the second quarter of 2008 as a
result of accelerated vesting of certain stock options and restricted stock awards and the
extension of the exercise period on certain stock options.
Fiscal Year
We operate on a manufacturing calendar with our fiscal year always ending on December 31. Each
quarter is 13 weeks, consisting of one five-week and two four-week periods.
F-14
Reclassifications
Certain amounts reported in our consolidated financial statements for the previous reporting
periods have been reclassified to conform to the current period presentation.
New Accounting Pronouncements
In the third quarter of 2009, we adopted the Financial Accounting Standards Boards (FASB)
Accounting Standards Codification (ASC) Topic 105 as the single official source of authoritative,
nongovernmental generally accepted accounting principles in the United States. On the effective
date, all then-existing non-SEC accounting literature and reporting standards were superseded and
deemed nonauthoritative. The adoption of this pronouncement did not have a material impact on our
consolidated financial statements; however, the ASC affected the way we reference authoritative
guidance in our consolidated financial statements.
In December 2007, the FASB issued additional guidance on business combinations contained in ASC
Topic 805 and additional guidance on noncontrolling interests in consolidated financial statements
contained in ASC Topic 810, which are effective for fiscal years beginning after December 15, 2008.
These new standards represent the completion of the FASBs first major joint project with the
International Accounting Standards Board and are intended to improve, simplify and converge
internationally the accounting for business combinations and the reporting of noncontrolling
interests (formerly minority interests) in consolidated financial statements.
ASC Topic 805 changes the application of the acquisition method in a number of significant
respects, including the requirement to expense transaction fees and expected restructuring costs as
incurred, rather than including these amounts in the allocated purchase price; the requirement to
recognize the fair value of contingent consideration at the acquisition date, rather than the
amount when the contingency is resolved; the requirement to recognize the fair value of acquired
in-process research and development assets at the acquisition date, rather than immediately
expensing; and the requirement to recognize a gain in relation to a bargain purchase price, rather
than reducing the allocated basis of long-lived assets. We adopted these standards at the beginning
of 2009. See Note 3 for further discussion of the impact the adoption of ASC Topic 805 had on our
results of operations and financial conditions as a result of our Chestnut acquisition in 2009.
In May 2009, the FASB issued additional guidance on managements assessment of subsequent events.
This guidance is contained in ASC Topic 855 and clarifies that management must evaluate, as of each
reporting period, events or transactions that occur for potential recognition or disclosure in the
financial statements and the circumstances under which an entity should recognize events or
transactions occurring after the balance sheet date through the date that the financial statements
are issued or are available to be issued. ASC Topic 855 requires the disclosure of the date
through which an entity has evaluated subsequent events and the basis for that date. This
disclosure alerts all users of financial statements that an entity has not evaluated subsequent
events after that date in the set of financial statements being presented. We adopted ASC Topic
855 in the second quarter of 2009. The implementation of ASC Topic 855 did not have a material
impact on our consolidated financial statements.
In April 2008, the FASB issued guidance on the determination of the useful life of intangible
assets, (ASC Topic 350-30-35-1), which amended the factors considered in developing renewal or
extension assumptions used to determine the useful life of recognized intangible assets. ASC Topic
350-30-35-1 requires a consistent approach between the useful life of a recognized intangible asset
and the period of expected cash flows used to measure the fair value of an asset. The ASC Topic
350-30-35-1 also requires enhanced disclosure when an intangible assets expected future cash flows
are affected by an entitys intent and/or ability to renew or extend the arrangement. We adopted
ASC Topic 350-30-35-1 as of January 1, 2009. The adoption did not have a significant impact on our
consolidated financial statements.
In 2006, the FASB issued an accounting pronouncement to provide enhanced guidance when using fair
value to measure assets and liabilities. The pronouncement defines fair value, establishes a
framework for measuring fair value in GAAP and expands disclosures about fair value measurements.
The pronouncement applies whenever other pronouncements require or permit assets or liabilities to
be measured by fair value. We adopted the pronouncement as of the beginning of 2008 as it relates
to recurring measurements of financial assets and liabilities, and as of the
F-15
beginning of 2009, as it relates to nonrecurring fair value measurement requirements for
nonfinancial assets and liabilities. These assets and liabilities include goodwill and intangible
assets not subject to amortization.
3. Acquisitions
Chestnut Acquisition
On June 23, 2009, we acquired Chestnut Medical Technologies, Inc., a then privately held,
California-based company focused on developing minimally invasive therapies for interventional
neuroradiology. The transaction broadens our neurovascular product portfolio by adding the Pipeline
Embolization Device for the treatment of cerebral aneurysms and the Alligator Retrieval Device for
foreign body retrieval to our existing neurovascular embolic products and neuro access
technologies.
We acquired 100 percent of the equity interests of Chestnut for total consideration valued at
$116.7 million, consisting of upfront consideration of common stock and cash valued at $79.4
million, as well as an additional milestone-based contingent payment of up to $75.0 million,
payable in a combination of common stock and equity, upon FDA pre-market approval of the Pipeline
Embolization Device.
The transaction has been accounted for under the acquisition method. Our consolidated financial
statements include the financial results of Chestnut subsequent to the acquisition date of June 23,
2009.
The following table presents the purchase price consideration (in thousands) for the acquisition:
|
|
|
|
|
Equity consideration |
|
$ |
53,186 |
|
Cash consideration |
|
|
26,240 |
|
|
|
|
|
Total cash and equity |
|
$ |
79,426 |
|
Contingent consideration |
|
|
37,275 |
|
|
|
|
|
Total purchase price consideration |
|
$ |
116,701 |
|
|
|
|
|
We issued 5,060,510 shares of our common stock, with an estimated fair value of $53.2 million.
The estimated fair value per share of common stock of $10.51 was based on the closing price of our
common stock on June 23, 2009, the date of the acquisition. The cash consideration, net of cash
acquired, was approximately $24.7 million. We have also incurred $1.0 million in direct
acquisition costs which were expensed as incurred.
In addition, we have agreed to pay an additional milestone-based payment of cash and equity upon
the FDA pre-market approval of the Pipeline Embolization Device. This milestone-based contingent
payment could range from: (1) $75.0 million upon FDA approval prior to October 1, 2011, (2) $75.0
million less $3.75 million per month upon FDA approval from October 1, 2011 through December 31,
2012 and (3) no payment required if FDA approval is not obtained by December 31, 2012. The
milestone-based payment of up to $75.0 million will consist of cash and equity paid in the form of
shares of our common stock ranging from 30% cash and 70% equity to 85% cash and 15% equity. We
have recorded the acquisition-date estimated fair value of the contingent milestone payment of
$37.3 million as a component of the consideration transferred in exchange for the equity interests
of Chestnut. The acquisition-date fair value was measured based on the probability-adjusted
present value of the consideration expected to be transferred, discounted at 26%, the weighted
average cost of capital for the Chestnut transaction. The fair value of the contingent milestone
payment was remeasured as of December 31, 2009 at $42.2 million and is reflected in Other
long-term liabilities in our consolidated balance sheets. The change in fair value of $4.9 million
for the year ended December 31, 2009 is reflected as Contingent consideration in our consolidated
statements of operations.
The assets acquired and liabilities assumed in the Chestnut acquisition were measured and
recognized at their fair values, with limited exceptions, at the date of the acquisition. The
excess of the purchase price over the net identifiable assets acquired and liabilities assumed was
recognized as goodwill, and reflect the future benefit we expect from leveraging our commercial
operations to market the acquired products. None of the goodwill or intangible assets resulting
from our acquisition of Chestnut are deductible for tax purposes.
F-16
The following table summarizes the preliminary amounts (in thousands) recognized on the acquisition
date as part of the acquisition of Chestnut:
|
|
|
|
|
Intangible assets |
|
$ |
93,070 |
|
Tangible assets acquired, net of liabilities assumed |
|
|
822 |
|
Deferred tax liabilities acquired, net |
|
|
(29,323 |
) |
Goodwill |
|
|
52,132 |
|
|
|
|
|
Estimated fair value of net assets acquired |
|
$ |
116,701 |
|
|
|
|
|
In connection with the Chestnut acquisition, we recorded deferred tax liabilities of $29.3
million, which includes $19.0 million related to amortizable intangible assets and $10.3 million
related to indefinite-lived acquired in-process research and development. For additional
discussion regarding deferred tax liabilities, see Note 17.
The following table presents the preliminary allocation of the purchase consideration to
identifiable intangible assets acquired, excluding goodwill and the weighted average amortization
period in total and by major intangible asset class (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average |
|
|
|
|
|
|
|
Amortization Period |
|
Intangible
Asset Description |
|
Fair Value Assigned |
|
|
(in years) |
|
Developed and core technology |
|
$ |
64,130 |
|
|
|
12 |
|
Customer and distributor relationships |
|
|
220 |
|
|
|
3 |
|
Trademarks and tradenames |
|
|
960 |
|
|
|
5 |
|
Non-compete agreements |
|
|
360 |
|
|
|
3 |
|
|
|
|
|
|
|
|
|
Total amortizable intangible assets acquired |
|
$ |
65,670 |
|
|
|
11 |
|
|
|
|
|
|
|
|
|
Acquired in-process research and development |
|
|
27,400 |
|
|
|
Indefinite |
|
|
|
|
|
|
|
|
|
Total intangible assets acquired (excluding goodwill) |
|
$ |
93,070 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The acquired in-process research and development asset relates primarily to the Pipeline
Embolization Device, which is a new class of embolization device that is designed to divert blood
flow away from an aneurysm in order to provide a complete and durable aneurysm embolization while
maintaining patency of the parent vessel. This asset is recognized and measured at the estimated
fair value at the date of acquisition. As of the date of the acquisition, the in-process project
had not yet reached technological feasibility in the United States and had no alternative use. The
primary basis for determining technological feasibility of the project in the United States is
obtaining FDA regulatory approval to market the device.
The income approach was used to determine the fair value of the acquired in-process research and
development asset. This approach measures fair value by estimating the after-tax cash flows
attributable to the in-process project over its useful life on a discounted basis. The costs to
complete each project were based on estimated direct project expenses as well as the remaining
labor hours and related overhead costs. In arriving at the value of the acquired in-process
research and development project, we considered the projects stage of completion, the complexity
of the work to be completed, the costs already incurred, the remaining costs to complete the
project, the contribution of core technologies, the expected introduction date and the estimated
useful life of the technology. We expect to incur approximately $8.0 million of development
expense to obtain the regulatory approval required to commercialize the Pipeline Embolization
Device in the United States. The discount rate used to arrive at the present value of acquired
in-process research and development as of the date of the acquisition was approximately 27% and was
based on the time value of money and medical technology investment risk factors.
The value attributable to this project, which had not yet obtained regulatory approval in the
United States, has been capitalized as an indefinite-lived intangible asset. Development costs
incurred on this project after the acquisition are charged to expense as incurred. If the project
is not successful, or completed in a timely manner, we may not realize the financial benefit
expected from this project. Upon completion of development and the obtaining of regulatory
approval in the United States, this asset will become an amortizable intangible asset.
F-17
Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of the
acquisition based on managements assessment.
FoxHollow Acquisition
On October 4, 2007, we acquired FoxHollow Technologies, Inc., a medical device company that
designs, develops, manufactures and sells medical devices primarily for the treatment of peripheral
artery disease. With this acquisition, we expanded our product portfolio to include
technologically advanced products to treat vascular disease in the peripheral vascular market. At
the time of the acquisition, FoxHollow was also engaged in a research collaboration with Merck &
Co., Inc. for the analysis of atherosclerotic plaque removed from patient arteries with the goal of
identifying new biomarkers for atherosclerotic disease progression and new therapies for
atherosclerotic disease.
We paid $857.0 million to acquire FoxHollow through a combination of common stock, cash and fully
vested and partially vested stock options and stock awards. In the transaction, we acquired all of
the outstanding shares of FoxHollow in exchange for 43,118,667 shares of our common stock, which
represented approximately 41% of the outstanding common stock of the combined company at that time,
with an estimated fair value of $725.7 million. At the effective date and as a result of the
acquisition, each share of common stock of FoxHollow issued and outstanding immediately prior to
the effective date of the acquisition was converted into the right to receive 1.45 shares of our
common stock and $2.75 in cash. Alternatively, FoxHollow stockholders could have elected to receive
either 1.62 shares of our common stock or $25.92 in cash for each share of FoxHollow common stock
by making an all-stock or an all-cash election, respectively. Stock and cash elections were subject
to pro-ration to preserve an overall mix of 1.45 shares of our common stock and $2.75 in cash for
all of the outstanding shares of FoxHollow common stock in the aggregate.
The fair value of the shares of our common stock issued as a result of the acquisition was $16.83
per share based on the average trading price of our common stock for the two full trading days
prior to and subsequent to the date of the announcement, July 22, 2007.
We paid $81.8 million in cash and approximately $17.7 million in direct acquisition costs,
including a payment of $8.8 million to Merck. The purchase price net of cash acquired was
approximately $690.0 million and cash acquired was comprised of $81.5 million of cash on hand and
$85.4 million of short-term investments.
At the effective time of the acquisition, each outstanding option to purchase shares of FoxHollow
common stock and other awards based on FoxHollow common stock were converted into and became
respectively an option to purchase 1.618 shares of our common stock or an award based on shares of
our common stock. The number of shares of our common stock exchanged for FoxHollow options and
stock awards was 6,605,663 shares, with an estimated fair value of $45.9 million, of which $31.9
million related to the vested portion of the options and therefore represented additional purchase
price consideration and $14.0 million related to the unvested portion of the options which will be
recognized as compensation cost over the remaining service periods.
We determined the estimated fair value of the ev3 stock options and awards exchanged for FoxHollow
options and awards was $6.34 per share. We used a Black-Scholes option pricing model to determine
the fair value of the exchanged options and awards. The determination of the fair value for the
exchanged options and awards requires the use of significant estimates and assumptions which
include the expected life of the award, the expected stock price volatility over the expected life
of the awards and the risk-free interest rate. A change in any of the estimates or assumptions
used could significantly change the valuation and fair value of the options and awards. Our
estimates and assumptions were based upon information that we believed to be reasonable as of the
date of the acquisition.
F-18
The following table presents the assumptions used to determine the fair value of the options
and awards assuming no expected dividends:
|
|
|
|
|
Expected term (in years) |
|
|
2.7 |
|
Expected volatility |
|
|
45.00 |
% |
Risk-free interest rate |
|
|
4.60 |
% |
Stock price on date of grant |
|
$ |
16.83 |
|
Weighted-average exercise price |
|
$ |
14.99 |
|
There were no contingent payments, options or commitments specified in our merger agreement with
FoxHollow.
The following table presents the purchase price consideration (in thousands) for the acquisition:
|
|
|
|
|
FoxHollow common shares converted |
|
$ |
725,687 |
|
Cash consideration |
|
|
81,811 |
|
FoxHollow options converted |
|
|
31,875 |
|
|
|
|
|
Total cash and equity |
|
$ |
839,373 |
|
Merck consideration |
|
|
8,824 |
|
Deal costs |
|
|
8,846 |
|
|
|
|
|
Total purchase price consideration |
|
$ |
857,043 |
|
|
|
|
|
The acquisition has been accounted for under the purchase method. Our consolidated financial
statements include the financial results of FoxHollow subsequent to the acquisition date of October
4, 2007.
The aggregate FoxHollow purchase price was allocated to the assets acquired and liabilities assumed
based on their fair values at the date of the acquisition. The excess of purchase price over the
fair value of net tangible assets acquired was allocated to identifiable intangible assets and
goodwill. The following table summarizes the estimate of fair value (in thousands) of net assets
that were acquired as part of the acquisition:
|
|
|
|
|
Intangible assets |
|
$ |
199,500 |
|
Acquired in-process research and development |
|
|
70,700 |
|
Tangible assets acquired, net of liabilities assumed |
|
|
145,854 |
|
Goodwill |
|
|
440,989 |
|
|
|
|
|
Estimated fair value of net assets acquired |
|
$ |
857,043 |
|
|
|
|
|
The following table presents the identifiable intangible assets acquired, excluding goodwill and
the weighted average amortization period in total and by major intangible asset class:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average |
|
|
|
|
|
|
|
Amortization Period |
|
Intangible
Asset Description |
|
Fair Value Assigned |
|
|
(in years) |
|
Developed and core technology |
|
$ |
138,800 |
|
|
|
12 |
|
Customer relationships |
|
|
40,000 |
|
|
|
12 |
|
Merck exclusivity |
|
|
13,600 |
|
|
|
3.25 |
|
Trademarks and tradenames |
|
|
7,100 |
|
|
|
10 |
|
|
|
|
|
|
|
|
|
Total intangible assets acquired (excluding goodwill) |
|
$ |
199,500 |
|
|
|
11 |
|
|
|
|
|
|
|
|
|
The acquired in-process research and development charges represented the estimated fair value of
the in-process projects at the date of the acquisition. As of the date of the acquisition, the
in-process projects had not yet reached technological feasibility and had no alternative use. The
primary basis for determining technological feasibility of these projects was obtaining regulatory
approval to market the products. Accordingly, the value attributable to these projects, which had
yet to obtain regulatory approval, was expensed in conjunction with the acquisition. If the
F-19
projects are not successful, or completed in a timely manner, we may not realize the financial
benefits expected from these projects.
The income approach was used to determine the fair value of the acquired in-process research and
development. This approach establishes fair value by estimating the after-tax cash flows
attributable to any in-process project over its useful life and then discounting these after-tax
cash flows back to the present value. The costs to complete each project were based on estimated
direct project expenses as well as the remaining labor hours and related overhead costs. In
arriving at the value of acquired in-process research and development projects, we considered the
projects stage of completion, the complexity of the work to be completed, the costs already
incurred, and the remaining costs to complete the project, the contribution of core technologies,
the expected introduction date and the estimated useful life of the technology. The discount rate
used to arrive at the present value of acquired in-process research and development as of the date
of the acquisition was based on the time value of money and medical technology investment risk
factors. The discount rate used was approximately 14%.
The most significant acquired research and development projects were the RockHawk and Next
Generation SilverHawk (TurboHawk) projects which represents 92% of the acquired research and
development projects. We attributed approximately $64.9 million of fair value to the RockHawk and
TurboHawk projects.
The RockHawk is designed to treat calcified lesions with an improved cutting blade. In February
2008, we received FDA clearance for surgical use of the RockHawk device in the United States. The
TurboHawk is designed to improve the procedure time, cutting efficiency and ease of use of the
SilverHawk system. The TurboHawk was cleared by the FDA for endovascular use in soft lesions as
well as mild to moderate calcified lesions in November 2009. It is also FDA cleared for surgical
use in heavily calcified lesions. We incurred approximately $3.2 million to bring the TurboHawk
device to commercial viability.
The TurboHawk device has been approved by the FDA for inclusion in our Investigational Device
Exemption trial for treatment of moderate to severe calcified lesions using an endovascular
surgical approach. The realization of increased cash flow relating to the TurboHawk endovascular
use in severe calcified lesions is contingent on the timing of FDA clearance for this expanded
indication.
Tangible assets acquired, net of liabilities assumed, were stated at fair value at the date of the
acquisition based on managements assessment or third party appraisals and included a $1.8 million
inventory step-up which was fully amortized at December 31, 2007. The amortization for the
inventory step-up is included in product cost of goods sold in the consolidated statements of
operations for the year ended December 31, 2007 as the acquired inventory was sold subsequent to
the merger.
None of the goodwill resulting from the FoxHollow acquisition is deductible for tax purposes.
Pro Forma Results of Operations
The unaudited pro forma combined consolidated statements of operations for the year ended December
31, 2007 combines the historical results of ev3 and the unaudited pro forma combined results of
FoxHollow for the year ended December 31, 2007 and gives effect to the acquisition as if it
occurred on January 1, 2007. Pro forma adjustments have been made related to amortization of
identified intangible assets. Pro forma net earnings for 2007 include the $70.7 million IPR&D
charge that was a direct result of the acquisition. The pro forma consolidated results do not
purport to be indicative of results that would have occurred had the acquisition been in effect for
the periods presented, nor do they claim to be indicative of the results that will be obtained in
the future, and do not include any adjustments for cost savings or other synergies. The pro forma
financial results include the results of continuing operations of FoxHollow in its entirety during
this period.
F-20
The following table contains unaudited pro forma results (in thousands except per share data) for
the year ended December 31, 2007, as if the acquisition had occurred at January 1, 2007:
|
|
|
|
|
|
|
|
|
|
|
Reported |
|
Pro Forma |
Net revenues |
|
$ |
284,183 |
|
|
$ |
439,893 |
|
Net loss |
|
$ |
(165,744 |
) |
|
$ |
(202,337 |
) |
Net loss per share: |
|
|
|
|
|
|
|
|
Basic and diluted |
|
$ |
(2.37 |
) |
|
$ |
(1.98 |
) |
4. Fair Value Measurements
The fair value of assets and liabilities is determined on the exchange price which would be
received for an asset or paid to transfer a liability (an exit price) in the principal or most
advantageous market for the asset or liability in an orderly transaction between market
participants. The determination of fair value is based upon a three-tier fair value hierarchy,
which prioritizes the inputs used in fair value measurements. The three-tier hierarchy for inputs
used in measuring fair value is as follows:
|
|
|
Level 1. Observable inputs such as quoted prices in active markets; |
|
|
|
|
Level 2. Inputs, other than the quoted prices in active markets, that are observable
either directly or indirectly; and |
|
|
|
|
Level 3. Unobservable inputs in which there is little or no market data, which require
the reporting entity to develop its own assumptions. |
Assets and Liabilities Measured at Fair Value on a Recurring Basis
As of December 31, 2009 and 2008, we held approximately $55.4 million and $45.6 million,
respectively, in money market accounts measured at fair value on a recurring basis using Level 1
inputs. Our money market accounts are reflected as Cash and cash equivalents in our consolidated
balance sheets.
In connection with our 2009 acquisition of Chestnut, we entered into an agreement to pay a
contingent milestone-based payment of cash and equity upon the U.S. Food and Drug Administration
(FDA) pre-market approval of the Pipeline Embolization Device (Pipeline). We recorded the
acquisition-date estimated fair value of the contingent milestone payment of $37.3 million as a
component of the consideration transferred in exchange for the equity interests of Chestnut. We
measured the initial amount and remeasure the liability each reporting period using Level 3 inputs.
For additional discussion regarding the valuation of contingent consideration, see Note 3.
The following table presents a summary of the contingent consideration long-term liability
and activity (in thousands) for the periods presented:
|
|
|
|
|
Balance as of December 31, 2008 |
|
$ |
|
|
Purchase price contingent consideration |
|
|
37,275 |
|
Change in fair value of contingent consideration |
|
|
4,876 |
|
|
|
|
|
Balance as of December 31, 2009 |
|
$ |
42,151 |
|
|
|
|
|
5. Restructuring
In conjunction with our acquisition of FoxHollow, our management began to assess and formulate a
plan to restructure certain activities of FoxHollow and to terminate certain contractual agreements
assumed in the acquisition. A significant portion of these costs were related to managements plan
to reduce the workforce and included costs for severance and change of control provisions provided
for under certain FoxHollow employment contracts. The workforce reductions began during the fourth
quarter of 2007 and were completed as of the end of the third quarter of 2008. The unpaid portion
of the workforce reductions represents salary continuance, which was paid over subsequent periods.
We finalized our restructuring costs in conjunction with our plans to consolidate our manufacturing
and other operations including the closure of our facilities located in Redwood City, California,
F-21
which we acquired in connection with our acquisition of FoxHollow. We have completed the
relocation of the sales, manufacturing and research and development activities performed in
FoxHollows former Redwood City facilities to our existing facilities located in Irvine, California
and Plymouth, Minnesota.
During 2009, it was determined the estimated salary continuance costs to be incurred were $300,000
less than the amount previously estimated. An adjustment to the purchase price allocation was made
to reduce the restructuring accrual and the amount allocated to goodwill. In addition, in light of
the current economic environment and continued downward pressures in the California real estate
markets, we revised certain sub-lease rental assumptions related to our vacated leased FoxHollow
facilities, which resulted in an increase in the estimated liability related to future lease
payments of $3.4 million in 2009. The changes in assumptions relate to the additional time it will
likely take to find a sub-lessor and the rental rate of the sub-lessor. Since this adjustment was
made as a result of changes in market conditions subsequent to the acquisition and was made outside
of the purchase price allocation period, the adjustment was included in the determination of net
income (loss) for the year ended December 31, 2009 and is reflected in Sales, general, and
administrative expenses on the consolidated statement of operations.
The following table represents a summary of activity (in thousands) associated with the FoxHollow
restructuring accruals that occurred during 2008 and 2009. The unpaid portions of these costs are
included in Accrued compensation and benefits, Accrued liabilities, and Other long-term
liabilities on the consolidated balance sheets for the periods presented:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reflected in |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments to |
|
|
Consolidated |
|
|
|
|
|
|
|
|
|
|
Balance at |
|
|
Purchase Price |
|
|
Statements of |
|
|
|
|
|
|
Balance at |
|
|
|
December 31, 2007 |
|
|
Allocation |
|
|
Operations |
|
|
Amounts Paid |
|
|
December 31, 2008 |
|
Workforce reductions |
|
$ |
7,605 |
|
|
$ |
848 |
|
|
$ |
|
|
|
$ |
(7,783 |
) |
|
$ |
670 |
|
Termination of
contractual commitments |
|
|
2,476 |
|
|
|
6,294 |
|
|
|
|
|
|
|
(1,275 |
) |
|
|
7,495 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
10,081 |
|
|
$ |
7,142 |
|
|
$ |
|
|
|
$ |
(9,058 |
) |
|
$ |
8,165 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reflected in |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjustments to |
|
|
Consolidated |
|
|
|
|
|
|
|
|
|
|
Balance at |
|
|
Purchase Price |
|
|
Statements of |
|
|
|
|
|
|
Balance at |
|
|
|
December 31, 2008 |
|
|
Allocation |
|
|
Operations |
|
|
Amounts Paid |
|
|
December 31, 2009 |
|
Workforce reductions |
|
$ |
670 |
|
|
$ |
(300 |
) |
|
$ |
(49 |
) |
|
$ |
(321 |
) |
|
$ |
|
|
Termination of
contractual commitments |
|
|
7,495 |
|
|
|
|
|
|
|
3,421 |
|
|
|
(3,211 |
) |
|
|
7,705 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
8,165 |
|
|
$ |
(300 |
) |
|
$ |
3,372 |
|
|
$ |
(3,532 |
) |
|
$ |
7,705 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As part of our restructuring plan, we also incurred costs related to workforce reductions of
the ev3 pre-acquisition workforce of approximately 40 employees in 2007, which were recognized when
the amounts became probable and estimable. All amounts were paid prior to December 31, 2008.
6. Inventories, Net
Inventories, net consists of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2009 |
|
|
2008 |
|
Raw materials |
|
$ |
10,927 |
|
|
$ |
10,472 |
|
Work-in-progress |
|
|
4,849 |
|
|
|
4,144 |
|
Finished goods |
|
|
40,252 |
|
|
|
43,408 |
|
|
|
|
|
|
|
|
|
|
|
56,028 |
|
|
|
58,024 |
|
Inventory reserve |
|
|
(10,974 |
) |
|
|
(10,337 |
) |
|
|
|
|
|
|
|
Inventories, net |
|
$ |
45,054 |
|
|
$ |
47,687 |
|
|
|
|
|
|
|
|
Consigned inventories as of December 31, 2009 and 2008 were $21.7 million and $20.9 million,
respectively.
F-22
7. Property and Equipment
Property and equipment consists of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2009 |
|
|
2008 |
|
Machinery and equipment |
|
$ |
32,126 |
|
|
$ |
29,550 |
|
Office furniture and equipment |
|
|
21,508 |
|
|
|
18,466 |
|
Leasehold improvements |
|
|
16,846 |
|
|
|
14,131 |
|
Construction in progress |
|
|
3,567 |
|
|
|
5,670 |
|
|
|
|
|
|
|
|
|
|
|
74,047 |
|
|
|
67,817 |
|
Less: |
|
|
|
|
|
|
|
|
Accumulated depreciation and amortization |
|
|
(44,888 |
) |
|
|
(37,136 |
) |
|
|
|
|
|
|
|
Property and equipment, net |
|
$ |
29,159 |
|
|
$ |
30,681 |
|
|
|
|
|
|
|
|
Depreciation and amortization expense for property and equipment for the years ended December 31,
2009, 2008 and 2007 was $11.2 million, $11.5 million and $8.4 million, respectively.
8. Goodwill and Intangible Assets
The changes in the carrying amount of goodwill by operating segment for the years ended December
31, 2009 and 2008 were as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Peripheral |
|
|
Neuro- |
|
|
|
|
|
|
Vascular |
|
|
vascular |
|
|
Total |
|
Balance as of January 1, 2008 |
|
$ |
501,394 |
|
|
$ |
85,254 |
|
|
$ |
586,648 |
|
Adjustments to finalize purchase accounting |
|
|
10,902 |
|
|
|
|
|
|
|
10,902 |
|
Goodwill impairment (see Note 9) |
|
|
(281,896 |
) |
|
|
|
|
|
|
(281,896 |
) |
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2008 |
|
|
230,400 |
|
|
|
85,254 |
|
|
|
315,654 |
|
Adjustments to goodwill related to acquisition of
FoxHollow (see Note 3) |
|
|
(300 |
) |
|
|
|
|
|
|
(300 |
) |
Goodwill related to acquisition of Chestnut (see Note 3) |
|
|
|
|
|
|
52,132 |
|
|
|
52,132 |
|
|
|
|
|
|
|
|
|
|
|
Balance as of December 31, 2009 |
|
$ |
230,100 |
|
|
$ |
137,386 |
|
|
$ |
367,486 |
|
|
|
|
|
|
|
|
|
|
|
Intangible assets, net consist of the following (dollars in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
Weighted |
|
|
2009 |
|
|
2008 |
|
|
|
average |
|
|
Gross |
|
|
|
|
|
|
Net |
|
|
Gross |
|
|
|
|
|
|
Net |
|
|
|
useful life |
|
|
Carrying |
|
|
Accumulated |
|
|
Carrying |
|
|
Carrying |
|
|
Accumulated |
|
|
Carrying |
|
|
|
(in years) |
|
|
Amount |
|
|
Amortization |
|
|
Amount |
|
|
Amount |
|
|
Amortization |
|
|
Amount |
|
Patents and licenses |
|
|
5.0 |
|
|
$ |
16,016 |
|
|
$ |
(7,743 |
) |
|
$ |
8,273 |
|
|
$ |
15,413 |
|
|
$ |
(6,264 |
) |
|
$ |
9,149 |
|
Developed technology |
|
|
11.0 |
|
|
|
260,147 |
|
|
|
(83,242 |
) |
|
|
176,905 |
|
|
|
196,016 |
|
|
|
(66,312 |
) |
|
|
129,704 |
|
Trademarks and tradenames |
|
|
8.0 |
|
|
|
13,182 |
|
|
|
(5,562 |
) |
|
|
7,620 |
|
|
|
12,222 |
|
|
|
(4,457 |
) |
|
|
7,765 |
|
Customer relationships |
|
|
10.0 |
|
|
|
56,314 |
|
|
|
(22,520 |
) |
|
|
33,794 |
|
|
|
56,094 |
|
|
|
(17,967 |
) |
|
|
38,127 |
|
Acquired in-process
research and development. |
|
|
|
|
|
|
27,400 |
|
|
|
|
|
|
|
27,400 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Distribution rights |
|
|
2.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,966 |
|
|
|
(7,419 |
) |
|
|
547 |
|
Other intangible assets |
|
|
3.0 |
|
|
|
360 |
|
|
|
(64 |
) |
|
|
296 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible assets, net |
|
|
|
|
|
$ |
373,419 |
|
|
$ |
(119,131 |
) |
|
$ |
254,288 |
|
|
$ |
287,711 |
|
|
$ |
(102,419 |
) |
|
$ |
185,292 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible assets are amortized using methods which approximate the benefit provided by the
utilization of the assets. Patents and licenses, developed technology and trademarks and tradenames
are amortized on a straight-line basis. Customer relationships are amortized using both
straight-line and accelerated methods that approximate the pattern of economic benefit. Acquired
in-process research and development is an indefinite-lived intangible asset until it reaches
technological feasibility, at which time it would become a finite-lived asset and be amortized over
its estimated useful life.
F-23
Total amortization of intangible assets was $25.1 million, $31.1 million and $20.3 million for the
years ended December 31, 2009, 2008 and 2007, respectively.
Based on the intangible assets in service as of December 31, 2009, estimated amortization expense,
excluding any possible future amortization associated with acquired in-process research and
development which has not reached technological feasibility, for the next five years ending
December 31 is as follows (in thousands):
|
|
|
|
|
2010 |
|
$ |
25,383 |
|
2011 |
|
|
23,860 |
|
2012 |
|
|
23,652 |
|
2013 |
|
|
23,285 |
|
2014 |
|
|
20,799 |
|
9. Goodwill and Intangible Asset Impairment
During 2008, we performed our annual goodwill impairment test as of October 1, 2008 in accordance
with our accounting policy. We performed our tests using our 2009 Annual Operating Plan (AOP) as
well as forecasts for 2010 through 2012. The AOP and three-year forecast were based upon our
strategic plan for those years which included a detailed revenue build-up by technology. The AOP
and strategic plan contain revenue assumptions that were derived from existing technology as well
as future revenues attributed to in-process technologies and the associated launch, growth and
decline assumptions normal for the life cycle of those technologies. In addition, we considered
relevant market information, peer company data and five years of historical financial information.
Finally, as part of the step 1 test, we performed a market capitalization reconciliation to ensure
the resulting outputs of the test and the total enterprise fair value were consistent with those of
a market participant. Based upon the step 1 test results, both our neurovascular and peripheral
vascular reporting units passed the test and there was no goodwill impairment indicated.
Subsequent to our annual impairment test in 2008, there was a substantial disruption in the general
credit and equity markets and in particular a substantial decline in our stock price and market
capitalization during our fourth quarter of 2008. The decline in our stock price and market
capitalization were primarily a result of the then general market conditions and the associated
increase in general market risk as well as changes in our future estimated cash flows which were
significantly driven by the changes in the performance of our plaque excision (formerly
atherectomy) business. A substantial decline in market capitalization is an indicator of
impairment, and we were required to reassess the carrying value of our goodwill. We re-performed
the step 1 test. There was no indication of impairment for our neurovascular reporting unit, but
the carrying amount of our peripheral vascular reporting unit was less than the estimated fair
value. Therefore, we performed a step 2 valuation of impairment for the peripheral vascular
reporting unit.
We performed a hypothetical valuation of the peripheral vascular reporting unit to determine the
implied fair value of goodwill. The amount of impairment was determined by comparing the fair
value of the goodwill to its carrying amount. In order to determine the fair value of goodwill,
the fair value of the reporting unit was allocated to the assets and liabilities of that unit. The
unallocated amount represented the fair value of goodwill. All of the data and key assumptions
used to derive the fair value were consistent with those used in step 1 testing.
We used the income and the market approaches to determine the fair value of goodwill. After
consideration of both approaches, the concluded fair values were weighted entirely on the income
approach. We determined that the market approach was not appropriate to use for this valuation as
there was no direct comparability between the reporting units and companies that were included in
the market valuation. As part of our step 2 valuation, we identified and valued all of our
recorded and unrecorded tangible and intangible assets. The most significant assumptions used in
the valuation of our assets included a weighted average cost of capital (WACC) of 19% and a
terminal value of 2.0 times 2012 estimated revenues. The estimated proportion of debt and equity
financing is an important component of the WACC calculation. In our analysis, the capital
structure was based on the median equity-to-capital structure for comparable companies and the
proportion of debt to equity was 0% and 100%, respectively. Based upon the results of our step 2
test, we recorded a $281.9 million impairment charge associated
F-24
with our peripheral vascular business which we recognized in Goodwill and intangible asset
impairment in our consolidated statements of operations.
During 2008, we made the decision to discontinue selling a developed technology acquired in our
FoxHollow acquisition. Prior to this decision, we had discussions with various third parties to
ascertain whether or not the technology had any perceived market value. We concluded there was no
viable interest to acquire the technology and estimated there was no market value for the asset.
As a result, we impaired the remaining carrying amount of this developed technology and recognized
a $5.6 million intangible asset impairment charge reflected in Goodwill and intangible asset
impairment in our consolidated statements of operations.
Additionally, during 2008, we assessed the distribution rights intangible asset associated with our
former agreement with Invatec S.r.l. (Invatec) to distribute their PTA balloons. We had entered
into a distribution agreement with Invatec that gave us non-exclusive rights to distribute
Invatecs products, which expired on December 31, 2008, but allowed us to sell our remaining
inventory of Invatec products through June 30, 2009. We estimated the undiscounted cash flows for
the six month period following the December 31, 2008 termination date and recorded a $1.3 million
intangible asset impairment charge to write-down the carrying amount of the asset to its estimated
fair value. We adjusted the amortization period of the asset to correspond with the period we
expected to generate future cash flows. We recognized the intangible asset impairment in Goodwill
and intangible asset impairment in our consolidated statements of operations.
Merck exercised its right to terminate the amended and restated collaboration and license
agreement, dated September 26, 2006, between Merck and FoxHollow, effective July 22, 2008. As a
result of the termination of the agreement, we recorded an intangible asset impairment charge of
$10.5 million during 2008 to write-off the Merck intangible asset that was established at the time
of our acquisition of FoxHollow, as no further cash flows were expected to be generated from the
agreement.
10. Accrued Liabilities
Accrued liabilities consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2009 |
|
|
2008 |
|
Accrued clinical studies |
|
$ |
3,085 |
|
|
$ |
2,714 |
|
Accrued royalties |
|
|
3,062 |
|
|
|
2,527 |
|
Deferred rent and lease liabilities |
|
|
2,885 |
|
|
|
3,607 |
|
Tax liabilities |
|
|
2,144 |
|
|
|
1,865 |
|
Accrued legal and professional services |
|
|
1,899 |
|
|
|
1,971 |
|
Accrued sales rebates |
|
|
1,530 |
|
|
|
852 |
|
Accrued other |
|
|
7,848 |
|
|
|
6,208 |
|
|
|
|
|
|
|
|
Total accrued liabilities |
|
$ |
22,453 |
|
|
$ |
19,744 |
|
|
|
|
|
|
|
|
11. Long-Term Debt
Long-term debt consists of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2009 |
|
|
2008 |
|
Equipment term loan |
|
$ |
6,458 |
|
|
$ |
8,958 |
|
Less: current portion |
|
|
(2,500 |
) |
|
|
(2,500 |
) |
|
|
|
|
|
|
|
Total long-term debt |
|
$ |
3,958 |
|
|
$ |
6,458 |
|
|
|
|
|
|
|
|
Our operating subsidiaries, ev3 Endovascular, Inc., ev3 International, Inc., Micro Therapeutics,
Inc. and FoxHollow Technologies, Inc. which we collectively refer to as the borrowers, are
parties to a loan and security agreement with Silicon Valley Bank, which was amended most recently
in December 2008. The amended facility consists of a $50.0 million revolving line of credit and
$10.0 million term loan. The revolving line of credit expires June 25, 2010 and the term loan
matures on June 23, 2012. Pursuant to the terms of the loan agreement, and subject to
F-25
specified reserves, we may borrow under the revolving line of credit up to $12.0 million without
any borrowing base limitations. Aggregate borrowings under the revolving line of credit that exceed
$12.0 million will subject the revolving line to borrowing base limitations. These limitations
allow us to borrow, subject to specified reserves, up to 80% of eligible domestic and foreign
accounts receivables plus up to 30% of eligible inventory. Additionally, borrowings against the
eligible inventory may not exceed the lesser of 33% of the amount advanced against accounts
receivable or $10.0 million. As of December 31, 2009, we had $6.5 million of outstanding borrowings
under the term loan and no outstanding borrowings under the revolving line of credit; however, we
had $934,000 of outstanding letters of credit issued by Silicon Valley Bank, which reduced the
maximum amount available under our revolving line of credit to $49.1 million.
Borrowings under the revolving line of credit bear interest at a variable annual rate equal to
Silicon Valley Banks prime rate plus 0.5%. Borrowings under the term loan bear interest at a
variable annual rate equal to Silicon Valley Banks prime rate plus 1.0%. Silicon Valley Banks
prime rate at December 31, 2009 was 4.0%. Accrued interest on any outstanding balance under the
revolving line and the term loan is payable monthly in arrears. Principal amounts outstanding
under the term loan are payable in 48 consecutive equal monthly installments on the last day of
each month. We incurred $150,000 of debt issuance costs which are being amortized over the term of
the revolving line of credit.
Both the revolving line of credit and term loan are secured by a first priority security interest
in substantially all of our assets, excluding intellectual property, which is subject to a negative
pledge, and are guaranteed by ev3 Inc. and all of our U.S. direct and indirect subsidiaries which
are not borrowers. We are required to maintain a minimum adjusted quick ratio and a minimum
consolidated earnings level. The loan agreement contains customary events of default, including
the failure to make required payments, the failure to comply with certain covenants or other
agreements, the occurrence of a material adverse change, failure to pay certain other indebtedness
and certain events of bankruptcy or insolvency. Upon the occurrence and during the continuation of
an event of default, amounts due under the loan agreement may be accelerated. We were in
compliance with all of our financial and non-financial covenants at December 31, 2009.
Annual maturities of our long-term debt at December 31, 2009 are as follows (in thousands):
|
|
|
|
|
2010 |
|
$ |
2,500 |
|
2011 |
|
|
2,500 |
|
2012 |
|
|
1,458 |
|
|
|
|
|
Total |
|
$ |
6,458 |
|
|
|
|
|
12. Other Long-Term Liabilities
Other long-term liabilities consist of the following (in thousands):
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2009 |
|
|
2008 |
|
Contingent consideration (see Notes 3 and 4) |
|
$ |
42,151 |
|
|
$ |
|
|
Deferred tax liability (see Notes 3 and 17) |
|
|
10,360 |
|
|
|
|
|
Other long-term liabilities |
|
|
11,397 |
|
|
|
6,217 |
|
|
|
|
|
|
|
|
Total other long-term liabilities |
|
$ |
63,908 |
|
|
$ |
6,217 |
|
|
|
|
|
|
|
|
13. (Gain) Loss on Investments, Net
On June 15, 2007, we entered into an intellectual property transfer agreement pursuant to which we
sold and licensed, on a royalty-free perpetual basis, certain intellectual property. In exchange
for the assets and license, we received $2.0 million in cash, shares of common stock and an
unsecured, subordinated, non-interest-bearing promissory note, and recognized a gain of $1.0
million in Sales, general and administrative expenses in our consolidated statements of
operations. In 2009, we recognized a gain of $4.1 million in connection with the sale of
F-26
the common stock and promissory note, which is recognized as Gain (loss) on investments, net on
our 2009 consolidated statement of operations.
14. Interest Expense (Income), Net
Interest expense (income), net for the years ended December 31, 2009, 2008 and 2007 are as follows
(in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31, |
|
|
|
2009 |
|
|
2008 |
|
|
2007 |
|
Interest income |
|
$ |
(278 |
) |
|
$ |
(1,369 |
) |
|
$ |
(3,284 |
) |
Interest expense |
|
|
1,066 |
|
|
|
1,146 |
|
|
|
1,374 |
|
|
|
|
|
|
|
|
|
|
|
Interest expense (income), net |
|
$ |
788 |
|
|
$ |
(223 |
) |
|
$ |
(1,910 |
) |
|
|
|
|
|
|
|
|
|
|
15. Equity-Based Compensation Plans
We have several stock-based compensation plans under which stock options and other equity-based
incentive awards have been granted. Under the ev3 Inc. Second Amended and Restated 2005 Incentive
Stock Plan, eligible employees, outside directors and consultants may be awarded options, stock
grants, stock units or stock appreciation rights. The terms and conditions of an option, stock
grant, stock unit or stock appreciation right (including any vesting or forfeiture conditions) are
set forth in the certificate evidencing the grant. Subject to adjustment as provided in the plan,
11.3 million shares of our common stock are authorized for issuance under the plan, including 3.3
million shares that were unallocated and available for grant under stock plans assumed by ev3 in
connection with our acquisition of FoxHollow and became available for issuance under the 2005 plan.
As of December 31, 2009, 7.9 million shares of our common stock had been issued under the 2005
plan or were subject to outstanding awards and options granted under the 2005 plan and 2.0 million
shares remained available for future grants. As of December 31, 2009, 2.3 million shares of our
common stock were issuable pursuant to outstanding stock options and other awards granted under
predecessor and/or assumed plans, including the ev3 LLC plan, Micro Therapeutics, Inc. stock plans
and FoxHollow plans.
We granted non-plan options to purchase 754,000 shares of our common stock outside of the terms of
our existing stockholder-approved equity incentive plans to Robert J. Palmisano, our President and
Chief Executive Officer, as an inducement grant in April 2008.
Options, other than those granted to outside consultants and our board of directors, generally vest
over a four-year period and expire within a period of not more than ten years from the date of
grant. Vested options generally expire 90 days after termination of employment. Options granted to
outside consultants generally vest over the term of their consulting contract and generally expire
90 days after termination of the consulting relationship. The exercise price per share for each
option is set by the board of directors or the compensation committee at the time of grant and
pursuant to the terms of the plan may not be less than the fair market value per share on the grant
date.
In addition to our 2005 Incentive Stock Plan, we maintain the ev3 Inc. Employee Stock Purchase Plan
(ESPP). The ESPP was amended and restated by our Board of Directors in December 2009 to increase
the number of shares of our common stock available for sale under the plan and make other minor
revisions. The amended and restated ESPP is subject to the approval of our stockholders at our
next annual meeting of stockholders anticipated to be held in May 2010. The maximum number of
shares of our common stock available for issuance under the amended and restated ESPP is 1.75
million shares, subject to adjustment as provided in the ESPP. The ESPP provides for six-month
offering periods beginning on January 1 and July 1 of each year. The purchase price of the shares
is 85% of the lower of the fair market value of our common stock at the beginning or end of the
offering period. This discount does not exceed the maximum discount rate permitted for plans of
this type under Section 423 of the Internal Revenue Code of 1986, as amended. The ESPP is
compensatory for financial reporting purposes.
F-27
A summary of option activity for all plans (dollars in thousands, except per share amounts)
during the year is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-Average |
|
|
Aggregate |
|
|
|
Awarded Shares |
|
|
Exercise Price Per |
|
|
Intrinsic |
|
|
|
Outstanding |
|
|
Share |
|
|
Value |
|
Balance at January 1, 2009 |
|
|
9,747,532 |
|
|
$ |
12.98 |
|
|
$ |
721 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Granted |
|
|
2,108,446 |
|
|
$ |
7.07 |
|
|
|
|
|
Exercised |
|
|
(254,461 |
) |
|
$ |
7.27 |
|
|
|
|
|
Forfeited |
|
|
(305,354 |
) |
|
$ |
13.82 |
|
|
|
|
|
Expired |
|
|
(1,772,160 |
) |
|
$ |
14.94 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at December 31, 2009 |
|
|
9,524,003 |
|
|
$ |
11.44 |
|
|
$ |
28,252 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options exercisable at December 31, 2009 |
|
|
5,728,621 |
|
|
$ |
13.01 |
|
|
$ |
10,235 |
|
|
|
|
|
|
|
|
|
|
|
The weighted average grant date fair value of options issued under all plans for 2009, 2008 and
2007 was $2.96, $3.37 and $6.55, respectively.
As of December 31, 2009, the total compensation cost for nonvested options not yet recognized in
our statements of operations was $14.3 million, net of estimated forfeitures. This amount is
expected to be recognized over a weighted average period of 2.58 years.
The intrinsic value of a stock option award is the amount by which the fair market value of the
underlying stock exceeds the exercise price of the award. The total intrinsic value of options
exercised was $789,000, $1.1 million, and $4.8 million during 2009, 2008 and 2007, respectively.
For options outstanding and exercisable at December 31, 2009, the exercise price ranges and average
remaining lives were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options Outstanding |
|
Options Exercisable |
|
|
|
|
|
|
Weighted- |
|
Weighted- |
|
|
|
|
|
Weighted- |
|
|
|
|
|
|
Average |
|
Average |
|
|
|
|
|
Average |
|
|
Number |
|
Per Share |
|
Remaining |
|
Number |
|
Exercise Price |
Exercise Price Per Share |
|
Outstanding |
|
Exercise Price |
|
Contractual Life |
|
Exercisable |
|
Per Share |
$0.20 - $8.06 |
|
|
2,051,063 |
|
|
$ |
6.01 |
|
|
8.3 years |
|
|
307,388 |
|
|
$ |
5.23 |
|
$8.07 - $8.82 |
|
|
1,999,201 |
|
|
$ |
8.71 |
|
|
5.6 years |
|
|
1,367,800 |
|
|
$ |
8.74 |
|
$8.84 - $13.26 |
|
|
1,914,111 |
|
|
$ |
11.28 |
|
|
7.8 years |
|
|
983,360 |
|
|
$ |
11.86 |
|
$13.41 - $16.64 |
|
|
2,435,239 |
|
|
$ |
15.08 |
|
|
4.6 years |
|
|
2,145,488 |
|
|
$ |
14.91 |
|
$16.66 - $96.06 |
|
|
1,124,389 |
|
|
$ |
18.56 |
|
|
6.1 years |
|
|
924,585 |
|
|
$ |
18.73 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,524,003 |
|
|
$ |
11.44 |
|
|
6.4 years |
|
|
5,728,621 |
|
|
$ |
13.01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
A summary of restricted stock awards activity for all plans during 2009 is as follows:
|
|
|
|
|
|
|
|
|
|
|
Awarded |
|
|
Weighted-Average |
|
|
|
Shares |
|
|
Grant Date Fair |
|
|
|
Outstanding |
|
|
Value |
|
Nonvested balance at January 1, 2009 |
|
|
1,241,830 |
|
|
$ |
12.04 |
|
Granted |
|
|
921,965 |
|
|
$ |
7.21 |
|
Vested |
|
|
(572,721 |
) |
|
$ |
10.62 |
|
Forfeited |
|
|
(161,037 |
) |
|
$ |
12.06 |
|
|
|
|
|
|
|
|
|
Nonvested balance at December 31, 2009 |
|
|
1,430,037 |
|
|
$ |
9.26 |
|
|
|
|
|
|
|
|
The value of these shares of restricted stock was measured at the closing market price of our
common stock on the grant date. The unamortized compensation expense for these awards was $14.4
million as of December 31, 2009, which will be recognized over the remaining weighted average
vesting period of approximately 2.25 years.
F-28
16. Defined Contribution Plans
We offer substantially all of our employees the opportunity to participate in defined contribution
retirement plans qualifying under the provisions of Section 401(k) of the Internal Revenue Code of
1986, as amended (IRC). The plans provide for a match of 50% of the employees pre-tax
contribution, up to a maximum of 3% of eligible earnings. The employee is immediately vested in the
matching contribution. Compensation expense related to this plan was $2.5 million, $2.7 million and
$1.9 million for the years ended December 31, 2009, 2008 and 2007, respectively.
17. Income Taxes
The
components of our income tax (benefit) expense are as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31, |
|
|
|
2009 |
|
|
2008 |
|
|
2007 |
|
Current: |
|
|
|
|
|
|
|
|
|
|
|
|
U.S |
|
$ |
1,906 |
|
|
$ |
245 |
|
|
$ |
|
|
Foreign |
|
|
1,442 |
|
|
|
1,571 |
|
|
|
949 |
|
|
|
|
|
|
|
|
|
|
|
Total current |
|
|
3,348 |
|
|
|
1,816 |
|
|
|
949 |
|
Deferred: |
|
|
(19,171 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income tax (benefit) expense |
|
$ |
(15,823 |
) |
|
$ |
1,816 |
|
|
$ |
949 |
|
|
|
|
|
|
|
|
|
|
|
Following is a reconciliation of the U.S. federal statutory rate to our effective tax rate:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31, |
|
|
|
2009 |
|
|
2008 |
|
|
2007 |
|
U.S. federal statutory tax rate |
|
|
35.0 |
% |
|
|
(35.0 |
)% |
|
|
(35.0 |
)% |
Goodwill and intangible asset impairment |
|
|
|
|
|
|
29.6 |
% |
|
|
|
|
Change in valuation allowance |
|
|
(39.5 |
)% |
|
|
5.7 |
% |
|
|
20.2 |
% |
Change in valuation allowance Chestnut
acquisition |
|
|
(72.8 |
)% |
|
|
|
|
|
|
|
|
Alternative minimum tax |
|
|
3.9 |
% |
|
|
|
|
|
|
|
|
Stock options |
|
|
1.5 |
% |
|
|
0.9 |
% |
|
|
|
|
State income taxes |
|
|
2.3 |
% |
|
|
(0.4 |
)% |
|
|
(0.1 |
)% |
Research and development tax credits |
|
|
(3.8 |
)% |
|
|
(0.3 |
)% |
|
|
|
|
Meals and entertainment |
|
|
2.5 |
% |
|
|
0.2 |
% |
|
|
0.3 |
% |
Foreign income taxes |
|
|
1.8 |
% |
|
|
0.1 |
% |
|
|
0.6 |
% |
Acquired in-process research and development |
|
|
|
|
|
|
|
|
|
|
15.1 |
% |
Contingent consideration |
|
|
6.6 |
% |
|
|
|
|
|
|
|
|
Other, net |
|
|
1.7 |
% |
|
|
(0.3 |
)% |
|
|
(0.5 |
)% |
|
|
|
|
|
|
|
|
|
|
Effective tax rate |
|
|
(60.8 |
)% |
|
|
0.5 |
% |
|
|
0.6 |
% |
|
|
|
|
|
|
|
|
|
|
F-29
Deferred tax assets and liabilities were attributed to the following items (in thousands):
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2009 |
|
|
2008 |
|
Deferred Tax Assets: |
|
|
|
|
|
|
|
|
Net operating loss carryforwards |
|
$ |
199,741 |
|
|
$ |
212,443 |
|
Capitalized research & development costs |
|
|
30,226 |
|
|
|
35,878 |
|
Other reserves and accruals |
|
|
13,520 |
|
|
|
11,576 |
|
Stock options |
|
|
8,854 |
|
|
|
6,453 |
|
Tax credit carryforwards |
|
|
7,366 |
|
|
|
5,439 |
|
Inventories |
|
|
3,994 |
|
|
|
4,677 |
|
Unrealized losses on investments |
|
|
|
|
|
|
3,362 |
|
Capital loss carryforward |
|
|
1,905 |
|
|
|
|
|
Property and equipment |
|
|
6,161 |
|
|
|
2,764 |
|
Other |
|
|
484 |
|
|
|
609 |
|
Valuation allowance |
|
|
(190,253 |
) |
|
|
(220,077 |
) |
|
|
|
|
|
|
|
Total deferred tax assets |
|
$ |
81,998 |
|
|
$ |
63,124 |
|
|
|
|
|
|
|
|
Deferred Tax Liabilities: |
|
|
|
|
|
|
|
|
Intangible assets |
|
|
(92,358 |
) |
|
|
(63,124 |
) |
|
|
|
|
|
|
|
Net deferred tax liability |
|
$ |
(10,360 |
) |
|
$ |
|
|
|
|
|
|
|
|
|
In connection with the Chestnut acquisition, we recorded deferred tax liabilities of $29.3 million,
which included $19.0 million related to amortizable intangible assets and $10.3 million related to
indefinite-lived acquired in-process research and development. The deferred tax liabilities of
$19.0 million related to the amortizable intangibles reduces our net deferred tax assets by a like
amount and in a manner that provides predictable future taxable income over the asset amortization
period. As a result, we reduced our pre-acquisition deferred tax asset valuation allowance in 2009
by $19.0 million, which has been reflected as an Income tax benefit in our consolidated
statements of operations. Although the deferred tax liability of $10.3 million related to acquired
in-process research and development also reduces our net deferred tax assets by a like amount, it
does so in a manner that does not provide predictable future taxable income because the related
asset is indefinite-lived. Therefore, the deferred tax asset valuation allowance was not reduced as
a result of this item, and we have reported the net $10.3 million deferred tax liability under the
caption Other long-term liabilities in our consolidated balance sheet.
We have assessed all available evidence to determine the necessity of maintaining a valuation
allowance for our deferred tax assets. A valuation allowance has been recorded against our
remaining net deferred tax assets as we have concluded that it is more likely than not that the
deferred tax assets will not be utilized. If it is determined in a future period that it is more
likely than not that the deferred tax assets will be utilized, we will reverse all or part of the
valuation allowance for our deferred tax assets.
In December 2007, the FASB issued additional guidance on business combinations contained in ASC
Topic 805 (ASC Topic 805), which was effective beginning in 2009 and where acquired income tax
contingencies and reversals of valuation allowances related to previous acquisitions will impact
income tax expense in the period of reversal.
F-30
A reconciliation of the beginning and ending balances of the total amounts of gross unrecognized
tax benefits is as follows (in thousands):
|
|
|
|
|
Gross unrecognized tax benefits at December 31, 2007 |
|
$ |
9,430 |
|
Increase for tax positions in prior years |
|
|
1,260 |
|
Decrease for tax positions in prior years |
|
|
(334 |
) |
Settlements |
|
|
(80 |
) |
Increase for tax positions in current years |
|
|
415 |
|
|
|
|
|
Gross unrecognized tax benefits at December 31, 2008 |
|
$ |
10,691 |
|
Increase for tax positions in prior years |
|
|
67 |
|
Purchase accounting |
|
|
225 |
|
Increase for tax positions in current years |
|
|
208 |
|
|
|
|
|
Gross unrecognized tax benefits at December 31, 2009 |
|
$ |
11,191 |
|
|
|
|
|
The total amount of net unrecognized tax benefits that, if recognized, would affect tax expense was
$1.2 million at December 31, 2009. We accrue interest and penalties related to unrecognized tax
benefits and recognized the expense in our provision for income taxes. At December 31, 2009, we
had accrued interest and penalties related to unrecognized tax benefits of $88,000 and $317,000,
respectively.
We do not believe within the next twelve months there will be a significant change in the total
amount of unrecognized tax benefits as of December 31, 2009.
We, or one of our subsidiaries, file income tax returns in the U.S. federal jurisdiction and in
various U.S. state and foreign jurisdictions. With few exceptions, as a result of net operating
loss carryforwards generated, we are subject to U.S. federal and state income tax examinations by
tax authorities for years after 1994, and for years after 2002 in foreign jurisdictions.
At December 31, 2009, we had U.S. net operating loss carryforwards of $484.8 million (net of $35.6
million expected to expire before utilization due to the IRC Section 382 limitation) and foreign
net operating loss carryforwards of $36.2 million (net of uncertain tax positions recorded). The
general time frame of the net operating loss carryforwards expiration is as follows (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Carryforward |
|
U. S. |
|
|
Foreign |
|
|
Total |
|
|
Expiration Period |
|
$ |
27,826 |
|
|
$ |
21,852 |
|
|
$ |
49,678 |
|
|
2010 - 2019 |
|
|
206,991 |
|
|
|
|
|
|
|
206,991 |
|
|
2020 - 2023 |
|
|
250,002 |
|
|
|
|
|
|
|
250,002 |
|
|
2024 - 2029 |
|
|
|
|
|
|
14,313 |
|
|
|
14,313 |
|
|
No expiration date |
|
|
|
|
|
|
|
|
|
|
|
|
$ |
484,819 |
|
|
$ |
36,165 |
|
|
$ |
520,984 |
|
|
|
|
|
|
|
|
|
|
|
|
|
In addition, we currently have approximately $303.1 million in state net operating loss
carryforwards. These net operating loss carryforwards will expire in varying amounts between 2010
and 2029.
We have research and experimentation credit carryforwards for U.S. and California purposes of
approximately $4.4 million and $1.4 million, respectively (collectively net of $5.9 million
expected to expire before utilization due to the IRC Section 382 limitation and net of uncertain
tax positions recorded) which will expire between 2010 and 2023. In addition, we have business
loss carryforwards in the state of Texas in the amount of $300,000 to be utilized between 2010 and
2017.
As of December 31, 2009, our deferred tax assets also included $1.1 million of alternative minimum
tax credits carryforwards which may be carried forward indefinitely.
Certain acquisitions made since 2001 have resulted in ownership changes which limit our ability to
utilize our net operating loss and credit carryforwards pursuant to IRC Section 382. Additionally,
a number of our subsidiaries, including Chestnut acquired in June 2009, have more than one IRC
Section 382 limitation associated with their net
F-31
operating loss carryovers as a result of multiple past ownership changes. Subsequent changes in
equity could further limit the utilization of our federal and state net operating loss and credit
carryforwards. Such limitations could result in expiration of carryforward periods prior to
utilization of the net operating loss and credit carryforwards. The net operating losses of
certain subsidiaries acquired in prior years are subject to the separate return limitation year
provisions of the Treasury Regulations. Net operating loss carryforwards from these acquisitions
may only be used to offset future taxable income generated by these subsidiaries.
18. Commitments and Contingencies
Operating Leases
We lease various manufacturing and office facilities and certain equipment under operating leases,
which include standard terms of renewal and rent escalation clauses which we account for on a
straight-line basis over the term of the operating lease.
Total future non-cancelable minimum lease commitments are as follows (in thousands):
|
|
|
|
|
Years
ending December 31: |
|
|
|
|
2010 |
|
$ |
7,316 |
|
2011 |
|
|
5,069 |
|
2012 |
|
|
3,479 |
|
2013 |
|
|
2,952 |
|
2014 |
|
|
2,952 |
|
Thereafter |
|
|
5,470 |
|
|
|
|
|
|
|
$ |
27,238 |
|
|
|
|
|
Rent expense related to non-cancelable operating leases for the years ended December 31, 2009, 2008
and 2007 was $5.8 million, $6.3 million and $5.1 million, respectively.
We recorded a lease termination reserve associated with three FoxHollow leased facilities which we
effectively abandoned during 2008 as part of our consolidation strategy. During 2009, we recorded
a $3.4 million adjustment to our lease termination reserve. For additional discussion regarding
the termination of these contractual commitments see Note 5.
Letters of Credit
As of December 31, 2009, we had outstanding commitments of $4.2 million which are supported by
irrevocable standby letters of credit and restricted cash. The letters of credit and restricted
cash support various obligations, such as operating leases, tender arrangements with customers and
automobile leases.
Royalties
We have various licensing agreements with third parties for the use of certain technologies for
which we are required to pay royalties ranging from 0.5% to 6.0% of net sales. We incurred costs of
$11.7 million, $10.1 million and $8.1 million in connection with these agreements in 2009, 2008 and
2007, respectively.
Contingent Consideration
Under the terms of our Chestnut acquisition agreement, we may be obligated to make an additional
milestone-based payment of cash and equity totaling up to $75 million upon the FDA pre-market
approval of the Pipeline device. For additional discussion regarding the contingent consideration,
see Notes 3 and 4.
F-32
Other Contingencies
We are from time to time subject to, and are presently involved in, various pending or threatened
legal actions and proceedings, including those that arise in the ordinary course of our business.
Such matters are subject to many uncertainties and to outcomes that are not predictable with
assurance and that may not be known for extended periods of time. We record a liability in our
consolidated financial statements for costs related to claims, including future legal costs,
settlements and judgments, where we have assessed that a loss is probable and an amount can be
reasonably estimated. Our significant legal proceedings are discussed below. While it is not
possible to predict the outcome for most of the legal proceedings discussed below, the costs
associated with such proceedings could have a material adverse effect on our consolidated results
of operations, financial position or cash flows of a future period.
The acquisition agreement relating to our acquisition of Appriva Medical, Inc. contains four
milestones to which payments relate totaling $125 million. We believe that the milestones were not
achieved by the applicable dates and that none of the milestones are payable. On May 20, 2005,
Michael Lesh, as an individual seller of Appriva stock and purporting to represent certain other
sellers of Appriva stock, filed a complaint in the Superior Court of the State of Delaware with
individually specified damages aggregating $70 million and other unspecified damages. On or about
November 21, 2005, a second lawsuit was filed in Delaware Superior Court relating to the
acquisition of Appriva Medical, Inc. The named plaintiff of that action was Appriva Shareholder
Litigation Company, LLC, which according to the complaint was formed for the purpose of pursuing
claims against us. That complaint alleged specified damages in the form of the second milestone
payment ($25 million), which was claimed to be due and payable, and further alleged unspecified
damages. On November 26, 2008, in a consolidated proceeding, the trial court granted our motion
for summary judgment on the issue of standing and dismissed both complaints without prejudice. On
April 7, 2009, Michael Lesh and Erik Van Der Burg, acting jointly as the Shareholder
Representatives for the former shareholders of Appriva Medical, Inc., filed a motion to amend their
complaints in Superior Court of the State of Delaware. The proposed amended complaint seeks the
recovery of all of the milestone payments and punitive damages. The plaintiffs assert several
claims, including breach of contract, fraudulent inducement and violation of California securities
law. We filed a motion to dismiss the entire amended complaint, but the trial court has yet to
rule on the motion. Because this matter is in the early stages, we cannot estimate the possible
loss or range of loss, if any, associated with its resolution. However, there can be no assurance
that the ultimate resolution of this matter will not result in a material adverse effect on our
business, financial condition, results of operations or cash flows of a future period.
In July 2006, August 2006 and February 2007, three separate shareholder class action complaints
were filed against FoxHollow and two of its officers in the U.S. District Court for the Northern
District of California. These cases were subsequently consolidated into a single matter. On May
27, 2008, the U.S. District Court dismissed the consolidated case without leave to amend the
complaint and judgment was enforced that day against the plaintiffs. The plaintiffs subsequently
filed a notice of appeal to the United States Court of Appeals for the Ninth Circuit. On December
4, 2009, the Court of Appeals affirmed the U.S. District Courts dismissal of the consolidated
cases.
In February 2007, David Martin, FoxHollows former chief operating officer, filed a wrongful
termination and defamation suit against FoxHollow and one of its officers in the Superior Court of
the State of California, San Mateo County. During 2009, the parties settled this dispute. We have
made the appropriate provision in our consolidated financial statements, which did not have a
material adverse effect on our business, financial condition, results of operations or cash flows.
Pursuant to the acquisition agreement relating to FoxHollows purchase of Kerberos Proximal
Solutions, Inc., FoxHollow agreed to pay certain earn-out payments up to an aggregate of $117.0
million upon the achievement of contractually defined net sales milestones. Counsel for the
shareholder representatives of Kerberos have alleged that FoxHollow has not used commercially
reasonable efforts to market, promote, sell and distribute Kerbeross Rinspirator products, as
required under the agreement. We discontinued the sale of the Rinspirator products in January
2009. Although no formal litigation has been commenced by the stockholder representatives of
Kerberos regarding the alleged claims, there can be no assurance that the ultimate resolution of
this matter will not result in a material adverse effect on our business, financial condition,
results of operations or cash flows of a future period.
F-33
19. Segment and Geographic Information
Our management, including our chief executive officer who is our chief operating decision maker,
report and manage our operations in two reportable business segments based on similarities in the
products sold, customer base and distribution system. Our peripheral vascular segment contains
products that are used primarily in peripheral vascular procedures by radiologists, vascular
surgeons and cardiologists. Our neurovascular operating segment contains products that are used
primarily by neuroradiologists, interventional neurosurgeons and neurosurgeons.
Management measures segment profitability on the basis of gross profit calculated as net sales less
cost of goods sold excluding amortization of intangible assets. Other operating expenses are not
allocated to individual operating segments for internal decision making activities.
We sell our products through a direct sales force in the United States, Europe, Canada, Australia
and other countries as well as through distributors in other international markets. Our customers
include a broad physician base consisting of vascular surgeons, neurosurgeons, other endovascular
specialists, radiologists, neuroradiologists and cardiologists.
Selected financial information related to our segments is presented below (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Years Ended December 31, |
|
|
|
2009 |
|
|
2008 |
|
|
2007 |
|
Net sales |
|
|
|
|
|
|
|
|
|
|
|
|
Net product sales: |
|
|
|
|
|
|
|
|
|
|
|
|
Peripheral vascular |
|
|
|
|
|
|
|
|
|
|
|
|
Plaque excision |
|
$ |
84,072 |
|
|
$ |
88,800 |
|
|
$ |
20,884 |
|
Stents |
|
|
114,900 |
|
|
|
107,146 |
|
|
|
86,035 |
|
Thrombectomy and embolic protection |
|
|
31,513 |
|
|
|
27,779 |
|
|
|
25,998 |
|
Procedural support and other |
|
|
49,046 |
|
|
|
46,204 |
|
|
|
40,858 |
|
|
|
|
|
|
|
|
|
|
|
Total peripheral vascular |
|
|
279,531 |
|
|
|
269,929 |
|
|
|
173,775 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Neurovascular |
|
|
|
|
|
|
|
|
|
|
|
|
Embolic products |
|
|
103,081 |
|
|
|
74,642 |
|
|
|
56,003 |
|
Neuro access and delivery products
and other |
|
|
66,460 |
|
|
|
57,662 |
|
|
|
48,448 |
|
|
|
|
|
|
|
|
|
|
|
Total neurovascular |
|
|
169,541 |
|
|
|
132,304 |
|
|
|
104,451 |
|
|
|
|
|
|
|
|
|
|
|
Total net product sales |
|
$ |
449,072 |
|
|
$ |
402,233 |
|
|
$ |
278,226 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research collaboration: |
|
|
|
|
|
|
19,895 |
|
|
|
5,957 |
|
|
|
|
|
|
|
|
|
|
|
Total net sales |
|
$ |
449,072 |
|
|
$ |
422,128 |
|
|
$ |
284,183 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
|
|
|
|
|
|
|
|
|
|
Peripheral vascular |
|
$ |
198,704 |
|
|
$ |
167,505 |
|
|
$ |
100,693 |
|
Neurovascular |
|
|
129,755 |
|
|
|
97,881 |
|
|
|
77,654 |
|
Research collaboration |
|
|
|
|
|
|
13,844 |
|
|
|
4,892 |
|
|
|
|
|
|
|
|
|
|
|
Total gross profit (1) |
|
$ |
328,459 |
|
|
$ |
279,230 |
|
|
$ |
183,239 |
|
|
|
|
|
|
|
|
|
|
|
Operating expense |
|
|
304,102 |
|
|
|
611,319 |
|
|
|
352,762 |
|
|
|
|
|
|
|
|
|
|
|
Income (loss) from operations |
|
$ |
24,357 |
|
|
$ |
(332,089 |
) |
|
$ |
(169,523 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets |
|
|
|
|
|
|
|
|
|
|
|
|
Peripheral vascular |
|
$ |
548,641 |
|
|
$ |
545,588 |
|
|
|
|
|
Neurovascular |
|
|
347,648 |
|
|
|
175,076 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total |
|
$ |
896,289 |
|
|
$ |
720,664 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Gross profit for internal measurement purposes is defined as net sales less cost of
goods sold which excludes amortization of intangible assets. |
F-34
For the years ended December 31, 2009, 2008 and 2007, no single customer represented more than
10% of our consolidated net sales.
The following table presents net sales and long-lived assets by geographic area (in thousands):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
Geographic
Data |
|
2009 |
|
|
2008 |
|
|
2007 |
|
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
United States |
|
$ |
270,961 |
|
|
$ |
275,433 |
|
|
$ |
177,198 |
|
International |
|
|
178,111 |
|
|
|
146,695 |
|
|
|
106,985 |
|
|
|
|
|
|
|
|
|
|
|
Total net sales |
|
$ |
449,072 |
|
|
$ |
422,128 |
|
|
$ |
284,183 |
|
|
|
|
|
|
|
|
|
|
|
Long-lived Assets |
|
|
|
|
|
|
|
|
|
|
|
|
United States |
|
$ |
27,823 |
|
|
$ |
29,603 |
|
|
|
|
|
International |
|
|
1,336 |
|
|
|
1,078 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total long-lived assets |
|
$ |
29,159 |
|
|
$ |
30,681 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20. Related Party Transactions
During the second quarter of 2007, we entered into a distribution agreement with Beijing Lepu
Medical Device, Inc. (Lepu), a Chinese domiciled manufacturer and distributor of interventional
cardiology and peripheral products. The agreement was amended in the fourth quarter of 2009
allowing Lepu to sell certain of our embolic protection devices and stents in China, through the
expiration date of the amendment, December 31, 2010. We believe that having access to Lepu and
their sub-distributor network is a strategic way for us to quickly gain access and market share in
these strategic markets. Warburg Pincus Equity Partners, L.P. (Warburg Pincus), who owned
approximately 24% of our outstanding common stock as of December 31, 2009, and who together with
Vertical Group, L.P. (Vertical) has two designees on our board of directors, has approximately
18% ownership interest in Lepu and has a designee on Lepus board of directors. Lepu purchased
peripheral vascular products from us that we have recognized as net product sales totaling $2.7
million, $2.3 million and $1.5 million for the years ended December 31, 2009, 2008, and 2007,
respectively. As of December 31, 2009, 2008 and 2007, Lepu owed us approximately $70,000, $364,000
and $306,000, respectively, that is recorded as Accounts receivable.
During the third quarter of 2007, we entered into a distribution agreement with Bacchus Vascular,
Inc. (Bacchus), a provider of medical devices used by interventional radiologists and vascular
surgeons for the minimally invasive treatment of deep vein thrombosis and other peripheral vascular
disease. The six-year agreement allowed Bacchus to sell certain of our products. We also entered
into an option agreement with Bacchus, which granted us a call option and Bacchus a put option to
cause us to acquire Bacchus at a formula price in 2010. The call and put options were terminable by
either party prior to December 31, 2009. Warburg Pincus and Vertical and certain of their
affiliates, who collectively owned over 56% of our outstanding common stock at that time and who
have two designees on our board of directors, owned an interest of approximately 64% in Bacchus and
had designees on Bacchus board of directors at the time we entered into the agreements. During
the year ended December 31, 2007, Bacchus purchased peripheral vascular products from us totaling
$486,000 that we recognized as net product sales, and as of December 31, 2007, owed us $182,000
that was recorded as Accounts receivable and was paid prior to the end of the first quarter of
2008. Bacchus did not purchase products from us in either 2009 or 2008. The distribution
agreement and option agreement were both terminated prior to the end of the first quarter of 2009.
As a result of our acquisition of FoxHollow, we assumed the obligations of FoxHollow under a
time-sharing agreement, effective as of September 1, 2005, between FoxHollow and JBS Consulting,
LLC, an entity affiliated with John B. Simpson, Ph.D., M.D., who served as our vice chairman, chief
scientist and a director from October 4, 2007 through February 7, 2008, and a reimbursement
agreement, also effective as of September 1, 2005, among FoxHollow, JBS Consulting and Dr. Simpson.
Under the terms of the time-sharing agreement, FoxHollow leased an airplane owned by JBS
Consulting and a flight crew in exchange for FoxHollows payment of the aggregate incremental cost
of each flight conducted at the request of FoxHollow. We terminated the time-sharing agreement and
reimbursement agreement after Dr. Simpsons resignation in February 2008.
F-35
21. Net Income (Loss) Per Common Share
Basic net earnings (loss) per share is computed based on the weighted average number of common
shares outstanding. Diluted net earnings (loss) per share is computed based on the weighted
average number of common shares outstanding adjusted, to the extent dilutive, by the number of
additional shares that would have been outstanding had the potentially dilutive common shares been
issued and reduced by the number of shares we could have repurchased with the proceeds from the
potentially dilutive shares. Potentially dilutive shares include options to purchase shares of our
common stock and other share-based awards granted under our share-based compensation plans.
The weighted average number of common shares outstanding for basic and diluted earnings per share
purposes is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended |
|
|
December 31, |
|
|
2009 |
|
2008 |
|
2007 |
Weighted average number of shares outstanding, basic
|
|
|
107,997,738 |
|
|
|
104,378,828 |
|
|
|
69,909,708 |
|
Incremental effect of stock options and awards
|
|
|
1,000,790 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average number of shares outstanding, diluted
|
|
|
108,998,528 |
|
|
|
104,378,828 |
|
|
|
69,909,708 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
There were 7,471,704, 10,304,801 and 7,709,924 stock options and awards at the end of 2009,
2008 and 2007, respectively, that were excluded from the incremental effect of stock options and
awards in the table above as their effect would have been anti-dilutive.
In connection with our Chestnut acquisition, we may be obligated to make an additional
milestone-based payment of cash and equity totaling up to $75 million upon the FDA pre-market
approval of the Pipeline Embolization Device. The contingently issuable shares of common stock
associated with the equity portion of the milestone-based contingent payment are not included in
our basic or diluted shares outstanding. For additional discussion regarding our potential
milestone-based contingent payment, see Notes 3 and 4.
F-36
22. Quarterly Financial Data (Unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(Loss) |
|
|
|
|
|
|
|
|
|
|
Income (Loss) |
|
|
|
|
|
Per Basic and |
|
|
|
|
|
|
|
|
|
|
from |
|
|
|
|
|
Diluted |
|
|
Net Sales |
|
Cost of Sales |
|
Operations |
|
Net Income (Loss) |
|
Share |
2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First Quarter |
|
$ |
100,395 |
|
|
$ |
30,988 |
|
|
$ |
(3,647 |
) |
(1) |
$ |
(1,809 |
) |
(1) |
$ |
(0.02 |
) |
Second Quarter |
|
|
109,086 |
|
|
|
30,478 |
|
|
|
5,327 |
|
(2) |
|
23,989 |
|
(2) |
|
0.23 |
|
Third Quarter |
|
|
112,838 |
|
|
|
28,608 |
|
|
|
7,582 |
|
|
|
6,736 |
|
|
|
0.06 |
|
Fourth Quarter |
|
|
126,753 |
|
|
|
30,539 |
|
|
|
15,095 |
|
|
|
13,001 |
|
|
|
0.12 |
|
2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First Quarter |
|
$ |
101,257 |
|
|
$ |
33,618 |
|
|
$ |
(12,158 |
) |
|
$ |
(9,770 |
) |
|
$ |
(0.09 |
) |
Second Quarter |
|
|
107,717 |
|
|
|
36,189 |
|
|
|
(26,862 |
) |
(3) |
|
(27,422 |
) |
(3) |
|
(0.26 |
) |
Third Quarter |
|
|
107,029 |
|
|
|
38,282 |
|
|
|
(4,608 |
) |
|
|
(7,310 |
) |
|
|
(0.07 |
) |
Fourth Quarter |
|
|
106,125 |
|
|
|
34,809 |
|
|
|
(288,461 |
) |
(4) |
|
(291,120 |
|
(4) |
|
(2.78 |
) |
|
|
|
(1) |
|
During the first quarter of 2009, in light of the current economic environment and
continued downward pressures in the California real estate markets, we recorded a $3.4 million
adjustment to increase our liability related to our vacated leased FoxHollow facilities. For
additional discussion, see Note 5 above. During the first quarter of 2009, we also recorded a
gain of $4.1 million attributed to the divestiture of non-strategic investment assets. For
additional discussion, see Note 13 above. |
|
(2) |
|
As a result of the acquisition of Chestnut, we recorded a one-time non-cash tax benefit of
$19.0 million in the second quarter of 2009. For additional discussion, see Note 3 above. |
|
(3) |
|
During the second quarter of 2008, as a result of the termination of our research and
collaboration with Merck, we recorded an asset impairment charge of $10.5 million to write-off
the remaining carrying value of the related Merck intangible asset that was established at the
time of our acquisition of FoxHollow. For additional discussion, see Note 9 above. |
|
(4) |
|
During the fourth quarter of 2008, we recorded $288.8 million non-cash, asset impairment
charges in our peripheral vascular segment to reduce the carrying values of goodwill and other
intangible assets to their estimated fair values. For additional discussion, see Note 9
above. |
F-37
ev3 Inc.
Schedule II
Valuation and Qualifying Accounts
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at |
|
Charged to |
|
|
|
|
|
|
|
|
|
|
Beginning of |
|
Revenue, Costs |
|
Other |
|
|
|
|
|
Balance at |
Description |
|
Period |
|
or Expenses |
|
Additions |
|
Deductions |
|
End of Period |
Reserves deducted from assets to
which it applies: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reserve for deferred income tax asset |
|
$ |
220,077 |
|
|
$ |
(29,275 |
) |
|
$ |
|
|
|
$ |
(549 |
) |
|
$ |
190,253 |
|
Accounts receivable allowances |
|
|
8,098 |
|
|
|
(942 |
) |
|
|
104 |
|
|
|
|
|
|
|
7,260 |
|
Reserve for inventory obsolescence |
|
|
10,337 |
|
|
|
8,582 |
|
|
|
25 |
|
|
|
(7,970 |
) |
|
|
10,974 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, 2008 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reserve for deferred income tax asset |
|
$ |
199,040 |
|
|
$ |
19,418 |
|
|
$ |
1,619 |
|
|
$ |
|
|
|
$ |
220,077 |
|
Accounts receivable allowances |
|
|
6,783 |
|
|
|
2,538 |
|
|
|
|
|
|
|
(1,223 |
) |
|
|
8,098 |
|
Reserve for inventory obsolescence |
|
|
10,968 |
|
|
|
9,235 |
|
|
|
|
|
|
|
(9,866 |
) |
|
|
10,337 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year ended December 31, 2007 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Reserve for deferred income tax asset |
|
$ |
191,960 |
|
|
$ |
34,273 |
|
|
$ |
|
|
|
$ |
(27,193 |
)(b) |
|
$ |
199,040 |
|
Accounts receivable allowances |
|
|
3,924 |
|
|
|
2,024 |
|
|
|
1,661 |
(a) |
|
|
(826 |
) |
|
|
6,783 |
|
Reserve for inventory obsolescence |
|
|
4,725 |
|
|
|
9,018 |
|
|
|
1,513 |
(a) |
|
|
(4,288 |
) |
|
|
10,968 |
|
|
|
|
(a) |
|
Other additions primarily related to acquisitions. |
|
(b) |
|
Other deductions primarily related to acquisitions. |
F-38
|
|
|
ITEM 9. |
|
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL
DISCLOSURE |
None.
|
|
|
ITEM 9A. |
|
CONTROLS AND PROCEDURES |
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under
the Securities Exchange Act of 1934, as amended) that are designed to reasonably ensure that
information required to be disclosed by us in the reports we file or submit under the Securities
Exchange Act of 1934, as amended, is recorded, processed, summarized and reported, within the time
periods specified in the Securities and Exchange Commissions rules and forms and that such
information is accumulated and communicated to our management, including our principal executive
officer and principal financial officer, or persons performing similar functions, as appropriate to
allow timely decisions regarding required disclosure. In designing and evaluating our disclosure
controls and procedures, we recognize that any controls and procedures, no matter how well designed
and operated can provide only reasonable assurance of achieving the desired control objectives.
Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial
Officer, the effectiveness of the design and operation of our disclosure controls and procedures as
of the end of the period covered in this annual report on Form 10-K. Based on that evaluation, our
Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and
procedures were effective as of the end of such period to provide reasonable assurance that
information required to be disclosed in our Exchange Act reports is recorded, processed,
summarized, and reported within the time periods specified in the SECs rules and forms, and that
material information relating to our company and our consolidated subsidiaries is made known to
management, including our Chief Executive Officer and Chief Financial Officer, particularly during
the period when our periodic reports are being prepared.
Managements Report on Internal Control Over Financial Reporting
Our management report on internal control over financial reporting is included in this report in
Part II. Item 8. Financial Statements and Supplementary Data under Managements Report on
Internal Control over Financial Reporting.
The report of Ernst & Young LLP, our independent registered public accounting firm, regarding the
effectiveness of our internal control over financial reporting is included in this report in Part
II. Item 8. Financial Statements and Supplementary Data under Report of Independent Registered
Public Accounting Firm.
Change in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting that occurred during our
fourth quarter ended December 31, 2009 that has materially affected, or is reasonably likely to
materially affect, our internal control over financial reporting.
|
|
|
ITEM 9B. |
|
OTHER INFORMATION |
Not applicable.
91
PART III
|
|
|
ITEM 10. |
|
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE |
Directors
The information in the Proposal One Election of Directors section of our proxy statement in
connection with our 2010 annual meeting of stockholders to be filed with the Securities and
Exchange Commission is incorporated in this annual report on Form 10-K by reference.
Executive Officers
Information about our executive officers is included in this annual report on Form 10-K under Part
I. Item 4A, Executive Officers of the Registrant.
Section 16(a) Beneficial Ownership Reporting Compliance
The information in the Stock Ownership Section 16(a) Beneficial Ownership Reporting Compliance
section of our proxy statement in connection with our 2010 annual meeting of stockholders to be
filed with the Securities and Exchange Commission is incorporated in this annual report on Form
10-K by reference.
Code of Ethics
The information in the Corporate Governance Code of Business Conduct section of our proxy
statement in connection with our 2010 annual meeting of stockholders to be filed with the
Securities and Exchange Commission is incorporated in this annual report on Form 10-K by reference.
Changes to Nomination Procedures
We have made no material changes to the procedures by which stockholders may recommend nominees to
our board of directors, as described in our most recent proxy statement.
Audit Committee Matters
The information under the heading Corporate Governance Audit Committee section of our proxy
statement in connection with our 2010 annual meeting of stockholders to be filed with the
Securities and Exchange Commission is incorporated in this annual report on Form 10-K by reference.
92
ITEM 11. EXECUTIVE COMPENSATION
The information in the Compensation Discussion and Analysis, Executive Compensation and
Director Compensation sections of our proxy statement in connection with our 2010 annual meeting
of stockholders to be filed with the Securities and Exchange Commission is incorporated in this
annual report on Form 10-K by reference.
|
|
|
ITEM 12. |
|
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS |
Securities Authorized for Issuance Under Equity Compensation Plans
The following table and notes provide information about shares of our common stock that may be
issued under all of our equity compensation plans as of December 31, 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(c) |
|
|
|
|
|
|
|
|
|
|
|
Number of Securities |
|
|
|
|
|
|
|
|
|
Remaining Available for |
|
|
|
(a) |
|
|
(b) |
|
|
Future Issuance Under |
|
|
|
Number of Securities to |
|
|
Weighted-Average |
|
|
Equity Compensation |
|
|
|
be Issued Upon Exercise |
|
|
Exercise Price of |
|
|
Plans |
|
|
|
of Outstanding Options, |
|
|
Outstanding Options, |
|
|
(excluding securities |
|
Plan Category |
|
Warrants and Rights |
|
|
Warrants and Rights |
|
|
reflected in column (a)) |
|
Equity compensation plans
approved by security holders |
|
|
8,839,309 |
(1)(2)(5)(6) |
|
$ |
9.60 |
(3) |
|
|
3,010,110 |
(4) |
Equity compensation plans not
approved by security holders |
|
|
754,000 |
(7) |
|
|
8.64 |
|
|
|
0 |
|
|
|
|
|
|
|
|
|
|
|
Total |
|
|
9,593,309 |
|
|
$ |
9.53 |
|
|
|
3,010,110 |
|
|
|
|
(1) |
|
Amount includes shares of our common stock issuable upon the exercise of stock options
outstanding as of December 31, 2009 under the ev3 Inc. Second Amended and Restated 2005
Incentive Stock Plan and the ev3 LLC Amended and Restated 2003 Incentive Plan and shares of
our common stock issuable upon the vesting of restricted stock units outstanding as of
December 31, 2009 under the ev3 Inc. Second Amended and Restated 2005 Incentive Stock Plan. |
|
(2) |
|
Excludes employee stock purchase rights under the ev3 Inc. Employee Stock Purchase Plan.
Under such plan, each eligible employee may purchase up to 2,500 shares of our common stock at
semi-annual intervals on June 30th and December 31st each year at a purchase price per share
equal to 85% of the lower of (i) the closing sales price per share of our common stock on the
first day of the offering period or (ii) the closing sales price per share of our common stock
on the last day of the offering period. |
|
(3) |
|
Included in the weighted-average exercise price calculation are 1,429,795 restricted stock
units with an exercise price of $0.00. The weighted-average exercise price of all outstanding
stock options as of December 31, 2009 and reflected in column (a) was $11.19. |
|
(4) |
|
Amount includes 2,009,924 shares remaining available at December 31, 2009 for future issuance
under the ev3 Inc. Second Amended and Restated 2005 Incentive Stock Plan and 1,000,186 shares
remaining available at December 31, 2009 for future issuance under the ev3 Inc. Employee Stock
Purchase Plan, of which 1,000,000 shares remaining available under the ev3 Inc. Employee Stock
Purchase Plan are subject to approval by ev3s stockholders at the next annual meeting of
stockholders. No shares remain available for grant under the ev3 LLC Amended and Restated
2003 Incentive Plan since such plan was terminated with respect to future grants in June 2005. |
|
(5) |
|
Excludes options assumed by us in connection with our acquisitions of Micro Therapeutics,
Inc. and FoxHollow Technologies, Inc. As of December 31, 2009, a total of 1,360,489 shares of
our common stock were issuable upon exercise of the assumed options. The weighted average
exercise price of the outstanding assumed options as of such date was $12.86 per share and
they have an average weighted life remaining of 5.18 years. All of the 520,087 options
outstanding in connection with our acquisition of Micro Therapeutics, Inc. were exercisable as
of December 31, 2009. 798,618 of the 840,644 options assumed and outstanding in connection
with our acquisition of FoxHollow Technologies, Inc. were exercisable as of December 31, 2009.
No additional options, restricted stock units or other |
93
|
|
|
|
|
equity incentive awards may be granted
under the assumed Micro Therapeutics, Inc. and FoxHollow Technologies, Inc. plans. |
|
(6) |
|
Excludes shares issuable upon the vesting of restricted stock units assumed by us in
connection with our acquisition of FoxHollow Technologies, Inc. As of December 31, 2009, a
total of 242 shares of our common stock were issuable upon the vesting of the assumed
restricted stock units. |
|
(7) |
|
Consists of a non-plan option to purchase 754,000 shares of our common stock granted outside
of the terms of our existing stockholder-approved equity incentive plans to Robert J.
Palmisano, our President and Chief Executive Officer, as an inducement grant in April 2008
pursuant to an exemption from NASDAQs shareholder approval requirements under former NASDAQ
Marketplace Rule Section 4350(i)(1)(A)(iv). |
Stock Ownership
The information in the Stock Ownership section of our proxy statement in connection with our 2010
annual meeting of stockholders to be filed with the Securities and Exchange Commission is
incorporated in this annual report on Form 10-K by reference.
ITEM 13. CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information in the Related Person Relationships and Transactions, the Proposal One -
Election of Directors Board Designation Rights, and Corporate Governance Director
Independence section of our proxy statement in connection with our 2010 annual meeting of
stockholders to be filed with the Securities and Exchange Commission is incorporated in this annual
report on Form 10-K by reference.
ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The information in the Proposal Four Ratification of Selection of Independent Registered Public
Accounting Firm Audit, Audit-Related, Tax and Other Fees and the Proposal Four Ratification
of Selection of Independent Registered Public Accounting Firm Pre-Approval Policies and
Procedures sections of our proxy statement in connection with our 2010 annual meeting of
stockholders to be filed with the Securities and Exchange Commission is incorporated in this annual
report on Form 10-K by reference.
94
PART IV
ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
Our consolidated financial statements are included in Item 8 of Part II of this report.
The following financial statement schedule is included in Item 8 of Part II of this report:
Schedule IIValuation and Qualifying Accounts. All other schedules are omitted because the
required information is inapplicable or the information is presented in the consolidated financial
statements or related notes.
The exhibits to this report are listed on the Exhibit Index to this report. A copy of any of the
exhibits will be furnished at a reasonable cost, upon receipt from any such person of a written
request for any such exhibit. Such request should be sent to ev3 Inc., 3033 Campus Drive, Plymouth,
Minnesota 55441, Attn: Stockholder Information.
The following is a list of each management contract or compensatory plan or arrangement required to
be filed as an exhibit to this annual report on Form 10-K pursuant to Item 13(a):
|
1. |
|
ev3 Inc. Second Amended and Restated 2005 Incentive Stock Plan (incorporated by
reference to Exhibit 10.1 to ev3s Current Report on Form 8-K as filed with the Securities
and Exchange Commission on May 17, 2007 (File No. 000-51348)). |
|
|
2. |
|
Form of Option Certificate under the ev3 Inc. Second Amended and Restated 2005
Incentive Stock Plan (incorporated by reference to Exhibit 10.5 to ev3s Quarterly Report
on Form 10-Q for the fiscal quarter ended September 28, 2008 (File No. 000-51348)). |
|
|
3. |
|
Form of Restricted Stock Grant Certificate under the ev3 Inc. Second Amended and
Restated 2005 Incentive Stock Plan (incorporated by reference to Exhibit 10.6 to ev3s
Quarterly Report on Form 10-Q for the fiscal quarter ended September 28, 2008 (File No.
000-51348)). |
|
|
4. |
|
Form of Stock Grant Certificate applicable to French Participants under the ev3 Inc.
Amended and Restated 2005 Incentive Stock Plan (incorporated by reference to Exhibit 10.7
to ev3s Quarterly Report on Form 10-Q for the fiscal quarter ended September 28, 2008
(File No. 000-51348)). |
|
|
5. |
|
ev3 LLC Amended and Restated 2003 Incentive Plan, as amended (incorporated by
reference to Exhibit 10.2 to ev3s Quarterly Report on Form 10-Q for the fiscal quarter
ended July 2, 2006 (File No. 000-51348)). |
|
|
6. |
|
Micro Therapeutics, Inc. 1996 Stock Incentive Plan, as amended (incorporated by
reference to Exhibit 10.7.1 to Micro Therapeutics, Inc.s Annual Report on Form 10-KSB for
the fiscal year ended December 31, 2002 (File No. 000-06523)). |
|
|
7. |
|
FoxHollow Technologies, Inc. 2004 Equity Incentive Plan (incorporated by reference to
Exhibit 10.3 to FoxHollows Amendment No. 2 to Registration Statement on Form S-1 filed
with the Securities and Exchange Commission on October 13, 2004 (Registration No.
333-118191)). |
|
|
8. |
|
ev3 Inc. Employee Stock Purchase Plan (As Amended and Restated and Subject to
Stockholder Approval) (incorporated by reference to Exhibit 10.1 to ev3s Registration
Statement on Form S-8 filed with the Securities and Exchange Commission on December 15,
2009 (File No. 333-163742)). |
|
|
9. |
|
ev3 Inc. Employee Performance Incentive Compensation Plan Effective January 1, 2010
(filed herewith). |
|
|
10. |
|
Form of Indemnification Agreement between ev3 Inc. and each of its directors and
officers (incorporated by reference to Exhibit 10.11 to ev3s Annual Report on Form 10-K
for the fiscal year ended December 31, 2008 (File No. 000-51348)). |
95
|
11. |
|
Form of Change in Control Agreement among ev3 Inc., ev3 Endovascular, Inc., Micro
Therapeutics, Inc. or FoxHollow Technologies, Inc. and each executive officer of ev3 Inc.
(incorporated by reference to Exhibit 10.12 to ev3s Annual Report on Form 10-K for the
fiscal year ended December 31, 2008 (File No. 000-51348)). |
|
|
12. |
|
Employment and Change in Control Agreement dated as of April 6, 2008 between ev3 Inc.
and Robert J. Palmisano (incorporated by reference to Exhibit 10.1 to ev3s Current Report
on Form 8-K as filed with the Securities and Exchange Commission on April 7, 2008 (File
No. 000-51348)). |
|
|
13. |
|
Confidentiality, Non-Competition and Non-Solicitation Agreement dated as of April 6,
2008 between ev3 Inc. and Robert J. Palmisano (incorporated by reference to Exhibit 10.2
to ev3s Current Report on Form 8-K as filed with the Securities and Exchange Commission
on April 7, 2008 (File No. 000-51348)). |
|
|
14. |
|
Robert J. Palmisano Inducement Grant Option Agreement (incorporated by reference to
Exhibit 10.4 to ev3s Current Report on Form 8-K as filed with the Securities and Exchange
Commission on April 7, 2008 (File No. 000-51348)). |
|
|
15. |
|
Offer Letter dated January 5, 2009 between ev3 Inc. and Shawn McCormick (incorporated
by reference to Exhibit 10.1 to ev3s Current Report on Form 8-K as filed with the
Securities and Exchange Commission on January 9, 2009 (File No. 000-51348)). |
|
|
16. |
|
Employment Agreement effective as of January 19, 2009 between ev3 Endovascular, Inc.
and Shawn McCormick (incorporated by reference to Exhibit 10.2 to ev3s Current Report on
Form 8-K as filed with the Securities and Exchange Commission on January 9, 2009 (File No.
000-51348)). |
|
|
17. |
|
Separation Agreement and Release of Claims effective as of January 19, 2009 between
ev3 Endovascular, Inc. and Patrick D. Spangler (incorporated by reference to Exhibit 10.5
to ev3s Current Report on Form 8-K as filed with the Securities and Exchange Commission
on January 9, 2009 (File No. 000-51348)). |
|
|
18. |
|
Consulting Agreement effective as of January 20, 2009 between ev3 Endovascular, Inc.
and Patrick D. Spangler (incorporated by reference to Exhibit 10.6 to ev3s Current Report
on Form 8-K as filed with the Securities and Exchange Commission on January 9, 2009 (File
No. 000-51348)). |
|
|
19. |
|
Employment Agreement, dated as of September 17, 2009, between ev3 Europe SAS and
Pascal E.R. Girin (incorporated by reference to Exhibit 10.1 to ev3s Quarterly Report on
Form 10-Q for the fiscal quarter ended October 4, 2009 (File No. 000 51348)). |
|
|
20. |
|
Offer Letter effective December 5, 2008 between ev3 Endovascular, Inc. and Stacy
Enxing Seng (incorporated by reference to Exhibit 10.27 to ev3s
Annual Report on Form 10-K for the
fiscal year ended December 31, 2008 (File No. 000-51348)). |
|
|
21. |
|
Letter Agreement Regarding Foreign Assignment dated January 20, 2010 between ev3 Inc.
and Brett Wall (filed herewith). |
96
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
|
|
|
|
Dated: February 25, 2010 |
ev3 INC.
|
|
|
By |
/s/ Robert J. Palmisano
|
|
|
|
Robert J. Palmisano |
|
|
|
President and Chief Executive Officer
(principal executive officer) |
|
|
|
|
|
|
By |
/s/ Shawn McCormick
|
|
|
|
Shawn McCormick |
|
|
|
Senior Vice President and Chief Financial Officer
(principal financial and accounting officer) |
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed
below by the following persons on behalf of the registrant and in the capacities and on the dates
indicated.
|
|
|
|
|
Name and Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Robert J. Palmisano
Robert J. Palmisano
|
|
President and Chief
Executive Officer
|
|
February 25, 2010 |
|
|
|
|
|
/s/ Daniel J. Levangie
Daniel J. Levangie
|
|
Chairman of the Board
|
|
February 25, 2010 |
|
|
|
|
|
/s/ John K. Bakewell
John K. Bakewell
|
|
Director
|
|
February 25, 2010 |
|
|
|
|
|
/s/ Jeffrey B. Child
Jeffrey B. Child
|
|
Director
|
|
February 25, 2010 |
|
|
|
|
|
/s/ Richard B. Emmitt
Richard B. Emmitt
|
|
Director
|
|
February 25, 2010 |
|
|
|
|
|
/s/ Douglas W. Kohrs
Douglas W. Kohrs
|
|
Director
|
|
February 25, 2010 |
|
|
|
|
|
/s/ John L. Miclot
John L. Miclot
|
|
Director
|
|
February 25, 2010 |
|
|
|
|
|
/s/ Thomas E. Timbie
Thomas E. Timbie
|
|
Director
|
|
February 25, 2010 |
|
|
|
|
|
/s/ Elizabeth H. Weatherman
Elizabeth H. Weatherman
|
|
Director
|
|
February 25, 2010 |
97
ev3 INC.
EXHIBIT INDEX TO ANNUAL REPORT ON FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 2009
|
|
|
|
|
Exhibit No. |
|
Exhibit |
|
Method of Filing |
|
|
|
|
|
2.1
|
|
Agreement and Plan of Merger, dated as
of April 4, 2005, by and between ev3
LLC and ev3 Inc.
|
|
Incorporated by
reference to
Exhibit 2.1 to
ev3s Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on April 5, 2005
(File No.
333-123851) |
|
|
|
|
|
2.2
|
|
Contribution and Exchange Agreement,
dated as of April 4, 2005, by and
among the institutional stockholders
listed on Schedule I thereto, ev3 LLC,
ev3 Inc. and Micro Therapeutics, Inc.
|
|
Incorporated by
reference to
Exhibit 2.2 to
ev3s Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on April 5, 2005
(File No.
333-123851) |
|
|
|
|
|
2.3
|
|
Note Contribution and Exchange
Agreement, dated as of April 4, 2005,
by and among the noteholders listed on
Schedule I thereto and ev3 Inc.
|
|
Incorporated by
reference to
Exhibit 2.3 to
ev3s Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on April 5, 2005
(File No.
333-123851) |
|
|
|
|
|
2.4
|
|
Agreement and Plan of Merger, dated as
of July 15, 2002, by and among
Microvena Corporation, Appriva
Acquisition Corp. and Appriva Medical,
Inc.
|
|
Incorporated by
reference to
Exhibit 2.4 to
ev3s Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on April 5, 2005
(File No.
333-123851) |
|
|
|
|
|
2.5
|
|
Agreement and Plan of Merger, dated
November 14, 2005, by and between ev3
Inc., Micro Investment, LLC and Micro
Therapeutics, Inc.
|
|
Incorporated by
reference to
Exhibit 2.1 to
ev3s Current
Report on Form 8-K
filed with the
Securities and
Exchange Commission
on November 14,
2005 (File No.
000-51348) |
|
|
|
|
|
2.6
|
|
Agreement and Plan of Merger dated as
of July 21, 2007 by and among ev3
Inc., Foreigner Merger Sub, Inc. and
FoxHollow Technologies, Inc.(1)
|
|
Incorporated by
reference to
Exhibit 2.1 to
ev3s Current
Report on Form 8-K
filed with the
Securities and
Exchange Commission
on July 23, 2007
(File No.
000-51348) |
|
|
|
|
|
2.7
|
|
Agreement and Plan of Merger, dated as
of August 26, 2006, by and between
FoxHollow Technologies, Inc. and
Kerberos Proximal Solutions, Inc.
|
|
Incorporated by
reference to
Exhibit 2.1 to
FoxHollows Current
Report on Form 8-K
filed with the
Securities and
Exchange Commission
on August 28, 2006
(File No.
000-50998) |
|
|
|
|
|
2.8
|
|
Agreement and Plan of Merger, dated as
of June 2, 2009, by and among ev3
Inc., Starsky Merger Sub, Inc.,
Starsky Acquisition Sub, Inc.,
Chestnut Medical Technologies, Inc.
and CMT SR, Inc. (1)
|
|
Incorporated by
reference to
Exhibit 2.1 to
ev3s Current
Report on Form 8-K
filed with the
Securities and
Exchange Commission
on June 3, 2009
(File No.
000-51348) |
|
|
|
|
|
3.1
|
|
Amended and Restated Certificate of
Incorporation of ev3 Inc.
|
|
Incorporated by
reference to
Exhibit 3.1 to
ev3s Amendment No.
5 to Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on June 14, 2005
(File No.
333-123851) |
|
|
|
|
|
3.2
|
|
Amendment to Amended and Restated
Certificate of Incorporation of ev3
Inc.
|
|
Incorporated by
reference to
Exhibit 99.1 to
ev3s Current
Report on Form 8-K
filed with the
Securities and
Exchange Commission
on June 27, 2005
(File No.
000-51348) |
98
|
|
|
|
|
Exhibit No. |
|
Exhibit |
|
Method of Filing |
|
|
|
|
|
3.3
|
|
Amendment to Amended and Restated
Certificate of Incorporation of ev3
Inc.
|
|
Incorporated by
reference to
Exhibit 3.1 to
ev3s Current
Report on Form 8-K
filed with the
Securities and
Exchange Commission
on July 23, 2007
(File No.
000-51348) |
|
|
|
|
|
3.4
|
|
Amended and Restated Bylaws of ev3 Inc.
|
|
Incorporated by
reference to
Exhibit 3.1 to
ev3s Current
Report on Form 8-K
filed with the
Securities and
Exchange Commission
on December 3, 2008
(File No.
000-51348) |
|
|
|
|
|
4.1
|
|
Form of Stock Certificate
|
|
Incorporated by
reference to
Exhibit 4.1 to
ev3s Amendment No.
4 to Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on June 2, 2005
(File No.
333-123851) |
|
|
|
|
|
4.2
|
|
Holders Agreement dated as of August
29, 2003 among the institutional
investors listed on Schedule I
thereto, Dale A. Spencer, Paul
Buckman, the individuals whose names
and addresses appear from time to time
on Schedule II thereto, the
individuals whose names and addresses
appear from time to time on Schedule
III thereto and ev3 LLC
|
|
Incorporated by
reference to
Exhibit 4.2 to
ev3s Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on April 5, 2005
(File No.
333-123851) |
|
|
|
|
|
4.3
|
|
Operating Agreement of ev3 LLC dated
as of August 29, 2003 by and among ev3
LLC, Warburg, Pincus Equity Partners,
L.P., Warburg, Pincus Netherlands
Equity Partners I, C.V., Warburg,
Pincus Netherlands Equity Partners II,
C.V., Warburg, Pincus Netherlands
Equity Partners III, C.V., Vertical
Fund I, L.P., Vertical Fund II, L.P.
and certain other persons party
thereto
|
|
Incorporated by
reference to
Exhibit 4.3 to
ev3s Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on April 5, 2005
(File No.
333-123851) |
|
|
|
|
|
4.4
|
|
Amendment No. 1 to Operating Agreement
of ev3 LLC dated as of March 1, 2005
by and among ev3 LLC, Warburg, Pincus
Equity Partners, L.P., Warburg, Pincus
Netherlands Equity Partners I, C.V.,
Warburg, Pincus Netherlands Equity
Partners II, C.V., Warburg, Pincus
Netherlands Equity Partners III, C.V.,
Vertical Fund I, L.P., Vertical Fund
II, L.P. and certain other persons
party thereto
|
|
Incorporated by
reference to
Exhibit 4.4 to
ev3s Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on April 5, 2005
(File No.
333-123851) |
|
|
|
|
|
4.5
|
|
Registration Rights Agreement dated as
of June 21, 2005 by and among ev3
Inc., Warburg, Pincus Equity Partners,
L.P., Warburg, Pincus Netherlands
Equity Partners I, C.V., Warburg,
Pincus Netherlands Equity Partners II,
C.V., Warburg, Pincus Netherlands
Equity Partners III, C.V., Vertical
Fund I, L.P., Vertical Fund II, L.P.
and certain other investors party
thereto
|
|
Incorporated by
reference to
Exhibit 4.2 to
ev3s Quarterly
Report on Form 10-Q
for the fiscal
quarter ended July
3, 2005 (File No.
000-51348) |
99
|
|
|
|
|
Exhibit No. |
|
Exhibit |
|
Method of Filing |
|
10.1
|
|
ev3 Inc. Second Amended and Restated
2005 Incentive Stock Plan
|
|
Incorporated by
reference to
Exhibit 10.1 to
ev3s Current
Report on Form 8-K
as filed with the
Securities and
Exchange Commission
on May 17, 2007
(File No.
000-51348) |
|
|
|
|
|
10.2
|
|
Form of Option Certificate under the
ev3 Inc. Second Amended and Restated
2005 Incentive Stock Plan
|
|
Incorporated by
reference to
Exhibit 10.5 to
ev3s Quarterly
Report on Form 10-Q
for the fiscal
quarter ended
September 28, 2008
(File No.
000-51348) |
|
|
|
|
|
10.3
|
|
Form of Restricted Stock Grant
Certificate under the ev3 Inc. Second
Amended and Restated 2005 Incentive
Stock Plan
|
|
Incorporated by
reference to
Exhibit 10.6 to
ev3s Quarterly
Report on Form 10-Q
for the fiscal
quarter ended
September 28, 2008
(File No.
000-51348) |
|
|
|
|
|
10.4
|
|
Form of Stock Grant Certificate
applicable to French Participants
under the ev3 Inc. Amended and
Restated 2005 Incentive Stock Plan
|
|
Incorporated by
reference to
Exhibit 10.7 to
ev3s Quarterly
Report on Form 10-Q
for the fiscal
quarter ended
September 28, 2008
(File No.
000-51348) |
|
|
|
|
|
10.5
|
|
ev3 LLC Amended and Restated 2003
Incentive Plan, as amended
|
|
Incorporated by
reference to
Exhibit 10.2 to
ev3s Quarterly
Report on Form 10-Q
for the fiscal
quarter ended July
2, 2006 (File No.
000-51348) |
|
|
|
|
|
10.6
|
|
Micro Therapeutics, Inc. 1996 Stock
Incentive Plan, as amended
|
|
Incorporated by
reference to
Exhibit 10.7.1 to
Micro Therapeutics,
Inc.s Annual
Report on Form
10-KSB for the
fiscal year ended
December 31, 2002
(File No.
000-06523) |
|
|
|
|
|
10.7
|
|
FoxHollow Technologies, Inc. 2004
Equity Incentive Plan
|
|
Incorporated by
reference to
Exhibit 10.3 to
FoxHollow
Technologies,
Inc.s Amendment
No. 2 to
Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on October 13, 2004
(Registration No.
333-118191) |
|
|
|
|
|
10.8
|
|
ev3 Inc. Employee Stock Purchase Plan
(As Amended and Restated and Subject
to Stockholder Approval)
|
|
Incorporated by
reference to
Exhibit 10.1 to
ev3s Registration
Statement on Form
S-8 filed with the
Securities and
Exchange Commission
on December 15,
2009 (File No.
333-163742) |
|
|
|
|
|
10.9
|
|
ev3 Inc. Employee Performance
Incentive Compensation Plan Effective
January 1, 2010
|
|
Filed herewith |
|
|
|
|
|
10.10
|
|
Form of Indemnification Agreement
between ev3 Inc. and each of its
directors and officers
|
|
Incorporated by
reference to
Exhibit 10.11 to
ev3s Annual Report
on Form 10-K for
the fiscal year
ended December 31,
2008 (File No. 000
51348) |
|
|
|
|
|
10.11
|
|
Form of Change in Control Agreement
among ev3 Inc., ev3 Endovascular,
Inc., Micro Therapeutics, Inc. or
FoxHollow Technologies, Inc. and each
of executive officer of ev3 Inc.
|
|
Incorporated by
reference to
Exhibit 10.12 to
ev3s Annual Report
on Form 10-K for
the fiscal year
ended December 31,
2008 (File No.
000-51348) |
|
|
|
|
|
10.12
|
|
Employment and Change in Control
Agreement dated as of April 6, 2008
between ev3 Inc. and Robert J.
Palmisano
|
|
Incorporated by
reference to
Exhibit 10.1 to
ev3s Current
Report on Form 8-K
as filed with the
Securities and
Exchange Commission
on April 7, 2008
(File No.
000-51348) |
100
|
|
|
|
|
Exhibit No. |
|
Exhibit |
|
Method of Filing |
|
|
|
|
|
10.13
|
|
Confidentiality, Non-Competition and
Non-Solicitation Agreement dated as of
April 6, 2008 between ev3 Inc. and
Robert J. Palmisano
|
|
Incorporated by
reference to
Exhibit 10.2 to
ev3s Current
Report on Form 8-K
as filed with the
Securities and
Exchange Commission
on April 7, 2008
(File No.
000-51348) |
|
|
|
|
|
10.14
|
|
Robert J. Palmisano Inducement Grant
Option Agreement
|
|
Incorporated by
reference to
Exhibit 10.4 to
ev3s Current
Report on Form 8-K
as filed with the
Securities and
Exchange Commission
on April 7, 2008
(File No.
000-51348) |
|
|
|
|
|
10.15
|
|
Offer Letter dated January 5, 2009
between ev3 Inc. and Shawn McCormick
|
|
Incorporated by
reference to
Exhibit 10.1 to
ev3s Current
Report on Form 8-K
as filed with the
Securities and
Exchange Commission
on January 9, 2009
(File No.
000-51348) |
|
|
|
|
|
10.16
|
|
Employment Agreement effective as of
January 19, 2009 between ev3
Endovascular, Inc. and Shawn McCormick
|
|
Incorporated by
reference to
Exhibit 10.2 to
ev3s Current
Report on Form 8-K
as filed with the
Securities and
Exchange Commission
on January 9, 2009
(File No.
000-51348) |
|
|
|
|
|
10.17
|
|
Separation Agreement and Release of
Claims effective as of January 19,
2009 between ev3 Endovascular, Inc.
and Patrick D. Spangler
|
|
Incorporated by
reference to
Exhibit 10.5 to
ev3s Current
Report on Form 8-K
as filed with the
Securities and
Exchange Commission
on January 9, 2009
(File No.
000-51348) |
|
|
|
|
|
10.18
|
|
Consulting Agreement effective as of
January 20, 2009 between ev3
Endovascular, Inc. and Patrick D.
Spangler
|
|
Incorporated by
reference to
Exhibit 10.6 to
ev3s Current
Report on Form 8-K
as filed with the
Securities and
Exchange Commission
on January 9, 2009
(File No.
000-51348) |
|
|
|
|
|
10.19
|
|
Employment Agreement, dated as of
September 17, 2009, between ev3 Europe
SAS and Pascal E.R. Girin
|
|
Incorporated by
reference to
Exhibit 10.1 to
ev3s Quarterly
Report on Form 10-Q
for the fiscal
quarter ended
October 4, 2009
(File No.
000-51348) |
|
|
|
|
|
10.20
|
|
Offer Letter effective as of December
5, 2008 between ev3 Endovascular, Inc.
and Stacy Enxing Seng
|
|
Incorporated by
reference to
Exhibit 10.27 to
ev3s Annual Report
on Form 10-K for
the fiscal year
ended December 31,
2008 (File No.
000-51348) |
|
|
|
|
|
10.21
|
|
Letter Agreement Regarding Foreign
Assignment dated January 20, 2010
between ev3 Inc. and Brett Wall
|
|
Filed herewith |
|
|
|
|
|
10.22
|
|
Form of Subscription Agreement between
ev3 Endovascular, Inc. (formerly known
as ev3 Inc.) and Warburg, Pincus
Equity Partners, L.P., Warburg, Pincus
Netherlands Equity Partners I, C.V.,
Warburg, Pincus Netherlands Equity
Partners II, C.V., Warburg, Pincus
Netherlands Equity Partners III, C.V.,
Vertical Fund I, L.P., Vertical Fund
II, L.P.
|
|
Incorporated by
reference to
Exhibit 10.33 to
ev3s Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on April 5, 2005
(File No.
333-123851) |
|
|
|
|
|
10.23
|
|
Loan and Security Agreement dated as
of June 28, 2006 among Silicon Valley
Bank, ev3 Endovascular, Inc., ev3
International, Inc. and Micro
Therapeutics, Inc.
|
|
Incorporated by
reference to
Exhibit 10.8 to
ev3s Quarterly
Report on Form 10-Q
for the fiscal
quarter ended July
2, 2006 (File No.
000-51348) |
101
|
|
|
|
|
Exhibit No. |
|
Exhibit |
|
Method of Filing |
|
|
|
|
|
10.24
|
|
First Amendment to Loan and Security
Agreement dated March 15, 2007 between
Silicon Valley Bank and ev3
Endovascular, Inc., ev3 International,
Inc. and Micro Therapeutics, Inc.
|
|
Incorporated by
reference to
Exhibit 10.1 to
ev3s Current
Report on Form 8-K
as filed with the
Securities and
Exchange Commission
on March 21, 2007
(File No.
000-51348) |
|
|
|
|
|
10.25
|
|
Consent and Second Amendment to Loan
and Security Agreement dated October
4, 2007 between Silicon Valley Bank
and ev3 Endovascular, Inc., ev3
International, Inc. and Micro
Therapeutics, Inc.
|
|
Incorporated by
reference to
Exhibit 10.38 to
ev3s Annual Report
on Form 10-K for
the fiscal year
ended December 31,
2007 (File No.
000-51348) |
|
|
|
|
|
10.26
|
|
Third Amendment to Loan and Security
Agreement dated November 2, 2007
between Silicon Valley Bank and ev3
Endovascular, Inc., ev3 International,
Inc. and Micro Therapeutics, Inc.
|
|
Incorporated by
reference to
Exhibit 10.39 to
ev3s Annual Report
on Form 10-K for
the fiscal year
ended December 31,
2007 (File No.
000-51348) |
|
|
|
|
|
10.27
|
|
Assumption Agreement and Fourth
Amendment to Loan and Security
Agreement dated December 14, 2007
between Silicon Valley Bank and ev3
Endovascular, Inc., ev3 International,
Inc., Micro Therapeutics, Inc., and
FoxHollow Technologies, Inc.
|
|
Incorporated by
reference to
Exhibit 10.40 to
ev3s Annual Report
on Form 10-K for
the fiscal year
ended December 31,
2007 (File No.
000-51348) |
|
|
|
|
|
10.28
|
|
Fifth Amendment to Loan and Security
Agreement dated June 24, 2008 between
Silicon Valley Bank and ev3
Endovascular, Inc., ev3 International,
Inc., Micro Therapeutics, Inc. and
FoxHollow Technologies, Inc.
|
|
Incorporated by
reference to
Exhibit 10.1 to
ev3s Current
Report on Form 8-K
as filed with the
Securities and
Exchange Commission
on June 25, 2008
(File No.
000-51348) |
|
|
|
|
|
10.29
|
|
Sixth Amendment to Loan and Security
Agreement dated December 22, 2008
between Silicon Valley Bank and ev3
Endovascular, Inc., ev3 International,
Inc. , Micro Therapeutics, Inc. and
FoxHollow Technologies, Inc.
|
|
Incorporated by
reference to
Exhibit 10.1 to
ev3s Current
Report on Form 8-K
as filed with the
Securities and
Exchange Commission
on December 24,
2008 (File No.
000-51348) |
|
|
|
|
|
10.30
|
|
Consent Regarding Loan and Security
Agreement, dated June 19, 2009,
between Silicon Valley Bank and ev3
Endovascular, Inc., ev3 International,
Inc. , Micro Therapeutics, Inc. and
FoxHollow Technologies, Inc.
|
|
Incorporated by
reference to
Exhibit 10.2 to
ev3s Quarterly
Report on Form 10-Q
for the fiscal
quarter ended July
5, 2009 (File No.
000- 51348) |
|
|
|
|
|
10.31
|
|
Lease Agreement dated May 3, 2002 by
and between Liberty Property Limited
Partnership and ev3 Endovascular, Inc.
(formerly known as ev3 Inc.)
|
|
Incorporated by
reference to
Exhibit 10.1 to
ev3s Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on April 5, 2005
(File No.
333-123851) |
|
|
|
|
|
10.32
|
|
First Amendment to the May 3, 2002
Lease Agreement between Liberty
Property Limited Partnership and ev3
Endovascular, Inc. (formerly known as
ev3 Inc.) effective as of October 17,
2005
|
|
Incorporated by
reference to
Exhibit 10.2 to
ev3s Annual Report
on Form 10-K for
the fiscal year
ended December 31,
2006 (File No.
000-51348) |
102
|
|
|
|
|
Exhibit No. |
|
Exhibit |
|
Method of Filing |
|
|
|
|
|
10.33
|
|
Second Amendment to the May 3, 2002
Lease Agreement between Liberty
Property Limited Partnership and ev3
Endovascular, Inc. (formerly known as
ev3 Inc.) effective as of October 1,
2005
|
|
Incorporated by
reference to
Exhibit 10.3 to
ev3s Annual Report
on Form 10-K for
the fiscal year
ended December 31,
2006 (File No.
000-51348) |
|
|
|
|
|
10.34
|
|
Lease dated October 13, 2005 by and
between Micro Therapeutics, Inc. and
The Irvine Company
|
|
Incorporated by
reference to
Exhibit 10.53 to
Micro Therapeutics,
Inc.s Current
Report on Form 8-K
filed with the
Securities and
Exchange Commission
on October 18, 2005
(File No.
000-06523) |
|
|
|
|
|
10.35
|
|
Office Lease for Atria Corporate
Center, dated April 2, 2009, by and
between Talcott III Atria, LLC and ev3
Inc.
|
|
Incorporated by
reference to
Exhibit 10.1 to
ev3s Current
Report on Form 8-K
as filed with the
Securities and
Exchange Commission
on April 2, 2009
(File No. 000
51348) |
|
|
|
|
|
10.36
|
|
Corporate Opportunity Agreement dated
as of April 4, 2005 by and between the
institutional stockholders listed on
Schedule I thereto and ev3 Inc.
|
|
Incorporated by
reference to
Exhibit 10.32 to
ev3s Registration
Statement on Form
S-1 filed with the
Securities and
Exchange Commission
on April 5, 2005
(File No.
333-123851) |
|
|
|
|
|
21.1
|
|
Subsidiaries of ev3 Inc.
|
|
Filed herewith |
|
|
|
|
|
23.1
|
|
Consent of Ernst & Young LLP
|
|
Filed herewith |
|
|
|
|
|
31.1
|
|
Certification of Chief Executive
Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 and SEC
Rule 13a-14(a)
|
|
Filed herewith |
|
|
|
|
|
31.2
|
|
Certification of Chief Financial
Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act of 2002 and SEC
Rule 13a-14(a)
|
|
Filed herewith |
|
|
|
|
|
32.1
|
|
Certification of Chief Executive
Officer Pursuant to 18 U.S.C. Section
1350, as Adopted Pursuant to Section
906 of the Sarbanes-Oxley Act of 2002
|
|
Furnished herewith |
|
|
|
|
|
32.2
|
|
Certification of Chief Financial
Officer Pursuant to 18 U.S.C. Section
1350, as Adopted Pursuant to Section
906 of the Sarbanes-Oxley Act of 2002
|
|
Furnished herewith |
|
|
|
(1) |
|
All exhibits and schedules to the Agreement and Plan of Merger have been omitted pursuant
to Item 601(b)(2) of Regulation S-K. ev3 will furnish the omitted exhibits and schedules to
the Securities and Exchange Commission upon request by the Commission. |
103